<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE chapter PUBLIC "-//ES//DTD book DTD version 5.5.0//EN//XML" "book550.dtd" [<!ENTITY b016-031-9780702070280 SYSTEM "b016-031-9780702070280" NDATA IMAGE><!ENTITY b016-058-9780702070280 SYSTEM "b016-058-9780702070280" NDATA IMAGE><!ENTITY b016-081-9780702070280 SYSTEM "b016-081-9780702070280" NDATA IMAGE><!ENTITY f016-001-9780702070280 SYSTEM "f016-001-9780702070280" NDATA IMAGE><!ENTITY f016-002-9780702070280 SYSTEM "f016-002-9780702070280" NDATA IMAGE><!ENTITY f016-003-9780702070280 SYSTEM "f016-003-9780702070280" NDATA IMAGE><!ENTITY f016-004-9780702070280 SYSTEM "f016-004-9780702070280" NDATA IMAGE><!ENTITY f016-005ae-9780702070280 SYSTEM "f016-005ae-9780702070280" NDATA IMAGE><!ENTITY f016-006-9780702070280 SYSTEM "f016-006-9780702070280" NDATA IMAGE><!ENTITY f016-007ac-9780702070280 SYSTEM "f016-007ac-9780702070280" NDATA IMAGE><!ENTITY f016-008ab-9780702070280 SYSTEM "f016-008ab-9780702070280" NDATA IMAGE><!ENTITY f016-009-9780702070280 SYSTEM "f016-009-9780702070280" NDATA IMAGE><!ENTITY f016-010-9780702070280 SYSTEM "f016-010-9780702070280" NDATA IMAGE><!ENTITY f016-011a-9780702070280 SYSTEM "f016-011a-9780702070280" NDATA IMAGE><!ENTITY f016-011b-9780702070280 SYSTEM "f016-011b-9780702070280" NDATA IMAGE><!ENTITY f016-012-9780702070280 SYSTEM "f016-012-9780702070280" NDATA IMAGE><!ENTITY f016-013ab-9780702070280 SYSTEM "f016-013ab-9780702070280" NDATA IMAGE><!ENTITY f016-014ab-9780702070280 SYSTEM "f016-014ab-9780702070280" NDATA IMAGE><!ENTITY f016-015ab-9780702070280 SYSTEM "f016-015ab-9780702070280" NDATA IMAGE><!ENTITY f016-016-9780702070280 SYSTEM "f016-016-9780702070280" NDATA IMAGE><!ENTITY f016-017-9780702070280 SYSTEM "f016-017-9780702070280" NDATA IMAGE><!ENTITY f016-018-9780702070280 SYSTEM "f016-018-9780702070280" NDATA IMAGE><!ENTITY f016-019-9780702070280 SYSTEM "f016-019-9780702070280" NDATA IMAGE><!ENTITY f016-020-9780702070280 SYSTEM "f016-020-9780702070280" NDATA IMAGE><!ENTITY f016-021-9780702070280 SYSTEM "f016-021-9780702070280" NDATA IMAGE><!ENTITY f016-022-9780702070280 SYSTEM "f016-022-9780702070280" NDATA IMAGE><!ENTITY f016-023-9780702070280 SYSTEM "f016-023-9780702070280" NDATA IMAGE><!ENTITY f016-024-9780702070280 SYSTEM "f016-024-9780702070280" NDATA IMAGE><!ENTITY f016-025-9780702070280 SYSTEM "f016-025-9780702070280" NDATA IMAGE><!ENTITY f016-026-9780702070280 SYSTEM "f016-026-9780702070280" NDATA IMAGE><!ENTITY f016-027ab-9780702070280 SYSTEM "f016-027ab-9780702070280" NDATA IMAGE><!ENTITY f016-028-9780702070280 SYSTEM "f016-028-9780702070280" NDATA IMAGE><!ENTITY f016-029-9780702070280 SYSTEM "f016-029-9780702070280" NDATA IMAGE><!ENTITY f016-030-9780702070280 SYSTEM "f016-030-9780702070280" NDATA IMAGE><!ENTITY f016-031-9780702070280 SYSTEM "f016-031-9780702070280" NDATA IMAGE><!ENTITY f016-032-9780702070280 SYSTEM "f016-032-9780702070280" NDATA IMAGE><!ENTITY f016-033-9780702070280 SYSTEM "f016-033-9780702070280" NDATA IMAGE><!ENTITY f016-034-9780702070280 SYSTEM "f016-034-9780702070280" NDATA IMAGE><!ENTITY f016-035-9780702070280 SYSTEM "f016-035-9780702070280" NDATA IMAGE><!ENTITY f016-036-9780702070280 SYSTEM "f016-036-9780702070280" NDATA IMAGE><!ENTITY f016-037ab-9780702070280 SYSTEM "f016-037ab-9780702070280" NDATA IMAGE><!ENTITY f016-038-9780702070280 SYSTEM "f016-038-9780702070280" NDATA IMAGE><!ENTITY f016-039ad-9780702070280 SYSTEM "f016-039ad-9780702070280" NDATA IMAGE><!ENTITY f016-040ab-9780702070280 SYSTEM "f016-040ab-9780702070280" NDATA IMAGE><!ENTITY f016-041-9780702070280 SYSTEM "f016-041-9780702070280" NDATA IMAGE><!ENTITY f016-042-9780702070280 SYSTEM "f016-042-9780702070280" NDATA IMAGE><!ENTITY f016-043-9780702070280 SYSTEM "f016-043-9780702070280" NDATA IMAGE><!ENTITY f016-044-9780702070280 SYSTEM "f016-044-9780702070280" NDATA IMAGE><!ENTITY f016-045-9780702070280 SYSTEM "f016-045-9780702070280" NDATA IMAGE><!ENTITY f016-046-9780702070280 SYSTEM "f016-046-9780702070280" NDATA IMAGE><!ENTITY f016-047-9780702070280 SYSTEM "f016-047-9780702070280" NDATA IMAGE><!ENTITY f016-048-9780702070280 SYSTEM "f016-048-9780702070280" NDATA IMAGE><!ENTITY f016-049-9780702070280 SYSTEM "f016-049-9780702070280" NDATA IMAGE><!ENTITY f016-050-9780702070280 SYSTEM "f016-050-9780702070280" NDATA IMAGE><!ENTITY f016-051-9780702070280 SYSTEM "f016-051-9780702070280" NDATA IMAGE><!ENTITY f016-052-9780702070280 SYSTEM "f016-052-9780702070280" NDATA IMAGE><!ENTITY f016-053-9780702070280 SYSTEM "f016-053-9780702070280" NDATA IMAGE><!ENTITY f016-054-9780702070280 SYSTEM "f016-054-9780702070280" NDATA IMAGE><!ENTITY f016-055-9780702070280 SYSTEM "f016-055-9780702070280" NDATA IMAGE><!ENTITY f016-056ac-9780702070280 SYSTEM "f016-056ac-9780702070280" NDATA IMAGE><!ENTITY f016-057-9780702070280 SYSTEM "f016-057-9780702070280" NDATA IMAGE><!ENTITY f016-058-9780702070280 SYSTEM "f016-058-9780702070280" NDATA IMAGE><!ENTITY f016-059-9780702070280 SYSTEM "f016-059-9780702070280" NDATA IMAGE><!ENTITY f016-060ac-9780702070280 SYSTEM "f016-060ac-9780702070280" NDATA IMAGE><!ENTITY f016-061a-9780702070280 SYSTEM "f016-061a-9780702070280" NDATA IMAGE><!ENTITY f016-061b-9780702070280 SYSTEM "f016-061b-9780702070280" NDATA IMAGE><!ENTITY f016-062-9780702070280 SYSTEM "f016-062-9780702070280" NDATA IMAGE><!ENTITY f016-063-9780702070280 SYSTEM "f016-063-9780702070280" NDATA IMAGE><!ENTITY f016-064-9780702070280 SYSTEM "f016-064-9780702070280" NDATA IMAGE><!ENTITY f016-065-9780702070280 SYSTEM "f016-065-9780702070280" NDATA IMAGE><!ENTITY f016-066-9780702070280 SYSTEM "f016-066-9780702070280" NDATA IMAGE><!ENTITY f016-067-9780702070280 SYSTEM "f016-067-9780702070280" NDATA IMAGE><!ENTITY f016-068-9780702070280 SYSTEM "f016-068-9780702070280" NDATA IMAGE><!ENTITY f016-069-9780702070280 SYSTEM "f016-069-9780702070280" NDATA IMAGE><!ENTITY f016-070-9780702070280 SYSTEM "f016-070-9780702070280" NDATA IMAGE><!ENTITY f016-071-9780702070280 SYSTEM "f016-071-9780702070280" NDATA IMAGE><!ENTITY f016-072ab-9780702070280 SYSTEM "f016-072ab-9780702070280" NDATA IMAGE><!ENTITY f016-073-9780702070280 SYSTEM "f016-073-9780702070280" NDATA IMAGE><!ENTITY f016-074ae-9780702070280 SYSTEM "f016-074ae-9780702070280" NDATA IMAGE><!ENTITY f016-075-9780702070280 SYSTEM "f016-075-9780702070280" NDATA IMAGE><!ENTITY f016-076a-9780702070280 SYSTEM "f016-076a-9780702070280" NDATA IMAGE><!ENTITY f016-076b-9780702070280 SYSTEM "f016-076b-9780702070280" NDATA IMAGE><!ENTITY f016-077-9780702070280 SYSTEM "f016-077-9780702070280" NDATA IMAGE><!ENTITY f016-078-9780702070280 SYSTEM "f016-078-9780702070280" NDATA IMAGE><!ENTITY f016-079-9780702070280 SYSTEM "f016-079-9780702070280" NDATA IMAGE><!ENTITY f016-080-9780702070280 SYSTEM "f016-080-9780702070280" NDATA IMAGE><!ENTITY f016-081ab-9780702070280 SYSTEM "f016-081ab-9780702070280" NDATA IMAGE><!ENTITY f016-082-9780702070280 SYSTEM "f016-082-9780702070280" NDATA IMAGE><!ENTITY f016-082ab-9780702070280 SYSTEM "f016-082ab-9780702070280" NDATA IMAGE><!ENTITY f016-084-9780702070280 SYSTEM "f016-084-9780702070280" NDATA IMAGE><!ENTITY f016-085ad-9780702070280 SYSTEM "f016-085ad-9780702070280" NDATA IMAGE><!ENTITY f016-086-9780702070280 SYSTEM "f016-086-9780702070280" NDATA IMAGE><!ENTITY f016-087-9780702070280 SYSTEM "f016-087-9780702070280" NDATA IMAGE><!ENTITY f016-088-9780702070280 SYSTEM "f016-088-9780702070280" NDATA IMAGE><!ENTITY f016-089-9780702070280 SYSTEM "f016-089-9780702070280" NDATA IMAGE><!ENTITY f016-090ab-9780702070280 SYSTEM "f016-090ab-9780702070280" NDATA IMAGE><!ENTITY f016-091-9780702070280 SYSTEM "f016-091-9780702070280" NDATA IMAGE><!ENTITY f016-092-9780702070280 SYSTEM "f016-092-9780702070280" NDATA IMAGE><!ENTITY f016-093-9780702070280 SYSTEM "f016-093-9780702070280" NDATA IMAGE><!ENTITY f016-094-9780702070280 SYSTEM "f016-094-9780702070280" NDATA IMAGE><!ENTITY f016-095-9780702070280 SYSTEM "f016-095-9780702070280" NDATA IMAGE><!ENTITY f016-096-9780702070280 SYSTEM "f016-096-9780702070280" NDATA IMAGE><!ENTITY f016-097-9780702070280 SYSTEM "f016-097-9780702070280" NDATA IMAGE><!ENTITY f016-098-9780702070280 SYSTEM "f016-098-9780702070280" NDATA IMAGE><!ENTITY f016-099ah-9780702070280 SYSTEM "f016-099ah-9780702070280" NDATA IMAGE><!ENTITY f016-100-9780702070280 SYSTEM "f016-100-9780702070280" NDATA IMAGE><!ENTITY f016-101-9780702070280 SYSTEM "f016-101-9780702070280" NDATA IMAGE><!ENTITY f016-102-9780702070280 SYSTEM "f016-102-9780702070280" NDATA IMAGE><!ENTITY f016-103-9780702070280 SYSTEM "f016-103-9780702070280" NDATA IMAGE><!ENTITY icon01-9780702070280 SYSTEM "icon01-9780702070280" NDATA IMAGE><!ENTITY icon02-9780702070280 SYSTEM "icon02-9780702070280" NDATA IMAGE><!ENTITY icon03-9780702070280 SYSTEM "icon03-9780702070280" NDATA IMAGE><!ENTITY icon04-9780702070280 SYSTEM "icon04-9780702070280" NDATA IMAGE><!ENTITY icon05-9780702070280 SYSTEM "icon05-9780702070280" NDATA IMAGE><!ENTITY icon06-9780702070280 SYSTEM "icon06-9780702070280" NDATA IMAGE><!ENTITY u016-001-9780702070280 SYSTEM "u016-001-9780702070280" NDATA IMAGE><!ENTITY u016-002-9780702070280 SYSTEM "u016-002-9780702070280" NDATA IMAGE><!ENTITY u016-003-9780702070280 SYSTEM "u016-003-9780702070280" NDATA IMAGE><!ENTITY u016-004-9780702070280 SYSTEM "u016-004-9780702070280" NDATA IMAGE><!ENTITY u016-005-9780702070280 SYSTEM "u016-005-9780702070280" NDATA IMAGE>]><chapter docsubtype="chp" id="c00016" version="5.5" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink"><info><ce:pii>B978-0-7020-7028-0.00016-0</ce:pii><ce:doi>10.1016/B978-0-7020-7028-0.00016-0</ce:doi><ce:isbn>978-0-7020-7028-0</ce:isbn><ce:copyright type="full-transfer" year="2018">Elsevier Ltd</ce:copyright></info><ce:floats><ce:figure id="f0035"><ce:label>Fig. 16.1</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0010" role="title">Direction of blood flow through the heart.</ce:simple-para><ce:simple-para id="sp0015" role="caption">The blue arrows show deoxygenated blood moving through the right heart to the lungs. The red arrows show oxygenated blood moving from the lungs to the systemic circulation. The normal pressures are shown for each chamber in mmHg.</ce:simple-para></ce:caption><ce:alt-text id="atte0010" role="short">Fig. 16.1</ce:alt-text><ce:link id="ln0035" locator="f016-001-9780702070280" xlink:href="pii:B9780702070280000160/f016-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 16.2</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0020" role="title">Surface anatomy of the heart.</ce:simple-para><ce:simple-para id="sp0025" role="caption">The positions of the major cardiac chambers and heart valves are shown. (LV = left ventricle; RA = right atrium; RV = right ventricle)</ce:simple-para></ce:caption><ce:alt-text id="atte0015" role="short">Fig. 16.2</ce:alt-text><ce:link id="ln0040" locator="f016-002-9780702070280" xlink:href="pii:B9780702070280000160/f016-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 16.3</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0030" role="title">The coronary arteries: anterior view.</ce:simple-para></ce:caption><ce:alt-text id="atte0020" role="short">Fig. 16.3</ce:alt-text><ce:link id="ln0045" locator="f016-003-9780702070280" xlink:href="pii:B9780702070280000160/f016-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0050"><ce:label>Fig. 16.4</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0035" role="title">The cardiac conduction system.</ce:simple-para><ce:simple-para id="sp0040" role="caption">Depolarisation starts in the sinoatrial node and spreads through the atria (blue arrows), and then through the atrioventricular node (black arrows). Depolarisation then spreads through the bundle of His and the bundle branches to reach the ventricular muscle (red arrows). Repolarisation spreads from epicardium to endocardium (green arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0025" role="short">Fig. 16.4</ce:alt-text><ce:link id="ln0050" locator="f016-004-9780702070280" xlink:href="pii:B9780702070280000160/f016-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0055"><ce:label>Fig. 16.5</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0045" role="title">Schematic of myocytes and the contraction process within a muscle fibre.</ce:simple-para><ce:simple-para id="sp0050" role="caption"><ce:bold>A</ce:bold> Myocytes are joined together through intercalated discs. <ce:bold>B</ce:bold> Within the myocytes, myofibrils are composed of longitudinal and transverse tubules extending from the sarcoplasmic reticulum. <ce:bold>C</ce:bold> The expanded section shows a schematic of an individual sarcomere with thick filaments composed of myosin and thin filaments composed primarily of actin. <ce:bold>D</ce:bold> Actin filaments are composed of troponin, tropomyosin and actin subunits. <ce:bold>E</ce:bold> The three stages of contraction, resulting in shortening of the sarcomere. (1) The actin-binding site is blocked by tropomyosin. (2) ATP-dependent release of calcium ions, which bind to troponin, displacing tropomyosin. The binding site is exposed. (3) Tilting of the angle of attachment of the myosin head, resulting in fibre shortening. (ADP = adenosine diphosphate; ATP = adenosine triphosphate)</ce:simple-para></ce:caption><ce:alt-text id="atte0030" role="short">Fig. 16.5</ce:alt-text><ce:link id="ln0055" locator="f016-005ae-9780702070280" xlink:href="pii:B9780702070280000160/f016-005ae-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0060"><ce:label>Fig. 16.6</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0055" role="title">The electrocardiogram.</ce:simple-para><ce:simple-para id="sp0060" role="caption">The components correspond to depolarisation and repolarisation, as depicted in <ce:cross-ref id="crf0340" refid="f0050">Figure 16.4</ce:cross-ref>. The upper limit of the normal range for each interval is given in brackets.</ce:simple-para></ce:caption><ce:alt-text id="atte0035" role="short">Fig. 16.6</ce:alt-text><ce:link id="ln0065" locator="f016-006-9780702070280" xlink:href="pii:B9780702070280000160/f016-006-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0065"><ce:label>Fig. 16.7</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0065" role="title">The appearance of the ECG from different leads in the frontal plane.</ce:simple-para><ce:simple-para id="sp0070" role="caption"><ce:bold>A</ce:bold> Normal. <ce:bold>B</ce:bold> Left axis deviation, with negative deflection in lead II and positive in lead I. <ce:bold>C</ce:bold> Right axis deviation, with negative deflection in lead I and positive in lead II.</ce:simple-para></ce:caption><ce:alt-text id="atte0040" role="short">Fig. 16.7</ce:alt-text><ce:link id="ln0075" locator="f016-007ac-9780702070280" xlink:href="pii:B9780702070280000160/f016-007ac-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0070"><ce:label>Fig. 16.8</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0075" role="title">The sequence of activation of the ventricles.</ce:simple-para><ce:simple-para id="sp0080" role="caption"><ce:bold>A</ce:bold> Activation of the septum occurs first (red arrows), followed by spreading of the impulse through the left ventricle (LV, blue arrows) and then the right ventricle (RV, green arrows). <ce:bold>B</ce:bold> Normal electrocardiographic complexes from leads V<ce:inf loc="post">1</ce:inf> and V<ce:inf loc="post">6</ce:inf>.</ce:simple-para></ce:caption><ce:alt-text id="atte0045" role="short">Fig. 16.8</ce:alt-text><ce:link id="ln0080" locator="f016-008ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-008ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0085"><ce:label>Fig. 16.9</ce:label><ce:caption id="ca0060"><ce:simple-para id="sp0105" role="title">Chest X-ray of a patient with mitral stenosis and regurgitation indicating enlargement of the LA and prominence of the pulmonary artery trunk.</ce:simple-para></ce:caption><ce:alt-text id="atte0050" role="short">Fig. 16.9</ce:alt-text><ce:link id="ln0100" locator="f016-009-9780702070280" xlink:href="pii:B9780702070280000160/f016-009-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0090"><ce:label>Fig. 16.10</ce:label><ce:caption id="ca0065"><ce:simple-para id="sp0110" role="title">Chest X-ray of a patient with aortic regurgitation, left ventricular enlargement and dilatation of the ascending aorta.</ce:simple-para></ce:caption><ce:alt-text id="atte0055" role="short">Fig. 16.10</ce:alt-text><ce:link id="ln0105" locator="f016-010-9780702070280" xlink:href="pii:B9780702070280000160/f016-010-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0100"><ce:label>Fig. 16.11</ce:label><ce:caption id="ca0075"><ce:simple-para id="sp0125" role="title">Doppler echocardiography in aortic stenosis.</ce:simple-para><ce:simple-para id="sp0130" role="caption"><ce:bold>A</ce:bold> The aortic valve is imaged and a Doppler beam passed directly through the left ventricular outflow tract and the aorta into the turbulent flow beyond the stenosed valve. <ce:bold>B</ce:bold> The velocity of the blood cells is recorded to determine the maximum velocity and hence the pressure gradient across the valve. In this example, the peak velocity is approximately 450 cm/sec (4.5 m/sec), indicating severe aortic stenosis (peak gradient of 81 mmHg).</ce:simple-para></ce:caption><ce:alt-text id="atte0060" role="short">Fig. 16.11</ce:alt-text><ce:link id="ln0120" locator="f016-011a-9780702070280" xlink:href="pii:B9780702070280000160/f016-011a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0125" locator="f016-011b-9780702070280" xlink:href="pii:B9780702070280000160/f016-011b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0105"><ce:label>Fig. 16.12</ce:label><ce:caption id="ca0080"><ce:simple-para id="sp0135" role="title">Echocardiographic illustration of the principal cardiac structures in the ‘four-chamber’ view.</ce:simple-para><ce:simple-para id="sp0140" role="caption">Colour-flow Doppler has been used to demonstrate mitral regurgitation: a flame-shaped (yellow/blue) turbulent jet into the left atrium.</ce:simple-para></ce:caption><ce:alt-text id="atte0065" role="short">Fig. 16.12</ce:alt-text><ce:link id="ln0130" locator="f016-012-9780702070280" xlink:href="pii:B9780702070280000160/f016-012-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0110"><ce:label>Fig. 16.13</ce:label><ce:caption id="ca0085"><ce:simple-para id="sp0145" role="title">Computed tomography coronary angiography, demonstrating normal coronary arteries (arrows).</ce:simple-para><ce:simple-para id="sp0150" role="caption"><ce:bold>A</ce:bold> Three-dimensional image. <ce:bold>B</ce:bold> Two-dimensional image.</ce:simple-para></ce:caption><ce:alt-text id="atte0070" role="short">Fig. 16.13</ce:alt-text><ce:link id="ln0140" locator="f016-013ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-013ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0115"><ce:label>Fig. 16.14</ce:label><ce:caption id="ca0090"><ce:simple-para id="sp0155" role="title">Cardiac magnetic resonance imaging.</ce:simple-para><ce:simple-para id="sp0160" role="caption"><ce:bold>A</ce:bold> Recent inferior myocardial infarction with black area of microvascular obstruction (arrow). <ce:bold>B</ce:bold> Old anterior myocardial infarction with large area of subendocardial delayed gadolinium enhancement (white area, arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0075" role="short">Fig. 16.14</ce:alt-text><ce:link id="ln0145" locator="f016-014ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-014ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0120"><ce:label>Fig. 16.15</ce:label><ce:caption id="ca0095"><ce:simple-para id="sp0165" role="title">The left anterior descending and circumflex coronary arteries with a stenosis (arrow) in the left anterior descending vessel.</ce:simple-para><ce:simple-para id="sp0170" role="caption"><ce:bold>A</ce:bold> Coronary artery angiogram. <ce:bold>B</ce:bold> Schematic of the vessels and branches.</ce:simple-para></ce:caption><ce:alt-text id="atte0080" role="short">Fig. 16.15</ce:alt-text><ce:link id="ln0150" locator="f016-015ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-015ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0130"><ce:label>Fig. 16.16</ce:label><ce:caption id="ca0105"><ce:simple-para id="sp0185" role="title">Typical ischaemic cardiac pain.</ce:simple-para><ce:simple-para id="sp0190" role="caption">Characteristic hand gestures used to describe cardiac pain. Typical radiation of pain is shown in the schematic.</ce:simple-para></ce:caption><ce:alt-text id="atte0085" role="short">Fig. 16.16</ce:alt-text><ce:link id="ln0165" locator="f016-016-9780702070280" xlink:href="pii:B9780702070280000160/f016-016-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0140"><ce:label>Fig. 16.17</ce:label><ce:caption id="ca0115"><ce:simple-para id="sp0205" role="title">A simple approach to the diagnosis of palpitation.</ce:simple-para></ce:caption><ce:alt-text id="atte0090" role="short">Fig. 16.17</ce:alt-text><ce:link id="ln0185" locator="f016-017-9780702070280" xlink:href="pii:B9780702070280000160/f016-017-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0145"><ce:label>Fig. 16.18</ce:label><ce:caption id="ca0120"><ce:simple-para id="sp0210" role="title">Ventricular fibrillation.</ce:simple-para><ce:simple-para id="sp0215" role="caption">A bizarre chaotic rhythm, initiated in this case by two ventricular ectopic beats in rapid succession.</ce:simple-para></ce:caption><ce:alt-text id="atte0095" role="short">Fig. 16.18</ce:alt-text><ce:link id="ln0190" locator="f016-018-9780702070280" xlink:href="pii:B9780702070280000160/f016-018-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0150"><ce:label>Fig. 16.19</ce:label><ce:caption id="ca0125"><ce:simple-para id="sp0220" role="title">Algorithm for adult basic life support.</ce:simple-para><ce:simple-para id="sp0225" role="caption">For further information, see <ce:inter-ref id="iw0010" xlink:href="http://www.resus.org.uk">www.resus.org.uk</ce:inter-ref>. (CPR = cardiopulmonary resuscitation)</ce:simple-para></ce:caption><ce:alt-text id="atte0100" role="short">Fig. 16.19</ce:alt-text><ce:source>From Resuscitation Council (UK) guidelines: <ce:inter-ref id="iw0015" xlink:href="https://www.resus.org.uk/resuscitation-guidelines/in-hospital-resuscitation/">https://www.resus.org.uk/resuscitation-guidelines/in-hospital-resuscitation/</ce:inter-ref>.</ce:source><ce:link id="ln0200" locator="f016-019-9780702070280" xlink:href="pii:B9780702070280000160/f016-019-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0155"><ce:label>Fig. 16.20</ce:label><ce:caption id="ca0130"><ce:simple-para id="sp0230" role="title">Algorithm for adult advanced life support.</ce:simple-para><ce:simple-para id="sp0235" role="caption">For further information, see <ce:inter-ref id="iw0020" xlink:href="http://www.resus.org.uk">www.resus.org.uk</ce:inter-ref>. (CPR = cardiopulmonary resuscitation: PEA = pulseless electrical activity; VF = ventricular fibrillation; VT = ventricular tachycardia)</ce:simple-para></ce:caption><ce:alt-text id="atte0105" role="short">Fig. 16.20</ce:alt-text><ce:source>From Resuscitation Council (UK) guidelines: <ce:inter-ref id="iw0025" xlink:href="https://www.resus.org.uk/resuscitation-guidelines/adult-advanced-life-support/">https://www.resus.org.uk/resuscitation-guidelines/adult-advanced-life-support/</ce:inter-ref>.</ce:source><ce:link id="ln0205" locator="f016-020-9780702070280" xlink:href="pii:B9780702070280000160/f016-020-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0160"><ce:label>Fig. 16.21</ce:label><ce:caption id="ca0135"><ce:simple-para id="sp0240" role="title">The Chain of Survival in cardiac arrest.</ce:simple-para><ce:simple-para id="sp0245" role="caption">(ALS = advanced life support; CPR = cardiopulmonary resuscitation)</ce:simple-para></ce:caption><ce:alt-text id="atte0110" role="short">Fig. 16.21</ce:alt-text><ce:link id="ln0210" locator="f016-021-9780702070280" xlink:href="pii:B9780702070280000160/f016-021-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0165"><ce:label>Fig. 16.22</ce:label><ce:caption id="ca0140"><ce:simple-para id="sp0250" role="title">The relationship of the cardiac cycle to the ECG, the left ventricular pressure wave and the position of heart sounds.</ce:simple-para></ce:caption><ce:alt-text id="atte0115" role="short">Fig. 16.22</ce:alt-text><ce:link id="ln0230" locator="f016-022-9780702070280" xlink:href="pii:B9780702070280000160/f016-022-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0170"><ce:label>Fig. 16.23</ce:label><ce:caption id="ca0145"><ce:simple-para id="sp0255" role="title">The timing and pattern of cardiac murmurs.</ce:simple-para></ce:caption><ce:alt-text id="atte0120" role="short">Fig. 16.23</ce:alt-text><ce:link id="ln0235" locator="f016-023-9780702070280" xlink:href="pii:B9780702070280000160/f016-023-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0175"><ce:label>Fig. 16.24</ce:label><ce:caption id="ca0150"><ce:simple-para id="sp0260" role="title">Starling's Law.</ce:simple-para><ce:simple-para id="sp0265" role="caption">Normal (A), mild (B), moderate (C) and severe (D) heart failure. Ventricular performance is related to the degree of myocardial stretching. An increase in preload (end-diastolic volume, end-diastolic pressure, filling pressure or atrial pressure) will therefore enhance function; however, overstretching causes marked deterioration. In heart failure, the curve moves to the right and becomes flatter. An increase in myocardial contractility or a reduction in afterload will shift the curve upwards and to the left (green arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0125" role="short">Fig. 16.24</ce:alt-text><ce:link id="ln0250" locator="f016-024-9780702070280" xlink:href="pii:B9780702070280000160/f016-024-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0180"><ce:label>Fig. 16.25</ce:label><ce:caption id="ca0155"><ce:simple-para id="sp0270" role="title">Neurohumoral activation and compensatory mechanisms in heart failure.</ce:simple-para><ce:simple-para id="sp0275" role="caption">There is a vicious circle in progressive heart failure.</ce:simple-para></ce:caption><ce:alt-text id="atte0130" role="short">Fig. 16.25</ce:alt-text><ce:link id="ln0255" locator="f016-025-9780702070280" xlink:href="pii:B9780702070280000160/f016-025-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0190"><ce:label>Fig. 16.26</ce:label><ce:caption id="ca0165"><ce:simple-para id="sp0290" role="title">Clinical features of left and right heart failure.</ce:simple-para><ce:simple-para id="sp0295" role="caption">(JVP = jugular venous pressure)</ce:simple-para></ce:caption><ce:alt-text id="atte0135" role="short">Fig. 16.26</ce:alt-text><ce:link id="ln0270" locator="f016-026-9780702070280" xlink:href="pii:B9780702070280000160/f016-026-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0095"><ce:label>Fig. 16.27</ce:label><ce:caption id="ca0070"><ce:simple-para id="sp0115" role="title">Radiological features of heart failure.</ce:simple-para><ce:simple-para id="sp0120" role="caption"><ce:bold>A</ce:bold> Chest X-ray of a patient with pulmonary oedema. <ce:bold>B</ce:bold> Enlargement of lung base showing septal or ‘Kerley B’ lines (arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0140" role="short">Fig. 16.27</ce:alt-text><ce:link id="ln0110" locator="f016-027ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-027ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0195"><ce:label>Fig. 16.28</ce:label><ce:caption id="ca0170"><ce:simple-para id="sp0300" role="title">The effect of treatment on ventricular performance curves in heart failure.</ce:simple-para><ce:simple-para id="sp0305" role="caption">Diuretics and venodilators (A), angiotensin-converting enzyme (ACE) inhibitors and mixed vasodilators (B), and positive inotropic agents (C).</ce:simple-para></ce:caption><ce:alt-text id="atte0145" role="short">Fig. 16.28</ce:alt-text><ce:link id="ln0290" locator="f016-028-9780702070280" xlink:href="pii:B9780702070280000160/f016-028-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0200"><ce:label>Fig. 16.29</ce:label><ce:caption id="ca0175"><ce:simple-para id="sp0310" role="title">Neurohumoral activation and sites of action of drugs used in the treatment of heart failure.</ce:simple-para></ce:caption><ce:alt-text id="atte0150" role="short">Fig. 16.29</ce:alt-text><ce:link id="ln0300" locator="f016-029-9780702070280" xlink:href="pii:B9780702070280000160/f016-029-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0205"><ce:label>Fig. 16.30</ce:label><ce:caption id="ca0180"><ce:simple-para id="sp0315" role="title">Chest X-ray of a biventricular pacemaker and defibrillator (cardiac resynchronisation therapy).</ce:simple-para><ce:simple-para id="sp0320" role="caption">The right ventricular lead (RV) is in position in the ventricular apex and is used for both pacing and defibrillation. The left ventricular lead (LV) is placed via the coronary sinus, and the right atrial lead (RA) is placed in the right atrial appendage; both are used for pacing only.</ce:simple-para></ce:caption><ce:alt-text id="atte0155" role="short">Fig. 16.30</ce:alt-text><ce:link id="ln0310" locator="f016-030-9780702070280" xlink:href="pii:B9780702070280000160/f016-030-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0210"><ce:label>Fig. 16.31</ce:label><ce:caption id="ca0185"><ce:simple-para id="sp0325" role="title">The mechanism of re-entry.</ce:simple-para><ce:simple-para id="sp0330" role="caption">Re-entry can occur when there are two alternative pathways with different conducting properties, such as the atrioventricular node and an accessory pathway, or an area of normal and an area of ischaemic tissue. Here, pathway A conducts slowly and recovers quickly, while pathway B conducts rapidly and recovers slowly. (1) In sinus rhythm, each impulse passes down both pathways before entering a common distal pathway. (2) As the pathways recover at different rates, a premature impulse may find pathway A open and B closed. (3) Pathway B may recover while the premature impulse is travelling selectively down pathway A. The impulse can then travel retrogradely up pathway B, setting up a closed loop or re-entry circuit. (4) This may initiate a tachycardia that continues until the circuit is interrupted by a change in conduction rates or electrical depolarisation.</ce:simple-para></ce:caption><ce:alt-text id="atte0160" role="short">Fig. 16.31</ce:alt-text><ce:link id="ln0315" locator="f016-031-9780702070280" xlink:href="pii:B9780702070280000160/f016-031-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0080"><ce:label>Fig. 16.32</ce:label><ce:caption id="ca0055"><ce:simple-para id="sp0095" role="title">Sinoatrial disease (sick sinus syndrome).</ce:simple-para><ce:simple-para id="sp0100" role="caption">A continuous rhythm strip from a 24-hour ECG tape recording illustrating periods of sinus rhythm, atrial ectopics, junctional beats, sinus bradycardia, sinus arrest and paroxysmal atrial fibrillation.</ce:simple-para></ce:caption><ce:alt-text id="atte0165" role="short">Fig. 16.32</ce:alt-text><ce:link id="ln0095" locator="f016-032-9780702070280" xlink:href="pii:B9780702070280000160/f016-032-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0215"><ce:label>Fig. 16.33</ce:label><ce:caption id="ca0190"><ce:simple-para id="sp0335" role="title">Atrial ectopic beats.</ce:simple-para><ce:simple-para id="sp0340" role="caption">The first, second and fifth complexes are normal sinus beats. The third, fourth and sixth complexes are atrial ectopic beats with identical QRS complexes and abnormal (sometimes barely visible) P waves.</ce:simple-para></ce:caption><ce:alt-text id="atte0170" role="short">Fig. 16.33</ce:alt-text><ce:link id="ln0330" locator="f016-033-9780702070280" xlink:href="pii:B9780702070280000160/f016-033-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0220"><ce:label>Fig. 16.34</ce:label><ce:caption id="ca0195"><ce:simple-para id="sp0345" role="title">Atrial flutter.</ce:simple-para><ce:simple-para id="sp0350" role="caption">Simultaneous recording showing atrial flutter with 4 : 1 atrioventricular block. Flutter waves are visible only in leads II and III.</ce:simple-para></ce:caption><ce:alt-text id="atte0175" role="short">Fig. 16.34</ce:alt-text><ce:link id="ln0335" locator="f016-034-9780702070280" xlink:href="pii:B9780702070280000160/f016-034-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0225"><ce:label>Fig. 16.35</ce:label><ce:caption id="ca0200"><ce:simple-para id="sp0355" role="title">Carotid sinus pressure in atrial flutter: continuous trace.</ce:simple-para><ce:simple-para id="sp0360" role="caption">The diagnosis of atrial flutter with 2 : 1 block was established when carotid sinus pressure produced temporary atrioventricular block, revealing the flutter waves.</ce:simple-para></ce:caption><ce:alt-text id="atte0180" role="short">Fig. 16.35</ce:alt-text><ce:link id="ln0340" locator="f016-035-9780702070280" xlink:href="pii:B9780702070280000160/f016-035-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0230"><ce:label>Fig. 16.36</ce:label><ce:caption id="ca0205"><ce:simple-para id="sp0365" role="title">Mechanisms initiating atrial fibrillation.</ce:simple-para><ce:simple-para id="sp0370" role="caption">(1) Ectopic beats, often arising from the pulmonary veins, trigger atrial fibrillation. (2) Re-entry within the atria maintains atrial fibrillation, with multiple interacting re-entry circuits operating simultaneously.</ce:simple-para></ce:caption><ce:alt-text id="atte0185" role="short">Fig. 16.36</ce:alt-text><ce:link id="ln0345" locator="f016-036-9780702070280" xlink:href="pii:B9780702070280000160/f016-036-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0235"><ce:label>Fig. 16.37</ce:label><ce:caption id="ca0210"><ce:simple-para id="sp0375" role="title">Two examples of atrial fibrillation.</ce:simple-para><ce:simple-para id="sp0380" role="caption">The QRS complexes are irregular and there are no P waves. <ce:bold>A</ce:bold> There is usually a fast ventricular rate, between 120 and 160/min, at the onset of atrial fibrillation. <ce:bold>B</ce:bold> In chronic atrial fibrillation, the ventricular rate may be much slower, due to the effects of medication and AV nodal fatigue.</ce:simple-para></ce:caption><ce:alt-text id="atte0190" role="short">Fig. 16.37</ce:alt-text><ce:link id="ln0350" locator="f016-037ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-037ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0240"><ce:label>Fig. 16.38</ce:label><ce:caption id="ca0215"><ce:simple-para id="sp0385" role="title">Supraventricular tachycardia.</ce:simple-para><ce:simple-para id="sp0390" role="caption">The rate is 180/min and the QRS complexes are normal.</ce:simple-para></ce:caption><ce:alt-text id="atte0195" role="short">Fig. 16.38</ce:alt-text><ce:link id="ln0375" locator="f016-038-9780702070280" xlink:href="pii:B9780702070280000160/f016-038-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0245"><ce:label>Fig. 16.39</ce:label><ce:caption id="ca0220"><ce:simple-para id="sp0395" role="title">Atrioventricular nodal re-entrant tachycardia (AVNRT) and Wolff–Parkinson–White (WPW) syndrome.</ce:simple-para><ce:simple-para id="sp0400" role="caption"><ce:bold>A</ce:bold> AV node re-entrant tachycardia. The mechanism of AVNRT occurs via two right atrial AV nodal input pathways: the slow (S) and fast (F) pathways. Antegrade conduction occurs via the slow pathway; the wavefront enters the AV node and passes into the ventricles, at the same time re-entering the atria via the fast pathway. In WPW syndrome, there is a strip of accessory conducting tissue that allows electricity to bypass the AV node and spread from the atria to the ventricles rapidly and without delay. When the ventricles are depolarised through the AV node the ECG is normal, but when the ventricles are depolarised through the accessory conducting tissue the ECG shows a very short PR interval and a broad QRS complex. <ce:bold>B</ce:bold> Sinus rhythm. In sinus rhythm, the ventricles are depolarised through (1) the AV node and (2) the accessory pathway, producing an ECG with a short PR interval and broadened QRS complexes; the characteristic slurring of the upstroke of the QRS complex is known as a delta wave. The degree of pre-excitation (the proportion of activation passing down the accessory pathway) and therefore the ECG appearances may vary a lot, and at times the ECG can look normal. <ce:bold>C</ce:bold> Orthodromic tachycardia. This is the most common form of tachycardia in WPW. The re-entry circuit passes antegradely through the AV node and retrogradely through the accessory pathway. The ventricles are therefore depolarised in the normal way, producing a narrow-complex tachycardia that is indistinguishable from other forms of supraventricular tachycardia. <ce:bold>D</ce:bold> Atrial fibrillation. In this rhythm, the ventricles are largely depolarised through the accessory pathway, producing an irregular broad-complex tachycardia that is often more rapid than the example shown.</ce:simple-para></ce:caption><ce:alt-text id="atte0200" role="short">Fig. 16.39</ce:alt-text><ce:link id="ln0380" locator="f016-039ad-9780702070280" xlink:href="pii:B9780702070280000160/f016-039ad-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0250"><ce:label>Fig. 16.40</ce:label><ce:caption id="ca0225"><ce:simple-para id="sp0405" role="title">Ventricular ectopic beats.</ce:simple-para><ce:simple-para id="sp0410" role="caption"><ce:bold>A</ce:bold> There are broad, bizarre QRS complexes (arrows) with no preceding P wave in between normal sinus beats. Their configuration varies, so these are multifocal ectopics. <ce:bold>B</ce:bold> A simultaneous arterial pressure trace is shown. The ectopic beats result in a weaker pulse (arrows), which may be perceived as a ‘dropped beat’.</ce:simple-para></ce:caption><ce:alt-text id="atte0205" role="short">Fig. 16.40</ce:alt-text><ce:link id="ln0385" locator="f016-040ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-040ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0255"><ce:label>Fig. 16.41</ce:label><ce:caption id="ca0230"><ce:simple-para id="sp0415" role="title">Ventricular tachycardia: fusion beat (arrow).</ce:simple-para><ce:simple-para id="sp0420" role="caption">In ventricular tachycardia, there is independent atrial and ventricular activity. Occasionally, a P wave is conducted to the ventricles through the AV node, producing a normal sinus beat in the middle of the tachycardia (a capture beat); more commonly, however, the conducted impulse fuses with an impulse from the tachycardia (a fusion beat). This can occur only when there is atrioventricular dissociation and is therefore diagnostic of ventricular tachycardia.</ce:simple-para></ce:caption><ce:alt-text id="atte0210" role="short">Fig. 16.41</ce:alt-text><ce:link id="ln0390" locator="f016-041-9780702070280" xlink:href="pii:B9780702070280000160/f016-041-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0260"><ce:label>Fig. 16.42</ce:label><ce:caption id="ca0235"><ce:simple-para id="sp0425" role="title">Ventricular tachycardia: 12-lead ECG.</ce:simple-para><ce:simple-para id="sp0430" role="caption">There are typically very broad QRS complexes and marked left axis deviation. There is also atrioventricular dissociation; some P waves are visible and others are buried in the QRS complexes (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0215" role="short">Fig. 16.42</ce:alt-text><ce:link id="ln0400" locator="f016-042-9780702070280" xlink:href="pii:B9780702070280000160/f016-042-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0265"><ce:label>Fig. 16.43</ce:label><ce:caption id="ca0240"><ce:simple-para id="sp0435" role="title">Torsades de pointes.</ce:simple-para><ce:simple-para id="sp0440" role="caption">A bradycardia with a long QT interval is followed by polymorphic ventricular tachycardia that is triggered by an R on T ectopic.</ce:simple-para></ce:caption><ce:alt-text id="atte0220" role="short">Fig. 16.43</ce:alt-text><ce:link id="ln0405" locator="f016-043-9780702070280" xlink:href="pii:B9780702070280000160/f016-043-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0270"><ce:label>Fig. 16.44</ce:label><ce:caption id="ca0245"><ce:simple-para id="sp0445" role="title">First-degree atrioventricular block.</ce:simple-para><ce:simple-para id="sp0450" role="caption">The PR interval is prolonged and measures 0.26 sec.</ce:simple-para></ce:caption><ce:alt-text id="atte0225" role="short">Fig. 16.44</ce:alt-text><ce:link id="ln0415" locator="f016-044-9780702070280" xlink:href="pii:B9780702070280000160/f016-044-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0275"><ce:label>Fig. 16.45</ce:label><ce:caption id="ca0250"><ce:simple-para id="sp0455" role="title">Second-degree atrioventricular block (Mobitz type I – the Wenckebach phenomenon).</ce:simple-para><ce:simple-para id="sp0460" role="caption">The PR interval progressively increases until a P wave is not conducted. The cycle then repeats itself. In this example, conduction is at a ratio of 4 : 3, leading to groupings of three ventricular complexes in a row.</ce:simple-para></ce:caption><ce:alt-text id="atte0230" role="short">Fig. 16.45</ce:alt-text><ce:link id="ln0420" locator="f016-045-9780702070280" xlink:href="pii:B9780702070280000160/f016-045-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0280"><ce:label>Fig. 16.46</ce:label><ce:caption id="ca0255"><ce:simple-para id="sp0465" role="title">Second-degree atrioventricular block (Mobitz type II).</ce:simple-para><ce:simple-para id="sp0470" role="caption">The PR interval of conducted beats is normal but some P waves are not conducted. The constant PR interval distinguishes this from the Wenckebach phenomenon.</ce:simple-para></ce:caption><ce:alt-text id="atte0235" role="short">Fig. 16.46</ce:alt-text><ce:link id="ln0425" locator="f016-046-9780702070280" xlink:href="pii:B9780702070280000160/f016-046-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0285"><ce:label>Fig. 16.47</ce:label><ce:caption id="ca0260"><ce:simple-para id="sp0475" role="title">Second-degree atrioventricular block with fixed 2 : 1 block.</ce:simple-para><ce:simple-para id="sp0480" role="caption">Alternate P waves are not conducted. This may be due to Mobitz type I or II block.</ce:simple-para></ce:caption><ce:alt-text id="atte0240" role="short">Fig. 16.47</ce:alt-text><ce:link id="ln0430" locator="f016-047-9780702070280" xlink:href="pii:B9780702070280000160/f016-047-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0290"><ce:label>Fig. 16.48</ce:label><ce:caption id="ca0265"><ce:simple-para id="sp0485" role="title">Complete (third-degree) atrioventricular block.</ce:simple-para><ce:simple-para id="sp0490" role="caption">There is complete dissociation of atrial and ventricular complexes. The atrial rate is 80/min and the ventricular rate is 38/min.</ce:simple-para></ce:caption><ce:alt-text id="atte0245" role="short">Fig. 16.48</ce:alt-text><ce:link id="ln0435" locator="f016-048-9780702070280" xlink:href="pii:B9780702070280000160/f016-048-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0295"><ce:label>Fig. 16.49</ce:label><ce:caption id="ca0270"><ce:simple-para id="sp0495" role="title">Right bundle branch block.</ce:simple-para><ce:simple-para id="sp0500" role="caption">Note the wide QRS complexes with ‘M’-shaped configuration in leads V<ce:inf loc="post">1</ce:inf> and V<ce:inf loc="post">2</ce:inf> and a wide S wave in lead I.</ce:simple-para></ce:caption><ce:alt-text id="atte0250" role="short">Fig. 16.49</ce:alt-text><ce:link id="ln0450" locator="f016-049-9780702070280" xlink:href="pii:B9780702070280000160/f016-049-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0300"><ce:label>Fig. 16.50</ce:label><ce:caption id="ca0275"><ce:simple-para id="sp0505" role="title">Left bundle branch block.</ce:simple-para><ce:simple-para id="sp0510" role="caption">Note the wide QRS complexes with loss of the Q wave or septal vector in lead I and ‘M’-shaped QRS complexes in V<ce:inf loc="post">5</ce:inf> and V<ce:inf loc="post">6</ce:inf>.</ce:simple-para></ce:caption><ce:alt-text id="atte0255" role="short">Fig. 16.50</ce:alt-text><ce:link id="ln0455" locator="f016-050-9780702070280" xlink:href="pii:B9780702070280000160/f016-050-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0305"><ce:label>Fig. 16.51</ce:label><ce:caption id="ca0280"><ce:simple-para id="sp0515" role="title">Classification of anti-arrhythmic drugs by site of action.</ce:simple-para></ce:caption><ce:alt-text id="atte0260" role="short">Fig. 16.51</ce:alt-text><ce:link id="ln0465" locator="f016-051-9780702070280" xlink:href="pii:B9780702070280000160/f016-051-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0315"><ce:label>Fig. 16.52</ce:label><ce:caption id="ca0285"><ce:simple-para id="sp0520" role="title">Dual-chamber pacing.</ce:simple-para><ce:simple-para id="sp0525" role="caption">The first three beats show atrial and ventricular pacing with narrow pacing spikes in front of each P wave and QRS complex. The last four beats show spontaneous P waves with a different morphology and no pacing spike; the pacemaker senses or tracks these P waves and maintains atrioventricular synchrony by pacing the ventricle after an appropriate interval.</ce:simple-para></ce:caption><ce:alt-text id="atte0265" role="short">Fig. 16.52</ce:alt-text><ce:link id="ln0495" locator="f016-052-9780702070280" xlink:href="pii:B9780702070280000160/f016-052-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0320"><ce:label>Fig. 16.53</ce:label><ce:caption id="ca0290"><ce:simple-para id="sp0530" role="title">Radiofrequency ablation.</ce:simple-para><ce:simple-para id="sp0535" role="caption">Ablation of the accessory conducting pathway in Wolff–Parkinson–White syndrome (see text for details). (AV = atrioventricular node)</ce:simple-para></ce:caption><ce:alt-text id="atte0270" role="short">Fig. 16.53</ce:alt-text><ce:link id="ln0510" locator="f016-053-9780702070280" xlink:href="pii:B9780702070280000160/f016-053-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0325"><ce:label>Fig. 16.54</ce:label><ce:caption id="ca0295"><ce:simple-para id="sp0540" role="title">The six stages of atherosclerosis.</ce:simple-para><ce:simple-para id="sp0545" role="caption">American Heart Association classification.</ce:simple-para></ce:caption><ce:alt-text id="atte0275" role="short">Fig. 16.54</ce:alt-text><ce:source>From Stary HC, Chandler B, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation 1995; 92:1355<ce:italic>–</ce:italic>1374. © 1995 American Heart Association.</ce:source><ce:copyright type="other" year="1995"/><ce:link id="ln0520" locator="f016-054-9780702070280" xlink:href="pii:B9780702070280000160/f016-054-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0330"><ce:label>Fig. 16.55</ce:label><ce:caption id="ca0300"><ce:simple-para id="sp0550" role="title">A scheme for the investigation and treatment of stable angina on effort.</ce:simple-para><ce:simple-para id="sp0555" role="caption">This scheme is best adopted for patients without prior known coronary artery disease. For patients with known coronary artery disease, further stress imaging (echocardiography, radionuclide perfusion or magnetic resonance perfusion) rather than computed tomography coronary angiography is recommended.</ce:simple-para></ce:caption><ce:alt-text id="atte0280" role="short">Fig. 16.55</ce:alt-text><ce:link id="ln0540" locator="f016-055-9780702070280" xlink:href="pii:B9780702070280000160/f016-055-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0335"><ce:label>Fig. 16.56</ce:label><ce:caption id="ca0305"><ce:simple-para id="sp0560" role="title">Forms of exercise-induced ST depression.</ce:simple-para><ce:simple-para id="sp0565" role="caption"><ce:bold>A</ce:bold> Planar ST depression is usually indicative of myocardial ischaemia. <ce:bold>B</ce:bold> Down-sloping depression also usually indicates myocardial ischaemia. <ce:bold>C</ce:bold> Up-sloping depression may be a normal finding.</ce:simple-para></ce:caption><ce:alt-text id="atte0285" role="short">Fig. 16.56</ce:alt-text><ce:link id="ln0545" locator="f016-056ac-9780702070280" xlink:href="pii:B9780702070280000160/f016-056ac-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0075"><ce:label>Fig. 16.57</ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0085" role="title">A positive exercise test (chest leads only).</ce:simple-para><ce:simple-para id="sp0090" role="caption">The resting 12-lead ECG shows some minor T-wave changes in the inferolateral leads but is otherwise normal. After 3 minutes' exercise on a treadmill, there is marked planar ST depression in leads V<ce:inf loc="post">4</ce:inf> and V<ce:inf loc="post">5</ce:inf> (right-hand offset). Subsequent coronary angiography revealed critical three-vessel coronary artery disease.</ce:simple-para></ce:caption><ce:alt-text id="atte0290" role="short">Fig. 16.57</ce:alt-text><ce:link id="ln0090" locator="f016-057-9780702070280" xlink:href="pii:B9780702070280000160/f016-057-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0125"><ce:label>Fig. 16.58</ce:label><ce:caption id="ca0100"><ce:simple-para id="sp0175" role="title">A myocardial perfusion scan showing reversible anterior myocardial ischaemia.</ce:simple-para><ce:simple-para id="sp0180" role="caption">The images are cross-sectional tomograms of the left ventricle. The resting scans (left) show even uptake of the <ce:sup loc="post">99</ce:sup>technetium-labelled tetrofosmin and look like doughnuts. During stress there is reduced uptake of technetium, particularly along the anterior wall (arrows), and the scans look like crescents (right).</ce:simple-para></ce:caption><ce:alt-text id="atte0295" role="short">Fig. 16.58</ce:alt-text><ce:link id="ln0155" locator="f016-058-9780702070280" xlink:href="pii:B9780702070280000160/f016-058-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0340"><ce:label>Fig. 16.59</ce:label><ce:caption id="ca0310"><ce:simple-para id="sp0575" role="title">Percutaneous coronary intervention.</ce:simple-para><ce:simple-para id="sp0580" role="caption">A guidewire is advanced from the radial (or femoral) artery to the coronary artery under radiographic control (1). A fine balloon catheter is then advanced over the guidewire to the stenotic coronary artery and the balloon is inflated to dilate the stenosis (2). When this has been achieved, a stent is usually placed at the site of the stenosis to maintain patency of the artery (3) (see text for more details).</ce:simple-para></ce:caption><ce:alt-text id="atte0300" role="short">Fig. 16.59</ce:alt-text><ce:link id="ln0570" locator="f016-059-9780702070280" xlink:href="pii:B9780702070280000160/f016-059-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0385"><ce:label>Fig. 16.60</ce:label><ce:caption id="ca0355"><ce:simple-para id="sp0665" role="title">Primary percutaneous coronary intervention.</ce:simple-para><ce:simple-para id="sp0670" role="caption"><ce:bold>A</ce:bold> Acute right coronary artery occlusion. <ce:bold>B</ce:bold> Initial angioplasty demonstrates a large thrombus filling defect (arrows). <ce:bold>C</ce:bold> Complete restoration of normal flow following intracoronary stenting.</ce:simple-para></ce:caption><ce:alt-text id="atte0305" role="short">Fig. 16.60</ce:alt-text><ce:link id="ln0660" locator="f016-060ac-9780702070280" xlink:href="pii:B9780702070280000160/f016-060ac-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0345"><ce:label>Fig. 16.61</ce:label><ce:caption id="ca0315"><ce:simple-para id="sp0585" role="title">Coronary artery bypass graft surgery.</ce:simple-para><ce:simple-para id="sp0590" role="caption"><ce:bold>A</ce:bold> Narrowed or stenosed arteries are bypassed using saphenous vein grafts connected to the aorta or by utilising the internal mammary artery. <ce:bold>B</ce:bold> Three-dimensional reconstruction of multidetector CT of the heart. The image shows the patent saphenous vein grafts (SVG) to the right coronary artery (RCA), obtuse marginal branch (OM) and diagonal branch (LADD), and left internal mammary artery graft (LIMA) to the left anterior descending (LAD) coronary artery.</ce:simple-para></ce:caption><ce:alt-text id="atte0310" role="short">Fig. 16.61</ce:alt-text><ce:link id="ln0575" locator="f016-061a-9780702070280" xlink:href="pii:B9780702070280000160/f016-061a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0580" locator="f016-061b-9780702070280" xlink:href="pii:B9780702070280000160/f016-061b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0350"><ce:label>Fig. 16.62</ce:label><ce:caption id="ca0320"><ce:simple-para id="sp0595" role="title">Risk stratification in the acute coronary syndrome: the GRACE score.</ce:simple-para><ce:simple-para id="sp0600" role="caption">Killip class refers to a categorisation of the severity of heart failure based on easily obtained clinical signs. The main clinical features are as follows: class I = no heart failure; class II = crackles audible halfway up the chest; class III = crackles heard in all the lung fields; class IV = cardiogenic shock. To convert creatinine in µmol/L to mg/dL, divide by 88.4. (SBP = systolic blood pressure)</ce:simple-para></ce:caption><ce:alt-text id="atte0315" role="short">Fig. 16.62</ce:alt-text><ce:source>From Scottish Intercollegiate Guidelines Network (SIGN) Guideline no. 93 – Acute coronary syndromes; February 2007.</ce:source><ce:link id="ln0610" locator="f016-062-9780702070280" xlink:href="pii:B9780702070280000160/f016-062-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0355"><ce:label>Fig. 16.63</ce:label><ce:caption id="ca0325"><ce:simple-para id="sp0605" role="title">The time course of myocardial infarction<ce:bold>.</ce:bold></ce:simple-para><ce:simple-para id="sp0610" role="caption">The relative proportion of ischaemic, infarcting and infarcted tissue slowly changes over a period of 12 hours. In the early stages of myocardial infarction, a significant proportion of the myocardium in jeopardy is potentially salvageable.</ce:simple-para></ce:caption><ce:alt-text id="atte0320" role="short">Fig. 16.63</ce:alt-text><ce:link id="ln0615" locator="f016-063-9780702070280" xlink:href="pii:B9780702070280000160/f016-063-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0185"><ce:label>Fig. 16.64</ce:label><ce:caption id="ca0160"><ce:simple-para id="sp0280" role="title">Infarct expansion and ventricular remodelling.</ce:simple-para><ce:simple-para id="sp0285" role="caption">Full-thickness myocardial infarction causes thinning and stretching of the infarcted segment (infarct expansion), which leads to increased wall stress with progressive dilatation and hypertrophy of the remaining ventricle (ventricular remodelling).</ce:simple-para></ce:caption><ce:alt-text id="atte0325" role="short">Fig. 16.64</ce:alt-text><ce:link id="ln0260" locator="f016-064-9780702070280" xlink:href="pii:B9780702070280000160/f016-064-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0360"><ce:label>Fig. 16.65</ce:label><ce:caption id="ca0330"><ce:simple-para id="sp0615" role="title">The serial evolution of ECG changes in transmural myocardial infarction.</ce:simple-para><ce:simple-para id="sp0620" role="caption"><ce:bold>A</ce:bold> Normal ECG complex. <ce:bold>B</ce:bold> Acute ST elevation (‘the current of injury’). <ce:bold>C</ce:bold> Progressive loss of the R wave, developing Q wave, resolution of the ST elevation and terminal T-wave inversion. <ce:bold>D</ce:bold> Deep Q wave and T-wave inversion. <ce:bold>E</ce:bold> Old or established infarct pattern; the Q wave tends to persist but the T-wave changes become less marked. The rate of evolution is very variable but, in general, stage B appears within minutes, stage C within hours, stage D within days and stage E after several weeks or months. This should be compared with the 12-lead ECGs in <ce:cross-refs id="crfs0010" refid="f0365 f0370 f0375">Figures 16.66–16.68</ce:cross-refs>.</ce:simple-para></ce:caption><ce:alt-text id="atte0330" role="short">Fig. 16.65</ce:alt-text><ce:link id="ln0630" locator="f016-065-9780702070280" xlink:href="pii:B9780702070280000160/f016-065-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0365"><ce:label>Fig. 16.66</ce:label><ce:caption id="ca0335"><ce:simple-para id="sp0625" role="title">Recent anterior non-ST elevation (subendocardial) myocardial infarction.</ce:simple-para><ce:simple-para id="sp0630" role="caption">This ECG demonstrates deep symmetrical T-wave inversion, together with a reduction in the height of the R wave in leads V<ce:inf loc="post">1</ce:inf>, V<ce:inf loc="post">2</ce:inf>, V<ce:inf loc="post">3</ce:inf> and V<ce:inf loc="post">4</ce:inf>.</ce:simple-para></ce:caption><ce:alt-text id="atte0335" role="short">Fig. 16.66</ce:alt-text><ce:link id="ln0635" locator="f016-066-9780702070280" xlink:href="pii:B9780702070280000160/f016-066-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0370"><ce:label>Fig. 16.67</ce:label><ce:caption id="ca0340"><ce:simple-para id="sp0635" role="title">Acute transmural anterior myocardial infarction.</ce:simple-para><ce:simple-para id="sp0640" role="caption">This ECG was recorded from a patient who had developed severe chest pain 6 hours earlier. There is ST elevation in leads I, aVL, V<ce:inf loc="post">2</ce:inf>, V<ce:inf loc="post">3</ce:inf>, V<ce:inf loc="post">4</ce:inf>, V<ce:inf loc="post">5</ce:inf> and V<ce:inf loc="post">6</ce:inf>, and there are Q waves in leads V<ce:inf loc="post">3</ce:inf>, V<ce:inf loc="post">4</ce:inf> and V<ce:inf loc="post">5</ce:inf>. Anterior infarcts with prominent changes in leads V<ce:inf loc="post">2</ce:inf>, V<ce:inf loc="post">3</ce:inf> and V<ce:inf loc="post">4</ce:inf> are sometimes called ‘anteroseptal’ infarcts, as opposed to ‘anterolateral’ infarcts, in which the ECG changes are predominantly found in V<ce:inf loc="post">4</ce:inf>, V<ce:inf loc="post">5</ce:inf> and V<ce:inf loc="post">6</ce:inf>.</ce:simple-para></ce:caption><ce:alt-text id="atte0340" role="short">Fig. 16.67</ce:alt-text><ce:link id="ln0640" locator="f016-067-9780702070280" xlink:href="pii:B9780702070280000160/f016-067-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0375"><ce:label>Fig. 16.68</ce:label><ce:caption id="ca0345"><ce:simple-para id="sp0645" role="title">Acute transmural inferolateral myocardial infarction.</ce:simple-para><ce:simple-para id="sp0650" role="caption">This ECG was recorded from a patient who had developed severe chest pain 4 hours earlier. There is ST elevation in inferior leads II, III and aVF and lateral leads V<ce:inf loc="post">4</ce:inf>, V<ce:inf loc="post">5</ce:inf> and V<ce:inf loc="post">6</ce:inf>. There is also ‘reciprocal’ ST depression in leads aVL and V<ce:inf loc="post">2</ce:inf>.</ce:simple-para></ce:caption><ce:alt-text id="atte0345" role="short">Fig. 16.68</ce:alt-text><ce:link id="ln0645" locator="f016-068-9780702070280" xlink:href="pii:B9780702070280000160/f016-068-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0380"><ce:label>Fig. 16.69</ce:label><ce:caption id="ca0350"><ce:simple-para id="sp0655" role="title">Changes in plasma cardiac biomarker concentrations after myocardial infarction.</ce:simple-para><ce:simple-para id="sp0660" role="caption">Creatine kinase (CK) and troponins T (Tn-T) and I (Tn-I) are the first to rise, followed by aspartate aminotransferase (AST) and then lactate (hydroxybutyrate) dehydrogenase (LDH). In patients treated with reperfusion therapy, a rapid rise in plasma creatine kinase (curve CK(R)) occurs, due to a washout effect.</ce:simple-para></ce:caption><ce:alt-text id="atte0350" role="short">Fig. 16.69</ce:alt-text><ce:link id="ln0650" locator="f016-069-9780702070280" xlink:href="pii:B9780702070280000160/f016-069-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0135"><ce:label>Fig. 16.70</ce:label><ce:caption id="ca0110"><ce:simple-para id="sp0195" role="title">Summary of treatment for acute coronary syndrome (ACS).</ce:simple-para><ce:simple-para id="sp0200" role="caption">*Not required following PCI. For details of the GRACE score, see <ce:cross-ref id="crf0485" refid="f0350">Figure 16.62</ce:cross-ref>. (ACE = angiotensin-converting enzyme; ECG = electrocardiogram; GP = glycoprotein; IV = intravenous; LMW = low-molecular-weight; PCI = percutaneous coronary intervention; PO = by mouth; SC = subcutaneous)</ce:simple-para></ce:caption><ce:alt-text id="atte0355" role="short">Fig. 16.70</ce:alt-text><ce:source>Adapted from SIGN 93, Feb 2007, and updated in SIGN 148, April 2016.</ce:source><ce:link id="ln0170" locator="f016-070-9780702070280" xlink:href="pii:B9780702070280000160/f016-070-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0390"><ce:label>Fig. 16.71</ce:label><ce:caption id="ca0360"><ce:simple-para id="sp0680" role="title">Progressive night pain and the development of tissue loss.</ce:simple-para></ce:caption><ce:alt-text id="atte0360" role="short">Fig. 16.71</ce:alt-text><ce:link id="ln0690" locator="f016-071-9780702070280" xlink:href="pii:B9780702070280000160/f016-071-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0400"><ce:label>Fig. 16.72</ce:label><ce:caption id="ca0365"><ce:simple-para id="sp0685" role="title">Types of aortic disease and their complications.</ce:simple-para><ce:simple-para id="sp0690" role="caption"><ce:bold>A</ce:bold> Types of aortic aneurysm. <ce:bold>B</ce:bold> Types of aortic dissection.</ce:simple-para></ce:caption><ce:alt-text id="atte0365" role="short">Fig. 16.72</ce:alt-text><ce:link id="ln0725" locator="f016-072ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-072ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0405"><ce:label>Fig. 16.73</ce:label><ce:caption id="ca0370"><ce:simple-para id="sp0695" role="title">Sagittal view of an MRI scan from a patient with long-standing aortic dissection, illustrating a biluminal aorta.</ce:simple-para><ce:simple-para id="sp0700" role="caption">There is sluggish flow in the false lumen (FL), accounting for its grey appearance. (TL = true lumen)</ce:simple-para></ce:caption><ce:alt-text id="atte0370" role="short">Fig. 16.73</ce:alt-text><ce:link id="ln0740" locator="f016-073-9780702070280" xlink:href="pii:B9780702070280000160/f016-073-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0410"><ce:label>Fig. 16.74</ce:label><ce:caption id="ca0375"><ce:simple-para id="sp0705" role="title">Images from a patient with an acute type B aortic dissection that had ruptured into the left pleural space and was repaired by deploying an endoluminal stent graft.</ce:simple-para><ce:simple-para id="sp0710" role="caption"><ce:bold>A</ce:bold> CT scan illustrating an intimal flap (arrow) in the descending aorta and a large pleural effusion. <ce:bold>B</ce:bold> Aortogram illustrating aneurysmal dilatation; a stent graft has been introduced from the right femoral artery and is about to be deployed. <ce:bold>C</ce:bold> CT scan after endoluminal repair. The pleural effusion has been drained but there is a haematoma around the descending aorta. <ce:bold>D</ce:bold> Aortogram illustrating the stent graft. <ce:bold>E</ce:bold> Three-dimensional reconstruction of an aortic stent graft.</ce:simple-para></ce:caption><ce:alt-text id="atte0375" role="short">Fig. 16.74</ce:alt-text><ce:source><ce:italic>E,</ce:italic> Courtesy of Dr T. Lawton.</ce:source><ce:link id="ln0745" locator="f016-074ae-9780702070280" xlink:href="pii:B9780702070280000160/f016-074ae-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0415"><ce:label>Fig. 16.75</ce:label><ce:caption id="ca0380"><ce:simple-para id="sp0715" role="title">Echocardiograms from a patient with a chronic aortic dissection.</ce:simple-para><ce:simple-para id="sp0720" role="caption">Colour flow Doppler shows flow from the larger false lumen (FL) into the true lumen (TL), characteristic of chronic disease.</ce:simple-para></ce:caption><ce:alt-text id="atte0380" role="short">Fig. 16.75</ce:alt-text><ce:link id="ln0750" locator="f016-075-9780702070280" xlink:href="pii:B9780702070280000160/f016-075-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0420"><ce:label>Fig. 16.76</ce:label><ce:caption id="ca0385"><ce:simple-para id="sp0725" role="title">Retinal changes in hypertension.</ce:simple-para><ce:simple-para id="sp0730" role="caption"><ce:bold>A</ce:bold> Grade 4 hypertensive retinopathy showing swollen optic disc, retinal haemorrhages and multiple cotton wool spots (infarcts). <ce:bold>B</ce:bold> Central retinal vein thrombosis showing swollen optic disc and widespread fundal haemorrhage, commonly associated with systemic hypertension.</ce:simple-para></ce:caption><ce:alt-text id="atte0385" role="short">Fig. 16.76</ce:alt-text><ce:source><ce:italic>A and B,</ce:italic> Courtesy of Dr B. Cullen.</ce:source><ce:link id="ln0765" locator="f016-076a-9780702070280" xlink:href="pii:B9780702070280000160/f016-076a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0770" locator="f016-076b-9780702070280" xlink:href="pii:B9780702070280000160/f016-076b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0425"><ce:label>Fig. 16.77</ce:label><ce:caption id="ca0390"><ce:simple-para id="sp0735" role="title">Example of cardiovascular risk prediction chart for non-diabetic men.</ce:simple-para><ce:simple-para id="sp0740" role="caption">Cardiovascular risk is predicted from the patient's age, sex, smoking habit, BP and cholesterol ratio. The ratio of total to high-density lipoprotein (HDL) cholesterol can be determined in a non-fasting blood sample. Where HDL cholesterol concentration is unknown, it should be assumed to be 1 mmol/L; the lipid scale should be used as total serum cholesterol. Current guidelines suggest initiation of primary prevention in individuals with a 10-year cardiovascular risk ≥ 20%. Patients with diabetes mellitus should be assumed to have a 10-year cardiovascular risk of ≥ 20% and receive secondary prevention therapy. Modified charts exist for women. For further details, see <ce:inter-ref id="iw0035" xlink:href="http://www.who.int/cardiovascular_diseases/guidelines/Pocket_GL_information">www.who.int/cardiovascular_diseases/guidelines/Pocket_GL_information</ce:inter-ref>.</ce:simple-para><ce:simple-para id="sp0745" role="caption">• To estimate an individual's absolute 10-year risk of developing cardiovascular disease (CVD), choose the panel for the appropriate gender, smoking status and age. Within this, define the level of risk from the point where the coordinates for systolic blood pressure (SBP) and ratio of the total to HDL-cholesterol cross.</ce:simple-para><ce:simple-para id="sp0750" role="caption">• Highest-risk individuals (red areas) are those whose 10-year CVD risk exceeds 20%, which is approximately equivalent to a 10-year coronary artery disease risk of &#x003E; 15%. As a minimum, those with CVD risk &#x003E; 30% (shown by the line within the red area) should be targeted and treated now. When resources allow, others with a CVD risk &#x003E; 20% should be targeted progressively.</ce:simple-para><ce:simple-para id="sp0755" role="caption">• The chart also assists in identification of individuals with a moderately high 10-year CVD risk, in the range of 10–20% (orange area) and those in whom it is &#x003C; 10% (green area).</ce:simple-para><ce:simple-para id="sp0760" role="caption">• Smoking status should reflect lifetime exposure to tobacco. For further information, see <ce:inter-ref id="iw0040" xlink:href="http://www.bhf.org.uk">www.bhf.org.uk</ce:inter-ref>.</ce:simple-para></ce:caption><ce:alt-text id="atte0390" role="short">Fig. 16.77</ce:alt-text><ce:source>From Joint British Societies Cardiovascular Risk Prediction Chart, reproduced with permission from the University of Manchester.</ce:source><ce:link id="ln0795" locator="f016-077-9780702070280" xlink:href="pii:B9780702070280000160/f016-077-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0430"><ce:label>Fig. 16.78</ce:label><ce:caption id="ca0395"><ce:simple-para id="sp0765" role="title">Management of hypertension: British Hypertension Society guidelines.</ce:simple-para><ce:simple-para id="sp0770" role="caption"><ce:sup loc="post">1</ce:sup>Signs of papilloedema or retinal haemorrhage. <ce:sup loc="post">2</ce:sup>Labile or postural hypotension, headache, palpitations, pallor and diaphoresis. (ABPM = ambulatory blood pressure monitoring; HBPM = home blood pressure monitoring)</ce:simple-para></ce:caption><ce:alt-text id="atte0395" role="short">Fig. 16.78</ce:alt-text><ce:source>From NICE Clinical Guideline 127 – Hypertension in adults; August 2011.</ce:source><ce:link id="ln0800" locator="f016-078-9780702070280" xlink:href="pii:B9780702070280000160/f016-078-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0435"><ce:label>Fig. 16.79</ce:label><ce:caption id="ca0400"><ce:simple-para id="sp0780" role="title">Antihypertensive drug combinations.</ce:simple-para><ce:simple-para id="sp0785" role="caption">Black patients are those of African or Caribbean descent and not mixed-race, Asian or Chinese patients. <ce:sup loc="post">1</ce:sup>A = Angiotensin-converting enzyme (ACE) inhibitor or consider angiotensin II receptor blocker (ARB); choose a low-cost ARB. <ce:sup loc="post">2</ce:sup>C = calcium channel blocker (CCB); a CCB is preferred but consider a thiazide-like diuretic if a CCB is not tolerated or the person has oedema, evidence of heart failure or a high risk of heart failure. <ce:sup loc="post">3</ce:sup>D = thiazide-type diuretic. <ce:sup loc="post">4</ce:sup>Consider a low dose of spironolactone or higher doses of a thiazide-like diuretic. At the time of publication by NICE (August 2011), spironolactone did not have a UK marketing authorisation for this indication. Informed consent should be obtained and documented. <ce:sup loc="post">5</ce:sup>Consider an α- or β-blocker if further diuretic therapy is not tolerated, or is contraindicated or ineffective.</ce:simple-para></ce:caption><ce:alt-text id="atte0400" role="short">Fig. 16.79</ce:alt-text><ce:source>From NICE Clinical Guideline 127 – Hypertension in adults; August 2011.</ce:source><ce:link id="ln0820" locator="f016-079-9780702070280" xlink:href="pii:B9780702070280000160/f016-079-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0440"><ce:label>Fig. 16.80</ce:label><ce:caption id="ca0405"><ce:simple-para id="sp0790" role="title">Clinical features of rheumatic fever.</ce:simple-para><ce:simple-para id="sp0795" role="caption">Bold labels indicate Jones major criteria. (CCF = congestive cardiac failure)</ce:simple-para></ce:caption><ce:alt-text id="atte0405" role="short">Fig. 16.80</ce:alt-text><ce:source><ce:italic>Inset</ce:italic> <ce:italic>(Erythema marginatum)</ce:italic> From Savin JA, Hunter JAA, Hepburn NC. Skin signs in clinical medicine. London: Mosby<ce:italic>–</ce:italic>Wolfe, Elsevier; 1997.</ce:source><ce:link id="ln0830" locator="f016-080-9780702070280" xlink:href="pii:B9780702070280000160/f016-080-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0445"><ce:label>Fig. 16.81</ce:label><ce:caption id="ca0410"><ce:simple-para id="sp0800" role="title">Mitral stenosis: murmur and the diastolic pressure gradient between left atrium (LA) and left ventricle (LV).</ce:simple-para><ce:simple-para id="sp0805" role="caption">(Mean gradient is reflected by the area between LA and LV in diastole.) The first heart sound is loud, and there is an opening snap (OS) and mid-diastolic murmur (MDM) with pre-systolic accentuation. <ce:bold>A</ce:bold> Echocardiogram showing reduced opening of the mitral valve in diastole. <ce:bold>B</ce:bold> Colour Doppler showing turbulent flow.</ce:simple-para></ce:caption><ce:alt-text id="atte0410" role="short">Fig. 16.81</ce:alt-text><ce:link id="ln0850" locator="f016-081ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-081ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f9000"><ce:label>Fig. 16.82</ce:label><ce:caption id="ca9000"><ce:simple-para id="sp9005" role="title">Mitral valvuloplasty.</ce:simple-para><ce:simple-para id="sp9010" role="caption">A guidewire is introduced into the right atrium (RA) from the femoral vein and the inferior vena cava (IVC). The inter-atrial septum is punctured, providing access to the left atrium and mitral valve. A balloon catheter is then advanced over the guidewire across the mitral valve and the balloon dilated to stretch the valve and reduce the degree of stenosis.</ce:simple-para></ce:caption><ce:alt-text id="atte0415" role="short">Fig. 16.82</ce:alt-text><ce:link id="ln9015" locator="f016-082-9780702070280" xlink:href="pii:B9780702070280000160/f016-082-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0450"><ce:label>Fig. 16.83</ce:label><ce:caption id="ca0415"><ce:simple-para id="sp0810" role="title">Mitral regurgitation: murmur and systolic wave in left atrial pressure.</ce:simple-para><ce:simple-para id="sp0815" role="caption">The first sound is normal or soft and merges with a pansystolic murmur (PSM) extending to the second heart sound. A third heart sound occurs with severe regurgitation. <ce:bold>A</ce:bold> A transoesophageal echocardiogram shows mitral valve prolapse, with one leaflet bulging towards the left atrium (LA, arrow). <ce:bold>B</ce:bold> This results in a jet of mitral regurgitation on colour Doppler (arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0420" role="short">Fig. 16.83</ce:alt-text><ce:link id="ln9020" locator="f016-082ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-082ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0455"><ce:label>Fig. 16.84</ce:label><ce:caption id="ca0420"><ce:simple-para id="sp0820" role="title">Aortic stenosis.</ce:simple-para><ce:simple-para id="sp0825" role="caption">Pressure traces show the systolic gradient between left ventricle (LV) and aorta. The ‘diamond-shaped’ murmur is heard best with the diaphragm in the aortic outflow and also at the apex. An ejection click (EC) may be present in young patients with a bicuspid aortic valve but not in older patients with calcified valves. Aortic stenosis may lead to left ventricular hypertrophy with a fourth sound at the apex and post-stenotic dilatation of the aortic arch. <ce:cross-ref id="crf1630" refid="f0100">Figure 16.11</ce:cross-ref> (<ce:cross-ref id="crf9120" refid="s0140">p. 451</ce:cross-ref>) shows the typical Doppler signal with aortic stenosis.</ce:simple-para></ce:caption><ce:alt-text id="atte0425" role="short">Fig. 16.84</ce:alt-text><ce:link id="ln0900" locator="f016-084-9780702070280" xlink:href="pii:B9780702070280000160/f016-084-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0460"><ce:label>Fig. 16.85</ce:label><ce:caption id="ca0425"><ce:simple-para id="sp0830" role="title">Two-dimensional echocardiogram comparing a normal individual and a patient with calcific aortic stenosis.</ce:simple-para><ce:simple-para id="sp0835" role="caption"><ce:bold>A</ce:bold> Normal individual in diastole; the aortic leaflets are closed and thin, and a point of coaptation is seen (arrow). <ce:bold>B</ce:bold> Calcific aortic stenosis in diastole; the aortic leaflets are thick and calcified (arrow). <ce:bold>C</ce:bold> Normal in systole; the aortic leaflets are open (arrows). <ce:bold>D</ce:bold> Calcific aortic stenosis in systole; the thickened leaflets have barely moved (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0430" role="short">Fig. 16.85</ce:alt-text><ce:source>From Newby D, Grubb N. Cardiology: an illustrated colour text. Edinburgh: Churchill Livingstone, Elsevier Ltd; 2005.</ce:source><ce:link id="ln0905" locator="f016-085ad-9780702070280" xlink:href="pii:B9780702070280000160/f016-085ad-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0465"><ce:label>Fig. 16.86</ce:label><ce:caption id="ca0430"><ce:simple-para id="sp0840" role="title">Left ventricular hypertrophy.</ce:simple-para><ce:simple-para id="sp0845" role="caption">QRS complexes in limb leads have increased amplitude with a very large R wave in V<ce:inf loc="post">6</ce:inf> and S wave in V<ce:inf loc="post">2</ce:inf>. There is ST depression and T-wave inversion in leads II, III, aVF, V<ce:inf loc="post">5</ce:inf> and V<ce:inf loc="post">6</ce:inf>: a ‘left ventricular strain’ pattern.</ce:simple-para></ce:caption><ce:alt-text id="atte0435" role="short">Fig. 16.86</ce:alt-text><ce:link id="ln0915" locator="f016-086-9780702070280" xlink:href="pii:B9780702070280000160/f016-086-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0470"><ce:label>Fig. 16.87</ce:label><ce:caption id="ca0435"><ce:simple-para id="sp0850" role="title">Aortic regurgitation.</ce:simple-para><ce:simple-para id="sp0855" role="caption">The early diastolic murmur is best heard at the left sternal edge and may be accompanied by an ejection systolic (‘to and fro’) murmur. The aortic arch and left ventricle (LV) may become dilated.The inset shows a Doppler echocardiogram with the regurgitant jet (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0440" role="short">Fig. 16.87</ce:alt-text><ce:source><ce:italic>Inset</ce:italic> <ce:italic>(Colour Doppler echo)</ce:italic> From Newby D, Grubb N. Cardiology: an illustrated colour text. Edinburgh: Churchill Livingstone, Elsevier Ltd; 2005.</ce:source><ce:link id="ln0935" locator="f016-087-9780702070280" xlink:href="pii:B9780702070280000160/f016-087-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0475"><ce:label>Fig. 16.88</ce:label><ce:caption id="ca0440"><ce:simple-para id="sp0865" role="title">Transcatheter aortic valve implantation (TAVI): bioprosthetic valve.</ce:simple-para></ce:caption><ce:alt-text id="atte0445" role="short">Fig. 16.88</ce:alt-text><ce:link id="ln0955" locator="f016-088-9780702070280" xlink:href="pii:B9780702070280000160/f016-088-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0480"><ce:label>Fig. 16.89</ce:label><ce:caption id="ca0445"><ce:simple-para id="sp0875" role="title">Clinical features that may be present in endocarditis.</ce:simple-para></ce:caption><ce:alt-text id="atte0450" role="short">Fig. 16.89</ce:alt-text><ce:source><ce:italic>Insets</ce:italic> <ce:italic>(Petechial rash, nail-fold infarct)</ce:italic> From Newby D, Grubb N. Cardiology: an illustrated colour text. Edinburgh: Churchill Livingstone, Elsevier Ltd; 2005.</ce:source><ce:link id="ln0970" locator="f016-089-9780702070280" xlink:href="pii:B9780702070280000160/f016-089-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0485"><ce:label>Fig. 16.90</ce:label><ce:caption id="ca0450"><ce:simple-para id="sp0885" role="title">Changes in the circulation at birth.</ce:simple-para><ce:simple-para id="sp0890" role="caption"><ce:bold>A</ce:bold> In the fetus, oxygenated blood comes through the umbilical vein where it enters the inferior vena cava (IVC) via the ductus venosus (red). The oxygenated blood streams from the right atrium (RA) through the open foramen ovale to the left atrium (LA) and via the left ventricle (LV) into the aorta. Venous blood from the superior vena cava (SVC, blue) crosses under the main blood stream into the RA and then, partly mixed with oxygenated blood (purple), into the right ventricle (RV) and pulmonary artery (PA). The pulmonary vasculature has a high resistance and so little blood passes to the lungs; most blood passes through the ductus arteriosus to the descending aorta. The aortic isthmus is a constriction in the aorta that lies in the aortic arch before the junction with the ductus arteriosus and limits the flow of oxygen-rich blood to the descending aorta. This configuration means that less oxygen-rich blood is supplied to organ systems that take up their function mainly after birth, e.g. the kidneys and intestinal tract. <ce:bold>B</ce:bold> At birth, the lungs expand with air and pulmonary vascular resistance falls, so that blood now flows to the lungs and back to the LA. The left atrial pressure rises above right atrial pressure and the flap valve of the foramen ovale closes. The umbilical arteries and the ductus venosus close. In the next few days, the ductus arteriosus closes under the influence of hormonal changes (particularly prostaglandins) and the aortic isthmus expands. (PV = pulmonary vein)</ce:simple-para></ce:caption><ce:alt-text id="atte0455" role="short">Fig. 16.90</ce:alt-text><ce:source>Adapted from Drews U. Colour atlas of embryology. Stuttgart: Georg Thieme; 1995.</ce:source><ce:link id="ln1000" locator="f016-090ab-9780702070280" xlink:href="pii:B9780702070280000160/f016-090ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0490"><ce:label>Fig. 16.91</ce:label><ce:caption id="ca0455"><ce:simple-para id="sp0895" role="title">Radio-femoral delay.</ce:simple-para><ce:simple-para id="sp0900" role="caption">The difference in pulse pressures is shown.</ce:simple-para></ce:caption><ce:alt-text id="atte0460" role="short">Fig. 16.91</ce:alt-text><ce:link id="ln1005" locator="f016-091-9780702070280" xlink:href="pii:B9780702070280000160/f016-091-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0495"><ce:label>Fig. 16.92</ce:label><ce:caption id="ca0460"><ce:simple-para id="sp0905" role="title">Persistent ductus arteriosus.</ce:simple-para><ce:simple-para id="sp0910" role="caption">There is a connection between the aorta and the pulmonary artery with left-to-right shunting. (LA = left atrium; LV = left ventricle; PA = pulmonary artery; RA = right atrium; RV = right ventricle)</ce:simple-para></ce:caption><ce:alt-text id="atte0465" role="short">Fig. 16.92</ce:alt-text><ce:link id="ln1015" locator="f016-092-9780702070280" xlink:href="pii:B9780702070280000160/f016-092-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0500"><ce:label>Fig. 16.93</ce:label><ce:caption id="ca0465"><ce:simple-para id="sp0915" role="title">MRI scan of coarctation of the aorta.</ce:simple-para><ce:simple-para id="sp0920" role="caption">The aorta is severely narrowed just beyond the arch at the start of the descending aorta (arrow A). Extensive collaterals have developed; a large internal mammary artery (arrow B) and several intercostal arteries (arrows C) are shown. Unusually, in this case, there is also a coarctation of the abdominal aorta (arrow D).</ce:simple-para></ce:caption><ce:alt-text id="atte0470" role="short">Fig. 16.93</ce:alt-text><ce:link id="ln1020" locator="f016-093-9780702070280" xlink:href="pii:B9780702070280000160/f016-093-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0505"><ce:label>Fig. 16.94</ce:label><ce:caption id="ca0470"><ce:simple-para id="sp0925" role="title">Atrial septal defect.</ce:simple-para><ce:simple-para id="sp0930" role="caption">Blood flows across the atrial septum (arrow) from left to right. The murmur is produced by increased flow velocity across the pulmonary valve, as a result of left-to-right shunting and a large stroke volume. The density of shading is proportional to velocity of blood flow. (LV = left ventricle; PA = pulmonary artery; RA = right atrium; RV = right ventricle)</ce:simple-para></ce:caption><ce:alt-text id="atte0475" role="short">Fig. 16.94</ce:alt-text><ce:link id="ln1025" locator="f016-094-9780702070280" xlink:href="pii:B9780702070280000160/f016-094-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0510"><ce:label>Fig. 16.95</ce:label><ce:caption id="ca0475"><ce:simple-para id="sp0935" role="title">Transoesophageal echocardiogram of an atrial septal defect.</ce:simple-para><ce:simple-para id="sp0940" role="caption">The defect is clearly seen (arrow) between the left atrium above and right atrium below. Doppler colour-flow imaging shows flow (blue) across the defect.</ce:simple-para></ce:caption><ce:alt-text id="atte0480" role="short">Fig. 16.95</ce:alt-text><ce:link id="ln1030" locator="f016-095-9780702070280" xlink:href="pii:B9780702070280000160/f016-095-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0515"><ce:label>Fig. 16.96</ce:label><ce:caption id="ca0480"><ce:simple-para id="sp0945" role="title">Percutaneous closure of atrial septal defect.</ce:simple-para><ce:simple-para id="sp0950" role="caption">The closure device is delivered across the interatrial septum and a disc deployed on either side to seal the defect. (IVC = inferior vena cava; LV = left ventricle; PA = pulmonary artery; RA = right atrium; RV = right ventricle)</ce:simple-para></ce:caption><ce:alt-text id="atte0485" role="short">Fig. 16.96</ce:alt-text><ce:link id="ln1035" locator="f016-096-9780702070280" xlink:href="pii:B9780702070280000160/f016-096-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0520"><ce:label>Fig. 16.97</ce:label><ce:caption id="ca0485"><ce:simple-para id="sp0955" role="title">Ventricular septal defect.</ce:simple-para><ce:simple-para id="sp0960" role="caption">In this example, a large left-to-right shunt (arrows) has resulted in chamber enlargement. (LA = left atrium; LV = left ventricle; PA = pulmonary artery; RA = right atrium)</ce:simple-para></ce:caption><ce:alt-text id="atte0490" role="short">Fig. 16.97</ce:alt-text><ce:link id="ln1040" locator="f016-097-9780702070280" xlink:href="pii:B9780702070280000160/f016-097-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0525"><ce:label>Fig. 16.98</ce:label><ce:caption id="ca0490"><ce:simple-para id="sp0965" role="title">Tetralogy of Fallot.</ce:simple-para><ce:simple-para id="sp0970" role="caption">The tetralogy comprises (1) pulmonary stenosis, (2) overriding of the ventricular septal defect by the aorta, (3) a ventricular septal defect and (4) right ventricular hypertrophy. (LA = left atrium; LV = left ventricle; PA = pulmonary artery; RA = right atrium; RV = right ventricle)</ce:simple-para></ce:caption><ce:alt-text id="atte0495" role="short">Fig. 16.98</ce:alt-text><ce:link id="ln1045" locator="f016-098-9780702070280" xlink:href="pii:B9780702070280000160/f016-098-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0530"><ce:label>Fig. 16.99</ce:label><ce:caption id="ca0495"><ce:simple-para id="sp0975" role="title">Types of cardiomyopathy.</ce:simple-para><ce:simple-para id="sp0980" role="caption"><ce:bold>A</ce:bold> Normal heart. <ce:bold>B</ce:bold> Hypertrophic cardiomyopathy: asymmetric septal hypertrophy (ASH) with systolic anterior motion of the mitral valve (SAM), causing mitral reflux and dynamic left ventricular outflow tract obstruction. <ce:bold>C</ce:bold> Hypertrophic cardiomyopathy: concentric hypertrophy. <ce:bold>D</ce:bold> Hypertrophic cardiomyopathy: apical hypertrophy. <ce:bold>E</ce:bold> Dilated cardiomyopathy. <ce:bold>F</ce:bold> Arrhythmogenic right ventricular cardiomyopathy. <ce:bold>G</ce:bold> Obliterative cardiomyopathy. <ce:bold>H</ce:bold> Restrictive cardiomyopathy.</ce:simple-para></ce:caption><ce:alt-text id="atte0500" role="short">Fig. 16.99</ce:alt-text><ce:link id="ln1065" locator="f016-099ah-9780702070280" xlink:href="pii:B9780702070280000160/f016-099ah-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f9005"><ce:label>Fig. 16.100</ce:label><ce:caption id="ca9005"><ce:simple-para id="sp9015" role="title">Takotsubo cardiomyopathy.</ce:simple-para><ce:simple-para id="sp9020" role="caption">Left ventriculogram following injection of contrast in a patient with Takotsubo cardiomyopathy. The outline of the dilated left ventricle is indicated by arrows.</ce:simple-para></ce:caption><ce:alt-text id="atte0505" role="short">Fig. 16.100</ce:alt-text><ce:link id="ln9025" locator="f016-100-9780702070280" xlink:href="pii:B9780702070280000160/f016-100-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0535"><ce:label>Fig. 16.101</ce:label><ce:caption id="ca0500"><ce:simple-para id="sp0985" role="title">ECG in viral pericarditis.</ce:simple-para><ce:simple-para id="sp0990" role="caption">Widespread ST elevation (leads I, II, aVL and V<ce:inf loc="post">1</ce:inf>–V<ce:inf loc="post">6</ce:inf>) is shown. The upward concave shape of the ST segments (see leads II and V<ce:inf loc="post">6</ce:inf>) and the unusual distribution of changes (involving anterior and inferior leads) help to distinguish pericarditis from acute myocardial infarction.</ce:simple-para></ce:caption><ce:alt-text id="atte0510" role="short">Fig. 16.101</ce:alt-text><ce:link id="ln9030" locator="f016-101-9780702070280" xlink:href="pii:B9780702070280000160/f016-101-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0540"><ce:label>Fig. 16.102</ce:label><ce:caption id="ca0505"><ce:simple-para id="sp0995" role="title">Pericardial effusion: echocardiogram (apical view).</ce:simple-para><ce:simple-para id="sp1000" role="caption">Short-axis view of the heart showing a large circumferential pericardial effusion (arrows). (LV = left ventricle)</ce:simple-para></ce:caption><ce:alt-text id="atte0515" role="short">Fig. 16.102</ce:alt-text><ce:link id="ln1095" locator="f016-102-9780702070280" xlink:href="pii:B9780702070280000160/f016-102-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0545"><ce:label>Fig. 16.103</ce:label><ce:caption id="ca0510"><ce:simple-para id="sp1005" role="title">Lateral chest X-ray from a patient with severe heart failure due to chronic constrictive pericarditis.</ce:simple-para><ce:simple-para id="sp1010" role="caption">There is heavy calcification of the pericardium.</ce:simple-para></ce:caption><ce:alt-text id="atte0520" role="short">Fig. 16.103</ce:alt-text><ce:link id="ln1105" locator="f016-103-9780702070280" xlink:href="pii:B9780702070280000160/f016-103-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:textbox id="b0035" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0060" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0525" role="short">Image 1</ce:alt-text></ce:inline-figure>16.1</ce:label><ce:alt-text id="atte0530" role="short">16.1</ce:alt-text><ce:textbox-head><ce:title id="tit0040">Haemodynamic effects of respiration</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0535"><ce:display><ce:table frame="topbot" id="t0010"><ce:alt-text id="atte0535" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Inspiration</entry><entry align="left">Expiration</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Jugular venous pressure</ce:bold></entry><entry align="left">Falls</entry><entry align="left">Rises</entry></row><row rowsep="1"><entry align="left"><ce:bold>Blood pressure</ce:bold></entry><entry align="left">Falls (up to 10 mmHg)</entry><entry align="left">Rises</entry></row><row rowsep="1"><entry align="left"><ce:bold>Heart rate</ce:bold></entry><entry align="left">Accelerates</entry><entry align="left">Slows</entry></row><row><entry align="left"><ce:bold>Second heart sound</ce:bold></entry><entry align="left">Splits<ce:cross-ref id="crf0325" refid="tn0010">*</ce:cross-ref></entry><entry align="left">Fuses<ce:cross-ref id="crf0330" refid="tn0010">*</ce:cross-ref></entry></row></tbody></tgroup><ce:table-footnote id="tn0010"><ce:label>*</ce:label><ce:note-para id="np0010">Inspiration prolongs right ventricular ejection, delaying P<ce:inf loc="post">2</ce:inf>, and shortens left ventricular ejection, bringing forward A<ce:inf loc="post">2</ce:inf>; expiration produces the opposite effects.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0040" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0070" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000160/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0540" role="short">Image 2</ce:alt-text></ce:inline-figure>16.2</ce:label><ce:alt-text id="atte0545" role="short">16.2</ce:alt-text><ce:textbox-head><ce:title id="tit0045">How to read a 12-lead electrocardiogram: examination sequence</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0560"><ce:display><ce:table frame="topbot" id="t0015"><ce:alt-text id="atte0550" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row rowsep="1"><entry align="left"><ce:bold>Rhythm strip (lead II)</ce:bold></entry><entry align="left">To determine heart rate and rhythm</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cardiac axis</ce:bold></entry><entry align="left">Normal if QRS complexes +ve in leads I/II</entry></row><row rowsep="1"><entry align="left"><ce:bold>P-wave shape</ce:bold></entry><entry align="left">Tall P waves denote right atrial enlargement (P pulmonale) and notched P waves denote left atrial enlargement (P mitrale)</entry></row><row rowsep="1"><entry align="left"><ce:bold>PR interval</ce:bold></entry><entry align="left">Normal = 0.12–0.20 sec. Prolongation denotes impaired atrioventricular nodal conduction. A short PR interval occurs in Wolff–Parkinson–White syndrome (<ce:cross-ref id="crf9125" refid="s0810">p. 474</ce:cross-ref>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>QRS duration</ce:bold></entry><entry align="left">If &#x003E; 0.12 sec, ventricular conduction is abnormal (left or right bundle branch block)</entry></row><row rowsep="1"><entry align="left"><ce:bold>QRS amplitude</ce:bold></entry><entry align="left">Large QRS complexes occur in slim young patients and in patients with left ventricular hypertrophy</entry></row><row rowsep="1"><entry align="left"><ce:bold>Q waves</ce:bold></entry><entry align="left">May signify previous myocardial infarction</entry></row><row rowsep="1"><entry align="left"><ce:bold>ST segment</ce:bold></entry><entry align="left">ST elevation may signify myocardial infarction, pericarditis or left ventricular aneurysm; ST depression may signify ischaemia or infarction</entry></row><row rowsep="1"><entry align="left"><ce:bold>T waves</ce:bold></entry><entry align="left">T-wave inversion has many causes, including myocardial ischaemia or infarction, and electrolyte disturbances</entry></row><row rowsep="1"><entry align="left"><ce:bold>QT interval</ce:bold></entry><entry align="left">Normal &#x003C; 0.42 sec. QT prolongation may occur with congenital long QT syndrome, low K<ce:sup loc="post">+</ce:sup>, Mg<ce:sup loc="post">2+</ce:sup> or Ca<ce:sup loc="post">2+</ce:sup>, and some drugs (see <ce:cross-ref id="crf0350" refid="b0165">Box 16.26</ce:cross-ref>, <ce:cross-ref id="crf9130" refid="s0830">p. 476</ce:cross-ref>)</entry></row><row><entry align="left"><ce:bold>ECG conventions</ce:bold></entry><entry align="left">Depolarisation towards electrode: +ve deflection<ce:br/>Depolarisation away from electrode: −ve deflection<ce:br/>Sensitivity: 10 mm = 1 mV<ce:br/>Paper speed: 25 mm per sec<ce:br/>Each large (5 mm) square = 0.2 sec<ce:br/>Each small (1 mm) square = 0.04 sec<ce:br/>Heart rate = 1500/RR interval (mm) (i.e. 300 ÷ number of large squares between beats)</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0045" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0085" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0555" role="short">Image 3</ce:alt-text></ce:inline-figure>16.3</ce:label><ce:alt-text id="atte0560" role="short">16.3</ce:alt-text><ce:textbox-head><ce:title id="tit0050">Exercise testing</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0105"><ce:section-title id="st0105">Indications</ce:section-title><ce:para id="p0590"><ce:list id="ulist0090"><ce:list-item id="u0405"><ce:label>•</ce:label><ce:para id="p0595">To confirm the diagnosis of angina</ce:para></ce:list-item><ce:list-item id="u0410"><ce:label>•</ce:label><ce:para id="p0600">To evaluate stable angina</ce:para></ce:list-item><ce:list-item id="u0415"><ce:label>•</ce:label><ce:para id="p0605">To assess prognosis following myocardial infarction</ce:para></ce:list-item><ce:list-item id="u0420"><ce:label>•</ce:label><ce:para id="p0610">To assess outcome after coronary revascularisation, e.g. coronary angioplasty</ce:para></ce:list-item><ce:list-item id="u0425"><ce:label>•</ce:label><ce:para id="p0615">To diagnose and evaluate the treatment of exercise-induced arrhythmias</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0110"><ce:section-title id="st0110">High-risk findings</ce:section-title><ce:para id="p0620"><ce:list id="ulist0095"><ce:list-item id="u0430"><ce:label>•</ce:label><ce:para id="p0625">Low threshold for ischaemia (within stage 1 or 2 of the Bruce Protocol)</ce:para></ce:list-item><ce:list-item id="u0435"><ce:label>•</ce:label><ce:para id="p0630">Fall in blood pressure on exercise</ce:para></ce:list-item><ce:list-item id="u0440"><ce:label>•</ce:label><ce:para id="p0635">Widespread, marked or prolonged ischaemic ECG changes</ce:para></ce:list-item><ce:list-item id="u0445"><ce:label>•</ce:label><ce:para id="p0640">Exercise-induced arrhythmia</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0050" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0115" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0565" role="short">Image 4</ce:alt-text></ce:inline-figure>16.4</ce:label><ce:alt-text id="atte0570" role="short">16.4</ce:alt-text><ce:textbox-head><ce:title id="tit0055">Common indications for echocardiography</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0715"><ce:list id="ulist0105"><ce:list-item id="u0470"><ce:label>•</ce:label><ce:para id="p0720">Assessment of left ventricular function</ce:para></ce:list-item><ce:list-item id="u0475"><ce:label>•</ce:label><ce:para id="p0725">Diagnosis and quantification of severity of valve disease</ce:para></ce:list-item><ce:list-item id="u0480"><ce:label>•</ce:label><ce:para id="p0730">Identification of vegetations in endocarditis</ce:para></ce:list-item><ce:list-item id="u0485"><ce:label>•</ce:label><ce:para id="p0735">Identification of structural heart disease in atrial fibrillation, cardiomyopathies or congenital heart disease</ce:para></ce:list-item><ce:list-item id="u0490"><ce:label>•</ce:label><ce:para id="p0740">Detection of pericardial effusion</ce:para></ce:list-item><ce:list-item id="u0495"><ce:label>•</ce:label><ce:para id="p0745">Identification of structural heart disease or intracardiac thrombus in systemic embolism</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0055" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0160" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0575" role="short">Image 5</ce:alt-text></ce:inline-figure>16.5</ce:label><ce:alt-text id="atte0580" role="short">16.5</ce:alt-text><ce:textbox-head><ce:title id="tit0060">New York Heart Association (NYHA) functional classification</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0205"><ce:section-title id="st0205">Class I</ce:section-title><ce:para id="p0835"><ce:list id="ulist0110"><ce:list-item id="u0500"><ce:label>•</ce:label><ce:para id="p0840">No limitation during ordinary activity</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0210"><ce:section-title id="st0210">Class II</ce:section-title><ce:para id="p0845"><ce:list id="ulist0115"><ce:list-item id="u0505"><ce:label>•</ce:label><ce:para id="p0850">Slight limitation during ordinary activity</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0215"><ce:section-title id="st0215">Class III</ce:section-title><ce:para id="p0855"><ce:list id="ulist0120"><ce:list-item id="u0510"><ce:label>•</ce:label><ce:para id="p0860">Marked limitation of normal activities without symptoms at rest</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0220"><ce:section-title id="st0220">Class IV</ce:section-title><ce:para id="p0865"><ce:list id="ulist0125"><ce:list-item id="u0515"><ce:label>•</ce:label><ce:para id="p0870">Unable to undertake physical activity without symptoms; symptoms may be present at rest</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0065" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0180" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000160/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0585" role="short">Image 6</ce:alt-text></ce:inline-figure>16.6</ce:label><ce:alt-text id="atte0590" role="short">16.6</ce:alt-text><ce:textbox-head><ce:title id="tit0070">How to evaluate palpitation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0985"><ce:list id="ulist0145"><ce:list-item id="u0555"><ce:label>•</ce:label><ce:para id="p0990">Is the palpitation continuous or intermittent?</ce:para></ce:list-item><ce:list-item id="u0560"><ce:label>•</ce:label><ce:para id="p0995">Is the heart beat regular or irregular?</ce:para></ce:list-item><ce:list-item id="u0565"><ce:label>•</ce:label><ce:para id="p1000">What is the approximate heart rate?</ce:para></ce:list-item><ce:list-item id="u0570"><ce:label>•</ce:label><ce:para id="p1005">Do symptoms occur in discrete attacks?<ce:list id="ulist0150"><ce:list-item id="u0575"><ce:para id="p1010">Is the onset abrupt? How do attacks terminate?</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0580"><ce:label>•</ce:label><ce:para id="p1015">Are there any associated symptoms?<ce:list id="ulist0155"><ce:list-item id="u0585"><ce:para id="p1020">Chest pain, lightheadedness, polyuria (a feature of supraventricular tachycardia, <ce:cross-ref id="crf9135" refid="p2265">p. 473</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0590"><ce:label>•</ce:label><ce:para id="p1025">Are there any precipitating factors, such as exercise or alcohol excess?</ce:para></ce:list-item><ce:list-item id="u0595"><ce:label>•</ce:label><ce:para id="p1030">Is there a history of structural heart disease, such as coronary artery disease or valvular heart disease?</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0070" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0195" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0595" role="short">Image 7</ce:alt-text></ce:inline-figure>16.7</ce:label><ce:alt-text id="atte0600" role="short">16.7</ce:alt-text><ce:textbox-head><ce:title id="tit0075">Causes of sudden arrhythmic death</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0335"><ce:section-title id="st0315">Coronary artery disease (85%)</ce:section-title><ce:para id="p1060"><ce:list id="ulist0160"><ce:list-item id="u0600"><ce:label>•</ce:label><ce:para id="p1065">Myocardial ischaemia</ce:para></ce:list-item><ce:list-item id="u0605"><ce:label>•</ce:label><ce:para id="p1070">Acute myocardial infarction</ce:para></ce:list-item><ce:list-item id="u0610"><ce:label>•</ce:label><ce:para id="p1075">Prior myocardial infarction with myocardial scarring</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0340"><ce:section-title id="st0320">Structural heart disease (10%)</ce:section-title><ce:para id="p1080"><ce:list id="ulist0165"><ce:list-item id="u0615"><ce:label>•</ce:label><ce:para id="p1085">Aortic stenosis (<ce:cross-ref id="crf9140" refid="s2140">p. 521</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0620"><ce:label>•</ce:label><ce:para id="p1090">Hypertrophic cardiomyopathy (<ce:cross-ref id="crf9145" refid="s2680">p. 539</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0625"><ce:label>•</ce:label><ce:para id="p1095">Dilated cardiomyopathy (<ce:cross-ref id="crf9150" refid="s2680">p. 539</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0630"><ce:label>•</ce:label><ce:para id="p1100">Arrhythmogenic right ventricular dysplasia (<ce:cross-ref id="crf9155" refid="p7595">p. 540</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0635"><ce:label>•</ce:label><ce:para id="p1105">Congenital heart disease (<ce:cross-ref id="crf9160" refid="s2450">p. 531</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0345"><ce:section-title id="st0325">No structural heart disease (5%)</ce:section-title><ce:para id="p1110"><ce:list id="ulist0170"><ce:list-item id="u0640"><ce:label>•</ce:label><ce:para id="p1115">Long QT syndrome (<ce:cross-ref id="crf9165" refid="s0830">p. 476</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0645"><ce:label>•</ce:label><ce:para id="p1120">Brugada syndrome (<ce:cross-ref id="crf9170" refid="p2475">p. 477</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0650"><ce:label>•</ce:label><ce:para id="p1125">Wolff–Parkinson–White syndrome (<ce:cross-ref id="crf9175" refid="s0810">p. 474</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0655"><ce:label>•</ce:label><ce:para id="p1130">Adverse drug reactions (torsades de pointes, <ce:cross-ref id="crf9180" refid="s0830">p. 476</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0660"><ce:label>•</ce:label><ce:para id="p1135">Severe electrolyte abnormalities</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0075" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0215" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0605" role="short">Image 8</ce:alt-text></ce:inline-figure>16.8</ce:label><ce:alt-text id="atte0610" role="short">16.8</ce:alt-text><ce:textbox-head><ce:title id="tit0080">Normal and abnormal heart sounds</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1175"><ce:display><ce:table frame="topbot" id="t0020"><ce:alt-text id="atte0615" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Sound</entry><entry align="left">Timing</entry><entry align="left">Characteristics</entry><entry align="left">Mechanisms</entry><entry align="left">Variable features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>First heart sound (S1)</ce:bold></entry><entry align="left">Onset of systole</entry><entry align="left">Usually single or narrowly split</entry><entry align="left">Closure of mitral and tricuspid valves</entry><entry align="left">Loud: hyperdynamic circulation (anaemia, pregnancy, thyrotoxicosis); mitral stenosis<ce:br/>Soft: heart failure; mitral regurgitation</entry></row><row rowsep="1"><entry align="left"><ce:bold>Second heart sound (S2)</ce:bold></entry><entry align="left">End of systole</entry><entry align="left">Split on inspiration<ce:br/>Single on expiration (<ce:cross-ref id="crf9185" refid="p0510">p. 447</ce:cross-ref>)</entry><entry align="left">Closure of aortic and pulmonary valve<ce:br/>A<ce:inf loc="post">2</ce:inf> first<ce:br/>P<ce:inf loc="post">2</ce:inf> second</entry><entry align="left">Fixed wide splitting with atrial septal defect<ce:br/>Wide but variable splitting with delayed right heart emptying (right bundle branch block)<ce:br/>Reversed splitting due to delayed left heart emptying (left bundle branch block)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Third heart sound (S3)</ce:bold></entry><entry align="left">Early in diastole, just after S2</entry><entry align="left">Low pitch, often heard as ‘gallop’</entry><entry align="left">From ventricular wall due to abrupt cessation of rapid filling</entry><entry align="left">Physiological: young people, pregnancy<ce:br/>Pathological: heart failure, mitral regurgitation</entry></row><row rowsep="1"><entry align="left"><ce:bold>Fourth heart sound (S4)</ce:bold></entry><entry align="left">End of diastole, just before S1</entry><entry align="left">Low pitch</entry><entry align="left">Ventricular origin (stiff ventricle and augmented atrial contraction) related to atrial filling</entry><entry align="left">Absent in atrial fibrillation<ce:br/>A feature of severe left ventricular hypertrophy</entry></row><row rowsep="1"><entry align="left"><ce:bold>Systolic clicks</ce:bold></entry><entry align="left">Early or mid-systole</entry><entry align="left">Brief, high-intensity sound</entry><entry align="left">Valvular aortic stenosis<ce:br/>Valvular pulmonary stenosis<ce:br/>Floppy mitral valve<ce:br/>Prosthetic heart sounds from opening and closing of normally functioning mechanical valves</entry><entry align="left">Click may be lost when stenotic valve becomes thickened or calcified<ce:br/>Prosthetic clicks lost when valve obstructed by thrombus or vegetations</entry></row><row><entry align="left"><ce:bold>Opening snap (OS)</ce:bold></entry><entry align="left">Early in diastole</entry><entry align="left">High pitch, brief duration</entry><entry align="left">Opening of stenosed leaflets of mitral valve<ce:br/>Prosthetic heart sounds</entry><entry align="left">Moves closer to S2 as mitral stenosis becomes more severe. May be absent in calcific mitral stenosis</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0080" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0220" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0620" role="short">Image 9</ce:alt-text></ce:inline-figure>16.9</ce:label><ce:alt-text id="atte0625" role="short">16.9</ce:alt-text><ce:textbox-head><ce:title id="tit0085">Features of a benign or innocent heart murmur</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1195"><ce:display><ce:table frame="topbot" id="t0025"><ce:alt-text id="atte0630" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist0175"><ce:list-item id="u0665"><ce:label>•</ce:label><ce:para id="p1200">Soft</ce:para></ce:list-item><ce:list-item id="u0670"><ce:label>•</ce:label><ce:para id="p1205">Mid-systolic</ce:para></ce:list-item><ce:list-item id="u0675"><ce:label>•</ce:label><ce:para id="p1210">Heard at left sternal edge</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0180"><ce:list-item id="u0680"><ce:label>•</ce:label><ce:para id="p1215">No radiation</ce:para></ce:list-item><ce:list-item id="u0685"><ce:label>•</ce:label><ce:para id="p1220">No other cardiac abnormalities</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0085" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0225" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000160/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0635" role="short">Image 10</ce:alt-text></ce:inline-figure>16.10</ce:label><ce:alt-text id="atte0640" role="short">16.10</ce:alt-text><ce:textbox-head><ce:title id="tit0090">How to assess a heart murmur</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0405"><ce:section-title id="st0380">When does it occur?</ce:section-title><ce:para id="p1230"><ce:list id="ulist0185"><ce:list-item id="u0690"><ce:label>•</ce:label><ce:para id="p1235">Time the murmur using heart sounds, carotid pulse and the apex beat. Is it systolic or diastolic?</ce:para></ce:list-item><ce:list-item id="u0695"><ce:label>•</ce:label><ce:para id="p1240">Does the murmur extend throughout systole or diastole or is it confined to a shorter part of the cardiac cycle?</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0410"><ce:section-title id="st0385">How loud is it? (intensity)</ce:section-title><ce:para id="p1245"><ce:list id="ulist0190"><ce:list-item id="u0700"><ce:label>•</ce:label><ce:para id="p1250">Grade 1: very soft (audible only in ideal conditions)</ce:para></ce:list-item><ce:list-item id="u0705"><ce:label>•</ce:label><ce:para id="p1255">Grade 2: soft</ce:para></ce:list-item><ce:list-item id="u0710"><ce:label>•</ce:label><ce:para id="p1260">Grade 3: moderate</ce:para></ce:list-item><ce:list-item id="u0715"><ce:label>•</ce:label><ce:para id="p1265">Grade 4: loud with associated thrill</ce:para></ce:list-item><ce:list-item id="u0720"><ce:label>•</ce:label><ce:para id="p1270">Grade 5: very loud</ce:para></ce:list-item><ce:list-item id="u0725"><ce:label>•</ce:label><ce:para id="p1275">Grade 6: heard without stethoscope</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1280">Note: Diastolic murmurs are very rarely above grade 4</ce:para></ce:section><ce:section id="s0415"><ce:section-title id="st0390">Where is it heard best? (location)</ce:section-title><ce:para id="p1285"><ce:list id="ulist0195"><ce:list-item id="u0730"><ce:label>•</ce:label><ce:para id="p1290">Listen over the apex and base of the heart, including the aortic and pulmonary areas</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0420"><ce:section-title id="st0395">Where does it radiate?</ce:section-title><ce:para id="p1295"><ce:list id="ulist0200"><ce:list-item id="u0735"><ce:label>•</ce:label><ce:para id="p1300">Listen at the neck, axilla or back</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0425"><ce:section-title id="st0400">What does it sound like? (pitch and quality)</ce:section-title><ce:para id="p1305"><ce:list id="ulist0205"><ce:list-item id="u0740"><ce:label>•</ce:label><ce:para id="p1310">Pitch is determined by flow (high pitch indicates high-velocity flow)</ce:para></ce:list-item><ce:list-item id="u0745"><ce:label>•</ce:label><ce:para id="p1315">Is the intensity constant or variable?</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0090" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0240" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0645" role="short">Image 11</ce:alt-text></ce:inline-figure>16.11</ce:label><ce:alt-text id="atte0650" role="short">16.11</ce:alt-text><ce:textbox-head><ce:title id="tit0095">Features of some common systolic murmurs</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1325"><ce:display><ce:table frame="topbot" id="t0030"><ce:alt-text id="atte0655" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Condition</entry><entry align="left">Timing and duration</entry><entry align="left">Quality</entry><entry align="left">Location and radiation</entry><entry align="left">Associated features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Aortic stenosis</ce:bold></entry><entry align="left">Mid-systolic</entry><entry align="left">Loud, rasping</entry><entry align="left">Base and left sternal edge, radiating to suprasternal notch and carotids</entry><entry align="left">Single second heart sound<ce:br/>Ejection click (in young patients)<ce:br/>Slow rising pulse<ce:br/>Left ventricular hypertrophy (pressure overload)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mitral regurgitation</ce:bold></entry><entry align="left">Pansystolic</entry><entry align="left">Blowing</entry><entry align="left">Apex, radiating to axilla</entry><entry align="left">Soft first heart sound<ce:br/>Third heart sound<ce:br/>Left ventricular hypertrophy (volume overload)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ventricular septal defect</ce:bold></entry><entry align="left">Pansystolic</entry><entry align="left">Harsh</entry><entry align="left">Lower left sternal edge, radiating to whole precordium</entry><entry align="left">Thrill<ce:br/>Biventricular hypertrophy</entry></row><row><entry align="left"><ce:bold>Benign</ce:bold></entry><entry align="left">Mid-systolic</entry><entry align="left">Soft</entry><entry align="left">Left sternal edge, no radiation</entry><entry align="left">No other signs of heart disease</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0095" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0245" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0660" role="short">Image 12</ce:alt-text></ce:inline-figure>16.12</ce:label><ce:alt-text id="atte0665" role="short">16.12</ce:alt-text><ce:textbox-head><ce:title id="tit0100">Mechanisms of heart failure</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1375"><ce:display><ce:table frame="topbot" id="t0035"><ce:alt-text id="atte0670" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Cause</entry><entry align="left">Examples</entry><entry align="left">Features</entry></row></thead><tbody><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Reduced ventricular contractility</ce:bold></entry><entry rowsep="0" align="left">Myocardial infarction (segmental dysfunction)</entry><entry rowsep="0" align="left">In coronary artery disease, ‘akinetic’ or ‘dyskinetic’ segments contract poorly and may impede the function of normal segments by distorting their contraction and relaxation patterns</entry></row><row rowsep="1"><entry align="left">Myocarditis/cardiomyopathy (global dysfunction)</entry><entry align="left">Progressive ventricular dilatation</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ventricular outflow obstruction (pressure overload)</ce:bold></entry><entry align="left">Hypertension, aortic stenosis (left heart failure)<ce:br/>Pulmonary hypertension, pulmonary valve stenosis (right heart failure)</entry><entry align="left">Initially, concentric ventricular hypertrophy allows the ventricle to maintain a normal output by generating a high systolic pressure. Later, secondary changes in the myocardium and increasing obstruction lead to failure with ventricular dilatation and rapid clinical deterioration</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ventricular inflow obstruction</ce:bold></entry><entry align="left">Mitral stenosis, tricuspid stenosis</entry><entry align="left">Small, vigorous ventricle; dilated, hypertrophied atrium. Atrial fibrillation is common and often causes marked deterioration because ventricular filling depends heavily on atrial contraction</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ventricular volume overload</ce:bold></entry><entry align="left">Left ventricular volume overload (mitral or aortic regurgitation)<ce:br/>Ventricular septal defect<ce:br/>Right ventricular volume overload (atrial septal defect)<ce:br/>Increased metabolic demand (high output)</entry><entry align="left">Dilatation and hypertrophy allow the ventricle to generate a high stroke volume and help to maintain a normal cardiac output. However, secondary changes in the myocardium lead to impaired contractility and worsening heart failure</entry></row><row><entry morerows="2" rowsep="1" align="left"><ce:bold>Arrhythmia</ce:bold></entry><entry rowsep="0" align="left">Atrial fibrillation</entry><entry rowsep="0" align="left">Tachycardia does not allow for adequate filling of the heart, resulting in reduced cardiac output and back pressure</entry></row><row rowsep="0"><entry align="left">Tachycardia</entry><entry align="left">Prolonged tachycardia causes myocardial fatigue</entry></row><row rowsep="1"><entry align="left">Complete heart block</entry><entry align="left">Bradycardia limits cardiac output, even if stroke volume is normal</entry></row><row><entry morerows="2" align="left"><ce:bold>Diastolic dysfunction</ce:bold></entry><entry rowsep="0" align="left">Constrictive pericarditis</entry><entry rowsep="0" align="left">Marked fluid retention and peripheral oedema, ascites, pleural effusions and elevated jugular veins</entry></row><row rowsep="0"><entry align="left">Restrictive cardiomyopathy</entry><entry align="left">Bi-atrial enlargement (restrictive filling pattern and high atrial pressures). Atrial fibrillation may cause deterioration</entry></row><row><entry align="left">Left ventricular hypertrophy and fibrosis<ce:br/>Cardiac tamponade</entry><entry align="left">Good systolic function but poor diastolic filling<ce:br/>Hypotension, elevated jugular veins, pulsus paradoxus, poor urine output</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0100" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0265" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0675" role="short">Image 13</ce:alt-text></ce:inline-figure>16.13</ce:label><ce:alt-text id="atte0680" role="short">16.13</ce:alt-text><ce:textbox-head><ce:title id="tit0105">Factors that may precipitate or aggravate heart failure in pre-existing heart disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1410"><ce:list id="ulist0210"><ce:list-item id="u0750"><ce:label>•</ce:label><ce:para id="p1415">Myocardial ischaemia or infarction</ce:para></ce:list-item><ce:list-item id="u0755"><ce:label>•</ce:label><ce:para id="p1420">Intercurrent illness</ce:para></ce:list-item><ce:list-item id="u0760"><ce:label>•</ce:label><ce:para id="p1425">Arrhythmia</ce:para></ce:list-item><ce:list-item id="u0765"><ce:label>•</ce:label><ce:para id="p1430">Inappropriate reduction of therapy</ce:para></ce:list-item><ce:list-item id="u0770"><ce:label>•</ce:label><ce:para id="p1435">Administration of a drug with negative inotropic (β-blocker) or fluid-retaining properties (non-steroidal anti-inflammatory drugs, glucocorticoids)</ce:para></ce:list-item><ce:list-item id="u0775"><ce:label>•</ce:label><ce:para id="p1440">Pulmonary embolism</ce:para></ce:list-item><ce:list-item id="u0780"><ce:label>•</ce:label><ce:para id="p1445">Conditions associated with increased metabolic demand (pregnancy, thyrotoxicosis, anaemia)</ce:para></ce:list-item><ce:list-item id="u0785"><ce:label>•</ce:label><ce:para id="p1450">Intravenous fluid overload</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0105" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0275" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0685" role="short">Image 14</ce:alt-text></ce:inline-figure>16.14</ce:label><ce:alt-text id="atte0690" role="short">16.14</ce:alt-text><ce:textbox-head><ce:title id="tit0110">Differential diagnosis of peripheral oedema</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1480"><ce:list id="ulist0215"><ce:list-item id="u0790"><ce:label>•</ce:label><ce:para id="p1485">Cardiac failure: right or combined left and right heart failure, pericardial constriction, cardiomyopathy</ce:para></ce:list-item><ce:list-item id="u0795"><ce:label>•</ce:label><ce:para id="p1490">Chronic venous insufficiency: varicose veins</ce:para></ce:list-item><ce:list-item id="u0800"><ce:label>•</ce:label><ce:para id="p1495">Hypoalbuminaemia: nephrotic syndrome, liver disease, protein-losing enteropathy; often widespread, can affect arms and face</ce:para></ce:list-item><ce:list-item id="u0805"><ce:label>•</ce:label><ce:para id="p1500">Drugs:<ce:list id="ulist0220"><ce:list-item id="u0810"><ce:para id="p1505">Sodium retention: fludrocortisone, non-steroidal anti-inflammatory drugs</ce:para></ce:list-item><ce:list-item id="u0815"><ce:para id="p1510">Increasing capillary permeability: nifedipine, amlodipine</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0820"><ce:label>•</ce:label><ce:para id="p1515">Idiopathic: women &#x003E; men</ce:para></ce:list-item><ce:list-item id="u0825"><ce:label>•</ce:label><ce:para id="p1520">Chronic lymphatic obstruction</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0110" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0280" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000160/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0695" role="short">Image 15</ce:alt-text></ce:inline-figure>16.15</ce:label><ce:alt-text id="atte0700" role="short">16.15</ce:alt-text><ce:textbox-head><ce:title id="tit0115">Management of acute pulmonary oedema</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1605"><ce:display><ce:table frame="topbot" id="t0040"><ce:alt-text id="atte0705" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Action</entry><entry align="left">Effect</entry></row></thead><tbody><row rowsep="1"><entry align="left">Sit the patient up</entry><entry align="left">Reduces preload</entry></row><row rowsep="1"><entry align="left">Give high-flow oxygen</entry><entry align="left">Corrects hypoxia</entry></row><row rowsep="1"><entry align="left">Ensure continuous positive airway pressure (CPAP) of 5–10 mmHg by tight-fitting mask</entry><entry align="left">Reduces preload and pulmonary capillary hydraulic gradient</entry></row><row rowsep="1"><entry align="left">Administer nitrates:<ce:cross-ref id="crf0630" refid="tn0015">*</ce:cross-ref><ce:br/> IV glyceryl trinitrate (10–200 µg/min)<ce:br/> Buccal glyceryl trinitrate 2–5 mg</entry><entry align="left">Reduces preload and afterload</entry></row><row><entry align="left">Administer a loop diuretic:<ce:br/> Furosemide (50–100 mg IV)</entry><entry align="left">Combats fluid overload</entry></row></tbody></tgroup><ce:table-footnote id="tn0015"><ce:label>*</ce:label><ce:note-para id="np0015">The dose of nitrate should be titrated upwards every 10 mins until there is an improvement or systolic blood pressure is &#x003C; 110 mmHg.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0115" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0285" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0710" role="short">Image 16</ce:alt-text></ce:inline-figure>16.16</ce:label><ce:alt-text id="atte0715" role="short">16.16</ce:alt-text><ce:textbox-head><ce:title id="tit0120">General measures for the management of heart failure</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0550"><ce:section-title id="st0515">Education</ce:section-title><ce:para id="p1625"><ce:list id="ulist0235"><ce:list-item id="u0885"><ce:label>•</ce:label><ce:para id="p1630">Explanation of nature of disease, treatment and self-help strategies</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0555"><ce:section-title id="st0520">Diet</ce:section-title><ce:para id="p1635"><ce:list id="ulist0240"><ce:list-item id="u0890"><ce:label>•</ce:label><ce:para id="p1640">Good general nutrition and weight reduction for the obese</ce:para></ce:list-item><ce:list-item id="u0895"><ce:label>•</ce:label><ce:para id="p1645">Avoidance of high-salt foods and added salt, especially for patients with severe congestive heart failure</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0560"><ce:section-title id="st0525">Alcohol</ce:section-title><ce:para id="p1650"><ce:list id="ulist0245"><ce:list-item id="u0900"><ce:label>•</ce:label><ce:para id="p1655">Moderation or elimination of alcohol consumption; alcohol-induced cardiomyopathy requires abstinence</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0565"><ce:section-title id="st0530">Smoking</ce:section-title><ce:para id="p1660"><ce:list id="ulist0250"><ce:list-item id="u0905"><ce:label>•</ce:label><ce:para id="p1665">Cessation</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0570"><ce:section-title id="st0535">Exercise</ce:section-title><ce:para id="p1670"><ce:list id="ulist0255"><ce:list-item id="u0910"><ce:label>•</ce:label><ce:para id="p1675">Regular moderate aerobic exercise within limits of symptoms</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0575"><ce:section-title id="st0540">Vaccination</ce:section-title><ce:para id="p1680"><ce:list id="ulist0260"><ce:list-item id="u0915"><ce:label>•</ce:label><ce:para id="p1685">Consideration of influenza and pneumococcal vaccination</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0120" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0295" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000160/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0720" role="short">Image 17</ce:alt-text></ce:inline-figure>16.17</ce:label><ce:alt-text id="atte0725" role="short">16.17</ce:alt-text><ce:textbox-head><ce:title id="tit0125">Congestive cardiac failure in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1710"><ce:list id="ulist0265"><ce:list-item id="u0920"><ce:label>•</ce:label><ce:para id="p1715"><ce:bold>Incidence</ce:bold>: rises with age and affects 5–10% of those in their eighties.</ce:para></ce:list-item><ce:list-item id="u0925"><ce:label>•</ce:label><ce:para id="p1720"><ce:bold>Common causes</ce:bold>: coronary artery disease, hypertension and calcific degenerative valvular disease.</ce:para></ce:list-item><ce:list-item id="u0930"><ce:label>•</ce:label><ce:para id="p1725"><ce:bold>Diastolic dysfunction</ce:bold>: often prominent, particularly in those with a history of hypertension.</ce:para></ce:list-item><ce:list-item id="u0935"><ce:label>•</ce:label><ce:para id="p1730"><ce:bold>ACE inhibitors</ce:bold>: improve symptoms and mortality but are more frequently associated with postural hypotension and renal impairment than in younger patients.</ce:para></ce:list-item><ce:list-item id="u0940"><ce:label>•</ce:label><ce:para id="p1735"><ce:bold>Loop diuretics</ce:bold>: usually required but may be poorly tolerated in those with urinary incontinence and men with prostate enlargement.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0125" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0305" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0730" role="short">Image 18</ce:alt-text></ce:inline-figure>16.18</ce:label><ce:alt-text id="atte0735" role="short">16.18</ce:alt-text><ce:textbox-head><ce:title id="tit0130">Dosages of ACE inhibitors, β-blockers and angiotensin receptor blockers in heart failure</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1760"><ce:display><ce:table frame="topbot" id="t0045"><ce:alt-text id="atte0740" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Starting dose</entry><entry align="left">Target dose</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>ACE inhibitors</ce:bold></entry></row><row rowsep="0"><entry align="left">Enalapril</entry><entry align="left">2.5 mg twice daily</entry><entry align="left">10 mg twice daily</entry></row><row rowsep="0"><entry align="left">Lisinopril</entry><entry align="left">2.5 mg daily</entry><entry align="left">20 mg daily</entry></row><row rowsep="1"><entry align="left">Ramipril</entry><entry align="left">1.25 mg daily</entry><entry align="left">10 mg daily</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Angiotensin receptor blockers</ce:bold></entry></row><row rowsep="0"><entry align="left">Losartan</entry><entry align="left">25 mg daily</entry><entry align="left">100 mg daily</entry></row><row rowsep="0"><entry align="left">Candesartan</entry><entry align="left">4 mg daily</entry><entry align="left">32 mg daily</entry></row><row rowsep="1"><entry align="left">Valsartan</entry><entry align="left">40 mg daily</entry><entry align="left">160 mg daily</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>β-blockers</ce:bold></entry></row><row rowsep="0"><entry align="left">Bisoprolol</entry><entry align="left">1.25 mg daily</entry><entry align="left">10 mg daily</entry></row><row rowsep="0"><entry align="left">Metoprolol</entry><entry align="left">25 mg twice daily</entry><entry align="left">100 mg twice daily</entry></row><row><entry align="left">Carvedilol</entry><entry align="left">3.125 mg twice daily</entry><entry align="left">25 mg twice daily</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0130" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0320" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0745" role="short">Image 19</ce:alt-text></ce:inline-figure>16.19</ce:label><ce:alt-text id="atte0750" role="short">16.19</ce:alt-text><ce:textbox-head><ce:title id="tit0135">Some pathological causes of sinus bradycardia and tachycardia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1915"><ce:display><ce:table frame="topbot" id="t0050"><ce:alt-text id="atte0755" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Sinus bradycardia</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0280"><ce:list-item id="u0975"><ce:label>•</ce:label><ce:para id="p1920">Myocardial infarction</ce:para></ce:list-item><ce:list-item id="u0980"><ce:label>•</ce:label><ce:para id="p1925">Sinus node disease (sick sinus syndrome)</ce:para></ce:list-item><ce:list-item id="u0985"><ce:label>•</ce:label><ce:para id="p1930">Hypothermia</ce:para></ce:list-item><ce:list-item id="u0990"><ce:label>•</ce:label><ce:para id="p1935">Hypothyroidism</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0285"><ce:list-item id="u0995"><ce:label>•</ce:label><ce:para id="p1940">Cholestatic jaundice</ce:para></ce:list-item><ce:list-item id="u1000"><ce:label>•</ce:label><ce:para id="p1945">Raised intracranial pressure</ce:para></ce:list-item><ce:list-item id="u1005"><ce:label>•</ce:label><ce:para id="p1950">Drugs (β-blockers, digoxin, verapamil)</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Sinus tachycardia</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0290"><ce:list-item id="u1010"><ce:label>•</ce:label><ce:para id="p1955">Anxiety</ce:para></ce:list-item><ce:list-item id="u1015"><ce:label>•</ce:label><ce:para id="p1960">Fever</ce:para></ce:list-item><ce:list-item id="u1020"><ce:label>•</ce:label><ce:para id="p1965">Anaemia</ce:para></ce:list-item><ce:list-item id="u1025"><ce:label>•</ce:label><ce:para id="p1970">Heart failure</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0295"><ce:list-item id="u1030"><ce:label>•</ce:label><ce:para id="p1975">Thyrotoxicosis</ce:para></ce:list-item><ce:list-item id="u1035"><ce:label>•</ce:label><ce:para id="p1980">Phaeochromocytoma</ce:para></ce:list-item><ce:list-item id="u1040"><ce:label>•</ce:label><ce:para id="p1985">Drugs (β-agonists)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0135" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0325" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0760" role="short">Image 20</ce:alt-text></ce:inline-figure>16.20</ce:label><ce:alt-text id="atte0765" role="short">16.20</ce:alt-text><ce:textbox-head><ce:title id="tit0140">Common features of sinoatrial disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2000"><ce:display><ce:table frame="topbot" id="t0055"><ce:alt-text id="atte0770" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist0300"><ce:list-item id="u1045"><ce:label>•</ce:label><ce:para id="p2005">Sinus bradycardia</ce:para></ce:list-item><ce:list-item id="u1050"><ce:label>•</ce:label><ce:para id="p2010">Sinoatrial block (sinus arrest)</ce:para></ce:list-item><ce:list-item id="u1055"><ce:label>•</ce:label><ce:para id="p2015">Paroxysmal atrial fibrillation</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0305"><ce:list-item id="u1060"><ce:label>•</ce:label><ce:para id="p2020">Paroxysmal atrial tachycardia</ce:para></ce:list-item><ce:list-item id="u1065"><ce:label>•</ce:label><ce:para id="p2025">Atrioventricular block</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0140" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0355" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0775" role="short">Image 21</ce:alt-text></ce:inline-figure>16.21</ce:label><ce:alt-text id="atte0780" role="short">16.21</ce:alt-text><ce:textbox-head><ce:title id="tit0145">Common causes of atrial fibrillation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2070"><ce:display><ce:table frame="topbot" id="t0060"><ce:alt-text id="atte0785" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist0310"><ce:list-item id="u1070"><ce:label>•</ce:label><ce:para id="p2075">Coronary artery disease (including acute MI)</ce:para></ce:list-item><ce:list-item id="u1075"><ce:label>•</ce:label><ce:para id="p2080">Valvular heart disease, especially rheumatic mitral valve disease</ce:para></ce:list-item><ce:list-item id="u1080"><ce:label>•</ce:label><ce:para id="p2085">Hypertension</ce:para></ce:list-item><ce:list-item id="u1085"><ce:label>•</ce:label><ce:para id="p2090">Sinoatrial disease</ce:para></ce:list-item><ce:list-item id="u1090"><ce:label>•</ce:label><ce:para id="p2095">Hyperthyroidism</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0315"><ce:list-item id="u1095"><ce:label>•</ce:label><ce:para id="p2100">Alcohol</ce:para></ce:list-item><ce:list-item id="u1100"><ce:label>•</ce:label><ce:para id="p2105">Cardiomyopathy</ce:para></ce:list-item><ce:list-item id="u1105"><ce:label>•</ce:label><ce:para id="p2110">Congenital heart disease</ce:para></ce:list-item><ce:list-item id="u1110"><ce:label>•</ce:label><ce:para id="p2115">Chest infection</ce:para></ce:list-item><ce:list-item id="u1115"><ce:label>•</ce:label><ce:para id="p2120">Pulmonary embolism</ce:para></ce:list-item><ce:list-item id="u1120"><ce:label>•</ce:label><ce:para id="p2125">Pericardial disease</ce:para></ce:list-item><ce:list-item id="u1125"><ce:label>•</ce:label><ce:para id="p2130">Idiopathic (lone atrial fibrillation)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0145" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0360" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000160/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0790" role="short">Image 22</ce:alt-text></ce:inline-figure>16.22</ce:label><ce:alt-text id="atte0795" role="short">16.22</ce:alt-text><ce:textbox-head><ce:title id="tit0150">Atrial fibrillation in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2175"><ce:list id="ulist0320"><ce:list-item id="u1130"><ce:label>•</ce:label><ce:para id="p2180"><ce:bold>Prevalence</ce:bold>: rises with age, reaching 9% in those over 80 years.</ce:para></ce:list-item><ce:list-item id="u1135"><ce:label>•</ce:label><ce:para id="p2185"><ce:bold>Symptoms</ce:bold>: sometimes asymptomatic but often accompanied by diastolic heart failure.</ce:para></ce:list-item><ce:list-item id="u1140"><ce:label>•</ce:label><ce:para id="p2190"><ce:bold>Hyperthyroidism</ce:bold>: atrial fibrillation may emerge as the dominant feature of otherwise silent or occult hyperthyroidism.</ce:para></ce:list-item><ce:list-item id="u1145"><ce:label>•</ce:label><ce:para id="p2195"><ce:bold>Cardioversion</ce:bold>: followed by high rates (~70% at 1 year) of recurrent atrial fibrillation.</ce:para></ce:list-item><ce:list-item id="u1150"><ce:label>•</ce:label><ce:para id="p2200"><ce:bold>Stroke</ce:bold>: atrial fibrillation is an important cause of cerebral embolism, found in 15% of all stroke patients and 2–8% of those with transient ischaemic attacks (TIAs).</ce:para></ce:list-item><ce:list-item id="u1155"><ce:label>•</ce:label><ce:para id="p2205"><ce:bold>Anticoagulation</ce:bold>: although the risk of thromboembolism rises, the hazards of anticoagulation also become greater with age because of increased comorbidity, particularly cognitive impairment and falls.</ce:para></ce:list-item><ce:list-item id="u1160"><ce:label>•</ce:label><ce:para id="p2210"><ce:bold>Target INR</ce:bold>: if anticoagulation is recommended in those over 75 years, care should be taken to maintain an INR below 3.0 because of the increased risk of intracranial haemorrhage.</ce:para></ce:list-item><ce:list-item id="u1165"><ce:label>•</ce:label><ce:para id="p2215"><ce:bold>Directly acting oral anticoagulants</ce:bold>: alternatives to warfarin. No blood monitoring is required, there are fewer drug interactions, and fixed dosing may aid adherence. Dabigatran dose is reduced from 150 mg twice daily to 110 mg twice daily in those over 80 or if creatinine clearance is less than 30 mL/min. Rivaroxaban dose is reduced from 20 mg once daily to 15 mg once daily if creatinine clearance is 30–49 mL/min, and is contraindicated below 30 mL/min.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0150" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0365" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0800" role="short">Image 23</ce:alt-text></ce:inline-figure>16.23</ce:label><ce:alt-text id="atte0805" role="short">16.23</ce:alt-text><ce:textbox-head><ce:title id="tit0155">CHA<ce:inf loc="post">2</ce:inf>DS<ce:inf loc="post">2</ce:inf>-VASc stroke risk scoring system for non-valvular atrial fibrillation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2240"><ce:display><ce:table frame="topbot" id="t0065"><ce:alt-text id="atte0810" role="short">Unlabelled table</ce:alt-text><ce:source>From European Society of Cardiology Clinical practice guidelines: atrial fibrillation (management of) 2010 and focused update (2012). Eur Heart J 2012; 33:2719–2747.</ce:source><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Parameter</entry><entry align="left">Score</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>C</ce:bold></entry><entry align="left">Congestive heart failure</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"><ce:bold>H</ce:bold></entry><entry align="left">Hypertension history</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"><ce:bold>A<ce:inf loc="post">2</ce:inf></ce:bold></entry><entry align="left">Age ≥ 75 years</entry><entry align="left">2 points</entry></row><row rowsep="1"><entry align="left"><ce:bold>D</ce:bold></entry><entry align="left">Diabetes mellitus</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"><ce:bold>S<ce:inf loc="post">2</ce:inf></ce:bold></entry><entry align="left">Previous stroke or transient ischemic attack (TIA)</entry><entry align="left">2 points</entry></row><row rowsep="1"><entry align="left"><ce:bold>V</ce:bold></entry><entry align="left">Vascular disease</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"><ce:bold>A</ce:bold></entry><entry align="left">Age 65–74 years</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sc</ce:bold></entry><entry align="left">Sex category female</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"/><entry align="left">Maximum total score</entry><entry align="left">9 points</entry></row><row><entry namest="col1" nameend="col3" align="center"><ce:bold>Annual stroke risk</ce:bold><ce:br/>0 points = 0% (no prophylaxis required)<ce:br/>1 point = 1.3% (oral anticoagulant recommended in males only)<ce:br/>2+ points = &#x003E; 2.2% (oral anticoagulant recommended)</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0155" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0370" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0815" role="short">Image 24</ce:alt-text></ce:inline-figure>16.24</ce:label><ce:alt-text id="atte0820" role="short">16.24</ce:alt-text><ce:textbox-head><ce:title id="tit0160">HAS-BLED bleeding risk scoring system for patients receiving oral anticoagulation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2245"><ce:display><ce:table frame="topbot" id="t0070"><ce:alt-text id="atte0825" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Parameter</entry><entry align="left">Score</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>H</ce:bold></entry><entry align="left">Hypertension; current systolic blood pressure &#x003E; 160 mmHg</entry><entry align="left">1 point</entry></row><row><entry morerows="1" rowsep="1" align="left"><ce:bold>A</ce:bold></entry><entry rowsep="0" align="left">Abnormal liver function (cirrhosis OR bilirubin &#x003E; twice upper limit of reference range or transaminases &#x003E; three times upper limit of reference range</entry><entry rowsep="0" align="left">1 point</entry></row><row rowsep="1"><entry align="left">Abnormal renal function (creatinine &#x003E; 200 µmol/L (2.26 mg/dL)</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"><ce:bold>S</ce:bold></entry><entry align="left">Stroke history</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"><ce:bold>B</ce:bold></entry><entry align="left">Bleeding: prior major event</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"><ce:bold>L</ce:bold></entry><entry align="left">Labile INR on warfarin</entry><entry align="left">1 point</entry></row><row rowsep="1"><entry align="left"><ce:bold>E</ce:bold></entry><entry align="left">Elderly: age ≥ 65 years</entry><entry align="left">1 point</entry></row><row rowsep="0"><entry morerows="1" align="left"><ce:bold>D</ce:bold></entry><entry align="left">Drugs:</entry><entry align="left"/></row><row rowsep="0"><entry align="left"><ce:hsp sp="1"/>Use of antiplatelet drugs<ce:br/> High alcohol consumption</entry><entry align="left">1 point<ce:br/>1 point</entry></row><row rowsep="1"><entry align="left"/><entry align="left"><ce:hsp sp="1"/>Maximum total score</entry><entry align="left">9 points</entry></row><row><entry namest="col1" nameend="col3" align="center">HAS-BLED score of ≥ 3 points requires close patient monitoring</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0160" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0395" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0830" role="short">Image 25</ce:alt-text></ce:inline-figure>16.25</ce:label><ce:alt-text id="atte0835" role="short">16.25</ce:alt-text><ce:textbox-head><ce:title id="tit0165">Features more in keeping with ventricular tachycardia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2320"><ce:list id="ulist0325"><ce:list-item id="u1170"><ce:label>•</ce:label><ce:para id="p2325">History of myocardial infarction</ce:para></ce:list-item><ce:list-item id="u1175"><ce:label>•</ce:label><ce:para id="p2330">Atrioventricular dissociation (pathognomonic)</ce:para></ce:list-item><ce:list-item id="u1180"><ce:label>•</ce:label><ce:para id="p2335">Capture/fusion beats (pathognomonic; see <ce:cross-ref id="crf0820" refid="f0255">Fig. 16.41</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u1185"><ce:label>•</ce:label><ce:para id="p2340">Extreme left axis deviation</ce:para></ce:list-item><ce:list-item id="u1190"><ce:label>•</ce:label><ce:para id="p2345">Very broad QRS complexes (&#x003E; 140 msecs)</ce:para></ce:list-item><ce:list-item id="u1195"><ce:label>•</ce:label><ce:para id="p2350">No response to carotid sinus massage or intravenous adenosine</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0165" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0410" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0840" role="short">Image 26</ce:alt-text></ce:inline-figure>16.26</ce:label><ce:alt-text id="atte0845" role="short">16.26</ce:alt-text><ce:textbox-head><ce:title id="tit0170">Causes of long QT interval and torsades de pointes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0835"><ce:section-title id="st0790">Bradycardia</ce:section-title><ce:para id="p2385"><ce:list id="ulist0330"><ce:list-item id="u1200"><ce:label>•</ce:label><ce:para id="p2390">Bradycardia compounds other factors that cause torsades de pointes</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0840"><ce:section-title id="st0795">Electrolyte disturbance</ce:section-title><ce:para id="p2395"><ce:list id="ulist0335"><ce:list-item id="u1205"><ce:label>•</ce:label><ce:para id="p2400">Hypokalaemia</ce:para></ce:list-item><ce:list-item id="u1210"><ce:label>•</ce:label><ce:para id="p2405">Hypomagnesaemia</ce:para></ce:list-item><ce:list-item id="u1215"><ce:label>•</ce:label><ce:para id="p2410">Hypocalcaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0845"><ce:section-title id="st0800">Drugs<ce:cross-ref id="crf0840" refid="fn0010">*</ce:cross-ref><ce:footnote id="fn0010"><ce:label>*</ce:label><ce:note-para id="np0020">Many other drugs that are not shown can be associated with prolongation of the QT interval. See <ce:inter-ref id="iw0030" xlink:href="http://www.crediblemeds.org">www.crediblemeds.org</ce:inter-ref> for a complete list.</ce:note-para></ce:footnote></ce:section-title><ce:para id="p2415"><ce:list id="ulist0340"><ce:list-item id="u1220"><ce:label>•</ce:label><ce:para id="p2420">Disopyramide, flecainide and other class Ia, Ic anti-arrhythmic drugs (<ce:cross-ref id="crf9190" refid="s0910">p. 479</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u1225"><ce:label>•</ce:label><ce:para id="p2425">Sotalol, amiodarone and other class III anti-arrhythmic drugs</ce:para></ce:list-item><ce:list-item id="u1230"><ce:label>•</ce:label><ce:para id="p2430">Amitriptyline and other tricyclic antidepressants</ce:para></ce:list-item><ce:list-item id="u1235"><ce:label>•</ce:label><ce:para id="p2435">Chlorpromazine and other phenothiazines</ce:para></ce:list-item><ce:list-item id="u1240"><ce:label>•</ce:label><ce:para id="p2440">Erythromycin and other macrolides</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0850"><ce:section-title id="st0805">Congenital syndromes</ce:section-title><ce:para id="p2445"><ce:list id="ulist0345"><ce:list-item id="u1245"><ce:label>•</ce:label><ce:para id="p2450">Long QT1: gene affected <ce:italic>KCNQI</ce:italic>: K<ce:sup loc="post">+</ce:sup> channel, 30–35%</ce:para></ce:list-item><ce:list-item id="u1250"><ce:label>•</ce:label><ce:para id="p2455">Long QT2: gene affected <ce:italic>HERG</ce:italic>: K<ce:sup loc="post">+</ce:sup> channel, 25–30%</ce:para></ce:list-item><ce:list-item id="u1255"><ce:label>•</ce:label><ce:para id="p2460">Long QT3: gene affected <ce:italic>SCNSA</ce:italic>: Na<ce:sup loc="post">+</ce:sup> channel, 5–10%</ce:para></ce:list-item><ce:list-item id="u1260"><ce:label>•</ce:label><ce:para id="p2465">Long QT4–12: rare; various genes implicated</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0170" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0440" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0850" role="short">Image 27</ce:alt-text></ce:inline-figure>16.27</ce:label><ce:alt-text id="atte0855" role="short">16.27</ce:alt-text><ce:textbox-head><ce:title id="tit0175">Causes of complete atrioventricular block</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0885"><ce:section id="s0890"><ce:section-title id="st0835">Congenital</ce:section-title><ce:para id="p2510">Acquired</ce:para><ce:para id="p2515"><ce:list id="ulist0350"><ce:list-item id="u1265"><ce:label>•</ce:label><ce:para id="p2520">Idiopathic fibrosis</ce:para></ce:list-item><ce:list-item id="u1270"><ce:label>•</ce:label><ce:para id="p2525">Myocardial infarction/ischaemia</ce:para></ce:list-item><ce:list-item id="u1275"><ce:label>•</ce:label><ce:para id="p2530">Inflammation:<ce:list id="ulist0355"><ce:list-item id="u1280"><ce:para id="p2535">Infective endocarditis</ce:para></ce:list-item><ce:list-item id="u1285"><ce:para id="p2540">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u1290"><ce:para id="p2545">Chagas' disease</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1295"><ce:label>•</ce:label><ce:para id="p2550">Trauma</ce:para></ce:list-item><ce:list-item id="u1300"><ce:label>•</ce:label><ce:para id="p2555">Drugs:<ce:list id="ulist0360"><ce:list-item id="u1305"><ce:para id="p2560">Digoxin</ce:para></ce:list-item><ce:list-item id="u1310"><ce:para id="p2565">β-blockers</ce:para></ce:list-item><ce:list-item id="u1315"><ce:para id="p2570">Calcium antagonists</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0175" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0445" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0860" role="short">Image 28</ce:alt-text></ce:inline-figure>16.28</ce:label><ce:alt-text id="atte0865" role="short">16.28</ce:alt-text><ce:textbox-head><ce:title id="tit0180">Common causes of bundle branch block</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2600"><ce:display><ce:table frame="topbot" id="t0075"><ce:alt-text id="atte0870" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Right bundle branch block</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0365"><ce:list-item id="u1320"><ce:label>•</ce:label><ce:para id="p2605">Normal variant</ce:para></ce:list-item><ce:list-item id="u1325"><ce:label>•</ce:label><ce:para id="p2610">Right ventricular hypertrophy or strain, e.g. pulmonary embolism</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0370"><ce:list-item id="u1330"><ce:label>•</ce:label><ce:para id="p2615">Congenital heart disease, e.g. atrial septal defect</ce:para></ce:list-item><ce:list-item id="u1335"><ce:label>•</ce:label><ce:para id="p2620">Coronary artery disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Left bundle branch block</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0375"><ce:list-item id="u1340"><ce:label>•</ce:label><ce:para id="p2625">Coronary artery disease</ce:para></ce:list-item><ce:list-item id="u1345"><ce:label>•</ce:label><ce:para id="p2630">Hypertension</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0380"><ce:list-item id="u1350"><ce:label>•</ce:label><ce:para id="p2635">Aortic valve disease</ce:para></ce:list-item><ce:list-item id="u1355"><ce:label>•</ce:label><ce:para id="p2640">Cardiomyopathy</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0180" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0460" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0875" role="short">Image 29</ce:alt-text></ce:inline-figure>16.29</ce:label><ce:alt-text id="atte0880" role="short">16.29</ce:alt-text><ce:textbox-head><ce:title id="tit0185">Classification of anti-arrhythmic drugs by effect on the intracellular action potential<ce:cross-ref id="crf0905" refid="fn0015">*</ce:cross-ref><ce:footnote id="fn0015"><ce:label>*</ce:label><ce:note-para id="np0025">Some drugs such as digoxin, ivabradine and adenosine have no place in this classification, while others such as amiodarone have properties in more than one class.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0920"><ce:section-title id="st0865">Class I: membrane-stabilising agents (sodium channel blockers)</ce:section-title><ce:section id="s0925"><ce:section-title id="st0870">(a) Block Na<ce:sup loc="post">+</ce:sup> channel and prolong action potential</ce:section-title><ce:para id="p2655"><ce:list id="ulist0385"><ce:list-item id="u1360"><ce:label>•</ce:label><ce:para id="p2660">Quinidine, disopyramide</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0930"><ce:section-title id="st0875">(b) Block Na<ce:sup loc="post">+</ce:sup> channel and shorten action potential</ce:section-title><ce:para id="p2665"><ce:list id="ulist0390"><ce:list-item id="u1365"><ce:label>•</ce:label><ce:para id="p2670">Lidocaine, mexiletine</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0935"><ce:section-title id="st0880">(c) Block Na<ce:sup loc="post">+</ce:sup> channel with no effect on action potential</ce:section-title><ce:para id="p2675"><ce:list id="ulist0395"><ce:list-item id="u1370"><ce:label>•</ce:label><ce:para id="p2680">Flecainide, propafenone</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0940"><ce:section-title id="st0885">Class II: β-adrenoceptor antagonists (β-blockers)</ce:section-title><ce:para id="p2685"><ce:list id="ulist0400"><ce:list-item id="u1375"><ce:label>•</ce:label><ce:para id="p2690">Atenolol, bisoprolol, metoprolol</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0945"><ce:section-title id="st0890">Class III: drugs whose main effect is to prolong the action potential</ce:section-title><ce:para id="p2695"><ce:list id="ulist0405"><ce:list-item id="u1380"><ce:label>•</ce:label><ce:para id="p2700">Amiodarone, dronedarone, sotalol</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0950"><ce:section-title id="st0895">Class IV: slow calcium channel blockers</ce:section-title><ce:para id="p2705"><ce:list id="ulist0410"><ce:list-item id="u1385"><ce:label>•</ce:label><ce:para id="p2710">Verapamil, diltiazem</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0185" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0470" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0885" role="short">Image 30</ce:alt-text></ce:inline-figure>16.30</ce:label><ce:alt-text id="atte0890" role="short">16.30</ce:alt-text><ce:textbox-head><ce:title id="tit0190">Uses, dosages and side-effects of anti-arrhythmic drugs</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2715"><ce:display><ce:figure id="f0310"><ce:alt-text id="atte0895" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0475" locator="b016-031-9780702070280" xlink:href="pii:B9780702070280000160/b016-031-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0190" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0480" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0900" role="short">Image 31</ce:alt-text></ce:inline-figure>16.31</ce:label><ce:alt-text id="atte0905" role="short">16.31</ce:alt-text><ce:textbox-head><ce:title id="tit0195">Anti-arrhythmic drugs: principles of use</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2720">Anti-arrhythmic drugs are potentially toxic and should be used carefully according to the following principles:<ce:list id="ulist0415"><ce:list-item id="u1390"><ce:label>•</ce:label><ce:para id="p2725">Many arrhythmias are benign and do not require specific treatment</ce:para></ce:list-item><ce:list-item id="u1395"><ce:label>•</ce:label><ce:para id="p2730">Precipitating or causal factors should be corrected if possible:<ce:list id="ulist0420"><ce:list-item id="u1400"><ce:para id="p2735">Alcohol excess</ce:para></ce:list-item><ce:list-item id="u1405"><ce:para id="p2740">Caffeine consumption</ce:para></ce:list-item><ce:list-item id="u1410"><ce:para id="p2745">Myocardial ischaemia</ce:para></ce:list-item><ce:list-item id="u1415"><ce:para id="p2750">Hyperthyroidism</ce:para></ce:list-item><ce:list-item id="u1420"><ce:para id="p2755">Acidosis</ce:para></ce:list-item><ce:list-item id="u1425"><ce:para id="p2760">Hypokalaemia</ce:para></ce:list-item><ce:list-item id="u1430"><ce:para id="p2765">Hypomagnesaemia</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1435"><ce:label>•</ce:label><ce:para id="p2770">If drug therapy is required, it is best to use as few drugs as possible</ce:para></ce:list-item><ce:list-item id="u1440"><ce:label>•</ce:label><ce:para id="p2775">In difficult cases, programmed electrical stimulation (electrophysiological study) may help to identify the optimum therapy</ce:para></ce:list-item><ce:list-item id="u1445"><ce:label>•</ce:label><ce:para id="p2780">When managing life-threatening arrhythmias, it is essential to ensure that prophylactic treatment is effective. Ambulatory monitoring and exercise testing may be of value</ce:para></ce:list-item><ce:list-item id="u1450"><ce:label>•</ce:label><ce:para id="p2785">Patients on long-term anti-arrhythmic drugs should be reviewed regularly and attempts made to withdraw therapy if the factors that precipitated the arrhythmias are no longer operative</ce:para></ce:list-item><ce:list-item id="u1455"><ce:label>•</ce:label><ce:para id="p2790">For patients with recurrent supraventricular tachycardia, radiofrequency ablation is often preferable to long-term drug therapy</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0195" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0485" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0910" role="short">Image 32</ce:alt-text></ce:inline-figure>16.32</ce:label><ce:alt-text id="atte0915" role="short">16.32</ce:alt-text><ce:textbox-head><ce:title id="tit0200">Response to intravenous adenosine</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2905"><ce:display><ce:table frame="topbot" id="t0080"><ce:alt-text id="atte0920" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Arrhythmia</entry><entry align="left">Response</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Supraventricular tachycardia</ce:bold></entry><entry align="left">Termination</entry></row><row rowsep="1"><entry align="left"><ce:bold>Atrial fibrillation, atrial flutter, atrial tachycardia</ce:bold></entry><entry align="left">Transient atrioventricular block</entry></row><row><entry align="left"><ce:bold>Ventricular tachycardia</ce:bold></entry><entry align="left">No effect</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0200" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0490" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0925" role="short">Image 33</ce:alt-text></ce:inline-figure>16.33</ce:label><ce:alt-text id="atte0930" role="short">16.33</ce:alt-text><ce:textbox-head><ce:title id="tit0205">Digoxin toxicity</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2915"><ce:display><ce:table frame="topbot" id="t0085"><ce:alt-text id="atte0935" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Extracardiac manifestations</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0425"><ce:list-item id="u1460"><ce:label>•</ce:label><ce:para id="p2920">Anorexia, nausea, vomiting</ce:para></ce:list-item><ce:list-item id="u1465"><ce:label>•</ce:label><ce:para id="p2925">Diarrhoea</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0430"><ce:list-item id="u1470"><ce:label>•</ce:label><ce:para id="p2930">Altered colour vision (xanthopsia)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cardiac manifestations</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0435"><ce:list-item id="u1475"><ce:label>•</ce:label><ce:para id="p2935">Bradycardia</ce:para></ce:list-item><ce:list-item id="u1480"><ce:label>•</ce:label><ce:para id="p2940">Multiple ventricular ectopics</ce:para></ce:list-item><ce:list-item id="u1485"><ce:label>•</ce:label><ce:para id="p2945">Ventricular bigeminy (alternate ventricular ectopics)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0440"><ce:list-item id="u1490"><ce:label>•</ce:label><ce:para id="p2950">Atrial tachycardia (with variable block)</ce:para></ce:list-item><ce:list-item id="u1495"><ce:label>•</ce:label><ce:para id="p2955">Ventricular tachycardia</ce:para></ce:list-item><ce:list-item id="u1500"><ce:label>•</ce:label><ce:para id="p2960">Ventricular fibrillation</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0205" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0500" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0940" role="short">Image 34</ce:alt-text></ce:inline-figure>16.34</ce:label><ce:alt-text id="atte0945" role="short">16.34</ce:alt-text><ce:textbox-head><ce:title id="tit0210">International generic pacemaker code</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3015"><ce:display><ce:table frame="topbot" id="t0090"><ce:alt-text id="atte0950" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Chamber paced</entry><entry align="left">Chamber sensed</entry><entry align="left">Response to sensing</entry></row></thead><tbody><row rowsep="1"><entry align="left">O = none</entry><entry align="left">O = none</entry><entry align="left">O = none</entry></row><row rowsep="1"><entry align="left">A = atrium</entry><entry align="left">A = atrium</entry><entry align="left">T = triggered</entry></row><row rowsep="1"><entry align="left">V = ventricle</entry><entry align="left">V = ventricle</entry><entry align="left">I = inhibited</entry></row><row><entry align="left">D = both</entry><entry align="left">D = both</entry><entry align="left">D = both</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0210" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0505" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0955" role="short">Image 35</ce:alt-text></ce:inline-figure>16.35</ce:label><ce:alt-text id="atte0960" role="short">16.35</ce:alt-text><ce:textbox-head><ce:title id="tit0215">Key indications for implantable cardiac defibrillator therapy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1125"><ce:section-title id="st1050">Primary prevention</ce:section-title><ce:para id="p3035"><ce:list id="ulist0445"><ce:list-item id="u1505"><ce:label>•</ce:label><ce:para id="p3040">After myocardial infarction, if the left ventricular ejection fraction is &#x003C; 30%</ce:para></ce:list-item><ce:list-item id="u1510"><ce:label>•</ce:label><ce:para id="p3045">Mild to moderate symptomatic heart failure on optimal drug therapy, with left ventricular ejection fraction &#x003C; 35%</ce:para></ce:list-item><ce:list-item id="u1515"><ce:label>•</ce:label><ce:para id="p3050">Some patients with inherited cardiac conditions (long QT syndrome, cardiomyopathy)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1130"><ce:section-title id="st1055">Secondary prevention</ce:section-title><ce:para id="p3055"><ce:list id="ulist0450"><ce:list-item id="u1520"><ce:label>•</ce:label><ce:para id="p3060">Survivors of ventricular fibrillation or ventricular tachycardia cardiac arrest not having a transient or reversible cause</ce:para></ce:list-item><ce:list-item id="u1525"><ce:label>•</ce:label><ce:para id="p3065">Ventricular tachycardia with haemodynamic compromise or significant left ventricular impairment (left ventricular ejection fraction &#x003C; 35%)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0215" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0515" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0965" role="short">Image 36</ce:alt-text></ce:inline-figure>16.36</ce:label><ce:alt-text id="atte0970" role="short">16.36</ce:alt-text><ce:textbox-head><ce:title id="tit0220">Coronary artery disease: clinical manifestations and pathology</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3105"><ce:display><ce:table frame="topbot" id="t0095"><ce:alt-text id="atte0975" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Clinical problem</entry><entry align="left">Pathology</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Stable angina</ce:bold></entry><entry align="left">Ischaemia due to fixed atheromatous stenosis of one or more coronary arteries</entry></row><row rowsep="1"><entry align="left"><ce:bold>Unstable angina</ce:bold></entry><entry align="left">Ischaemia caused by dynamic obstruction of a coronary artery due to plaque rupture or erosion with superimposed thrombosis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Myocardial infarction</ce:bold></entry><entry align="left">Myocardial necrosis caused by acute occlusion of a coronary artery due to plaque rupture or erosion with superimposed thrombosis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Heart failure</ce:bold></entry><entry align="left">Myocardial dysfunction due to infarction or ischaemia</entry></row><row rowsep="1"><entry align="left"><ce:bold>Arrhythmia</ce:bold></entry><entry align="left">Altered conduction due to ischaemia or infarction</entry></row><row><entry align="left"><ce:bold>Sudden death</ce:bold></entry><entry align="left">Ventricular arrhythmia, asystole or massive myocardial infarction</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0220" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0525" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0980" role="short">Image 37</ce:alt-text></ce:inline-figure>16.37</ce:label><ce:alt-text id="atte0985" role="short">16.37</ce:alt-text><ce:textbox-head><ce:title id="tit0225">Population-based strategies to prevent coronary disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3210"><ce:list id="ulist0455"><ce:list-item id="u1530"><ce:label>•</ce:label><ce:para id="p3215">Do not smoke</ce:para></ce:list-item><ce:list-item id="u1535"><ce:label>•</ce:label><ce:para id="p3220">Take regular exercise (minimum of 20 mins, three times per week)</ce:para></ce:list-item><ce:list-item id="u1540"><ce:label>•</ce:label><ce:para id="p3225">Maintain an ‘ideal’ body weight</ce:para></ce:list-item><ce:list-item id="u1545"><ce:label>•</ce:label><ce:para id="p3230">Eat a mixed diet rich in fresh fruit and vegetables</ce:para></ce:list-item><ce:list-item id="u1550"><ce:label>•</ce:label><ce:para id="p3235">Aim to get no more than 10% of energy intake from saturated fat</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0225" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0530" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0990" role="short">Image 38</ce:alt-text></ce:inline-figure>16.38</ce:label><ce:alt-text id="atte0995" role="short">16.38</ce:alt-text><ce:textbox-head><ce:title id="tit0230">Factors influencing myocardial oxygen supply and demand</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3255"><ce:display><ce:table frame="topbot" id="t0100"><ce:alt-text id="atte1000" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Oxygen demand: cardiac work</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0460"><ce:list-item id="u1555"><ce:label>•</ce:label><ce:para id="p3260">Heart rate</ce:para></ce:list-item><ce:list-item id="u1560"><ce:label>•</ce:label><ce:para id="p3265">Blood pressure</ce:para></ce:list-item><ce:list-item id="u1565"><ce:label>•</ce:label><ce:para id="p3270">Myocardial contractility</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0465"><ce:list-item id="u1570"><ce:label>•</ce:label><ce:para id="p3275">Left ventricular hypertrophy</ce:para></ce:list-item><ce:list-item id="u1575"><ce:label>•</ce:label><ce:para id="p3280">Valve disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Oxygen supply: coronary blood flow</ce:bold><ce:cross-ref id="crf1025" refid="tn0020"><ce:bold>*</ce:bold></ce:cross-ref></entry></row><row><entry align="left"><ce:list id="ulist0470"><ce:list-item id="u1580"><ce:label>•</ce:label><ce:para id="p3285">Duration of diastole</ce:para></ce:list-item><ce:list-item id="u1585"><ce:label>•</ce:label><ce:para id="p3290">Coronary perfusion pressure (aortic diastolic minus coronary sinus or right atrial diastolic pressure)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0475"><ce:list-item id="u1590"><ce:label>•</ce:label><ce:para id="p3295">Coronary vasomotor tone</ce:para></ce:list-item><ce:list-item id="u1595"><ce:label>•</ce:label><ce:para id="p3300">Oxygenation:<ce:list id="ulist0480"><ce:list-item id="u1600"><ce:para id="p3305">Haemoglobin</ce:para></ce:list-item><ce:list-item id="u1605"><ce:para id="p3310">Oxygen saturation</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0020"><ce:label>*</ce:label><ce:note-para id="np0030">Coronary blood flow occurs mainly in diastole.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0230" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0535" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1005" role="short">Image 39</ce:alt-text></ce:inline-figure>16.39</ce:label><ce:alt-text id="atte1010" role="short">16.39</ce:alt-text><ce:textbox-head><ce:title id="tit0235">Activities precipitating angina</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3340"><ce:display><ce:table frame="topbot" id="t0105"><ce:alt-text id="atte1015" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Common</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0485"><ce:list-item id="u1610"><ce:label>•</ce:label><ce:para id="p3345">Physical exertion</ce:para></ce:list-item><ce:list-item id="u1615"><ce:label>•</ce:label><ce:para id="p3350">Cold exposure</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0490"><ce:list-item id="u1620"><ce:label>•</ce:label><ce:para id="p3355">Heavy meals</ce:para></ce:list-item><ce:list-item id="u1625"><ce:label>•</ce:label><ce:para id="p3360">Intense emotion</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Uncommon</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0500"><ce:list-item id="u1635"><ce:label>•</ce:label><ce:para id="p3370">Vivid dreams (nocturnal angina)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0495"><ce:list-item id="u1630"><ce:label>•</ce:label><ce:para id="p3365">Lying flat (decubitus angina)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0265" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0595" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1020" role="short">Image 40</ce:alt-text></ce:inline-figure>16.40</ce:label><ce:alt-text id="atte1025" role="short">16.40</ce:alt-text><ce:textbox-head><ce:title id="tit0270">Canadian Cardiovascular Society (CCS) angina score</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1345"><ce:section-title id="st1255">Class I</ce:section-title><ce:para id="p3600"><ce:list id="ulist0520"><ce:list-item id="u1715"><ce:label>•</ce:label><ce:para id="p3605">Angina only during strenuous or prolonged physical activity</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1350"><ce:section-title id="st1260">Class II</ce:section-title><ce:para id="p3610"><ce:list id="ulist0525"><ce:list-item id="u1720"><ce:label>•</ce:label><ce:para id="p3615">Slight limitation, with angina only during vigorous physical activity</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1355"><ce:section-title id="st1265">Class III</ce:section-title><ce:para id="p3620"><ce:list id="ulist0530"><ce:list-item id="u1725"><ce:label>•</ce:label><ce:para id="p3625">Moderate limitation where symptoms occur with everyday activities</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1360"><ce:section-title id="st1270">Class IV</ce:section-title><ce:para id="p3630"><ce:list id="ulist0535"><ce:list-item id="u1730"><ce:label>•</ce:label><ce:para id="p3635">Inability to perform any activity without angina or angina at rest, i.e. severe limitation</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0235" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0550" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1030" role="short">Image 41</ce:alt-text></ce:inline-figure>16.41</ce:label><ce:alt-text id="atte1035" role="short">16.41</ce:alt-text><ce:textbox-head><ce:title id="tit0240">Risk stratification in stable angina<ce:cross-ref id="crf1055" refid="fn0020">*</ce:cross-ref><ce:footnote id="fn0020"><ce:label>*</ce:label><ce:note-para id="np0035">Patients may fall between these two categories.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3385"><ce:display><ce:table frame="topbot" id="t0110"><ce:alt-text id="atte1040" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">High risk</entry><entry align="left">Low risk</entry></row></thead><tbody><row rowsep="1"><entry align="left">Post-infarct angina</entry><entry align="left">Predictable exertional angina</entry></row><row rowsep="1"><entry align="left">Poor effort tolerance</entry><entry align="left">Good effort tolerance</entry></row><row rowsep="1"><entry align="left">Ischaemia at low workload</entry><entry align="left">Ischaemia only at high workload</entry></row><row rowsep="1"><entry align="left">Left main or three-vessel disease</entry><entry align="left">Single-vessel or two-vessel disease</entry></row><row><entry align="left">Poor left ventricular function</entry><entry align="left">Good left ventricular function</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0240" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0555" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1045" role="short">Image 42</ce:alt-text></ce:inline-figure>16.42</ce:label><ce:alt-text id="atte1050" role="short">16.42</ce:alt-text><ce:textbox-head><ce:title id="tit0245">Advice to patients with stable angina</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3400"><ce:list id="ulist0505"><ce:list-item id="u1640"><ce:label>•</ce:label><ce:para id="p3405">Do not smoke</ce:para></ce:list-item><ce:list-item id="u1645"><ce:label>•</ce:label><ce:para id="p3410">Aim for an ideal body weight</ce:para></ce:list-item><ce:list-item id="u1650"><ce:label>•</ce:label><ce:para id="p3415">Take regular exercise (exercise up to, but not beyond, the point of chest discomfort is beneficial and may promote collateral vessels)</ce:para></ce:list-item><ce:list-item id="u1655"><ce:label>•</ce:label><ce:para id="p3420">Avoid severe unaccustomed exertion, and vigorous exercise after a heavy meal or in very cold weather</ce:para></ce:list-item><ce:list-item id="u1660"><ce:label>•</ce:label><ce:para id="p3425">Take sublingual nitrate before undertaking exertion that may induce angina</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0245" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0560" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1055" role="short">Image 43</ce:alt-text></ce:inline-figure>16.43</ce:label><ce:alt-text id="atte1060" role="short">16.43</ce:alt-text><ce:textbox-head><ce:title id="tit0250">Duration of action of some nitrate preparations</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3475"><ce:display><ce:table frame="topbot" id="t0115"><ce:alt-text id="atte1065" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Preparation</entry><entry align="left">Peak action</entry><entry align="left">Duration of action</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Sublingual GTN</ce:bold></entry><entry align="left">4–8 mins</entry><entry align="left">10–30 mins</entry></row><row rowsep="1"><entry align="left"><ce:bold>Buccal GTN</ce:bold></entry><entry align="left">4–10 mins</entry><entry align="left">30–300 mins</entry></row><row rowsep="1"><entry align="left"><ce:bold>Transdermal GTN</ce:bold></entry><entry align="left">1–3 hrs</entry><entry align="left">Up to 24 hrs</entry></row><row rowsep="1"><entry align="left"><ce:bold>Oral isosorbide dinitrate</ce:bold></entry><entry align="left">45–120 mins</entry><entry align="left">2–6 hrs</entry></row><row><entry align="left"><ce:bold>Oral isosorbide mononitrate</ce:bold></entry><entry align="left">45–120 mins</entry><entry align="left">6–10 hrs</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0570">(GTN = glyceryl trinitrate)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0250" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0565" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1070" role="short">Image 44</ce:alt-text></ce:inline-figure>16.44</ce:label><ce:alt-text id="atte1075" role="short">16.44</ce:alt-text><ce:textbox-head><ce:title id="tit0255">Calcium channel antagonists used for the treatment of angina</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3490"><ce:display><ce:table frame="topbot" id="t0120"><ce:alt-text id="atte1080" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Drug</entry><entry align="left">Dose</entry><entry align="left">Feature</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Nifedipine</ce:bold></entry><entry align="left">5–20 mg 3 times daily<ce:cross-ref id="crf1090" refid="tn0025">*</ce:cross-ref></entry><entry align="left">May cause marked tachycardia</entry></row><row rowsep="1"><entry align="left"><ce:bold>Nicardipine</ce:bold></entry><entry align="left">20–40 mg 3 times daily</entry><entry align="left">May cause less myocardial depression than the other calcium antagonists</entry></row><row rowsep="1"><entry align="left"><ce:bold>Amlodipine</ce:bold></entry><entry align="left">2.5–10 mg daily</entry><entry align="left">Ultra-long-acting</entry></row><row rowsep="1"><entry align="left"><ce:bold>Verapamil</ce:bold></entry><entry align="left">40–80 mg 3 times daily<ce:cross-ref id="crf1095" refid="tn0025">*</ce:cross-ref></entry><entry align="left">Commonly causes constipation; useful anti-arrhythmic properties (<ce:cross-ref id="crf9195" refid="p2850">p. 481</ce:cross-ref>)</entry></row><row><entry align="left"><ce:bold>Diltiazem</ce:bold></entry><entry align="left">60–120 mg 3 times daily<ce:cross-ref id="crf1100" refid="tn0025">*</ce:cross-ref></entry><entry align="left">Similar anti-arrhythmic properties to verapamil</entry></row></tbody></tgroup><ce:table-footnote id="tn0025"><ce:label>*</ce:label><ce:note-para id="np0040">Once- or twice-daily slow-release preparations are available.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0255" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0585" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1085" role="short">Image 45</ce:alt-text></ce:inline-figure>16.45</ce:label><ce:alt-text id="atte1090" role="short">16.45</ce:alt-text><ce:textbox-head><ce:title id="tit0260">Comparison of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3555"><ce:display><ce:table frame="topbot" id="t0125"><ce:alt-text id="atte1095" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">PCI</entry><entry align="left">CABG</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Death</ce:bold></entry><entry align="left">&#x003C; 0.5%</entry><entry align="left">&#x003C; 1.5%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Myocardial infarction</ce:bold><ce:cross-ref id="crf1125" refid="tn0030"><ce:bold>*</ce:bold></ce:cross-ref></entry><entry align="left">2%</entry><entry align="left">10%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Hospital stay</ce:bold></entry><entry align="left">12–36 hrs</entry><entry align="left">5–8 days</entry></row><row rowsep="1"><entry align="left"><ce:bold>Return to work</ce:bold></entry><entry align="left">2–5 days</entry><entry align="left">6–12 weeks</entry></row><row rowsep="1"><entry align="left"><ce:bold>Recurrent angina</ce:bold></entry><entry align="left">15–20% at 6 months</entry><entry align="left">10% at 1 year</entry></row><row rowsep="1"><entry align="left"><ce:bold>Repeat revascularisation</ce:bold></entry><entry align="left">10–20% at 2 years</entry><entry align="left">2% at 2 years</entry></row><row rowsep="1"><entry align="left"><ce:bold>Neurological complications</ce:bold></entry><entry align="left">Rare</entry><entry align="left">Common (see text)</entry></row><row><entry align="left"><ce:bold>Other complications</ce:bold></entry><entry align="left">Emergency CABG<ce:br/>Vascular damage related to access site</entry><entry align="left">Diffuse myocardial damage<ce:br/>Infection (chest, wound)<ce:br/>Wound pain</entry></row></tbody></tgroup><ce:table-footnote id="tn0030"><ce:label>*</ce:label><ce:note-para id="np0045">Defined as CK-MB &#x003E; 2 × normal (<ce:cross-ref id="crf9200" refid="s1450">p. 497</ce:cross-ref>).</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0260" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0590" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000160/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1100" role="short">Image 46</ce:alt-text></ce:inline-figure>16.46</ce:label><ce:alt-text id="atte1105" role="short">16.46</ce:alt-text><ce:textbox-head><ce:title id="tit0265">Angina in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3565"><ce:list id="ulist0515"><ce:list-item id="u1690"><ce:label>•</ce:label><ce:para id="p3570"><ce:bold>Incidence</ce:bold>: coronary artery disease increases in old age and affects women almost as often as men.</ce:para></ce:list-item><ce:list-item id="u1695"><ce:label>•</ce:label><ce:para id="p3575"><ce:bold>Comorbid conditions</ce:bold>: anaemia and thyroid disease are common and may worsen angina.</ce:para></ce:list-item><ce:list-item id="u1700"><ce:label>•</ce:label><ce:para id="p3580"><ce:bold>Calcific aortic stenosis</ce:bold>: common and should be sought in all older people with angina.</ce:para></ce:list-item><ce:list-item id="u1705"><ce:label>•</ce:label><ce:para id="p3585"><ce:bold>Atypical presentations</ce:bold>: when myocardial ischaemia occurs, age-related changes in myocardial compliance and diastolic relaxation can cause the presentation to be with symptoms of heart failure, such as breathlessness, rather than with chest discomfort.</ce:para></ce:list-item><ce:list-item id="u1710"><ce:label>•</ce:label><ce:para id="p3590"><ce:bold>Angioplasty and coronary artery bypass surgery</ce:bold>: provide symptomatic relief, although with increased procedure-related morbidity and mortality. Outcome is determined by the number of diseased vessels, severity of cardiac dysfunction and the number of concomitant diseases, as much as by age itself.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0270" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0600" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1110" role="short">Image 47</ce:alt-text></ce:inline-figure>16.47</ce:label><ce:alt-text id="atte1115" role="short">16.47</ce:alt-text><ce:source>Adapted from Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33:2551–2267.</ce:source><ce:textbox-head><ce:title id="tit0275">Criteria for diagnosis of an acute myocardial infarction (MI)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3645"><ce:list id="ulist0540"><ce:list-item id="u1735"><ce:label>•</ce:label><ce:para id="p3650">Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin (cTn)), with at least one value above the 99th centile upper reference limit (URL) and with at least one of the following:<ce:list id="olist0545"><ce:list-item id="o1740"><ce:label>1</ce:label><ce:para id="p3655">Symptoms of ischaemia</ce:para></ce:list-item><ce:list-item id="o1745"><ce:label>2</ce:label><ce:para id="p3660">New or presumed new significant ST segment–T wave (ST–T) changes or new left bundle branch block (LBBB)</ce:para></ce:list-item><ce:list-item id="o1750"><ce:label>3</ce:label><ce:para id="p3665">Development of pathological Q waves in the ECG</ce:para></ce:list-item><ce:list-item id="o1755"><ce:label>4</ce:label><ce:para id="p3670">Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality</ce:para></ce:list-item><ce:list-item id="o1760"><ce:label>5</ce:label><ce:para id="p3675">Identification of an intracoronary thrombus by angiography or postmortem</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1765"><ce:label>•</ce:label><ce:para id="p3680">Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes or new LBBB, but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be increased</ce:para></ce:list-item><ce:list-item id="u1770"><ce:label>•</ce:label><ce:para id="p3685">Percutaneous coronary intervention (PCI)-related MI is arbitrarily defined by elevation of cTn values (&#x003E; 5 × 99th centile URL) in patients with normal baseline values (≤ 99th centile URL) or a rise of cTn values &#x003E; 20% if the baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial ischaemia, or (ii) new ischaemic ECG changes, or (iii) angiographic findings consistent with a procedural complication, or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality are required</ce:para></ce:list-item><ce:list-item id="u1775"><ce:label>•</ce:label><ce:para id="p3690">Stent thrombosis associated with MI when detected by coronary angiography or postmortem in the setting of myocardial ischaemia and with a rise and/or fall of cardiac biomarker values with at least one value above the 99th centile URL</ce:para></ce:list-item><ce:list-item id="u1780"><ce:label>•</ce:label><ce:para id="p3695">Coronary artery bypass grafting (CABG)-related MI is arbitrarily defined by elevation of cardiac biomarker values (&#x003E; 10 × 99th centile URL) in patients with normal baseline cTn values (≤ 99th centile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality is required</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0275" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0605" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1120" role="short">Image 48</ce:alt-text></ce:inline-figure>16.48</ce:label><ce:alt-text id="atte1125" role="short">16.48</ce:alt-text><ce:source>Adapted from Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33:2551–2267.</ce:source><ce:textbox-head><ce:title id="tit0280">Criteria for diagnosis of a prior myocardial infarction</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3700"><ce:list id="ulist0550"><ce:list-item id="u1785"><ce:label>•</ce:label><ce:para id="p3705">Pathological Q waves with or without symptoms in the absence of non-ischaemic causes</ce:para></ce:list-item><ce:list-item id="u1790"><ce:label>•</ce:label><ce:para id="p3710">Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischaemic cause</ce:para></ce:list-item><ce:list-item id="u1795"><ce:label>•</ce:label><ce:para id="p3715">Pathological findings of a prior myocardial infarction</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0280" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0620" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000160/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1130" role="short">Image 49</ce:alt-text></ce:inline-figure>16.49</ce:label><ce:alt-text id="atte1135" role="short">16.49</ce:alt-text><ce:textbox-head><ce:title id="tit0285">Clinical features of acute coronary syndromes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3735"><ce:display><ce:table frame="topbot" id="t0130"><ce:alt-text id="atte1140" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Symptoms</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0555"><ce:list-item id="u1800"><ce:label>•</ce:label><ce:para id="p3740">Prolonged cardiac pain: chest, throat, arms, epigastrium or back</ce:para></ce:list-item><ce:list-item id="u1805"><ce:label>•</ce:label><ce:para id="p3745">Anxiety and fear of impending death</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0560"><ce:list-item id="u1810"><ce:label>•</ce:label><ce:para id="p3750">Nausea and vomiting</ce:para></ce:list-item><ce:list-item id="u1815"><ce:label>•</ce:label><ce:para id="p3755">Breathlessness</ce:para></ce:list-item><ce:list-item id="u1820"><ce:label>•</ce:label><ce:para id="p3760">Collapse/syncope</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Physical signs</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Signs of sympathetic activation</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0570"><ce:list-item id="u1830"><ce:para id="p3770"><ce:list id="ulist0575"><ce:list-item id="u1835"><ce:label>•</ce:label><ce:para id="p3775">Pallor</ce:para></ce:list-item><ce:list-item id="u1840"><ce:label>•</ce:label><ce:para id="p3780">Sweating</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0580"><ce:list-item id="u1845"><ce:para id="p3785"><ce:list id="ulist0585"><ce:list-item id="u1850"><ce:label>•</ce:label><ce:para id="p3790">Tachycardia</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Signs of vagal activation</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0595"><ce:list-item id="u1860"><ce:para id="p3800"><ce:list id="ulist0600"><ce:list-item id="u1865"><ce:label>•</ce:label><ce:para id="p3805">Vomiting</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0605"><ce:list-item id="u1870"><ce:para id="p3810"><ce:list id="ulist0610"><ce:list-item id="u1875"><ce:label>•</ce:label><ce:para id="p3815">Bradycardia</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Signs of impaired myocardial function</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0620"><ce:list-item id="u1885"><ce:para id="p3825"><ce:list id="ulist0625"><ce:list-item id="u1890"><ce:label>•</ce:label><ce:para id="p3830">Hypotension, oliguria, cold peripheries</ce:para></ce:list-item><ce:list-item id="u1895"><ce:label>•</ce:label><ce:para id="p3835">Narrow pulse pressure</ce:para></ce:list-item><ce:list-item id="u1900"><ce:label>•</ce:label><ce:para id="p3840">Raised jugular venous pressure</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0630"><ce:list-item id="u1910"><ce:para id="p3850"><ce:list id="ulist0635"><ce:list-item id="u1905"><ce:label>•</ce:label><ce:para id="p3845">Third heart sound</ce:para></ce:list-item><ce:list-item id="u1915"><ce:label>•</ce:label><ce:para id="p3855">Quiet first heart sound</ce:para></ce:list-item><ce:list-item id="u1920"><ce:label>•</ce:label><ce:para id="p3860">Diffuse apical impulse</ce:para></ce:list-item><ce:list-item id="u1925"><ce:label>•</ce:label><ce:para id="p3865">Lung crepitations</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Low-grade fever</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Complications</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0650"><ce:list-item id="u1940"><ce:para id="p3880"><ce:list id="ulist0655"><ce:list-item id="u1945"><ce:label>•</ce:label><ce:para id="p3885">Mitral regurgitation</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0660"><ce:list-item id="u1950"><ce:para id="p3890"><ce:list id="ulist0665"><ce:list-item id="u1955"><ce:label>•</ce:label><ce:para id="p3895">Pericarditis</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0285" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0625" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1145" role="short">Image 50</ce:alt-text></ce:inline-figure>16.50</ce:label><ce:alt-text id="atte1150" role="short">16.50</ce:alt-text><ce:textbox-head><ce:title id="tit0290">Common arrhythmias in acute coronary syndrome</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3905"><ce:display><ce:table frame="topbot" id="t0135"><ce:alt-text id="atte1155" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist0670"><ce:list-item id="u1960"><ce:label>•</ce:label><ce:para id="p3910">Ventricular fibrillation</ce:para></ce:list-item><ce:list-item id="u1965"><ce:label>•</ce:label><ce:para id="p3915">Ventricular tachycardia</ce:para></ce:list-item><ce:list-item id="u1970"><ce:label>•</ce:label><ce:para id="p3920">Accelerated idioventricular rhythm</ce:para></ce:list-item><ce:list-item id="u1975"><ce:label>•</ce:label><ce:para id="p3925">Ventricular ectopics</ce:para></ce:list-item><ce:list-item id="u1980"><ce:label>•</ce:label><ce:para id="p3930">Atrial fibrillation</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0675"><ce:list-item id="u1985"><ce:label>•</ce:label><ce:para id="p3935">Atrial tachycardia</ce:para></ce:list-item><ce:list-item id="u1990"><ce:label>•</ce:label><ce:para id="p3940">Sinus bradycardia (particularly after inferior myocardial infarction)</ce:para></ce:list-item><ce:list-item id="u1995"><ce:label>•</ce:label><ce:para id="p3945">Atrioventricular block</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0290" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0655" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1160" role="short">Image 51</ce:alt-text></ce:inline-figure>16.51</ce:label><ce:alt-text id="atte1165" role="short">16.51</ce:alt-text><ce:textbox-head><ce:title id="tit0295">Late management of myocardial infarction</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4040"><ce:display><ce:table frame="topbot" id="t0140"><ce:alt-text id="atte1170" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Risk stratification and further investigation (see text)</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Lifestyle modification</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0680"><ce:list-item id="u2000"><ce:label>•</ce:label><ce:para id="p4045">Diet (weight control, lipid-lowering, ‘Mediterranean diet’)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0685"><ce:list-item id="u2005"><ce:label>•</ce:label><ce:para id="p4050">Cessation of smoking</ce:para></ce:list-item><ce:list-item id="u2010"><ce:label>•</ce:label><ce:para id="p4055">Regular exercise</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Secondary prevention drug therapy</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0690"><ce:list-item id="u2015"><ce:label>•</ce:label><ce:para id="p4060">Antiplatelet therapy (aspirin and/or clopidogrel)</ce:para></ce:list-item><ce:list-item id="u2020"><ce:label>•</ce:label><ce:para id="p4065">β-blocker</ce:para></ce:list-item><ce:list-item id="u2025"><ce:label>•</ce:label><ce:para id="p4070">ACE inhibitor/ARB</ce:para></ce:list-item><ce:list-item id="u2030"><ce:label>•</ce:label><ce:para id="p4075">Statin</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0695"><ce:list-item id="u2035"><ce:label>•</ce:label><ce:para id="p4080">Additional therapy for control of diabetes and hypertension</ce:para></ce:list-item><ce:list-item id="u2040"><ce:label>•</ce:label><ce:para id="p4085">Mineralocorticoid receptor antagonist</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Rehabilitation</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Devices</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0700"><ce:list-item id="u2045"><ce:label>•</ce:label><ce:para id="p4090">Implantable cardiac defibrillator (high-risk patients)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p4095">(ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0295" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0665" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1175" role="short">Image 52</ce:alt-text></ce:inline-figure>16.52</ce:label><ce:alt-text id="atte1180" role="short">16.52</ce:alt-text><ce:textbox-head><ce:title id="tit0300">Relative contraindications to thrombolytic therapy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4115"><ce:list id="ulist0705"><ce:list-item id="u2050"><ce:label>•</ce:label><ce:para id="p4120">Active internal bleeding</ce:para></ce:list-item><ce:list-item id="u2055"><ce:label>•</ce:label><ce:para id="p4125">Previous subarachnoid or intracerebral haemorrhage</ce:para></ce:list-item><ce:list-item id="u2060"><ce:label>•</ce:label><ce:para id="p4130">Uncontrolled hypertension</ce:para></ce:list-item><ce:list-item id="u2065"><ce:label>•</ce:label><ce:para id="p4135">Recent surgery (within 1 month)</ce:para></ce:list-item><ce:list-item id="u2070"><ce:label>•</ce:label><ce:para id="p4140">Recent trauma (including traumatic resuscitation)</ce:para></ce:list-item><ce:list-item id="u2075"><ce:label>•</ce:label><ce:para id="p4145">High probability of active peptic ulcer</ce:para></ce:list-item><ce:list-item id="u2080"><ce:label>•</ce:label><ce:para id="p4150">Pregnancy</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0300" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0670" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000160/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1185" role="short">Image 53</ce:alt-text></ce:inline-figure>16.53</ce:label><ce:alt-text id="atte1190" role="short">16.53</ce:alt-text><ce:textbox-head><ce:title id="tit0305">Myocardial infarction in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4165"><ce:list id="ulist0710"><ce:list-item id="u2085"><ce:label>•</ce:label><ce:para id="p4170"><ce:bold>Atypical presentation</ce:bold>: often with anorexia, fatigue, weakness, delirium or falls rather than chest pain.</ce:para></ce:list-item><ce:list-item id="u2090"><ce:label>•</ce:label><ce:para id="p4175"><ce:bold>Case fatality</ce:bold>: rises steeply. Hospital mortality exceeds 25% in those over 75 years old, which is five times greater than that seen in those aged less than 55 years.</ce:para></ce:list-item><ce:list-item id="u2095"><ce:label>•</ce:label><ce:para id="p4180"><ce:bold>Survival benefit of treatments</ce:bold>: not influenced by age. The absolute benefit of evidence-based treatments may therefore be greatest in older people.</ce:para></ce:list-item><ce:list-item id="u2100"><ce:label>•</ce:label><ce:para id="p4185"><ce:bold>Hazards of treatments</ce:bold>: rise with age (for example, increased risk of intracerebral bleeding after thrombolysis) and are due partly to increased comorbidity.</ce:para></ce:list-item><ce:list-item id="u2105"><ce:label>•</ce:label><ce:para id="p4190"><ce:bold>Quality of evidence</ce:bold>: older patients, particularly those with significant comorbidity, were under-represented in many of the randomised controlled clinical trials that helped to establish the treatment of myocardial infarction. The balance of risk and benefit for many treatments, such as thrombolysis and primary percutaneous transluminal coronary angiography, in frail older people is uncertain.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0305" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0675" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1195" role="short">Image 54</ce:alt-text></ce:inline-figure>16.54</ce:label><ce:alt-text id="atte1200" role="short">16.54</ce:alt-text><ce:textbox-head><ce:title id="tit0310">Major risk factors for cardiac complications of non-cardiac surgery</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4245"><ce:list id="ulist0715"><ce:list-item id="u2110"><ce:label>•</ce:label><ce:para id="p4250">Recent (&#x003C; 6 months) myocardial infarction or unstable angina</ce:para></ce:list-item><ce:list-item id="u2115"><ce:label>•</ce:label><ce:para id="p4255">Severe coronary artery disease: left main stem or three-vessel disease</ce:para></ce:list-item><ce:list-item id="u2120"><ce:label>•</ce:label><ce:para id="p4260">Severe stable angina on effort</ce:para></ce:list-item><ce:list-item id="u2125"><ce:label>•</ce:label><ce:para id="p4265">Severe left ventricular dysfunction</ce:para></ce:list-item><ce:list-item id="u2130"><ce:label>•</ce:label><ce:para id="p4270">Severe valvular heart disease (especially aortic stenosis)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0310" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0680" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1205" role="short">Image 55</ce:alt-text></ce:inline-figure>16.55</ce:label><ce:alt-text id="atte1210" role="short">16.55</ce:alt-text><ce:textbox-head><ce:title id="tit0315">Factors influencing the clinical manifestations of peripheral arterial disease (PAD)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1565"><ce:section-title id="st1460">Anatomical site</ce:section-title><ce:section id="s1570"><ce:section-title id="st1465">Cerebral circulation</ce:section-title><ce:para id="p4300"><ce:list id="ulist0720"><ce:list-item id="u2135"><ce:label>•</ce:label><ce:para id="p4305">TIA, amaurosis fugax, vertebrobasilar insufficiency</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1575"><ce:section-title id="st1470">Renal arteries</ce:section-title><ce:para id="p4310"><ce:list id="ulist0725"><ce:list-item id="u2140"><ce:label>•</ce:label><ce:para id="p4315">Hypertension and renal failure</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1580"><ce:section-title id="st1475">Mesenteric arteries</ce:section-title><ce:para id="p4320"><ce:list id="ulist0730"><ce:list-item id="u2145"><ce:label>•</ce:label><ce:para id="p4325">Mesenteric angina, acute intestinal ischaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1585"><ce:section-title id="st1480">Limbs (legs ≫ arms)</ce:section-title><ce:para id="p4330"><ce:list id="ulist0735"><ce:list-item id="u2150"><ce:label>•</ce:label><ce:para id="p4335">Intermittent claudication, critical limb ischaemia, acute limb ischaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s1590"><ce:section-title id="st1485">Collateral supply</ce:section-title><ce:para id="p4340"><ce:list id="ulist0740"><ce:list-item id="u2155"><ce:label>•</ce:label><ce:para id="p4345">In a patient with a complete circle of Willis, occlusion of one carotid artery may be asymptomatic</ce:para></ce:list-item><ce:list-item id="u2160"><ce:label>•</ce:label><ce:para id="p4350">In a patient without cross-circulation, stroke is likely</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1595"><ce:section-title id="st1490">Speed of onset</ce:section-title><ce:para id="p4355"><ce:list id="ulist0745"><ce:list-item id="u2165"><ce:label>•</ce:label><ce:para id="p4360">Where PAD develops slowly, a collateral supply will develop</ce:para></ce:list-item><ce:list-item id="u2170"><ce:label>•</ce:label><ce:para id="p4365">Sudden occlusion of a previously normal artery is likely to cause severe distal ischaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1600"><ce:section-title id="st1495">Mechanism of injury</ce:section-title><ce:section id="s1605"><ce:section-title id="st1500">Haemodynamic</ce:section-title><ce:para id="p4370"><ce:list id="ulist0750"><ce:list-item id="u2175"><ce:label>•</ce:label><ce:para id="p4375">Plaque must reduce arterial diameter by 70% (‘critical stenosis’) to reduce flow and pressure at rest. On exertion a moderate stenosis may become ‘critical’. This mechanism tends to have a relatively benign course due to collateralisation</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1610"><ce:section-title id="st1505">Thrombotic</ce:section-title><ce:para id="p4380"><ce:list id="ulist0755"><ce:list-item id="u2180"><ce:label>•</ce:label><ce:para id="p4385">Occlusion of a long-standing critical stenosis may be asymptomatic due to collateralisation. However, acute rupture and thrombosis of a non-haemodynamically significant plaque usually has severe consequences</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1615"><ce:section-title id="st1510">Atheroembolic</ce:section-title><ce:para id="p4390"><ce:list id="ulist0760"><ce:list-item id="u2185"><ce:label>•</ce:label><ce:para id="p4395">Symptoms depend on embolic load and size</ce:para></ce:list-item><ce:list-item id="u2190"><ce:label>•</ce:label><ce:para id="p4400">Carotid (TIA, amaurosis fugax or stroke) and peripheral arterial (blue toe/finger syndrome) plaque are common examples</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1620"><ce:section-title id="st1515">Thromboembolic</ce:section-title><ce:para id="p4405"><ce:list id="ulist0765"><ce:list-item id="u2195"><ce:label>•</ce:label><ce:para id="p4410">Usually secondary to atrial fibrillation</ce:para></ce:list-item><ce:list-item id="u2200"><ce:label>•</ce:label><ce:para id="p4415">The consequences are usually dramatic, as the thrombus load is often large and occludes a major, previously healthy, non-collateralised artery suddenly and completely</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4420">(TIA = transient ischaemic attack)</ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0315" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0685" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1215" role="short">Image 56</ce:alt-text></ce:inline-figure>16.56</ce:label><ce:alt-text id="atte1220" role="short">16.56</ce:alt-text><ce:textbox-head><ce:title id="tit0320">Peripheral vascular disease in diabetes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4425"><ce:display><ce:table frame="topbot" id="t0145"><ce:alt-text id="atte1225" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Feature</entry><entry align="left">Difficulty</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Arterial calcification</ce:bold></entry><entry align="left">Spuriously high ABPI due to incompressible ankle vessels. Inability to clamp arteries for the purposes of bypass surgery. Resistant to angioplasty</entry></row><row rowsep="1"><entry align="left"><ce:bold>Immunocompromise</ce:bold></entry><entry align="left">Prone to rapidly spreading cellulitis, gangrene and osteomyelitis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Multisystem arterial disease</ce:bold></entry><entry align="left">Coronary and cerebral arterial disease increase the risks of intervention</entry></row><row rowsep="1"><entry align="left"><ce:bold>Distal disease</ce:bold></entry><entry align="left">Diabetic vascular disease has a predilection for the calf vessels. Although vessels in the foot are often spared, performing a satisfactory bypass or angioplasty to these small vessels is a technical challenge</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sensory neuropathy</ce:bold></entry><entry align="left">Even severe ischaemia and/or tissue loss may be completely painless. Diabetic patients often present late with extensive destruction of the foot. Loss of proprioception leads to abnormal pressure loads and worsens joint destruction (Charcot joints)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Motor neuropathy</ce:bold></entry><entry align="left">Weakness of the long and short flexors and extensors leads to abnormal foot architecture, abnormal pressure loads, callus formation and ulceration</entry></row><row><entry align="left"><ce:bold>Autonomic neuropathy</ce:bold></entry><entry align="left">Leads to a dry foot deficient in sweat that normally lubricates the skin and is antibacterial. Scaling and fissuring create a portal of entry for bacteria. Abnormal blood flow in the bones of the ankle and foot may also contribute to osteopenia and bony collapse</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0675">(ABPI = ankle–brachial pressure index)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0320" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0695" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000160/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1230" role="short">Image 57</ce:alt-text></ce:inline-figure>16.57</ce:label><ce:alt-text id="atte1235" role="short">16.57</ce:alt-text><ce:textbox-head><ce:title id="tit0325">Symptoms AND signs of acute limb ischaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4450"><ce:display><ce:figure id="f0395"><ce:alt-text id="atte1240" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0700" locator="b016-058-9780702070280" xlink:href="pii:B9780702070280000160/b016-058-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0325" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0705" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1245" role="short">Image 58</ce:alt-text></ce:inline-figure>16.58</ce:label><ce:alt-text id="atte1250" role="short">16.58</ce:alt-text><ce:textbox-head><ce:title id="tit0330">Distinguishing features of embolism and thrombosis in peripheral arteries</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4455"><ce:display><ce:table frame="topbot" id="t0150"><ce:alt-text id="atte1255" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Clinical features</entry><entry align="left">Embolism</entry><entry align="left">Thrombosis</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Severity</ce:bold></entry><entry align="left">Complete (no collaterals)</entry><entry align="left">Incomplete (collaterals)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Onset</ce:bold></entry><entry align="left">Seconds or minutes</entry><entry align="left">Hours or days</entry></row><row rowsep="1"><entry align="left"><ce:bold>Limb</ce:bold></entry><entry align="left">Leg 3 : 1 arm</entry><entry align="left">Leg 10 : 1 arm</entry></row><row rowsep="1"><entry align="left"><ce:bold>Multiple sites</ce:bold></entry><entry align="left">Up to 15%</entry><entry align="left">Rare</entry></row><row rowsep="1"><entry align="left"><ce:bold>Embolic source</ce:bold></entry><entry align="left">Present (usually atrial fibrillation)</entry><entry align="left">Absent</entry></row><row rowsep="1"><entry align="left"><ce:bold>Previous claudication</ce:bold></entry><entry align="left">Absent</entry><entry align="left">Present</entry></row><row rowsep="1"><entry align="left"><ce:bold>Palpation of artery</ce:bold></entry><entry align="left">Soft, tender</entry><entry align="left">Hard, calcified</entry></row><row rowsep="1"><entry align="left"><ce:bold>Bruits</ce:bold></entry><entry align="left">Absent</entry><entry align="left">Present</entry></row><row rowsep="1"><entry align="left"><ce:bold>Contralateral leg pulses</ce:bold></entry><entry align="left">Present</entry><entry align="left">Absent</entry></row><row rowsep="1"><entry align="left"><ce:bold>Diagnosis</ce:bold></entry><entry align="left">Clinical</entry><entry align="left">Angiography</entry></row><row rowsep="1"><entry align="left"><ce:bold>Treatment</ce:bold></entry><entry align="left">Embolectomy, warfarin</entry><entry align="left">Medical, bypass, thrombolysis</entry></row><row><entry align="left"><ce:bold>Prognosis</ce:bold></entry><entry align="left">Loss of life &#x003E; loss of limb</entry><entry align="left">Loss of limb &#x003E; loss of life</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0330" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0710" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1260" role="short">Image 59</ce:alt-text></ce:inline-figure>16.59</ce:label><ce:alt-text id="atte1265" role="short">16.59</ce:alt-text><ce:textbox-head><ce:title id="tit0335">Clinical features of chronic lower limb ischaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4475"><ce:list id="ulist0770"><ce:list-item id="u2205"><ce:label>•</ce:label><ce:para id="p4480">Pulses: diminished or absent</ce:para></ce:list-item><ce:list-item id="u2210"><ce:label>•</ce:label><ce:para id="p4485">Bruits: denote turbulent flow but bear no relationship to the severity of the underlying disease</ce:para></ce:list-item><ce:list-item id="u2215"><ce:label>•</ce:label><ce:para id="p4490">Reduced skin temperature</ce:para></ce:list-item><ce:list-item id="u2220"><ce:label>•</ce:label><ce:para id="p4495">Pallor on elevation and rubor on dependency (Buerger's sign)</ce:para></ce:list-item><ce:list-item id="u2225"><ce:label>•</ce:label><ce:para id="p4500">Superficial veins that fill sluggishly and empty (‘gutter’) on minimal elevation</ce:para></ce:list-item><ce:list-item id="u2230"><ce:label>•</ce:label><ce:para id="p4505">Muscle-wasting</ce:para></ce:list-item><ce:list-item id="u2235"><ce:label>•</ce:label><ce:para id="p4510">Skin and nails: dry, thin and brittle</ce:para></ce:list-item><ce:list-item id="u2240"><ce:label>•</ce:label><ce:para id="p4515">Loss of hair</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0335" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0715" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1270" role="short">Image 60</ce:alt-text></ce:inline-figure>16.60</ce:label><ce:alt-text id="atte1275" role="short">16.60</ce:alt-text><ce:textbox-head><ce:title id="tit0340">Medical therapy for peripheral arterial disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4525"><ce:list id="ulist0775"><ce:list-item id="u2245"><ce:label>•</ce:label><ce:para id="p4530">Smoking cessation</ce:para></ce:list-item><ce:list-item id="u2250"><ce:label>•</ce:label><ce:para id="p4535">Regular exercise (30 mins of walking, three times per week)</ce:para></ce:list-item><ce:list-item id="u2255"><ce:label>•</ce:label><ce:para id="p4540">Antiplatelet agent (aspirin 75 mg or clopidogrel 75 mg daily)</ce:para></ce:list-item><ce:list-item id="u2260"><ce:label>•</ce:label><ce:para id="p4545">Reduction of cholesterol:<ce:list id="ulist0780"><ce:list-item id="u2265"><ce:para id="p4550">Statins</ce:para></ce:list-item><ce:list-item id="u2270"><ce:para id="p4555">Diet</ce:para></ce:list-item><ce:list-item id="u2275"><ce:para id="p4560">Weight loss</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2280"><ce:label>•</ce:label><ce:para id="p4565">Diagnosis and treatment of diabetes mellitus</ce:para></ce:list-item><ce:list-item id="u2285"><ce:label>•</ce:label><ce:para id="p4570">Diagnosis and treatment of associated conditions:<ce:list id="ulist0785"><ce:list-item id="u2290"><ce:para id="p4575">Hypertension</ce:para></ce:list-item><ce:list-item id="u2295"><ce:para id="p4580">Anaemia</ce:para></ce:list-item><ce:list-item id="u2300"><ce:para id="p4585">Heart failure</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0340" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0720" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000160/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1280" role="short">Image 61</ce:alt-text></ce:inline-figure>16.61</ce:label><ce:alt-text id="atte1285" role="short">16.61</ce:alt-text><ce:textbox-head><ce:title id="tit0345">Atherosclerotic vascular disease in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4595"><ce:list id="ulist0790"><ce:list-item id="u2305"><ce:label>•</ce:label><ce:para id="p4600"><ce:bold>Prevalence</ce:bold>: related almost exponentially to age in developed countries, although atherosclerosis is not considered part of the normal ageing process.</ce:para></ce:list-item><ce:list-item id="u2310"><ce:label>•</ce:label><ce:para id="p4605"><ce:bold>Statin therapy</ce:bold>: no role in the primary prevention of atherosclerotic disease in those over 75 years but reduces cardiovascular events in those with established vascular disease, albeit with no reduction in overall mortality.</ce:para></ce:list-item><ce:list-item id="u2315"><ce:label>•</ce:label><ce:para id="p4610"><ce:bold>Presentation in the frail</ce:bold>: frequently with advanced multisystem arterial disease, along with a host of other comorbidities.</ce:para></ce:list-item><ce:list-item id="u2320"><ce:label>•</ce:label><ce:para id="p4615"><ce:bold>Intervention in the frail</ce:bold>: in those with extensive disease and limited life expectancy, the risks of surgery may outweigh the benefits, and symptomatic care is all that should be offered.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0345" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0730" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1290" role="short">Image 62</ce:alt-text></ce:inline-figure>16.62</ce:label><ce:alt-text id="atte1295" role="short">16.62</ce:alt-text><ce:textbox-head><ce:title id="tit0350">Abdominal aortic aneurysm (AAA): common presentations</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1700"><ce:section-title id="st1590">Incidental</ce:section-title><ce:para id="p4645"><ce:list id="ulist0795"><ce:list-item id="u2325"><ce:label>•</ce:label><ce:para id="p4650">On physical examination, plain X-ray or, most commonly, abdominal ultrasound</ce:para></ce:list-item><ce:list-item id="u2330"><ce:label>•</ce:label><ce:para id="p4655">Even large AAAs can be difficult to feel, so many remain undetected until they rupture</ce:para></ce:list-item><ce:list-item id="u2335"><ce:label>•</ce:label><ce:para id="p4660">Studies are currently under way to determine whether screening will reduce the number of deaths from rupture</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1705"><ce:section-title id="st1595">Pain</ce:section-title><ce:para id="p4665"><ce:list id="ulist0800"><ce:list-item id="u2340"><ce:label>•</ce:label><ce:para id="p4670">In the central abdomen, back, loin, iliac fossa or groin</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1710"><ce:section-title id="st1600">Thromboembolic complications</ce:section-title><ce:para id="p4675"><ce:list id="ulist0805"><ce:list-item id="u2345"><ce:label>•</ce:label><ce:para id="p4680">Thrombus within the aneurysm sac may be a source of emboli to the lower limbs</ce:para></ce:list-item><ce:list-item id="u2350"><ce:label>•</ce:label><ce:para id="p4685">Less commonly, the aorta may undergo thrombotic occlusion</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1715"><ce:section-title id="st1605">Compression</ce:section-title><ce:para id="p4690"><ce:list id="ulist0810"><ce:list-item id="u2355"><ce:label>•</ce:label><ce:para id="p4695">Surrounding structures such as the duodenum (obstruction and vomiting) and the inferior vena cava (oedema and deep vein thrombosis)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1720"><ce:section-title id="st1610">Rupture</ce:section-title><ce:para id="p4700"><ce:list id="ulist0815"><ce:list-item id="u2360"><ce:label>•</ce:label><ce:para id="p4705">Into the retroperitoneum, the peritoneal cavity or surrounding structures (most commonly the inferior vena cava, leading to an aortocaval fistula)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0350" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0735" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1300" role="short">Image 63</ce:alt-text></ce:inline-figure>16.63</ce:label><ce:alt-text id="atte1305" role="short">16.63</ce:alt-text><ce:textbox-head><ce:title id="tit0355">Risk factors for aortic dissection</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4735"><ce:display><ce:table frame="topbot" id="t0155"><ce:alt-text id="atte1310" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist0820"><ce:list-item id="u2365"><ce:label>•</ce:label><ce:para id="p4740">Hypertension (in 80%)</ce:para></ce:list-item><ce:list-item id="u2370"><ce:label>•</ce:label><ce:para id="p4745">Atherosclerosis</ce:para></ce:list-item><ce:list-item id="u2375"><ce:label>•</ce:label><ce:para id="p4750">Coarctation</ce:para></ce:list-item><ce:list-item id="u2380"><ce:label>•</ce:label><ce:para id="p4755">Genetic:<ce:list id="ulist0825"><ce:list-item id="u2385"><ce:para id="p4760">Marfan's syndrome</ce:para></ce:list-item><ce:list-item id="u2390"><ce:para id="p4765">Ehlers–Danlos syndrome</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2395"><ce:label>•</ce:label><ce:para id="p4770">Fibromuscular dysplasia</ce:para></ce:list-item><ce:list-item id="u2400"><ce:label>•</ce:label><ce:para id="p4775">Previous cardiac surgery:<ce:list id="ulist0835"><ce:list-item id="u2405"><ce:para id="p4780">CABG</ce:para></ce:list-item><ce:list-item id="u2410"><ce:para id="p4785">Aortic valve replacement</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0830"><ce:list-item id="u2415"><ce:label>•</ce:label><ce:para id="p4790">Pregnancy (usually third trimester)</ce:para></ce:list-item><ce:list-item id="u2420"><ce:label>•</ce:label><ce:para id="p4795">Trauma</ce:para></ce:list-item><ce:list-item id="u2425"><ce:label>•</ce:label><ce:para id="p4800">Iatrogenic:<ce:list id="ulist0840"><ce:list-item id="u2430"><ce:para id="p4805">Cardiac catheterisation</ce:para></ce:list-item><ce:list-item id="u2435"><ce:para id="p4810">Intra-aortic balloon pumping</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p4815">(CABG = coronary artery bypass grafting)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0355" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0755" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1315" role="short">Image 64</ce:alt-text></ce:inline-figure>16.64</ce:label><ce:alt-text id="atte1320" role="short">16.64</ce:alt-text><ce:textbox-head><ce:title id="tit0360">Definition of hypertension</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4880"><ce:display><ce:table frame="topbot" id="t0160"><ce:alt-text id="atte1325" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Category</entry><entry align="left">Systolic blood pressure (mmHg)</entry><entry align="left">Diastolic blood pressure (mmHg)</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Blood pressure</ce:bold></entry></row><row rowsep="0"><entry align="left">Optimal</entry><entry align="left">&#x003C; 120</entry><entry align="left">&#x003C; 80</entry></row><row rowsep="0"><entry align="left">Normal</entry><entry align="left">&#x003C; 130</entry><entry align="left">85</entry></row><row rowsep="1"><entry align="left">High normal</entry><entry align="left">130–139</entry><entry align="left">85–89</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Hypertension</ce:bold></entry></row><row rowsep="0"><entry align="left">Grade 1 (mild)</entry><entry align="left">140–159</entry><entry align="left">90–99</entry></row><row rowsep="0"><entry align="left">Grade 2 (moderate)</entry><entry align="left">160–179</entry><entry align="left">100–109</entry></row><row rowsep="1"><entry align="left">Grade 3 (severe)</entry><entry align="left">≥ 180</entry><entry align="left">&#x003E; 110</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Isolated systolic hypertension</ce:bold></entry></row><row rowsep="0"><entry align="left">Grade 1</entry><entry align="left">140–159</entry><entry align="left">&#x003C; 90</entry></row><row><entry align="left">Grade 2</entry><entry align="left">≥ 160</entry><entry align="left">&#x003C; 90</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0360" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0760" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1330" role="short">Image 65</ce:alt-text></ce:inline-figure>16.65</ce:label><ce:alt-text id="atte1335" role="short">16.65</ce:alt-text><ce:textbox-head><ce:title id="tit0365">Causes of secondary hypertension</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4890"><ce:display><ce:table frame="topbot" id="t0165"><ce:alt-text id="atte1340" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Alcohol</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Obesity</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Pregnancy</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Renal disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0845"><ce:list-item id="u2440"><ce:label>•</ce:label><ce:para id="p4895">Parenchymal renal disease, particularly glomerulonephritis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0850"><ce:list-item id="u2445"><ce:label>•</ce:label><ce:para id="p4900">Renal vascular disease</ce:para></ce:list-item><ce:list-item id="u2450"><ce:label>•</ce:label><ce:para id="p4905">Polycystic kidney disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Endocrine disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0855"><ce:list-item id="u2455"><ce:label>•</ce:label><ce:para id="p4910">Phaeochromocytoma</ce:para></ce:list-item><ce:list-item id="u2460"><ce:label>•</ce:label><ce:para id="p4915">Cushing's syndrome</ce:para></ce:list-item><ce:list-item id="u2465"><ce:label>•</ce:label><ce:para id="p4920">Primary hyperaldosteronism (Conn's syndrome)</ce:para></ce:list-item><ce:list-item id="u2470"><ce:label>•</ce:label><ce:para id="p4925">Glucocorticoid-suppressible hyperaldosteronism</ce:para></ce:list-item><ce:list-item id="u2475"><ce:label>•</ce:label><ce:para id="p4930">Hyperparathyroidism</ce:para></ce:list-item><ce:list-item id="u2480"><ce:label>•</ce:label><ce:para id="p4935">Acromegaly</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0860"><ce:list-item id="u2490"><ce:label>•</ce:label><ce:para id="p4945">Thyrotoxicosis</ce:para></ce:list-item><ce:list-item id="u2495"><ce:label>•</ce:label><ce:para id="p4950">Congenital adrenal hyperplasia due to 11β-hydroxylase or 17α-hydroxylase deficiency</ce:para></ce:list-item><ce:list-item id="u2500"><ce:label>•</ce:label><ce:para id="p4955">Liddle's syndrome (<ce:intra-ref id="ii0610" xlink:href="pii:B978-0-7020-7028-0.00014-7#s0310">p. 361</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u2505"><ce:label>•</ce:label><ce:para id="p4960">11β-hydroxysteroid dehydrogenase deficiency</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs</ce:bold></entry></row><row role="thead2"><entry namest="col1" nameend="col2" align="left"><ce:bold>Coarctation of the aorta</ce:bold></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0365" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0775" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1345" role="short">Image 66</ce:alt-text></ce:inline-figure>16.66</ce:label><ce:alt-text id="atte1350" role="short">16.66</ce:alt-text><ce:textbox-head><ce:title id="tit0370">Hypertensive retinopathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1820"><ce:section-title id="st1695">Grade 1</ce:section-title><ce:para id="p4980"><ce:list id="ulist0865"><ce:list-item id="u2510"><ce:label>•</ce:label><ce:para id="p4985">Arteriolar thickening, tortuosity and increased reflectiveness (‘silver wiring’)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1825"><ce:section-title id="st1700">Grade 2</ce:section-title><ce:para id="p4990"><ce:list id="ulist0870"><ce:list-item id="u2515"><ce:label>•</ce:label><ce:para id="p4995">Grade 1 plus constriction of veins at arterial crossings (‘arteriovenous nipping’)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1830"><ce:section-title id="st1705">Grade 3</ce:section-title><ce:para id="p5000"><ce:list id="ulist0875"><ce:list-item id="u2520"><ce:label>•</ce:label><ce:para id="p5005">Grade 2 plus evidence of retinal ischaemia (flame-shaped or blot haemorrhages and ‘cotton wool’ exudates)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1835"><ce:section-title id="st1710">Grade 4</ce:section-title><ce:para id="p5010"><ce:list id="ulist0880"><ce:list-item id="u2525"><ce:label>•</ce:label><ce:para id="p5015">Grade 3 plus papilloedema</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0370" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0780" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000160/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1355" role="short">Image 67</ce:alt-text></ce:inline-figure>16.67</ce:label><ce:alt-text id="atte1360" role="short">16.67</ce:alt-text><ce:textbox-head><ce:title id="tit0375">How to measure blood pressure</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5055"><ce:list id="ulist0890"><ce:list-item id="u2555"><ce:label>•</ce:label><ce:para id="p5060">Use a machine that has been validated, well maintained and properly calibrated</ce:para></ce:list-item><ce:list-item id="u2560"><ce:label>•</ce:label><ce:para id="p5065">Measure sitting BP routinely, with additional standing BP in elderly and diabetic patients and those with possible postural hypotension; rest the patient for 2 minutes</ce:para></ce:list-item><ce:list-item id="u2565"><ce:label>•</ce:label><ce:para id="p5070">Remove tight clothing from the arm</ce:para></ce:list-item><ce:list-item id="u2570"><ce:label>•</ce:label><ce:para id="p5075">Support the arm at the level of the heart</ce:para></ce:list-item><ce:list-item id="u2575"><ce:label>•</ce:label><ce:para id="p5080">Use a cuff of appropriate size (the bladder must encompass more than two-thirds of the arm)</ce:para></ce:list-item><ce:list-item id="u2580"><ce:label>•</ce:label><ce:para id="p5085">Lower the pressure slowly (2 mmHg per second)</ce:para></ce:list-item><ce:list-item id="u2585"><ce:label>•</ce:label><ce:para id="p5090">Read the BP to the nearest 2 mmHg</ce:para></ce:list-item><ce:list-item id="u2590"><ce:label>•</ce:label><ce:para id="p5095">Use phase V (disappearance of sounds) to measure diastolic BP</ce:para></ce:list-item><ce:list-item id="u2595"><ce:label>•</ce:label><ce:para id="p5100">Take two measurements at each visit</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0375" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0785" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1365" role="short">Image 68</ce:alt-text></ce:inline-figure>16.68</ce:label><ce:alt-text id="atte1370" role="short">16.68</ce:alt-text><ce:textbox-head><ce:title id="tit0380">Investigation of hypertension</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5120"><ce:list id="ulist0895"><ce:list-item id="u2600"><ce:label>•</ce:label><ce:para id="p5125">Urinalysis for blood, protein and glucose</ce:para></ce:list-item><ce:list-item id="u2605"><ce:label>•</ce:label><ce:para id="p5130">Blood urea, electrolytes and creatinine<ce:list id="ulist0900"><ce:list-item id="u2610"><ce:para id="p5135">Hypokalaemic alkalosis may indicate primary hyperaldosteronism but is usually due to diuretic therapy</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2615"><ce:label>•</ce:label><ce:para id="p5140">Blood glucose</ce:para></ce:list-item><ce:list-item id="u2620"><ce:label>•</ce:label><ce:para id="p5145">Serum total and HDL cholesterol</ce:para></ce:list-item><ce:list-item id="u2625"><ce:label>•</ce:label><ce:para id="p5150">Thyroid function tests</ce:para></ce:list-item><ce:list-item id="u2630"><ce:label>•</ce:label><ce:para id="p5155">12-lead ECG (left ventricular hypertrophy, coronary artery disease)</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p5160">(HDL = high-density lipoprotein)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0380" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0790" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1375" role="short">Image 69</ce:alt-text></ce:inline-figure>16.69</ce:label><ce:alt-text id="atte1380" role="short">16.69</ce:alt-text><ce:textbox-head><ce:title id="tit0385">Specialised investigation of hypertension</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5165"><ce:list id="ulist0905"><ce:list-item id="u2635"><ce:label>•</ce:label><ce:para id="p5170">Chest X-ray: to detect cardiomegaly, heart failure, coarctation of the aorta</ce:para></ce:list-item><ce:list-item id="u2640"><ce:label>•</ce:label><ce:para id="p5175">Ambulatory BP recording: to assess borderline or ‘white coat’ hypertension</ce:para></ce:list-item><ce:list-item id="u2645"><ce:label>•</ce:label><ce:para id="p5180">Echocardiogram: to detect or quantify left ventricular hypertrophy</ce:para></ce:list-item><ce:list-item id="u2650"><ce:label>•</ce:label><ce:para id="p5185">Renal ultrasound: to detect possible renal disease</ce:para></ce:list-item><ce:list-item id="u2655"><ce:label>•</ce:label><ce:para id="p5190">Renal angiography: to detect or confirm the presence of renal artery stenosis</ce:para></ce:list-item><ce:list-item id="u2660"><ce:label>•</ce:label><ce:para id="p5195">Urinary catecholamines: to detect possible phaeochromocytoma (<ce:intra-ref id="ii0645" xlink:href="pii:B978-0-7020-7028-0.00018-4#p4045">p. 675</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u2665"><ce:label>•</ce:label><ce:para id="p5200">Urinary cortisol and dexamethasone suppression test: to detect possible Cushing's syndrome (<ce:intra-ref id="ii0650" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0930">p. 666</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u2670"><ce:label>•</ce:label><ce:para id="p5205">Plasma renin activity and aldosterone: to detect possible primary aldosteronism (<ce:intra-ref id="ii0655" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1165">p. 674</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0385" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0805" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000160/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1385" role="short">Image 70</ce:alt-text></ce:inline-figure>16.70</ce:label><ce:alt-text id="atte1390" role="short">16.70</ce:alt-text><ce:textbox-head><ce:title id="tit0390">Hypertension in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5230"><ce:list id="ulist0910"><ce:list-item id="u2675"><ce:label>•</ce:label><ce:para id="p5235"><ce:bold>Prevalence</ce:bold>: hypertension affects more than half of all people over the age of 60 years (including isolated systolic hypertension).</ce:para></ce:list-item><ce:list-item id="u2680"><ce:label>•</ce:label><ce:para id="p5240"><ce:bold>Risks</ce:bold>: hypertension is the most important risk factor for myocardial infarction, heart failure and stroke in older people.</ce:para></ce:list-item><ce:list-item id="u2685"><ce:label>•</ce:label><ce:para id="p5245"><ce:bold>Benefit of treatment</ce:bold>: absolute benefit from therapy is greatest in older people (at least up to age 80 years).</ce:para></ce:list-item><ce:list-item id="u2690"><ce:label>•</ce:label><ce:para id="p5250"><ce:bold>Target blood pressure</ce:bold>: targets be relaxed in older people to 150/90 mmHg.</ce:para></ce:list-item><ce:list-item id="u2695"><ce:label>•</ce:label><ce:para id="p5255"><ce:bold>Tolerance of treatment</ce:bold>: antihypertensives are tolerated as well as in younger patients.</ce:para></ce:list-item><ce:list-item id="u2700"><ce:label>•</ce:label><ce:para id="p5260"><ce:bold>Drug of choice</ce:bold>: low-dose thiazides but, in the presence of coexistent disease such as gout or diabetes, other agents may be more appropriate.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0390" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0810" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1395" role="short">Image 71</ce:alt-text></ce:inline-figure>16.71</ce:label><ce:alt-text id="atte1400" role="short">16.71</ce:alt-text><ce:textbox-head><ce:title id="tit0395">Optimal target blood pressures<ce:cross-ref id="crf1420" refid="tn0035"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5270"><ce:display><ce:table frame="topbot" id="t0170"><ce:alt-text id="atte1405" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Age</entry><entry align="left">Clinic BP (mmHg)</entry><entry align="left">Ambulatory or home<ce:br/>BP (mmHg)<ce:cross-ref id="crf1425" refid="tn0040"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>&#x003C;</ce:bold> <ce:bold>80</ce:bold> <ce:bold>years</ce:bold></entry><entry align="left">&#x003C; 140/90</entry><entry align="left">&#x003C; 135/85</entry></row><row><entry align="left"><ce:bold>≥</ce:bold> <ce:bold>80</ce:bold> <ce:bold>years</ce:bold></entry><entry align="left">&#x003C; 150/90</entry><entry align="left">&#x003C; 140/85</entry></row></tbody></tgroup><ce:table-footnote id="tn0035"><ce:label>1</ce:label><ce:note-para id="np0050">Both systolic and diastolic values should be attained.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0040"><ce:label>2</ce:label><ce:note-para id="np0055">Average BP during waking hours.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0395" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0815" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1410" role="short">Image 72</ce:alt-text></ce:inline-figure>16.72</ce:label><ce:alt-text id="atte1415" role="short">16.72</ce:alt-text><ce:textbox-head><ce:title id="tit0400">The influence of comorbidity on choice of antihypertensive drug therapy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5340"><ce:display><ce:table frame="topbot" id="t0175"><ce:alt-text id="atte1420" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Class of drug</entry><entry align="left">Compelling indications</entry><entry align="left">Possible indications</entry><entry align="left">Caution</entry><entry align="left">Compelling contraindications</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>α-blockers</ce:bold></entry><entry align="left">Benign prostatic hypertrophy</entry><entry align="left">–</entry><entry align="left">Postural hypotension, heart failure<ce:cross-ref id="crf1435" refid="tn0045"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left">Urinary incontinence</entry></row><row rowsep="1"><entry align="left"><ce:bold>ACE inhibitors</ce:bold></entry><entry align="left">Heart failure<ce:br/>Left ventricular dysfunction, post-MI or established CAD<ce:br/>Type 1 diabetic nephropathy<ce:br/>Secondary stroke prevention<ce:cross-ref id="crf1440" refid="tn0060"><ce:sup loc="post">4</ce:sup></ce:cross-ref></entry><entry align="left">Chronic renal disease<ce:cross-ref id="crf1445" refid="tn0050"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:br/>Type 2 diabetic nephropathy</entry><entry align="left">Renal impairment<ce:cross-ref id="crf1450" refid="tn0050"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:br/>PAD<ce:cross-ref id="crf1455" refid="tn0055"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">Pregnancy<ce:br/>Renovascular disease<ce:cross-ref id="crf1460" refid="tn0050"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold>Angiotensin II receptor blockers</ce:bold></entry><entry align="left">ACE inhibitor intolerance<ce:br/>Type 2 diabetic nephropathy<ce:br/>Hypertension with left ventricular hypertrophy<ce:br/>Heart failure in ACE-intolerant patients, after MI</entry><entry align="left">Left ventricular dysfunction after MI<ce:br/>Intolerance of other antihypertensive drugs<ce:br/>Proteinuric or chronic renal disease<ce:cross-ref id="crf1465" refid="tn0050"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:br/>Heart failure</entry><entry align="left">Renal impairment<ce:cross-ref id="crf1470" refid="tn0050"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:br/>PAD<ce:cross-ref id="crf1475" refid="tn0055"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left">Pregnancy</entry></row><row rowsep="1"><entry align="left"><ce:bold>β-blockers</ce:bold></entry><entry align="left">MI, angina<ce:br/>Heart failure<ce:cross-ref id="crf1480" refid="tn0065"><ce:sup loc="post">5</ce:sup></ce:cross-ref></entry><entry align="left">–</entry><entry align="left">Heart failure<ce:cross-ref id="crf1485" refid="tn0065"><ce:sup loc="post">5</ce:sup></ce:cross-ref><ce:br/>PAD<ce:br/>Diabetes (except with CAD)</entry><entry align="left">Asthma or chronic obstructive pulmonary disease<ce:br/>Heart block</entry></row><row rowsep="1"><entry align="left"><ce:bold>Calcium channel blockers (dihydropyridine)</ce:bold></entry><entry align="left">Older patients, isolated systolic hypertension</entry><entry align="left">Angina</entry><entry align="left">–</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left"><ce:bold>Calcium channel blockers (rate-limiting)</ce:bold></entry><entry align="left">Angina</entry><entry align="left">Older patients</entry><entry align="left">Combination with β-blockade</entry><entry align="left">Atrioventricular block, heart failure</entry></row><row><entry align="left"><ce:bold>Thiazides or thiazide-like diuretics</ce:bold></entry><entry align="left">Older patients, isolated systolic hypertension, heart failure, secondary stroke prevention</entry><entry align="left">–</entry><entry align="left">–</entry><entry align="left">Gout<ce:cross-ref id="crf1490" refid="tn0070"><ce:sup loc="post">6</ce:sup></ce:cross-ref></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0775">(ACE = angiotensin-converting enzyme; ARBs = angiotensin II receptor blockers; CAD = coronary artery disease; MI = myocardial infarction; PAD = peripheral arterial disease)</ce:simple-para></ce:legend><ce:table-footnote id="tn0045"><ce:label>1</ce:label><ce:note-para id="np0060">ln heart failure when used as monotherapy.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0050"><ce:label>2</ce:label><ce:note-para id="np0065">ACE inhibitors or ARBs may be beneficial in chronic renal failure and renovascular disease but should be used with caution, close supervision and specialist advice when there is established and significant renal impairment.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0055"><ce:label>3</ce:label><ce:note-para id="np0070">Caution with ACE inhibitors and ARBs in PAD because of association with renovascular disease.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0060"><ce:label>4</ce:label><ce:note-para id="np0075">In combination with a thiazide or thiazide-like diuretic.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0065"><ce:label>5</ce:label><ce:note-para id="np0080">β-blockers are used increasingly to treat stable heart failure but may worsen acute heart failure.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0070"><ce:label>6</ce:label><ce:note-para id="np0085">Thiazides or thiazide-like diuretics may sometimes be necessary to control BP in people with a history of gout, ideally used in combination with allopurinol.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0060" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0175" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000160/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1425" role="short">Image 73</ce:alt-text></ce:inline-figure>16.73</ce:label><ce:alt-text id="atte1430" role="short">16.73</ce:alt-text><ce:textbox-head><ce:title id="tit0065">Causes of acute valve failure</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0275"><ce:section-title id="st0265">Aortic regurgitation</ce:section-title><ce:para id="p0920"><ce:list id="ulist0130"><ce:list-item id="u0520"><ce:label>•</ce:label><ce:para id="p0925">Aortic dissection</ce:para></ce:list-item><ce:list-item id="u0525"><ce:label>•</ce:label><ce:para id="p0930">Infective endocarditis</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0280"><ce:section-title id="st0270">Mitral regurgitation</ce:section-title><ce:para id="p0935"><ce:list id="ulist0135"><ce:list-item id="u0530"><ce:label>•</ce:label><ce:para id="p0940">Papillary muscle rupture due to acute myocardial infarction</ce:para></ce:list-item><ce:list-item id="u0535"><ce:label>•</ce:label><ce:para id="p0945">Infective endocarditis</ce:para></ce:list-item><ce:list-item id="u0540"><ce:label>•</ce:label><ce:para id="p0950">Rupture of chordae due to myxomatous degeneration</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0285"><ce:section-title id="st0275">Prosthetic valve failure</ce:section-title><ce:para id="p0955"><ce:list id="ulist0140"><ce:list-item id="u0545"><ce:label>•</ce:label><ce:para id="p0960">Mechanical valves: fracture, jamming, thrombosis, dehiscence</ce:para></ce:list-item><ce:list-item id="u0550"><ce:label>•</ce:label><ce:para id="p0965">Biological valves: degeneration with cusp tear</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0400" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0825" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1435" role="short">Image 74</ce:alt-text></ce:inline-figure>16.74</ce:label><ce:alt-text id="atte1440" role="short">16.74</ce:alt-text><ce:textbox-head><ce:title id="tit0405">Principal causes of valve disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5375"><ce:display><ce:table frame="topbot" id="t0180"><ce:alt-text id="atte1445" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Valve regurgitation</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0915"><ce:list-item id="u2705"><ce:label>•</ce:label><ce:para id="p5380">Congenital</ce:para></ce:list-item><ce:list-item id="u2710"><ce:label>•</ce:label><ce:para id="p5385">Acute rheumatic carditis</ce:para></ce:list-item><ce:list-item id="u2715"><ce:label>•</ce:label><ce:para id="p5390">Chronic rheumatic carditis</ce:para></ce:list-item><ce:list-item id="u2720"><ce:label>•</ce:label><ce:para id="p5395">Infective endocarditis</ce:para></ce:list-item><ce:list-item id="u2725"><ce:label>•</ce:label><ce:para id="p5400">Cardiac failure<ce:cross-ref id="crf1505" refid="tn0075">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0920"><ce:list-item id="u2730"><ce:label>•</ce:label><ce:para id="p5405">Syphilitic aortitis</ce:para></ce:list-item><ce:list-item id="u2735"><ce:label>•</ce:label><ce:para id="p5410">Traumatic valve rupture</ce:para></ce:list-item><ce:list-item id="u2740"><ce:label>•</ce:label><ce:para id="p5415">Senile degeneration</ce:para></ce:list-item><ce:list-item id="u2745"><ce:label>•</ce:label><ce:para id="p5420">Damage to chordae and papillary muscles</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Valve stenosis</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0925"><ce:list-item id="u2750"><ce:label>•</ce:label><ce:para id="p5425">Congenital</ce:para></ce:list-item><ce:list-item id="u2755"><ce:label>•</ce:label><ce:para id="p5430">Rheumatic carditis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0930"><ce:list-item id="u2760"><ce:label>•</ce:label><ce:para id="p5435">Senile degeneration</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0075"><ce:label>*</ce:label><ce:note-para id="np0090">Causes dilatation of the valve ring.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0405" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0835" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1450" role="short">Image 75</ce:alt-text></ce:inline-figure>16.75</ce:label><ce:alt-text id="atte1455" role="short">16.75</ce:alt-text><ce:textbox-head><ce:title id="tit0410">Jones criteria for the diagnosis of rheumatic fever</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5455"><ce:display><ce:table frame="topbot" id="t0185"><ce:alt-text id="atte1460" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Major manifestations</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0935"><ce:list-item id="u2765"><ce:label>•</ce:label><ce:para id="p5460">Carditis</ce:para></ce:list-item><ce:list-item id="u2770"><ce:label>•</ce:label><ce:para id="p5465">Polyarthritis</ce:para></ce:list-item><ce:list-item id="u2775"><ce:label>•</ce:label><ce:para id="p5470">Chorea</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0940"><ce:list-item id="u2780"><ce:label>•</ce:label><ce:para id="p5475">Erythema marginatum</ce:para></ce:list-item><ce:list-item id="u2785"><ce:label>•</ce:label><ce:para id="p5480">Subcutaneous nodules</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Minor manifestations</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0945"><ce:list-item id="u2790"><ce:label>•</ce:label><ce:para id="p5485">Fever</ce:para></ce:list-item><ce:list-item id="u2795"><ce:label>•</ce:label><ce:para id="p5490">Arthralgia</ce:para></ce:list-item><ce:list-item id="u2805"><ce:label>•</ce:label><ce:para id="p5500">Raised erythrocyte sedimentation rate or C-reactive protein</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0950"><ce:list-item id="u2800"><ce:label>•</ce:label><ce:para id="p5495">Previous rheumatic fever</ce:para></ce:list-item><ce:list-item id="u2810"><ce:label>•</ce:label><ce:para id="p5505">Leucocytosis</ce:para></ce:list-item><ce:list-item id="u2815"><ce:label>•</ce:label><ce:para id="p5510">First-degree atrioventricular block</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Plus</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0955"><ce:list-item id="u2820"><ce:label>•</ce:label><ce:para id="p5515">Supporting evidence of preceding streptococcal infection: recent scarlet fever, raised antistreptolysin O or other streptococcal antibody titre, positive throat culture<ce:cross-ref id="crf1520" refid="tn0080">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0080"><ce:label>*</ce:label><ce:note-para id="np0095">Evidence of recent streptococcal infection is particularly important if there is only one major manifestation.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0410" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0840" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1465" role="short">Image 76</ce:alt-text></ce:inline-figure>16.76</ce:label><ce:alt-text id="atte1470" role="short">16.76</ce:alt-text><ce:textbox-head><ce:title id="tit0415">Investigations in acute rheumatic fever</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2015"><ce:section-title id="st1890">Evidence of a systemic illness</ce:section-title><ce:para id="p5550"><ce:list id="ulist0960"><ce:list-item id="u2825"><ce:label>•</ce:label><ce:para id="p5555">Leucocytosis, raised erythrocyte sedimentation rate and C-reactive protein</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2020"><ce:section-title id="st1895">Evidence of preceding streptococcal infection</ce:section-title><ce:para id="p5560"><ce:list id="ulist0965"><ce:list-item id="u2830"><ce:label>•</ce:label><ce:para id="p5565">Throat swab culture: group A β-haemolytic streptococci (also from family members and contacts)</ce:para></ce:list-item><ce:list-item id="u2835"><ce:label>•</ce:label><ce:para id="p5570">Antistreptolysin O antibodies (ASO titres): rising titres, or levels of &#x003E; 200 U (adults) or &#x003E; 300 U (children)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2025"><ce:section-title id="st1900">Evidence of carditis</ce:section-title><ce:para id="p5575"><ce:list id="ulist0970"><ce:list-item id="u2840"><ce:label>•</ce:label><ce:para id="p5580">Chest X-ray: cardiomegaly; pulmonary congestion</ce:para></ce:list-item><ce:list-item id="u2845"><ce:label>•</ce:label><ce:para id="p5585">ECG: first- and, rarely, second-degree atrioventricular block; features of pericarditis; T-wave inversion; reduction in QRS voltages</ce:para></ce:list-item><ce:list-item id="u2850"><ce:label>•</ce:label><ce:para id="p5590">Echocardiography: cardiac dilatation and valve abnormalities</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0415" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0845" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1475" role="short">Image 77</ce:alt-text></ce:inline-figure>16.77</ce:label><ce:alt-text id="atte1480" role="short">16.77</ce:alt-text><ce:textbox-head><ce:title id="tit0420">Clinical features of mitral stenosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5660"><ce:display><ce:table frame="topbot" id="t0190"><ce:alt-text id="atte1485" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Clinical feature</entry><entry align="left">Cause</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Symptoms</ce:bold></entry></row><row rowsep="0"><entry align="left">Breathlessness</entry><entry align="left">Pulmonary congestion, low cardiac output</entry></row><row rowsep="0"><entry align="left">Fatigue</entry><entry align="left">Low cardiac output</entry></row><row rowsep="0"><entry align="left">Oedema, ascites</entry><entry align="left">Right heart failure</entry></row><row rowsep="0"><entry align="left">Palpitation</entry><entry align="left">Atrial fibrillation</entry></row><row rowsep="0"><entry align="left">Haemoptysis</entry><entry align="left">Pulmonary congestion, pulmonary embolism</entry></row><row rowsep="0"><entry align="left">Cough</entry><entry align="left">Pulmonary congestion</entry></row><row rowsep="0"><entry align="left">Chest pain</entry><entry align="left">Pulmonary hypertension</entry></row><row rowsep="1"><entry align="left">Thromboembolism</entry><entry align="left">Atrial stasis and atrial fibrillation</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Signs</ce:bold></entry></row><row rowsep="0"><entry align="left">Atrial fibrillation</entry><entry align="left">Atrial dilatation</entry></row><row rowsep="0"><entry align="left">Mitral facies</entry><entry align="left">Low cardiac output</entry></row><row rowsep="0"><entry align="left">Auscultation:</entry><entry align="left"/></row><row rowsep="0"><entry align="left"><ce:hsp sp="1"/>Loud first heart sound, opening snap<ce:br/> Mid-diastolic murmur</entry><entry align="left">Pressure gradient across the valve</entry></row><row rowsep="0"><entry align="left">Crepitations<ce:br/>Pulmonary oedema<ce:br/>Pleural effusions</entry><entry align="left">Left heart failure</entry></row><row><entry align="left">Right ventricular heave, loud P<ce:inf loc="post">2</ce:inf></entry><entry align="left">Pulmonary hypertension</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0420" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0855" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1490" role="short">Image 78</ce:alt-text></ce:inline-figure>16.78</ce:label><ce:alt-text id="atte1495" role="short">16.78</ce:alt-text><ce:textbox-head><ce:title id="tit0425">Investigations in mitral stenosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5685"><ce:display><ce:table frame="topbot" id="t0195"><ce:alt-text id="atte1500" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>ECG</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0975"><ce:list-item id="u2855"><ce:label>•</ce:label><ce:para id="p5690">Right ventricular hypertrophy: tall R waves in V<ce:inf loc="post">1</ce:inf>–V<ce:inf loc="post">3</ce:inf></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0980"><ce:list-item id="u2860"><ce:label>•</ce:label><ce:para id="p5695">P mitrale or atrial fibrillation</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Chest X-ray</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0985"><ce:list-item id="u2865"><ce:label>•</ce:label><ce:para id="p5700">Enlarged left atrium and appendage</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0990"><ce:list-item id="u2870"><ce:label>•</ce:label><ce:para id="p5705">Signs of pulmonary venous congestion</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Echo</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0995"><ce:list-item id="u2875"><ce:label>•</ce:label><ce:para id="p5710">Thickened immobile cusps</ce:para></ce:list-item><ce:list-item id="u2880"><ce:label>•</ce:label><ce:para id="p5715">Reduced valve area</ce:para></ce:list-item><ce:list-item id="u2885"><ce:label>•</ce:label><ce:para id="p5720">Enlarged left atrium</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1000"><ce:list-item id="u2890"><ce:label>•</ce:label><ce:para id="p5725">Reduced rate of diastolic filling of left ventricle</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Doppler</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1005"><ce:list-item id="u2895"><ce:label>•</ce:label><ce:para id="p5730">Pressure gradient across mitral valve</ce:para></ce:list-item><ce:list-item id="u2900"><ce:label>•</ce:label><ce:para id="p5735">Pulmonary artery pressure</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1010"><ce:list-item id="u2905"><ce:label>•</ce:label><ce:para id="p5740">Left ventricular function</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cardiac catheterisation</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1015"><ce:list-item id="u2910"><ce:label>•</ce:label><ce:para id="p5745">Coronary artery disease</ce:para></ce:list-item><ce:list-item id="u2915"><ce:label>•</ce:label><ce:para id="p5750">Pulmonary artery pressure</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1020"><ce:list-item id="u2920"><ce:label>•</ce:label><ce:para id="p5755">Mitral stenosis and regurgitation</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0425" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0860" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1505" role="short">Image 79</ce:alt-text></ce:inline-figure>16.79</ce:label><ce:alt-text id="atte1510" role="short">16.79</ce:alt-text><ce:textbox-head><ce:title id="tit0430">Criteria for mitral valvuloplasty<ce:cross-ref id="crf1565" refid="fn0025">*</ce:cross-ref><ce:footnote id="fn0025"><ce:label>*</ce:label><ce:note-para id="np0100">For comprehensive guidelines on valvular heart disease, see <ce:inter-ref id="iw0045" xlink:href="http://www.acc.org">www.acc.org</ce:inter-ref>.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5775"><ce:list id="ulist1025"><ce:list-item id="u2925"><ce:label>•</ce:label><ce:para id="p5780">Significant symptoms</ce:para></ce:list-item><ce:list-item id="u2930"><ce:label>•</ce:label><ce:para id="p5785">Isolated mitral stenosis</ce:para></ce:list-item><ce:list-item id="u2935"><ce:label>•</ce:label><ce:para id="p5790">No (or trivial) mitral regurgitation</ce:para></ce:list-item><ce:list-item id="u2940"><ce:label>•</ce:label><ce:para id="p5795">Mobile, non-calcified valve/subvalve apparatus on echo</ce:para></ce:list-item><ce:list-item id="u2945"><ce:label>•</ce:label><ce:para id="p5800">Left atrium free of thrombus</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0430" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0865" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1515" role="short">Image 80</ce:alt-text></ce:inline-figure>16.80</ce:label><ce:alt-text id="atte1520" role="short">16.80</ce:alt-text><ce:textbox-head><ce:title id="tit0435">Causes of mitral regurgitation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5815"><ce:list id="ulist1030"><ce:list-item id="u2950"><ce:label>•</ce:label><ce:para id="p5820">Mitral valve prolapse</ce:para></ce:list-item><ce:list-item id="u2955"><ce:label>•</ce:label><ce:para id="p5825">Dilatation of the left ventricle and mitral valve ring (e.g. coronary artery disease, cardiomyopathy)</ce:para></ce:list-item><ce:list-item id="u2960"><ce:label>•</ce:label><ce:para id="p5830">Damage to valve cusps and chordae (e.g. rheumatic heart disease, endocarditis)</ce:para></ce:list-item><ce:list-item id="u2965"><ce:label>•</ce:label><ce:para id="p5835">Ischaemia or infarction of the papillary muscle</ce:para></ce:list-item><ce:list-item id="u2970"><ce:label>•</ce:label><ce:para id="p5840">Myocardial infarction</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0435" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0875" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1525" role="short">Image 81</ce:alt-text></ce:inline-figure>16.81</ce:label><ce:alt-text id="atte1530" role="short">16.81</ce:alt-text><ce:textbox-head><ce:title id="tit0440">Clinical features of mitral regurgitation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5875"><ce:display><ce:figure id="f9010"><ce:alt-text id="atte1535" role="short">Unlabelled image</ce:alt-text><ce:link id="ln9035" locator="b016-081-9780702070280" xlink:href="pii:B9780702070280000160/b016-081-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0440" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0880" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1540" role="short">Image 82</ce:alt-text></ce:inline-figure>16.82</ce:label><ce:alt-text id="atte1545" role="short">16.82</ce:alt-text><ce:textbox-head><ce:title id="tit0445">Investigations in mitral regurgitation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5890"><ce:display><ce:table frame="topbot" id="t0205"><ce:alt-text id="atte1550" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>ECG</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1035"><ce:list-item id="u2975"><ce:label>•</ce:label><ce:para id="p5895">Left atrial hypertrophy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1040"><ce:list-item id="u2980"><ce:label>•</ce:label><ce:para id="p5900">Atrial fibrillation</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Chest X-ray</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1045"><ce:list-item id="u2985"><ce:label>•</ce:label><ce:para id="p5905">Enlarged left atrium</ce:para></ce:list-item><ce:list-item id="u2990"><ce:label>•</ce:label><ce:para id="p5910">Enlarged left ventricle</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1050"><ce:list-item id="u2995"><ce:label>•</ce:label><ce:para id="p5915">Pulmonary venous congestion</ce:para></ce:list-item><ce:list-item id="u3000"><ce:label>•</ce:label><ce:para id="p5920">Pulmonary oedema (if acute)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Echo</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1055"><ce:list-item id="u3005"><ce:label>•</ce:label><ce:para id="p5925">Dilated left atrium, left ventricle</ce:para></ce:list-item><ce:list-item id="u3010"><ce:label>•</ce:label><ce:para id="p5930">Dynamic left ventricle (unless myocardial dysfunction predominates)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1060"><ce:list-item id="u3015"><ce:label>•</ce:label><ce:para id="p5935">Structural abnormalities of mitral valve</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Doppler</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1065"><ce:list-item id="u3020"><ce:label>•</ce:label><ce:para id="p5940">Detects and quantifies regurgitation</ce:para></ce:list-item></ce:list></entry><entry align="left"/></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cardiac catheterisation</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1070"><ce:list-item id="u3025"><ce:label>•</ce:label><ce:para id="p5945">Dilated left atrium, dilated left ventricle, mitral regurgitation</ce:para></ce:list-item><ce:list-item id="u3030"><ce:label>•</ce:label><ce:para id="p5950">Pulmonary hypertension</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1075"><ce:list-item id="u3035"><ce:label>•</ce:label><ce:para id="p5955">Coexisting coronary artery disease</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0445" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0885" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1555" role="short">Image 83</ce:alt-text></ce:inline-figure>16.83</ce:label><ce:alt-text id="atte1560" role="short">16.83</ce:alt-text><ce:textbox-head><ce:title id="tit0450">Medical management of mitral regurgitation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5965"><ce:list id="ulist1080"><ce:list-item id="u3040"><ce:label>•</ce:label><ce:para id="p5970">Diuretics</ce:para></ce:list-item><ce:list-item id="u3045"><ce:label>•</ce:label><ce:para id="p5975">Vasodilators if hypertension is present</ce:para></ce:list-item><ce:list-item id="u3050"><ce:label>•</ce:label><ce:para id="p5980">Digoxin if atrial fibrillation is present</ce:para></ce:list-item><ce:list-item id="u3055"><ce:label>•</ce:label><ce:para id="p5985">Anticoagulants if atrial fibrillation is present</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0450" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0890" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1565" role="short">Image 84</ce:alt-text></ce:inline-figure>16.84</ce:label><ce:alt-text id="atte1570" role="short">16.84</ce:alt-text><ce:textbox-head><ce:title id="tit0455">Causes of aortic stenosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2155"><ce:section-title id="st2030">Infants, children, adolescents</ce:section-title><ce:para id="p5995"><ce:list id="ulist1085"><ce:list-item id="u3060"><ce:label>•</ce:label><ce:para id="p6000">Congenital aortic stenosis</ce:para></ce:list-item><ce:list-item id="u3065"><ce:label>•</ce:label><ce:para id="p6005">Congenital subvalvular aortic stenosis</ce:para></ce:list-item><ce:list-item id="u3070"><ce:label>•</ce:label><ce:para id="p6010">Congenital supravalvular aortic stenosis</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2160"><ce:section-title id="st2035">Young adults to middle-aged</ce:section-title><ce:para id="p6015"><ce:list id="ulist1090"><ce:list-item id="u3075"><ce:label>•</ce:label><ce:para id="p6020">Calcification and fibrosis of congenitally bicuspid aortic valve</ce:para></ce:list-item><ce:list-item id="u3080"><ce:label>•</ce:label><ce:para id="p6025">Rheumatic aortic stenosis</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2165"><ce:section-title id="st2040">Middle-aged to elderly</ce:section-title><ce:para id="p6030"><ce:list id="ulist1095"><ce:list-item id="u3085"><ce:label>•</ce:label><ce:para id="p6035">Senile degenerative aortic stenosis</ce:para></ce:list-item><ce:list-item id="u3090"><ce:label>•</ce:label><ce:para id="p6040">Calcification of bicuspid valve</ce:para></ce:list-item><ce:list-item id="u3095"><ce:label>•</ce:label><ce:para id="p6045">Rheumatic aortic stenosis</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0455" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0895" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1575" role="short">Image 85</ce:alt-text></ce:inline-figure>16.85</ce:label><ce:alt-text id="atte1580" role="short">16.85</ce:alt-text><ce:textbox-head><ce:title id="tit0460">Clinical features of aortic stenosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6060"><ce:display><ce:table frame="topbot" id="t0210"><ce:alt-text id="atte1585" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Symptoms</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1100"><ce:list-item id="u3100"><ce:label>•</ce:label><ce:para id="p6065">Mild or moderate stenosis: usually asymptomatic</ce:para></ce:list-item><ce:list-item id="u3105"><ce:label>•</ce:label><ce:para id="p6070">Exertional dyspnoea</ce:para></ce:list-item><ce:list-item id="u3110"><ce:label>•</ce:label><ce:para id="p6075">Angina</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1105"><ce:list-item id="u3115"><ce:label>•</ce:label><ce:para id="p6080">Exertional syncope</ce:para></ce:list-item><ce:list-item id="u3120"><ce:label>•</ce:label><ce:para id="p6085">Sudden death</ce:para></ce:list-item><ce:list-item id="u3125"><ce:label>•</ce:label><ce:para id="p6090">Episodes of acute pulmonary oedema</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Signs</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1110"><ce:list-item id="u3130"><ce:label>•</ce:label><ce:para id="p6095">Ejection systolic murmur</ce:para></ce:list-item><ce:list-item id="u3135"><ce:label>•</ce:label><ce:para id="p6100">Slow-rising carotid pulse</ce:para></ce:list-item><ce:list-item id="u3140"><ce:label>•</ce:label><ce:para id="p6105">Thrusting apex beat (left ventricular pressure overload)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1115"><ce:list-item id="u3145"><ce:label>•</ce:label><ce:para id="p6110">Narrow pulse pressure</ce:para></ce:list-item><ce:list-item id="u3150"><ce:label>•</ce:label><ce:para id="p6115">Signs of pulmonary venous congestion</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0460" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0910" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1590" role="short">Image 86</ce:alt-text></ce:inline-figure>16.86</ce:label><ce:alt-text id="atte1595" role="short">16.86</ce:alt-text><ce:textbox-head><ce:title id="tit0465">Investigations in aortic stenosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2185"><ce:section-title id="st2060">ECG</ce:section-title><ce:para id="p6130"><ce:list id="ulist1120"><ce:list-item id="u3155"><ce:label>•</ce:label><ce:para id="p6135">Left ventricular hypertrophy</ce:para></ce:list-item><ce:list-item id="u3160"><ce:label>•</ce:label><ce:para id="p6140">Left bundle branch block</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2190"><ce:section-title id="st2065">Chest X-ray</ce:section-title><ce:para id="p6145"><ce:list id="ulist1125"><ce:list-item id="u3165"><ce:label>•</ce:label><ce:para id="p6150">May be normal; sometimes enlarged left ventricle and dilated ascending aorta on postero-anterior view, calcified valve on lateral view</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2195"><ce:section-title id="st2070">Echo</ce:section-title><ce:para id="p6155"><ce:list id="ulist1130"><ce:list-item id="u3170"><ce:label>•</ce:label><ce:para id="p6160">Calcified valve with restricted opening, hypertrophied left ventricle</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2200"><ce:section-title id="st2075">Doppler</ce:section-title><ce:para id="p6165"><ce:list id="ulist1135"><ce:list-item id="u3175"><ce:label>•</ce:label><ce:para id="p6170">Measurement of severity of stenosis</ce:para></ce:list-item><ce:list-item id="u3180"><ce:label>•</ce:label><ce:para id="p6175">Detection of associated aortic regurgitation</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2205"><ce:section-title id="st2080">Cardiac catheterisation</ce:section-title><ce:para id="p6180"><ce:list id="ulist1140"><ce:list-item id="u3185"><ce:label>•</ce:label><ce:para id="p6185">Mainly to identify associated coronary artery disease</ce:para></ce:list-item><ce:list-item id="u3190"><ce:label>•</ce:label><ce:para id="p6190">May be used to measure gradient between left ventricle and aorta</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0465" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0920" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000160/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1600" role="short">Image 87</ce:alt-text></ce:inline-figure>16.87</ce:label><ce:alt-text id="atte1605" role="short">16.87</ce:alt-text><ce:textbox-head><ce:title id="tit0470">Aortic stenosis in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6205"><ce:list id="ulist1145"><ce:list-item id="u3195"><ce:label>•</ce:label><ce:para id="p6210"><ce:bold>Incidence</ce:bold>: the most common form of valve disease affecting the very old.</ce:para></ce:list-item><ce:list-item id="u3200"><ce:label>•</ce:label><ce:para id="p6215"><ce:bold>Symptoms</ce:bold>: a common cause of syncope, angina and heart failure in the very old.</ce:para></ce:list-item><ce:list-item id="u3205"><ce:label>•</ce:label><ce:para id="p6220"><ce:bold>Signs</ce:bold>: because of increasing stiffening in the central arteries, low pulse pressure and a slow rising pulse may not be present.</ce:para></ce:list-item><ce:list-item id="o9000"><ce:label>•</ce:label><ce:para id="p9010"><ce:bold>Trans-catheter aortic valve implantation (TAVI)</ce:bold>: a good option in older individuals because less invasive than surgery.</ce:para></ce:list-item><ce:list-item id="u3210"><ce:label>•</ce:label><ce:para id="p6225"><ce:bold>Surgery</ce:bold>: can be successful in those aged 80 years or more in the absence of comorbidity, but with a higher operative mortality. The prognosis without surgery is poor once symptoms have developed.</ce:para></ce:list-item><ce:list-item id="u3215"><ce:label>•</ce:label><ce:para id="p6230"><ce:bold>Valve replacement type</ce:bold>: a biological valve is often preferable to a mechanical one because this obviates the need for anticoagulation, and the durability of biological valves usually exceeds the patient's anticipated life expectancy.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0470" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0925" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1610" role="short">Image 88</ce:alt-text></ce:inline-figure>16.88</ce:label><ce:alt-text id="atte1615" role="short">16.88</ce:alt-text><ce:textbox-head><ce:title id="tit0475">Causes of aortic regurgitation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2220"><ce:section-title id="st2095">Congenital</ce:section-title><ce:para id="p6245"><ce:list id="ulist1150"><ce:list-item id="u3220"><ce:label>•</ce:label><ce:para id="p6250">Bicuspid valve or disproportionate cusps</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2225"><ce:section-title id="st2100">Acquired</ce:section-title><ce:para id="p6255"><ce:list id="ulist1155"><ce:list-item id="u3225"><ce:label>•</ce:label><ce:para id="p6260">Rheumatic disease</ce:para></ce:list-item><ce:list-item id="u3230"><ce:label>•</ce:label><ce:para id="p6265">Infective endocarditis</ce:para></ce:list-item><ce:list-item id="u3235"><ce:label>•</ce:label><ce:para id="p6270">Trauma</ce:para></ce:list-item><ce:list-item id="u3240"><ce:label>•</ce:label><ce:para id="p6275">Causes of aortic dilatation:<ce:list id="ulist1160"><ce:list-item id="u3245"><ce:para id="p6280">Marfan's syndrome</ce:para></ce:list-item><ce:list-item id="u3250"><ce:para id="p6285">Aneurysm</ce:para></ce:list-item><ce:list-item id="u3255"><ce:para id="p6290">Aortic dissection</ce:para></ce:list-item><ce:list-item id="u3260"><ce:para id="p6295">Syphilis</ce:para></ce:list-item><ce:list-item id="u3265"><ce:para id="p6300">Ankylosing spondylitis</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0475" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0930" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1620" role="short">Image 89</ce:alt-text></ce:inline-figure>16.89</ce:label><ce:alt-text id="atte1625" role="short">16.89</ce:alt-text><ce:textbox-head><ce:title id="tit0480">Clinical features of aortic regurgitation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2240"><ce:section-title id="st2115">Symptoms</ce:section-title><ce:section id="s2245"><ce:section-title id="st2120">Mild to moderate aortic regurgitation</ce:section-title><ce:para id="p6315"><ce:list id="ulist1165"><ce:list-item id="u3270"><ce:label>•</ce:label><ce:para id="p6320">Often asymptomatic</ce:para></ce:list-item><ce:list-item id="u3275"><ce:label>•</ce:label><ce:para id="p6325">Palpitations</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2250"><ce:section-title id="st2125">Severe aortic regurgitation</ce:section-title><ce:para id="p6330"><ce:list id="ulist1170"><ce:list-item id="u3280"><ce:label>•</ce:label><ce:para id="p6335">Breathlessness</ce:para></ce:list-item><ce:list-item id="u3285"><ce:label>•</ce:label><ce:para id="p6340">Angina</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s2255"><ce:section-title id="st2130">Signs</ce:section-title><ce:section id="s2260"><ce:section-title id="st2135">Pulses</ce:section-title><ce:para id="p6345"><ce:list id="ulist1175"><ce:list-item id="u3290"><ce:label>•</ce:label><ce:para id="p6350">Large-volume or ‘collapsing’ pulse</ce:para></ce:list-item><ce:list-item id="u3295"><ce:label>•</ce:label><ce:para id="p6355">Low diastolic and increased pulse pressure</ce:para></ce:list-item><ce:list-item id="u3300"><ce:label>•</ce:label><ce:para id="p6360">Bounding peripheral pulses</ce:para></ce:list-item><ce:list-item id="u3305"><ce:label>•</ce:label><ce:para id="p6365">Capillary pulsation in nail beds: Quincke's sign</ce:para></ce:list-item><ce:list-item id="u3310"><ce:label>•</ce:label><ce:para id="p6370">Femoral bruit (‘pistol shot’): Duroziez's sign</ce:para></ce:list-item><ce:list-item id="u3315"><ce:label>•</ce:label><ce:para id="p6375">Head nodding with pulse: de Musset's sign</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2265"><ce:section-title id="st2140">Murmurs</ce:section-title><ce:para id="p6380"><ce:list id="ulist1180"><ce:list-item id="u3320"><ce:label>•</ce:label><ce:para id="p6385">Early diastolic murmur</ce:para></ce:list-item><ce:list-item id="u3325"><ce:label>•</ce:label><ce:para id="p6390">Systolic murmur (increased stroke volume)</ce:para></ce:list-item><ce:list-item id="u3330"><ce:label>•</ce:label><ce:para id="p6395">Austin Flint murmur (soft mid-diastolic)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2270"><ce:section-title id="st2145">Other signs</ce:section-title><ce:para id="p6400"><ce:list id="ulist1185"><ce:list-item id="u3335"><ce:label>•</ce:label><ce:para id="p6405">Displaced, heaving apex beat (volume overload)</ce:para></ce:list-item><ce:list-item id="u3340"><ce:label>•</ce:label><ce:para id="p6410">Pre-systolic impulse</ce:para></ce:list-item><ce:list-item id="u3345"><ce:label>•</ce:label><ce:para id="p6415">Fourth heart sound</ce:para></ce:list-item><ce:list-item id="u3350"><ce:label>•</ce:label><ce:para id="p6420">Crepitations (pulmonary venous congestion)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0480" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0940" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1630" role="short">Image 90</ce:alt-text></ce:inline-figure>16.90</ce:label><ce:alt-text id="atte1635" role="short">16.90</ce:alt-text><ce:textbox-head><ce:title id="tit0485">Investigations in aortic regurgitation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6435"><ce:display><ce:table frame="topbot" id="t0215"><ce:alt-text id="atte1640" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>ECG</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1190"><ce:list-item id="u3355"><ce:label>•</ce:label><ce:para id="p6440">Initially normal, later left ventricular hypertrophy and T-wave inversion</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Chest X-ray</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1195"><ce:list-item id="u3360"><ce:label>•</ce:label><ce:para id="p6445">Cardiac dilatation, maybe aortic dilatation</ce:para></ce:list-item><ce:list-item id="u3365"><ce:label>•</ce:label><ce:para id="p6450">Features of left heart failure</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Echo</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1200"><ce:list-item id="u3370"><ce:label>•</ce:label><ce:para id="p6455">Dilated left ventricle</ce:para></ce:list-item><ce:list-item id="u3375"><ce:label>•</ce:label><ce:para id="p6460">Hyperdynamic left ventricle</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1205"><ce:list-item id="u3380"><ce:label>•</ce:label><ce:para id="p6465">Doppler detects reflux</ce:para></ce:list-item><ce:list-item id="u3385"><ce:label>•</ce:label><ce:para id="p6470">Fluttering anterior mitral leaflet</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cardiac catheterisation</ce:bold><ce:cross-ref id="crf1680" refid="tn0085"><ce:bold>*</ce:bold></ce:cross-ref></entry></row><row><entry align="left"><ce:list id="ulist1210"><ce:list-item id="u3390"><ce:label>•</ce:label><ce:para id="p6475">Dilated left ventricle</ce:para></ce:list-item><ce:list-item id="u3395"><ce:label>•</ce:label><ce:para id="p6480">Aortic regurgitation</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1215"><ce:list-item id="u3400"><ce:label>•</ce:label><ce:para id="p6485">Dilated aortic root</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0085"><ce:label>*</ce:label><ce:note-para id="np0105">Not always required.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0485" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0945" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1645" role="short">Image 91</ce:alt-text></ce:inline-figure>16.91</ce:label><ce:alt-text id="atte1650" role="short">16.91</ce:alt-text><ce:textbox-head><ce:title id="tit0490">Causes of tricuspid regurgitation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2310"><ce:section-title id="st2185">Primary</ce:section-title><ce:para id="p6520"><ce:list id="ulist1220"><ce:list-item id="u3405"><ce:label>•</ce:label><ce:para id="p6525">Rheumatic heart disease</ce:para></ce:list-item><ce:list-item id="u3410"><ce:label>•</ce:label><ce:para id="p6530">Endocarditis, particularly in intravenous drug-users</ce:para></ce:list-item><ce:list-item id="u3415"><ce:label>•</ce:label><ce:para id="p6535">Ebstein's congenital anomaly (see <ce:cross-ref id="crf1690" refid="b0540">Box 16.102</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2315"><ce:section-title id="st2190">Secondary</ce:section-title><ce:para id="p6540"><ce:list id="ulist1225"><ce:list-item id="u3420"><ce:label>•</ce:label><ce:para id="p6545">Right ventricular failure</ce:para></ce:list-item><ce:list-item id="u3425"><ce:label>•</ce:label><ce:para id="p6550">Right ventricular infarction</ce:para></ce:list-item><ce:list-item id="u3430"><ce:label>•</ce:label><ce:para id="p6555">Pulmonary hypertension</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0490" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0950" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1655" role="short">Image 92</ce:alt-text></ce:inline-figure>16.92</ce:label><ce:alt-text id="atte1660" role="short">16.92</ce:alt-text><ce:textbox-head><ce:title id="tit0495">Anticoagulation targets and prosthetic heart valves</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6605"><ce:display><ce:table frame="topbot" id="t0220"><ce:alt-text id="atte1665" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Mechanical valves</entry><entry align="left">Target INR</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Ball and cage</ce:bold> (e.g. Starr–Edwards)<ce:br/><ce:bold>Tilting disc</ce:bold> (e.g. Bjork–Shiley)</entry><entry align="left">3.0–4.0</entry></row><row rowsep="1"><entry align="left"><ce:bold>Bi-leaflet</ce:bold> (e.g. St Jude)</entry><entry align="left">2.5–3.0</entry></row><row><entry align="left"><ce:bold>Biological valves with atrial fibrillation</ce:bold></entry><entry align="left">2.0–3.0</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0860">(INR = international normalised ratio)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0495" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0960" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000160/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1670" role="short">Image 93</ce:alt-text></ce:inline-figure>16.93</ce:label><ce:alt-text id="atte1675" role="short">16.93</ce:alt-text><ce:textbox-head><ce:title id="tit0500">Endocarditis in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6630"><ce:list id="ulist1230"><ce:list-item id="u3435"><ce:label>•</ce:label><ce:para id="p6635"><ce:bold>Symptoms and signs</ce:bold>: may be non-specific, with delirium, weight loss, malaise and weakness, and the diagnosis may not be suspected.</ce:para></ce:list-item><ce:list-item id="u3440"><ce:label>•</ce:label><ce:para id="p6640"><ce:bold>Common causative organisms</ce:bold>: often enterococci (from the urinary tract) and <ce:italic>Streptococcus gallolyticus</ce:italic> subsp. <ce:italic>gallolyticus</ce:italic> (from a colonic source).</ce:para></ce:list-item><ce:list-item id="u3445"><ce:label>•</ce:label><ce:para id="p6645"><ce:bold>Morbidity and mortality</ce:bold>: much higher.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0500" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0965" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1680" role="short">Image 94</ce:alt-text></ce:inline-figure>16.94</ce:label><ce:alt-text id="atte1685" role="short">16.94</ce:alt-text><ce:textbox-head><ce:title id="tit0505">Microbiology of infective endocarditis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6665"><ce:display><ce:table frame="topbot" id="t0225"><ce:alt-text id="atte1690" role="short">Unlabelled table</ce:alt-text><ce:source>Adapted from Moreillon P, Que YA. Infective endocarditis. Lancet 2004; 363:139–149.</ce:source><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry morerows="1" align="left">Pathogen</entry><entry morerows="1" align="left">Of native valve<ce:br/>(n = 280)</entry><entry morerows="1" align="left">In injection drug users<ce:br/>(n = 87)</entry><entry namest="col4" nameend="col5" align="center">Of prosthetic valve</entry></row><row role="tcolhead1" rowsep="1"><entry align="left">Early<ce:br/>(n = 15)</entry><entry align="left">Late<ce:br/>(n = 72)</entry></row></thead><tbody><row rowsep="0"><entry align="left"><ce:bold>Staphylococci</ce:bold></entry><entry align="left">124 (44%)</entry><entry align="left">60 (69%)</entry><entry align="left">10 (67%)</entry><entry align="left">33 (46%)</entry></row><row rowsep="0"><entry align="left"><ce:italic>Staph. aureus</ce:italic></entry><entry align="left">106 (38%)</entry><entry align="left">60 (69%)</entry><entry align="left">3 (20%)</entry><entry align="left">15 (21%)</entry></row><row rowsep="1"><entry align="left">Coagulase-negative</entry><entry align="left">18 (6%)</entry><entry align="left">0</entry><entry align="left">7 (47%)</entry><entry align="left">18 (25%)</entry></row><row rowsep="0"><entry align="left"><ce:bold>Streptococci</ce:bold></entry><entry align="left">86 (31%)</entry><entry align="left">7 (8%)</entry><entry align="left">0</entry><entry align="left">25 (35%)</entry></row><row rowsep="0"><entry align="left">Oral</entry><entry align="left">59 (21%)</entry><entry align="left">3 (3%)</entry><entry align="left">0</entry><entry align="left">19 (26%)</entry></row><row rowsep="1"><entry align="left">Others (non-enterococcal)</entry><entry align="left">27 (10%)</entry><entry align="left">4 (5%)</entry><entry align="left">0</entry><entry align="left">6 (8%)</entry></row><row rowsep="1"><entry align="left"><ce:bold><ce:italic>Enterococcus</ce:italic> spp</ce:bold>.</entry><entry align="left">21 (8%)</entry><entry align="left">2 (2%)</entry><entry align="left">1 (7%)</entry><entry align="left">5 (7%)</entry></row><row rowsep="1"><entry align="left"><ce:bold>HACEK</ce:bold></entry><entry align="left">12 (4%)</entry><entry align="left">0</entry><entry align="left">0</entry><entry align="left">1 (1%)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Polymicrobial</ce:bold></entry><entry align="left">6 (2%)</entry><entry align="left">8 (9%)</entry><entry align="left">0</entry><entry align="left">1 (1%)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Other bacteria</ce:bold></entry><entry align="left">12 (4%)</entry><entry align="left">4 (5%)</entry><entry align="left">0</entry><entry align="left">2 (3%)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Fungi</ce:bold></entry><entry align="left">3 (1%)</entry><entry align="left">2 (2%)</entry><entry align="left">0</entry><entry align="left">0</entry></row><row><entry align="left"><ce:bold>Negative blood culture</ce:bold></entry><entry align="left">16 (6%)</entry><entry align="left">4 (5%)</entry><entry align="left">4 (27%)</entry><entry align="left">5 (7%)</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0870">(HACEK = <ce:bold><ce:italic><ce:underline>H</ce:underline></ce:italic></ce:bold><ce:italic>aemophilus aphrophilus</ce:italic> – now known as <ce:italic>Aggregatibacter aphrophilus–<ce:bold><ce:underline>A</ce:underline></ce:bold>ggregatibacter actinomycetemcomitans</ce:italic>; <ce:bold><ce:italic><ce:underline>C</ce:underline></ce:italic></ce:bold><ce:italic>ardiobacterium hominis</ce:italic>; <ce:bold><ce:italic><ce:underline>E</ce:underline></ce:italic></ce:bold><ce:italic>ikenella corrodens</ce:italic>; and <ce:bold><ce:italic><ce:underline>K</ce:underline></ce:italic></ce:bold><ce:italic>ingella kingae</ce:italic>)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0505" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0975" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1695" role="short">Image 95</ce:alt-text></ce:inline-figure>16.95</ce:label><ce:alt-text id="atte1700" role="short">16.95</ce:alt-text><ce:textbox-head><ce:title id="tit0510">Diagnosis of infective endocarditis<ce:cross-ref id="crf1725" refid="fn0030">*</ce:cross-ref><ce:footnote id="fn0030"><ce:label>*</ce:label><ce:note-para id="np0110">Modified Duke criteria. Patients with two major, or one major and three minor, or five minor have definite endocarditis. Patients with one major and one minor, or three minor have possible endocarditis.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2420"><ce:section-title id="st2290">Major criteria</ce:section-title><ce:section id="s2425"><ce:section-title id="st2295">Positive blood culture</ce:section-title><ce:para id="p6720"><ce:list id="ulist1235"><ce:list-item id="u3450"><ce:label>•</ce:label><ce:para id="p6725">Typical organism from two cultures</ce:para></ce:list-item><ce:list-item id="u3455"><ce:label>•</ce:label><ce:para id="p6730">Persistent positive blood cultures taken &#x003E; 12 hrs apart</ce:para></ce:list-item><ce:list-item id="u3460"><ce:label>•</ce:label><ce:para id="p6735">Three or more positive cultures taken over &#x003E; 1 hr</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2430"><ce:section-title id="st2300">Endocardial involvement</ce:section-title><ce:para id="p6740"><ce:list id="ulist1240"><ce:list-item id="u3465"><ce:label>•</ce:label><ce:para id="p6745">Positive echocardiographic findings of vegetations</ce:para></ce:list-item><ce:list-item id="u3470"><ce:label>•</ce:label><ce:para id="p6750">New valvular regurgitation</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s2435"><ce:section-title id="st2305">Minor criteria</ce:section-title><ce:para id="p6755"><ce:list id="ulist1245"><ce:list-item id="u3475"><ce:label>•</ce:label><ce:para id="p6760">Predisposing valvular or cardiac abnormality</ce:para></ce:list-item><ce:list-item id="u3480"><ce:label>•</ce:label><ce:para id="p6765">Intravenous drug misuse</ce:para></ce:list-item><ce:list-item id="u3485"><ce:label>•</ce:label><ce:para id="p6770">Pyrexia ≥ 38°C</ce:para></ce:list-item><ce:list-item id="u3490"><ce:label>•</ce:label><ce:para id="p6775">Embolic phenomenon</ce:para></ce:list-item><ce:list-item id="u3495"><ce:label>•</ce:label><ce:para id="p6780">Vasculitic phenomenon</ce:para></ce:list-item><ce:list-item id="u3500"><ce:label>•</ce:label><ce:para id="p6785">Blood cultures suggestive: organism grown but not achieving major criteria</ce:para></ce:list-item><ce:list-item id="u3505"><ce:label>•</ce:label><ce:para id="p6790">Suggestive echocardiographic findings</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0510" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9010" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1705" role="short">Image 96</ce:alt-text></ce:inline-figure>16.96</ce:label><ce:alt-text id="atte1710" role="short">16.96</ce:alt-text><ce:textbox-head><ce:title id="tit9005">Antimicrobial treatment of common causative organisms in infective endocarditis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9005"><ce:display><ce:table frame="topbot" id="t9000"><ce:alt-text id="atte1715" role="short">Unlabelled table</ce:alt-text><ce:source>Adapted from Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the working party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269–289.</ce:source><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry morerows="1" align="left">Antimicrobial susceptibility</entry><entry morerows="1" align="left">Antimicrobial</entry><entry morerows="1" align="left">Dose</entry><entry namest="col4" nameend="col5" align="center">Duration</entry></row><row role="tcolhead1" rowsep="1"><entry align="left">Native valve</entry><entry align="left">Prosthetic valve</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col5" align="left"><ce:bold>Streptococci</ce:bold></entry></row><row rowsep="0"><entry align="left">Penicillin MIC ≤ 0.125 mg/L</entry><entry align="left">Benzylpenicillin IV</entry><entry align="left">1.2 g 6 times daily</entry><entry align="left">4 weeks<ce:cross-ref id="crf9005" refid="tn9000"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left">6 weeks</entry></row><row rowsep="0"><entry morerows="1" align="left">Penicillin MIC &#x003E; 0.125, ≤ 0.5 mg/L</entry><entry morerows="1" align="left">Benzylpenicillin IV and gentamicin IV</entry><entry morerows="1" align="left">2.4 g 6 times daily<ce:br/>1 mg/kg twice daily<ce:cross-ref id="crf9010" refid="tn9005"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">4 weeks</entry><entry align="left">6 weeks</entry></row><row rowsep="0"><entry align="left">2 weeks</entry><entry align="left">2 weeks</entry></row><row><entry morerows="1" rowsep="1" align="left">Penicillin MIC &#x003E; 0.5 mg/L</entry><entry morerows="1" rowsep="1" align="left">Vancomycin IV and gentamicin IV</entry><entry morerows="1" rowsep="1" align="left">1 g twice daily<ce:cross-ref id="crf9015" refid="tn9010"><ce:sup loc="post">3</ce:sup></ce:cross-ref><ce:br/>1 mg/kg twice daily<ce:cross-ref id="crf9020" refid="tn9005"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry rowsep="0" align="left">4 weeks</entry><entry rowsep="0" align="left">6 weeks</entry></row><row rowsep="1"><entry align="left">4 weeks</entry><entry align="left">6 weeks</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col5" align="left"><ce:bold>Enterococci</ce:bold></entry></row><row rowsep="0"><entry morerows="1" align="left">Amoxicillin MIC ≤ 4 mg/L and gentamicin MIC ≤ 128 mg/L</entry><entry morerows="1" align="left">Amoxicillin IV and gentamicin IV<ce:cross-ref id="crf9025" refid="tn9005"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry morerows="1" align="left">2 g 6 times daily<ce:br/>1 mg/kg twice daily<ce:cross-ref id="crf9030" refid="tn9005"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">4 weeks</entry><entry align="left">6 weeks</entry></row><row rowsep="0"><entry align="left">4 weeks</entry><entry align="left">6 weeks</entry></row><row><entry morerows="1" rowsep="1" align="left">Amoxicillin MIC &#x003E; 4 mg/L and gentamicin MIC ≤ 128 mg/L</entry><entry morerows="1" rowsep="1" align="left">Vancomycin IV and gentamicin IV<ce:cross-ref id="crf9035" refid="tn9005"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry morerows="1" rowsep="1" align="left">1 g twice daily<ce:cross-ref id="crf9040" refid="tn9010"><ce:sup loc="post">3</ce:sup></ce:cross-ref><ce:br/>1 mg/kg twice daily<ce:cross-ref id="crf9045" refid="tn9005"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry rowsep="0" align="left">4 weeks</entry><entry rowsep="0" align="left">6 weeks</entry></row><row rowsep="1"><entry align="left">4 weeks</entry><entry align="left">6 weeks</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col5" align="left"><ce:bold>Staphylococci – native valve</ce:bold></entry></row><row rowsep="0"><entry align="left">Meticillin-sensitive</entry><entry align="left">Flucloxacillin IV</entry><entry align="left">2 g 4–6 times daily<ce:cross-ref id="crf9050" refid="tn9015"><ce:sup loc="post">4</ce:sup></ce:cross-ref></entry><entry align="left">4 weeks</entry><entry align="left">–</entry></row><row><entry morerows="1" rowsep="1" align="left">Meticillin-resistant, vancomycin MIC ≤ 2 mg/L, rifampicin-sensitive</entry><entry rowsep="0" align="left">Vancomycin IV</entry><entry rowsep="0" align="left">1 g twice daily<ce:cross-ref id="crf9055" refid="tn9010"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry rowsep="0" align="left">4 weeks</entry><entry rowsep="0" align="left">–</entry></row><row rowsep="1"><entry align="left">Rifampicin orally</entry><entry align="left">300–600 mg twice daily</entry><entry align="left">4 weeks</entry><entry align="left">–</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col5" align="left"><ce:bold>Staphylococci – prosthetic valve</ce:bold></entry></row><row rowsep="0"><entry morerows="2" align="left">Meticillin-sensitive</entry><entry align="left">Flucloxacillin IV</entry><entry align="left">2 g 4–6 times daily</entry><entry align="left">–</entry><entry align="left">6 weeks</entry></row><row rowsep="0"><entry align="left">and gentamicin IV</entry><entry align="left">1 mg/kg twice daily<ce:cross-ref id="crf9060" refid="tn9005"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">–</entry><entry align="left">6 weeks</entry></row><row rowsep="0"><entry align="left">and rifampicin orally</entry><entry align="left">300–600 mg twice daily</entry><entry align="left">–</entry><entry align="left">6 weeks</entry></row><row><entry morerows="1" align="left">Meticillin-resistant, vancomycin MIC ≤ 2 mg/L, rifampicin-sensitive</entry><entry rowsep="0" align="left">Vancomycin IV</entry><entry rowsep="0" align="left">1 g twice daily<ce:cross-ref id="crf9065" refid="tn9010"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry rowsep="0" align="left">–</entry><entry rowsep="0" align="left">6 weeks</entry></row><row><entry align="left">and rifampicin orally</entry><entry align="left">300–600 mg twice daily</entry><entry align="left">–</entry><entry align="left">6 weeks</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp9000">(IV = intravenous; MIC = minimum inhibitory concentration)</ce:simple-para></ce:legend><ce:table-footnote id="tn9000"><ce:label>1</ce:label><ce:note-para id="np9000">When conditions in <ce:cross-ref id="crf9070" refid="b0515">Box 16.97</ce:cross-ref> are met, 2 weeks of benzylpenicillin and gentamicin (1 mg/kg twice daily) may be sufficient. Ceftriaxone 2 g once daily IV/IM can be used instead of benzylpenicillin for those with non-severe penicillin allergy.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn9005"><ce:label>2</ce:label><ce:note-para id="np9005">Pre-dose gentamicin level should be ≤ 1 mg/L, post-dose 3–5 mg/L. Adjust dose according to levels and renal function.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn9010"><ce:label>3</ce:label><ce:note-para id="np9010">Pre-dose vancomycin level should be 15–20 mg/L. Adjust dose according to levels and renal function.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn9015"><ce:label>4</ce:label><ce:note-para id="np9015">Use 6 times daily if weight &#x003E; 85 kg.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0515" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0985" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1720" role="short">Image 97</ce:alt-text></ce:inline-figure>16.97</ce:label><ce:alt-text id="atte1725" role="short">16.97</ce:alt-text><ce:textbox-head><ce:title id="tit0520">Conditions for the short-course treatment of endocarditis caused by fully sensitive streptococci</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6835"><ce:list id="ulist1250"><ce:list-item id="u3510"><ce:label>•</ce:label><ce:para id="p6840">Native valve infection</ce:para></ce:list-item><ce:list-item id="u3515"><ce:label>•</ce:label><ce:para id="p6845">Minimum inhibitory concentration (MIC) ≤ 0.125 mg/L</ce:para></ce:list-item><ce:list-item id="u3520"><ce:label>•</ce:label><ce:para id="p6850">No adverse prognostic factors (heart failure, aortic regurgitation, conduction defect)</ce:para></ce:list-item><ce:list-item id="u3525"><ce:label>•</ce:label><ce:para id="p6855">No evidence of thromboembolic disease</ce:para></ce:list-item><ce:list-item id="u3530"><ce:label>•</ce:label><ce:para id="p6860">No vegetations &#x003E; 5 mm diameter</ce:para></ce:list-item><ce:list-item id="u3535"><ce:label>•</ce:label><ce:para id="p6865">Clinical response within 7 days</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0520" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0990" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1730" role="short">Image 98</ce:alt-text></ce:inline-figure>16.98</ce:label><ce:alt-text id="atte1735" role="short">16.98</ce:alt-text><ce:textbox-head><ce:title id="tit0525">Indications for cardiac surgery in infective endocarditis<ce:cross-ref id="crf1785" refid="fn0040">*</ce:cross-ref><ce:footnote id="fn0040"><ce:label>*</ce:label><ce:note-para id="np0135">Patients with prosthetic valve endocarditis or fungal endocarditis often require cardiac surgery.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6875"><ce:list id="ulist1255"><ce:list-item id="u3540"><ce:label>•</ce:label><ce:para id="p6880">Heart failure due to valve damage</ce:para></ce:list-item><ce:list-item id="u3545"><ce:label>•</ce:label><ce:para id="p6885">Failure of antibiotic therapy (persistent/uncontrolled infection)</ce:para></ce:list-item><ce:list-item id="u3550"><ce:label>•</ce:label><ce:para id="p6890">Large vegetations on left-sided heart valves with echo appearance suggesting high risk of emboli</ce:para></ce:list-item><ce:list-item id="u3555"><ce:label>•</ce:label><ce:para id="p6895">Previous evidence of systemic emboli</ce:para></ce:list-item><ce:list-item id="u3560"><ce:label>•</ce:label><ce:para id="p6900">Abscess formation</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0525" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0995" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1740" role="short">Image 99</ce:alt-text></ce:inline-figure>16.99</ce:label><ce:alt-text id="atte1745" role="short">16.99</ce:alt-text><ce:textbox-head><ce:title id="tit0530">Incidence and relative frequency of congenital cardiac malformations</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6915"><ce:display><ce:table frame="topbot" id="t0235"><ce:alt-text id="atte1750" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Lesion</entry><entry align="left">% of all congenital heart defects</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Ventricular septal defect</ce:bold></entry><entry align="left">30</entry></row><row rowsep="1"><entry align="left"><ce:bold>Atrial septal defect</ce:bold></entry><entry align="left">10</entry></row><row rowsep="1"><entry align="left"><ce:bold>Persistent ductus arteriosus</ce:bold></entry><entry align="left">10</entry></row><row rowsep="1"><entry align="left"><ce:bold>Pulmonary stenosis</ce:bold></entry><entry align="left">7</entry></row><row rowsep="1"><entry align="left"><ce:bold>Coarctation of aorta</ce:bold></entry><entry align="left">7</entry></row><row rowsep="1"><entry align="left"><ce:bold>Aortic stenosis</ce:bold></entry><entry align="left">6</entry></row><row rowsep="1"><entry align="left"><ce:bold>Tetralogy of Fallot</ce:bold></entry><entry align="left">6</entry></row><row rowsep="1"><entry align="left"><ce:bold>Complete transposition of great arteries</ce:bold></entry><entry align="left">4</entry></row><row><entry align="left"><ce:bold>Others</ce:bold></entry><entry align="left">20</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0530" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9000" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1755" role="short">Image 100</ce:alt-text></ce:inline-figure>16.100</ce:label><ce:alt-text id="atte1760" role="short">16.100</ce:alt-text><ce:textbox-head><ce:title id="tit0535">Presentation of congenital heart disease throughout life</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6920"><ce:display><ce:table frame="topbot" id="t0240"><ce:alt-text id="atte1765" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Birth and neonatal period</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1260"><ce:list-item id="u3565"><ce:label>•</ce:label><ce:para id="p6925">Cyanosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1265"><ce:list-item id="u3570"><ce:label>•</ce:label><ce:para id="p6930">Heart failure</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infancy and childhood</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1270"><ce:list-item id="u3575"><ce:label>•</ce:label><ce:para id="p6935">Cyanosis</ce:para></ce:list-item><ce:list-item id="u3580"><ce:label>•</ce:label><ce:para id="p6940">Heart failure</ce:para></ce:list-item><ce:list-item id="u3585"><ce:label>•</ce:label><ce:para id="p6945">Arrhythmia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1275"><ce:list-item id="u3590"><ce:label>•</ce:label><ce:para id="p6950">Murmur</ce:para></ce:list-item><ce:list-item id="u3595"><ce:label>•</ce:label><ce:para id="p6955">Failure to thrive</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Adolescence and adulthood</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1280"><ce:list-item id="u3600"><ce:label>•</ce:label><ce:para id="p6960">Heart failure</ce:para></ce:list-item><ce:list-item id="u3605"><ce:label>•</ce:label><ce:para id="p6965">Murmur</ce:para></ce:list-item><ce:list-item id="u3610"><ce:label>•</ce:label><ce:para id="p6970">Arrhythmia</ce:para></ce:list-item><ce:list-item id="u3615"><ce:label>•</ce:label><ce:para id="p6975">Eisenmenger's syndrome</ce:para></ce:list-item><ce:list-item id="u3620"><ce:label>•</ce:label><ce:para id="p6980">Hypertension (coarctation)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1285"><ce:list-item id="u3625"><ce:label>•</ce:label><ce:para id="p6985">Complications of previous cardiac surgery:<ce:list id="ulist1290"><ce:list-item id="u3630"><ce:para id="p6990">Arrhythmia related to scarring</ce:para></ce:list-item><ce:list-item id="u3635"><ce:para id="p6995">Heart failure secondary to scarring</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0535" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1010" locator="icon05-9780702070280" xlink:href="pii:B9780702070280000160/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1770" role="short">Image 101</ce:alt-text></ce:inline-figure>16.101</ce:label><ce:alt-text id="atte1775" role="short">16.101</ce:alt-text><ce:textbox-head><ce:title id="tit0540">Pregnancy in women with congenital heart disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7050"><ce:list id="ulist1295"><ce:list-item id="u3640"><ce:label>•</ce:label><ce:para id="p7055"><ce:bold>Obstructive lesions</ce:bold>: poorly tolerated and associated with significant maternal morbidity and mortality.</ce:para></ce:list-item><ce:list-item id="u3645"><ce:label>•</ce:label><ce:para id="p7060"><ce:bold>Cyanotic conditions</ce:bold>: especially poorly tolerated. Specialised pre-conception counselling should explain the increased risks.</ce:para></ce:list-item><ce:list-item id="u3650"><ce:label>•</ce:label><ce:para id="p7065"><ce:bold>Surgically corrected disease</ce:bold>: patients often tolerate pregnancy well.</ce:para></ce:list-item><ce:list-item id="u3655"><ce:label>•</ce:label><ce:para id="p7070"><ce:bold>Children of patients with congenital heart disease</ce:bold>: 2–5% will be born with cardiac abnormalities, especially if the mother is affected. The risk may be up to 20% in babies born of women with left-sided lesions.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0540" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1050" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1780" role="short">Image 102</ce:alt-text></ce:inline-figure>16.102</ce:label><ce:alt-text id="atte1785" role="short">16.102</ce:alt-text><ce:textbox-head><ce:title id="tit0545">Other causes of cyanotic congenital heart disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7245"><ce:display><ce:table frame="topbot" id="t0245"><ce:alt-text id="atte1790" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Defect</entry><entry align="left">Features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Tricuspid atresia</ce:bold></entry><entry align="left">Absent tricuspid orifice, hypoplastic RV, RA-to-LA shunt, ventricular septal defect shunt, other anomalies<ce:br/>Surgical correction may be possible</entry></row><row rowsep="1"><entry align="left"><ce:bold>Transposition of the great vessels</ce:bold></entry><entry align="left">Aorta arises from the morphological RV, pulmonary artery from LV<ce:br/>Shunt via atria, ductus and possibly ventricular septal defect<ce:br/>Palliation by balloon atrial septostomy/enlargement<ce:br/>Surgical correction possible</entry></row><row rowsep="1"><entry align="left"><ce:bold>Pulmonary atresia</ce:bold></entry><entry align="left">Pulmonary valve atretic and pulmonary artery hypoplastic<ce:br/>RA-to-LA shunt, pulmonary flow via ductus<ce:br/>Palliation by balloon atrial septostomy<ce:br/>Surgical correction may be possible</entry></row><row><entry align="left"><ce:bold>Ebstein's anomaly</ce:bold></entry><entry align="left">Tricuspid valve is dysplastic and displaced into RV, RV ‘atrialised’<ce:br/>Tricuspid regurgitation and RA-to-LA shunt<ce:br/>Wide spectrum of severity<ce:br/>Arrhythmias<ce:br/>Surgical repair possible but significant risk</entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p7250">(LA = left atrium; LV = left ventricle; RA = right atrium; RV = right ventricle)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0545" role="alt4"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1055" locator="icon04-9780702070280" xlink:href="pii:B9780702070280000160/icon04-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1795" role="short">Image 103</ce:alt-text></ce:inline-figure>16.103</ce:label><ce:alt-text id="atte1800" role="short">16.103</ce:alt-text><ce:textbox-head><ce:title id="tit0550">Congenital heart disease in adolescence</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7260"><ce:list id="ulist1305"><ce:list-item id="u3670"><ce:label>•</ce:label><ce:para id="p7265"><ce:bold>Patients</ce:bold>: a heterogeneous population with residual disease and sequelae that vary according to the underlying lesion and in severity; each patient must be assessed individually.</ce:para></ce:list-item><ce:list-item id="u3675"><ce:label>•</ce:label><ce:para id="p7270"><ce:bold>Management plan</ce:bold>: should be agreed with the patient and include short- and long-term goals and timing of transition to adult care.</ce:para></ce:list-item><ce:list-item id="u3680"><ce:label>•</ce:label><ce:para id="p7275"><ce:bold>Risks of surgery</ce:bold>: non-cardiac surgery for associated congenital abnormalities carries increased risks and needs to be planned, with careful pre-operative assessment. Risks include thrombosis, embolism from synthetic shunts or patches, and volume overload from fluid shifts. Operative approaches should address cosmetic concerns, such as site of implantation of abdominal generator.</ce:para></ce:list-item><ce:list-item id="u3685"><ce:label>•</ce:label><ce:para id="p7280"><ce:bold>Exercise</ce:bold>: patients with mild or repaired defects can undertake moderately vigorous exercise but those with complex defects, cyanosis, ventricular dysfunction or arrhythmias require specialist evaluation and individualised advice regarding exercise.</ce:para></ce:list-item><ce:list-item id="u3690"><ce:label>•</ce:label><ce:para id="p7285"><ce:bold>Genetics</ce:bold>: Between 10% and 15% have a genetic basis and this should be assessed to understand the impact it may have for the patient's own future children. A family history, genetic evaluation of syndromic versus non-syndromic disorders and, sometimes, cytogenetics are required.</ce:para></ce:list-item><ce:list-item id="u3695"><ce:label>•</ce:label><ce:para id="p7290"><ce:bold>Education and employment</ce:bold>: may be adversely affected and occupational activity levels need to be assessed.</ce:para></ce:list-item><ce:list-item id="u3700"><ce:label>•</ce:label><ce:para id="p7295"><ce:bold>End of life</ce:bold>: some adolescents with complex disorders may misperceive and think they have been cured; transition to adult services may be the first time they receive information about mortality. Expectations on life expectancy need to be managed and adolescents are often willing to engage with this and play a role in decision-making.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0550" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1060" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1805" role="short">Image 104</ce:alt-text></ce:inline-figure>16.104</ce:label><ce:alt-text id="atte1810" role="short">16.104</ce:alt-text><ce:textbox-head><ce:title id="tit0555">Some causes of myocarditis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7315"><ce:display><ce:table frame="topbot" id="t0250"><ce:alt-text id="atte1815" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infections</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Viral</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1310"><ce:list-item id="u3705"><ce:label>•</ce:label><ce:para id="p7320">Coxsackie</ce:para></ce:list-item><ce:list-item id="u3710"><ce:label>•</ce:label><ce:para id="p7325">Adenovirus</ce:para></ce:list-item><ce:list-item id="u3715"><ce:label>•</ce:label><ce:para id="p7330">Influenza A</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1315"><ce:list-item id="u3720"><ce:label>•</ce:label><ce:para id="p7335">Human immunodeficiency virus (HIV)</ce:para></ce:list-item><ce:list-item id="o9005"><ce:label>•</ce:label><ce:para id="p9015">Influenza B</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bacterial</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1320"><ce:list-item id="u3725"><ce:label>•</ce:label><ce:para id="p7340"><ce:italic>Borrelia burgdorferi</ce:italic> (Lyme disease)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1325"><ce:list-item id="u3730"><ce:label>•</ce:label><ce:para id="p7345"><ce:italic>Mycoplasma pneumoniae</ce:italic></ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Protozoal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1330"><ce:list-item id="u3735"><ce:label>•</ce:label><ce:para id="p7350"><ce:italic>Trypanosoma cruzi</ce:italic> (Chagas' disease)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1335"><ce:list-item id="u3740"><ce:label>•</ce:label><ce:para id="p7355"><ce:italic>Toxoplasma gondii</ce:italic></ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fungal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1340"><ce:list-item id="u3745"><ce:label>•</ce:label><ce:para id="p7360"><ce:italic>Aspergillus</ce:italic></ce:para></ce:list-item></ce:list></entry><entry align="left"/></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Parasitic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1345"><ce:list-item id="u3750"><ce:label>•</ce:label><ce:para id="p7365"><ce:italic>Shistosoma</ce:italic></ce:para></ce:list-item></ce:list></entry><entry align="left"/></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs/Toxins</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1350"><ce:list-item id="u3755"><ce:label>•</ce:label><ce:para id="p7370">Alcohol</ce:para></ce:list-item><ce:list-item id="u3760"><ce:label>•</ce:label><ce:para id="p7375">Anthracyclines</ce:para></ce:list-item><ce:list-item id="u3765"><ce:label>•</ce:label><ce:para id="p7380">Clozapine</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1355"><ce:list-item id="u3770"><ce:label>•</ce:label><ce:para id="p7385">Cocaine</ce:para></ce:list-item><ce:list-item id="u3775"><ce:label>•</ce:label><ce:para id="p7390">Lithium</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Autoimmune</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1360"><ce:list-item id="u3780"><ce:label>•</ce:label><ce:para id="p7395">Systemic lupus erythematosus</ce:para></ce:list-item><ce:list-item id="u3785"><ce:label>•</ce:label><ce:para id="p7400">Systemic sclerosis</ce:para></ce:list-item><ce:list-item id="u3790"><ce:label>•</ce:label><ce:para id="p7405">Rheumatoid arthritis</ce:para></ce:list-item><ce:list-item id="u3795"><ce:label>•</ce:label><ce:para id="p7410">Sarcoidosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1365"><ce:list-item id="u3800"><ce:label>•</ce:label><ce:para id="p7415">Hypersensitivity reaction to penicillins, sulphonamides, lead, carbon monoxide</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0555" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1070" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1820" role="short">Image 105</ce:alt-text></ce:inline-figure>16.105</ce:label><ce:alt-text id="atte1825" role="short">16.105</ce:alt-text><ce:textbox-head><ce:title id="tit0560">Clinical features of hypertrophic cardiomyopathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7510"><ce:display><ce:table frame="topbot" id="t0255"><ce:alt-text id="atte1830" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Symptoms</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1375"><ce:list-item id="u3825"><ce:label>•</ce:label><ce:para id="p7515">Angina on effort</ce:para></ce:list-item><ce:list-item id="u3830"><ce:label>•</ce:label><ce:para id="p7520">Dyspnoea on effort</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1380"><ce:list-item id="u3835"><ce:label>•</ce:label><ce:para id="p7525">Syncope on effort</ce:para></ce:list-item><ce:list-item id="u3840"><ce:label>•</ce:label><ce:para id="p7530">Sudden death</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Signs</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1385"><ce:list-item id="u3845"><ce:label>•</ce:label><ce:para id="p7535">Jerky pulse<ce:cross-ref id="crf1910" refid="tn0105"><ce:bold>*</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u3850"><ce:label>•</ce:label><ce:para id="p7540">Palpable left ventricular hypertrophy</ce:para></ce:list-item><ce:list-item id="u3855"><ce:label>•</ce:label><ce:para id="p7545">Double impulse at the apex (palpable fourth heart sound due to left atrial hypertrophy)</ce:para></ce:list-item><ce:list-item id="u3860"><ce:label>•</ce:label><ce:para id="p7550">Mid-systolic murmur at the base<ce:cross-ref id="crf1915" refid="tn0105">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u3865"><ce:label>•</ce:label><ce:para id="p7555">Pansystolic murmur (due to mitral regurgitation) at the apex</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0105"><ce:label>*</ce:label><ce:note-para id="np0140">Signs of left ventricular outflow tract obstruction may be augmented by standing up (reduced venous return), inotropes and vasodilators (e.g. sublingual nitrate).</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0560" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1075" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1835" role="short">Image 106</ce:alt-text></ce:inline-figure>16.106</ce:label><ce:alt-text id="atte1840" role="short">16.106</ce:alt-text><ce:textbox-head><ce:title id="tit0565">Risk factors for sudden death in hypertrophic cardiomyopathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7560"><ce:list id="ulist1390"><ce:list-item id="u3870"><ce:label>•</ce:label><ce:para id="p7565">A history of previous cardiac arrest or sustained ventricular tachycardia</ce:para></ce:list-item><ce:list-item id="u3875"><ce:label>•</ce:label><ce:para id="p7570">Recurrent syncope</ce:para></ce:list-item><ce:list-item id="u3880"><ce:label>•</ce:label><ce:para id="p7575">An adverse genotype and/or family history</ce:para></ce:list-item><ce:list-item id="u3885"><ce:label>•</ce:label><ce:para id="p7580">Exercise-induced hypotension</ce:para></ce:list-item><ce:list-item id="u3890"><ce:label>•</ce:label><ce:para id="p7585">Non-sustained ventricular tachycardia on ambulatory ECG monitoring</ce:para></ce:list-item><ce:list-item id="u3895"><ce:label>•</ce:label><ce:para id="p7590">Marked increase in left ventricular wall thickness</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0565" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1080" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1845" role="short">Image 107</ce:alt-text></ce:inline-figure>16.107</ce:label><ce:alt-text id="atte1850" role="short">16.107</ce:alt-text><ce:textbox-head><ce:title id="tit0570">Specific diseases of heart muscle</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7635"><ce:display><ce:table frame="topbot" id="t0260"><ce:alt-text id="atte1855" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infections</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Viral</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1395"><ce:list-item id="u3900"><ce:label>•</ce:label><ce:para id="p7640">Coxsackie A and B</ce:para></ce:list-item><ce:list-item id="u3905"><ce:label>•</ce:label><ce:para id="p7645">Influenza</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1400"><ce:list-item id="u3910"><ce:label>•</ce:label><ce:para id="p7650">HIV</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bacterial</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1405"><ce:list-item id="u3915"><ce:label>•</ce:label><ce:para id="p7655">Diphtheria</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1410"><ce:list-item id="u3920"><ce:label>•</ce:label><ce:para id="p7660"><ce:italic>Borrelia burgdorferi</ce:italic></ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Protozoal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1415"><ce:list-item id="u3925"><ce:label>•</ce:label><ce:para id="p7665">Trypanosomiasis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="olist9000"><ce:list-item id="o9010"><ce:label>•</ce:label><ce:para id="p9020"><ce:italic>Toxoplasma gondii</ce:italic></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Endocrine and metabolic disorders</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1420"><ce:list-item id="u3930"><ce:label>•</ce:label><ce:para id="p7670">Diabetes</ce:para></ce:list-item><ce:list-item id="u3935"><ce:label>•</ce:label><ce:para id="p7675">Hypo- and hyperthyroidism</ce:para></ce:list-item><ce:list-item id="u3940"><ce:label>•</ce:label><ce:para id="p7680">Acromegaly</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1425"><ce:list-item id="u3945"><ce:label>•</ce:label><ce:para id="p7685">Carcinoid syndrome</ce:para></ce:list-item><ce:list-item id="u3950"><ce:label>•</ce:label><ce:para id="p7690">Phaeochromocytoma</ce:para></ce:list-item><ce:list-item id="u3955"><ce:label>•</ce:label><ce:para id="p7695">Inherited storage diseases</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Connective tissue diseases</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1430"><ce:list-item id="u3960"><ce:label>•</ce:label><ce:para id="p7700">Systemic sclerosis</ce:para></ce:list-item><ce:list-item id="u3965"><ce:label>•</ce:label><ce:para id="p7705">Systemic lupus erythematosus</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1435"><ce:list-item id="u3970"><ce:label>•</ce:label><ce:para id="p7710">Polyarteritis nodosa</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infiltrative disorders</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1440"><ce:list-item id="u3975"><ce:label>•</ce:label><ce:para id="p7715">Haemochromatosis</ce:para></ce:list-item><ce:list-item id="u3980"><ce:label>•</ce:label><ce:para id="p7720">Haemosiderosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1445"><ce:list-item id="u3985"><ce:label>•</ce:label><ce:para id="p7725">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u3990"><ce:label>•</ce:label><ce:para id="p7730">Amyloidosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Toxins</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1450"><ce:list-item id="u3995"><ce:label>•</ce:label><ce:para id="p7735">Doxorubicin</ce:para></ce:list-item><ce:list-item id="u4000"><ce:label>•</ce:label><ce:para id="p7740">Alcohol</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1455"><ce:list-item id="u4005"><ce:label>•</ce:label><ce:para id="p7745">Cocaine</ce:para></ce:list-item><ce:list-item id="u4010"><ce:label>•</ce:label><ce:para id="p7750">Irradiation</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Neuromuscular disorders</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1460"><ce:list-item id="u4015"><ce:label>•</ce:label><ce:para id="p7755">Dystrophia myotonica</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1465"><ce:list-item id="u4020"><ce:label>•</ce:label><ce:para id="p7760">Friedreich's ataxia</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0570" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1085" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1860" role="short">Image 108</ce:alt-text></ce:inline-figure>16.108</ce:label><ce:alt-text id="atte1865" role="short">16.108</ce:alt-text><ce:textbox-head><ce:title id="tit0575">Causes of acute pericarditis and pericardial effusion</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7805"><ce:display><ce:table frame="topbot" id="t0265"><ce:alt-text id="atte1870" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infection</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1470"><ce:list-item id="u4025"><ce:label>•</ce:label><ce:para id="p7810">Viral</ce:para></ce:list-item><ce:list-item id="u4030"><ce:label>•</ce:label><ce:para id="p7815">Bacterial</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1475"><ce:list-item id="u4035"><ce:label>•</ce:label><ce:para id="p7820">Tuberculosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1480"><ce:list-item id="u4040"><ce:label>•</ce:label><ce:para id="p7825">Rheumatoid arthritis</ce:para></ce:list-item><ce:list-item id="u4045"><ce:label>•</ce:label><ce:para id="p7830">Systemic lupus erythematosus</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1485"><ce:list-item id="u4050"><ce:label>•</ce:label><ce:para id="p7835">Rheumatic fever</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1490"><ce:list-item id="u4055"><ce:label>•</ce:label><ce:para id="p7840">Post-myocardial infarction</ce:para></ce:list-item><ce:list-item id="u4060"><ce:label>•</ce:label><ce:para id="p7845">Uraemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1495"><ce:list-item id="u4065"><ce:label>•</ce:label><ce:para id="p7850">Malignancy</ce:para></ce:list-item><ce:list-item id="u4070"><ce:label>•</ce:label><ce:para id="p7855">Trauma</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0575" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1100" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1875" role="short">Image 109</ce:alt-text></ce:inline-figure>16.109</ce:label><ce:alt-text id="atte1880" role="short">16.109</ce:alt-text><ce:textbox-head><ce:title id="tit0580">Clinical features of constrictive pericarditis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7915"><ce:display><ce:table frame="topbot" id="t0270"><ce:alt-text id="atte1885" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist1500"><ce:list-item id="u4075"><ce:label>•</ce:label><ce:para id="p7920">Fatigue</ce:para></ce:list-item><ce:list-item id="u4080"><ce:label>•</ce:label><ce:para id="p7925">Rapid, low-volume pulse</ce:para></ce:list-item><ce:list-item id="u4085"><ce:label>•</ce:label><ce:para id="p7930">Elevated JVP with a rapid <ce:italic>y</ce:italic> descent</ce:para></ce:list-item><ce:list-item id="u4095"><ce:label>•</ce:label><ce:para id="p7940">Loud early third heart sound or ‘pericardial knock’</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1505"><ce:list-item id="u4090"><ce:label>•</ce:label><ce:para id="p7935">Kussmaul's sign</ce:para></ce:list-item><ce:list-item id="u4100"><ce:label>•</ce:label><ce:para id="p7945">Hepatomegaly</ce:para></ce:list-item><ce:list-item id="u4105"><ce:label>•</ce:label><ce:para id="p7950">Ascites</ce:para></ce:list-item><ce:list-item id="u4110"><ce:label>•</ce:label><ce:para id="p7955">Peripheral oedema</ce:para></ce:list-item><ce:list-item id="u4115"><ce:label>•</ce:label><ce:para id="p7960">Pulsus paradoxus</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p7965">(JVP = jugular venous pressure)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0580" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln1110" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1890" role="short">Image 110</ce:alt-text></ce:inline-figure>16.110</ce:label><ce:alt-text id="atte1895" role="short">16.110</ce:alt-text><ce:textbox-head><ce:title id="tit0585">Clinical features of cardiac tamponade</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7990"><ce:list id="ulist1510"><ce:list-item id="u4120"><ce:label>•</ce:label><ce:para id="p7995">Dyspnoea</ce:para></ce:list-item><ce:list-item id="u4125"><ce:label>•</ce:label><ce:para id="p8000">Collapse</ce:para></ce:list-item><ce:list-item id="u4130"><ce:label>•</ce:label><ce:para id="p8005">Tachycardia</ce:para></ce:list-item><ce:list-item id="u4135"><ce:label>•</ce:label><ce:para id="p8010">Hypotension</ce:para></ce:list-item><ce:list-item id="u4140"><ce:label>•</ce:label><ce:para id="p8015">Gross elevation of the JVP</ce:para></ce:list-item><ce:list-item id="u4145"><ce:label>•</ce:label><ce:para id="p8020">Soft heart sounds with an early third heart sound</ce:para></ce:list-item><ce:list-item id="u4150"><ce:label>•</ce:label><ce:para id="p8025">Pulsus paradoxus (a large fall in BP during inspiration, when the pulse may be impalpable)</ce:para></ce:list-item><ce:list-item id="u4155"><ce:label>•</ce:label><ce:para id="p8030">Kussmaul's sign (a paradoxical rise in JVP during inspiration)</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p8035">(JVP = jugular venous pressure)</ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:floats><ce:label>16</ce:label><ce:title id="tit0010">Cardiology</ce:title><ce:author-group id="aug0010"><ce:author author-id="B9780702070280000160-4a38805bcf1038ea8f4148d0cffb171d" id="au0010"><ce:given-name>DE</ce:given-name><ce:surname>Newby</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0015"><ce:author author-id="B9780702070280000160-91300e8b061e5df8bd911c913d3e8db2" id="au0015"><ce:given-name>NR</ce:given-name><ce:surname>Grubb</ce:surname></ce:author></ce:author-group><outline id="out0010"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:para id="p0010"><ce:bold>Clinical examination of the cardiovascular system</ce:bold> <ce:cross-ref id="crf0010" refid="s0010"><ce:bold>442</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0015"><ce:para id="p0015"><ce:bold>Functional anatomy and physiology</ce:bold> <ce:cross-ref id="crf0015" refid="s0030"><ce:bold>444</ce:bold></ce:cross-ref><ce:list id="ulist0015"><ce:list-item id="u0020"><ce:para id="p0020">Anatomy <ce:cross-ref id="crf0020" refid="s0035">444</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0025"><ce:para id="p0025">Physiology <ce:cross-ref id="crf0025" refid="s0055">446</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0030"><ce:para id="p0030"><ce:bold>Investigation of cardiovascular disease</ce:bold> <ce:cross-ref id="crf0030" refid="s0085"><ce:bold>448</ce:bold></ce:cross-ref><ce:list id="ulist0020"><ce:list-item id="u0035"><ce:para id="p0035">Electrocardiogram <ce:cross-ref id="crf0035" refid="s0090">448</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0040"><ce:para id="p0040">Cardiac biomarkers <ce:cross-ref id="crf0040" refid="s0120">450</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0045"><ce:para id="p0045">Chest X-ray <ce:cross-ref id="crf0045" refid="s0135">450</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0050"><ce:para id="p0050">Echocardiography <ce:cross-ref id="crf0050" refid="s0140">451</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0055"><ce:para id="p0055">Computed tomography <ce:cross-ref id="crf0055" refid="s0165">452</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0060"><ce:para id="p0060">Magnetic resonance imaging <ce:cross-ref id="crf0060" refid="s0170">452</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0065"><ce:para id="p0065">Cardiac catheterisation <ce:cross-ref id="crf0065" refid="s0175">453</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0070"><ce:para id="p0070">Electrophysiology <ce:cross-ref id="crf0070" refid="s0180">454</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0075"><ce:para id="p0075">Radionuclide imaging <ce:cross-ref id="crf0075" refid="s0185">454</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0080"><ce:para id="p0080"><ce:bold>Presenting problems in cardiovascular disease</ce:bold> <ce:cross-ref id="crf0080" refid="s0200"><ce:bold>454</ce:bold></ce:cross-ref><ce:list id="ulist0025"><ce:list-item id="u0085"><ce:para id="p0085">Chest pain on exertion <ce:cross-ref id="crf0085" refid="s0225">454</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0090"><ce:para id="p0090">Severe prolonged chest pain <ce:cross-ref id="crf0090" refid="s0245">455</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0095"><ce:para id="p0095">Breathlessness <ce:cross-ref id="crf0095" refid="s0270">455</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0100"><ce:para id="p0100">Syncope <ce:cross-ref id="crf0100" refid="s0290">455</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0105"><ce:para id="p0105">Palpitation <ce:cross-ref id="crf0105" refid="s0295">455</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0110"><ce:para id="p0110">Cardiac arrest <ce:cross-ref id="crf0110" refid="s0320">456</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0115"><ce:para id="p0115">Abnormal heart sounds <ce:cross-ref id="crf0115" refid="s0375">457</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0120"><ce:para id="p0120">Heart failure <ce:cross-ref id="crf0120" refid="s0455">461</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0125"><ce:para id="p0125"><ce:bold>Cardiac arrhythmias</ce:bold> <ce:cross-ref id="crf0125" refid="s0660"><ce:bold>468</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0130"><ce:para id="p0130"><ce:bold>Principles of management of cardiac arrhythmias</ce:bold> <ce:cross-ref id="crf0130" refid="s0910"><ce:bold>479</ce:bold></ce:cross-ref><ce:list id="ulist0030"><ce:list-item id="u0135"><ce:para id="p0135">Anti-arrhythmic drugs <ce:cross-ref id="crf0135" refid="s0915">479</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0140"><ce:para id="p0140">Non-pharmacological treatments <ce:cross-ref id="crf0140" refid="s1095">482</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0145"><ce:para id="p0145"><ce:bold>Coronary artery disease</ce:bold> <ce:cross-ref id="crf0145" refid="s1145"><ce:bold>484</ce:bold></ce:cross-ref><ce:list id="ulist0035"><ce:list-item id="u0150"><ce:para id="p0150">Angina pectoris <ce:cross-ref id="crf0150" refid="s1245">487</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0155"><ce:para id="p0155">Acute coronary syndrome <ce:cross-ref id="crf0155" refid="s1365">493</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0160"><ce:para id="p0160">Non-cardiac surgery in patients with heart disease <ce:cross-ref id="crf0160" refid="s1540">501</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0165"><ce:para id="p0165"><ce:bold>Peripheral arterial disease</ce:bold> <ce:cross-ref id="crf0165" refid="s1545"><ce:bold>502</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0170"><ce:para id="p0170"><ce:bold>Diseases of the aorta</ce:bold> <ce:cross-ref id="crf0170" refid="s1675"><ce:bold>505</ce:bold></ce:cross-ref><ce:list id="ulist0040"><ce:list-item id="u0175"><ce:para id="p0175">Aortic aneurysm <ce:cross-ref id="crf0175" refid="s1680">505</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0180"><ce:para id="p0180">Aortic dissection <ce:cross-ref id="crf0180" refid="s1735">506</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0185"><ce:para id="p0185">Aortitis <ce:cross-ref id="crf0185" refid="s1765">508</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0190"><ce:para id="p0190">Marfan's syndrome <ce:cross-ref id="crf0190" refid="s1770">508</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0195"><ce:para id="p0195">Coarctation of the aorta <ce:cross-ref id="crf0195" refid="s1795">508</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0200"><ce:para id="p0200">Hypertension <ce:cross-ref id="crf0200" refid="s1800">508</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0205"><ce:para id="p0205"><ce:bold>Diseases of the heart valves</ce:bold> <ce:cross-ref id="crf0205" refid="s1960"><ce:bold>514</ce:bold></ce:cross-ref><ce:list id="ulist0045"><ce:list-item id="u0210"><ce:para id="p0210">Rheumatic heart disease <ce:cross-ref id="crf0210" refid="s1965">515</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0215"><ce:para id="p0215">Mitral valve disease <ce:cross-ref id="crf0215" refid="s2070">517</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0220"><ce:para id="p0220">Aortic valve disease <ce:cross-ref id="crf0220" refid="s2145">521</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0225"><ce:para id="p0225">Tricuspid valve disease <ce:cross-ref id="crf0225" refid="s2285">525</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0230"><ce:para id="p0230">Pulmonary valve disease <ce:cross-ref id="crf0230" refid="s2330">526</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0235"><ce:para id="p0235">Prosthetic valves <ce:cross-ref id="crf0235" refid="s2360">526</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0240"><ce:para id="p0240">Infective endocarditis <ce:cross-ref id="crf0240" refid="s2375">527</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0245"><ce:para id="p0245"><ce:bold>Congenital heart disease</ce:bold> <ce:cross-ref id="crf0245" refid="s2455"><ce:bold>531</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0250"><ce:para id="p0250"><ce:bold>Diseases of the myocardium</ce:bold> <ce:cross-ref id="crf0250" refid="s2645"><ce:bold>538</ce:bold></ce:cross-ref><ce:list id="ulist0050"><ce:list-item id="u0255"><ce:para id="p0255">Myocarditis <ce:cross-ref id="crf0255" refid="s2650">538</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0260"><ce:para id="p0260">Cardiomyopathy <ce:cross-ref id="crf0260" refid="s2675">538</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0265"><ce:para id="p0265">Cardiac tumours <ce:cross-ref id="crf0265" refid="s2755">541</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0270"><ce:para id="p0270"><ce:bold>Diseases of the pericardium</ce:bold> <ce:cross-ref id="crf0270" refid="s2765"><ce:bold>542</ce:bold></ce:cross-ref></ce:para></ce:list-item></ce:list></outline><ce:sections><ce:section id="s0010"><ce:section-title id="st0010">Clinical examination of the cardiovascular system</ce:section-title><ce:para id="p0275"><ce:display><ce:figure id="f0010"><ce:alt-text id="atte1900" role="short">Unlabelled image</ce:alt-text><ce:source>Insets (Splinter haemorrhage, jugular venous pulse, malar flush, tendon xanthomas) From Newby D, Grubb N. Cardiology: an illustrated colour text. Edinburgh: Churchill Livingstone, Elsevier Ltd; 2005.</ce:source><ce:link id="ln0010" locator="u016-001-9780702070280" xlink:href="pii:B9780702070280000160/u016-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:display><ce:textbox id="b0010" role="alt7"><ce:label>4</ce:label><ce:alt-text id="atte1905" role="short">4</ce:alt-text><ce:textbox-head><ce:title id="tit0015">Examination of the arterial pulse</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0280"><ce:list id="ulist0055"><ce:list-item id="u0275"><ce:label>•</ce:label><ce:para id="p0285">The character of the pulse is determined by stroke volume and arterial compliance, and is best assessed by palpating a major artery, such as the carotid or brachial artery.</ce:para></ce:list-item><ce:list-item id="u0280"><ce:label>•</ce:label><ce:para id="p0290">Aortic regurgitation, anaemia, sepsis and other causes of a large stroke volume typically produce a bounding pulse with a high amplitude and wide pulse pressure (panel A).</ce:para></ce:list-item><ce:list-item id="u0285"><ce:label>•</ce:label><ce:para id="p0295">Aortic stenosis impedes ventricular emptying. If severe, it causes a slow-rising, weak and delayed pulse (panel A).</ce:para></ce:list-item><ce:list-item id="u0290"><ce:label>•</ce:label><ce:para id="p0300">Sinus rhythm produces a pulse that is regular in time and force. Arrhythmias may cause irregularity. Atrial fibrillation produces a pulse that is irregular in time and volume (panel B).</ce:para></ce:list-item></ce:list><ce:display><ce:figure id="f0015"><ce:alt-text id="atte1910" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0015" locator="u016-002-9780702070280" xlink:href="pii:B9780702070280000160/u016-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:display><ce:figure id="f0020"><ce:alt-text id="atte1915" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0020" locator="u016-003-9780702070280" xlink:href="pii:B9780702070280000160/u016-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0015" role="alt7"><ce:label>5</ce:label><ce:alt-text id="atte1920" role="short">5</ce:alt-text><ce:textbox-head><ce:title id="tit0020">Examination of the jugular venous pulse</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0305">The internal jugular vein, superior vena cava and right atrium are in continuity, so the height of the jugular venous pulsation reflects right atrial pressure. When the patient is placed at 45°, with the head supported and turned to the left, the jugular venous pulse is visible along the line of the sternocleidomastoid muscle (see opposite). In health it is normally just visible above the clavicle.<ce:list id="ulist0060"><ce:list-item id="u0295"><ce:label>•</ce:label><ce:para id="p0310">The height of the jugular venous pulse is determined by right atrial pressure and is therefore elevated in right heart failure and reduced in hypovolaemia.</ce:para></ce:list-item><ce:list-item id="u0300"><ce:label>•</ce:label><ce:para id="p0315">If the jugular venous pulse is not easily seen, it may be exposed by applying firm pressure over the abdomen.</ce:para></ce:list-item><ce:list-item id="u0305"><ce:label>•</ce:label><ce:para id="p0320">In sinus rhythm, the two venous peaks, the <ce:italic>a</ce:italic> and <ce:italic>v</ce:italic> waves, approximate to atrial and ventricular systole, respectively.</ce:para></ce:list-item><ce:list-item id="u0310"><ce:label>•</ce:label><ce:para id="p0325">The <ce:italic>x</ce:italic> descent reflects atrial relaxation and apical displacement of the tricuspid valve ring. The <ce:italic>y</ce:italic> descent reflects atrial emptying early in diastole. These signs are subtle.</ce:para></ce:list-item><ce:list-item id="u0315"><ce:label>•</ce:label><ce:para id="p0330">Tricuspid regurgitation produces giant <ce:italic>v</ce:italic> waves that coincide with ventricular systole.</ce:para></ce:list-item></ce:list><ce:display><ce:figure id="f0025"><ce:alt-text id="atte1925" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0025" locator="u016-004-9780702070280" xlink:href="pii:B9780702070280000160/u016-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0020" role="alt1"><ce:alt-text id="atte1930" role="short">Unlabelled box</ce:alt-text><ce:textbox-head><ce:title id="tit0025"><ce:inline-figure baseline="0.0"><ce:link id="ln9005" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000160/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1935" role="short">Image 111</ce:alt-text></ce:inline-figure>Distinguishing venous/arterial pulsation in the neck</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0335"><ce:list id="ulist0065"><ce:list-item id="u0320"><ce:label>•</ce:label><ce:para id="p0340">The venous pulse has two peaks in each cardiac cycle; the arterial pulse has one peak.</ce:para></ce:list-item><ce:list-item id="u0325"><ce:label>•</ce:label><ce:para id="p0345">The height of the venous pulse varies with respiration (falls on inspiration) and position.</ce:para></ce:list-item><ce:list-item id="u0330"><ce:label>•</ce:label><ce:para id="p0350">Abdominal compression causes the venous pulse to rise.</ce:para></ce:list-item><ce:list-item id="u0335"><ce:label>•</ce:label><ce:para id="p0355">The venous pulse is not easily palpable and can be occluded with light pressure.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0025" role="alt7"><ce:label>7</ce:label><ce:alt-text id="atte1940" role="short">7</ce:alt-text><ce:textbox-head><ce:title id="tit0030">Palpation of the precordium</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0015"><ce:section-title id="st0015">Technique</ce:section-title><ce:para id="p0360"><ce:list id="ulist0070"><ce:list-item id="u0340"><ce:label>•</ce:label><ce:para id="p0365">Place fingertips over apex (1) to assess for position and character. Place heel of hand over left sternal edge (2) for a parasternal heave or ‘lift’. Assess for thrills in all areas, including the aortic and pulmonary areas (3). Normal position is the 5th or 6th intercostal space, at the mid-clavicular line.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0020"><ce:section-title id="st0020">Common abnormalities of the apex beat</ce:section-title><ce:para id="p0370"><ce:list id="ulist0075"><ce:list-item id="u0345"><ce:label>•</ce:label><ce:para id="p0375">Volume overload, such as mitral or aortic regurgitation: displaced, thrusting</ce:para></ce:list-item><ce:list-item id="u0350"><ce:label>•</ce:label><ce:para id="p0380">Pressure overload, such as aortic stenosis, hypertension: discrete, heaving</ce:para></ce:list-item><ce:list-item id="u0355"><ce:label>•</ce:label><ce:para id="p0385">Dyskinetic, such as left ventricular aneurysm: displaced, incoordinate</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0025"><ce:section-title id="st0025">Other abnormalities</ce:section-title><ce:para id="p0390"><ce:list id="ulist0080"><ce:list-item id="u0360"><ce:label>•</ce:label><ce:para id="p0395">Palpable S1 (tapping apex beat: mitral stenosis)</ce:para></ce:list-item><ce:list-item id="u0365"><ce:label>•</ce:label><ce:para id="p0400">Palpable P2 (severe pulmonary hypertension)</ce:para></ce:list-item><ce:list-item id="u0370"><ce:label>•</ce:label><ce:para id="p0405">Left parasternal heave or ‘lift’ felt by heel of hand (right ventricular hypertrophy)</ce:para></ce:list-item><ce:list-item id="u0375"><ce:label>•</ce:label><ce:para id="p0410">Palpable thrill (aortic stenosis)</ce:para></ce:list-item></ce:list><ce:display><ce:figure id="f0030"><ce:alt-text id="atte1945" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0030" locator="u016-005-9780702070280" xlink:href="pii:B9780702070280000160/u016-005-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0030" role="alt7"><ce:label>8</ce:label><ce:alt-text id="atte1950" role="short">8</ce:alt-text><ce:textbox-head><ce:title id="tit0035">Auscultation of the heart</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0415"><ce:list id="ulist0085"><ce:list-item id="u0380"><ce:label>•</ce:label><ce:para id="p0420">Use the diaphragm to examine at the apex, lower left sternal edge (tricuspid area) and upper left (pulmonary area) and right (aortic area) sternal edges.</ce:para></ce:list-item><ce:list-item id="u0385"><ce:label>•</ce:label><ce:para id="p0425">Use the bell to examine low-pitched noises, particularly at the apex for the mid-diastolic murmur of mitral stenosis.</ce:para></ce:list-item><ce:list-item id="u0390"><ce:label>•</ce:label><ce:para id="p0430">Time the sounds and murmurs by feeling the carotid pulse; the first heart sound (S1) just precedes the upstroke of the pulse and the second heart sound (S2) is out of step with it. If present, a third heart sound (S3) immediately follows S2, and a fourth heart sound (S4) just precedes S1. Systolic murmurs are synchronous with the pulse.</ce:para></ce:list-item><ce:list-item id="u0395"><ce:label>•</ce:label><ce:para id="p0435">Listen for radiation of systolic murmurs, over the base of the neck (aortic stenosis) and in the axilla (mitral incompetence).</ce:para></ce:list-item><ce:list-item id="u0400"><ce:label>•</ce:label><ce:para id="p0440">Listen over the left sternal border with the patient sitting forward (aortic incompetence), then at the apex with the patient rolled on to the left side (mitral stenosis).</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display>The haemodynamic effects of respiration are discussed on <ce:cross-ref id="crf9205" refid="p0510">page 447</ce:cross-ref>, and the analysis and interpretation of heart sounds and murmurs on <ce:cross-ref id="crf9210" refid="s0360">page 457</ce:cross-ref>.</ce:para><ce:para id="p0445">Cardiovascular disease is the most frequent cause of adult death in the Western world. In the UK, one-third of men and one-quarter of women will die as a result of ischaemic heart disease. In many developed countries, the incidence of ischaemic heart disease has been falling for the last two or three decades, but it is rising in Eastern Europe and Asia. Cardiovascular disease will soon become the leading cause of death on all continents. Strategies for the treatment and prevention of heart disease can be highly effective and have been subjected to rigorous evaluation. The evidence base for the treatment of cardiovascular disease is stronger than for almost any other disease group.</ce:para><ce:para id="p0450">Valvular heart disease is common but the aetiology varies in different parts of the world. On the Indian subcontinent and in Africa, it is predominantly due to rheumatic fever, whereas calcific aortic valve disease is the most common problem in developed countries.</ce:para><ce:para id="p0455">Prompt recognition of the development of heart disease is limited by two key factors. Firstly, it is often latent; coronary artery disease can proceed to an advanced stage before the patient notices any symptoms. Secondly, the diversity of symptoms attributable to heart disease is limited, so different pathologies may frequently present with the same symptoms.</ce:para></ce:section><ce:section id="s0030"><ce:section-title id="st0030">Functional anatomy and physiology</ce:section-title><ce:section id="s0035"><ce:section-title id="st0035">Anatomy</ce:section-title><ce:para id="p0460">The heart acts as two serial pumps that share several electrical and mechanical components. The right heart circulates blood to the lungs where it is oxygenated, and the left heart circulates it to the rest of the body (<ce:cross-ref id="crf0275" refid="f0035">Fig. 16.1</ce:cross-ref><ce:float-anchor refid="f0035"/>). The atria are thin-walled structures that act as priming pumps for the ventricles, which provide most of the energy required to maintain the circulation. The atria are situated posteriorly within the mediastinum where the left atrium (LA) sits anterior to the oesophagus and descending aorta. The right atrium (RA) receives blood from the superior and inferior venae cavae and the coronary sinus. The LA receives blood from four pulmonary veins, two from each of the left and right lungs. The ventricles are thick-walled structures, adapted to circulating blood through large vascular beds under pressure. The atria and ventricles are separated by the annulus fibrosus, which forms the skeleton for the atrioventricular (AV) valves and electrically insulates the atria from the ventricles. The right ventricle (RV) is about 2–3 mm thick and triangular in shape. It extends from the annulus fibrosus to near the cardiac apex and sits anterior and to the right of the left ventricle (LV). The anterosuperior surface of the RV is rounded and convex, and its posterior extent is bounded by the interventricular septum, which bulges into the chamber. Its upper extent is conical, forming the conus arteriosus or outflow tract, from which the pulmonary artery arises. The LV is more conical in shape and in cross-section is nearly circular. It extends from the LA to the apex of the heart. The LV myocardium is normally around 10 mm thick because it pumps blood at a higher pressure than the RV.</ce:para><ce:para id="p0465">Normally, the heart occupies less than 50% of the transthoracic diameter in the frontal plane, as seen on a chest X-ray. On the patient's left, the cardiac silhouette is formed by the aortic arch, the pulmonary trunk, the left atrial appendage and the LV. On the right, the silhouette is formed by the RA and the superior and inferior venae cavae, and the lower right border is formed by the RV (<ce:cross-ref id="crf0280" refid="f0040">Fig. 16.2</ce:cross-ref><ce:float-anchor refid="f0040"/>). In disease states or congenital cardiac abnormalities, the silhouette may change as a result of hypertrophy or dilatation.</ce:para><ce:section id="s0040"><ce:section-title id="st0040">Coronary circulation</ce:section-title><ce:para id="p0470">The left main and right coronary arteries arise from the left and right sinuses of the aortic root, distal to the aortic valve (<ce:cross-ref id="crf0285" refid="f0045">Fig. 16.3</ce:cross-ref><ce:float-anchor refid="f0045"/>). Within 2.5 cm of its origin, the left main coronary artery divides into the left anterior descending artery (LAD), which runs in the anterior interventricular groove, and the left circumflex artery (CX), which runs posteriorly in the atrioventricular groove. The LAD gives branches to supply the anterior part of the septum (septal perforators) and the anterior, lateral and apical walls of the LV. The CX gives marginal branches that supply the lateral, posterior and inferior segments of the LV. The right coronary artery (RCA) runs in the right atrioventricular groove, giving branches that supply the RA, RV and inferoposterior aspects of the LV. The posterior descending artery runs in the posterior interventricular groove and supplies the inferior part of the interventricular septum. This vessel is a branch of the RCA in approximately 90% of people (dominant right system) and is supplied by the CX in the remainder (dominant left system). The coronary anatomy varies greatly from person to person and there are many normal variants.</ce:para><ce:para id="p0475">The RCA supplies the sinoatrial (SA) node in about 60% of individuals and the AV node in about 90%. Proximal occlusion of the RCA therefore often results in sinus bradycardia and may also cause AV nodal block. Abrupt occlusion of the RCA, due to coronary thrombosis, results in infarction of the inferior part of the LV and often the RV. Abrupt occlusion of the LAD or CX causes infarction in the corresponding territory of the LV, and occlusion of the left main coronary artery is usually fatal.</ce:para><ce:para id="p0480">The venous system follows the coronary arteries but drains into the coronary sinus in the atrioventricular groove, and then to the RA. An extensive lymphatic system drains into vessels that travel with the coronary vessels and then into the thoracic duct.</ce:para></ce:section><ce:section id="s0045"><ce:section-title id="st0045">Conduction system</ce:section-title><ce:para id="p0485">The SA node is situated at the junction of the superior vena cava and RA (<ce:cross-ref id="crf0290" refid="f0050">Fig. 16.4</ce:cross-ref><ce:float-anchor refid="f0050"/>). It comprises specialised atrial cells that depolarise at a rate influenced by the autonomic nervous system and by circulating catecholamines. During normal (sinus) rhythm, this depolarisation wave propagates through both atria via sheets of atrial myocytes. The annulus fibrosus forms a conduction barrier between atria and ventricles, and the only pathway through it is the AV node. This is a midline structure, extending from the right side of the interatrial septum, penetrating the annulus fibrosus anteriorly. The AV node conducts relatively slowly, producing a necessary time delay between atrial and ventricular contraction. The His–Purkinje system is composed of the bundle of His extending from the AV node into the interventricular septum, the right and left bundle branches passing along the ventricular septum and into the respective ventricles, the anterior and posterior fascicles of the left bundle branch, and the smaller Purkinje fibres that ramify through the ventricular myocardium. The tissues of the His–Purkinje system conduct very rapidly and allow near-simultaneous depolarisation of the entire ventricular myocardium.</ce:para></ce:section><ce:section id="s0050"><ce:section-title id="st0050">Nerve supply of the heart</ce:section-title><ce:para id="p0490">The heart is innervated by both sympathetic and parasympathetic fibres. Adrenergic nerves from the cervical sympathetic chain supply muscle fibres in the atria and ventricles, and the electrical conducting system. Activation of β<ce:inf loc="post">1</ce:inf>-adrenoceptors in the heart results in positive inotropic and chronotropic effects, whereas activation of β<ce:inf loc="post">2</ce:inf>-adrenoceptors in vascular smooth muscle causes vasodilatation. Parasympathetic pre-ganglionic fibres and sensory fibres reach the heart through the vagus nerves. Cholinergic nerves supply the AV and SA nodes via muscarinic (M2) receptors. Under resting conditions, vagal inhibitory activity predominates and the heart rate is slow. Adrenergic stimulation, associated with exercise, emotional stress, fever and so on, causes the heart rate to increase. In disease states, the nerve supply to the heart may be affected. For example, in heart failure the sympathetic system may be up-regulated, and in diabetes mellitus the nerves themselves may be damaged by autonomic neuropathy (<ce:intra-ref id="ii0020" xlink:href="pii:B978-0-7020-7028-0.00020-2#p3310">p. 758</ce:intra-ref>) so that there is little variation in heart rate.</ce:para></ce:section></ce:section><ce:section id="s0055"><ce:section-title id="st0055">Physiology</ce:section-title><ce:section id="s0060"><ce:section-title id="st0060">Myocardial contraction</ce:section-title><ce:para id="p0495">Myocardial cells (myocytes) are about 50–100 µm long; each cell branches and interdigitates with adjacent cells. An intercalated disc permits electrical conduction via gap junctions, and mechanical conduction via the fascia adherens, to adjacent cells (<ce:cross-ref id="crf0295" refid="f0055">Fig. 16.5A</ce:cross-ref><ce:float-anchor refid="f0055"/>). The basic unit of contraction is the sarcomere (2 µm long), which is aligned to those of adjacent myofibrils, giving a striated appearance due to the Z-lines (<ce:cross-ref id="crf0300" refid="f0055">Fig. 16.5B and C</ce:cross-ref>). Actin filaments are attached at right angles to the Z-lines and interdigitate with thicker parallel myosin filaments. The cross-links between actin and myosin molecules contain myofibrillar adenosine triphosphatase (ATPase), which breaks down adenosine triphosphate (ATP) to provide the energy for contraction (<ce:cross-ref id="crf0305" refid="f0055">Fig. 16.5E</ce:cross-ref>). Two chains of actin molecules form a helical structure, with a second molecule, tropomyosin, in the grooves of the actin helix, and a further molecule complex, troponin, attached to every seventh actin molecule (<ce:cross-ref id="crf0310" refid="f0055">Fig. 16.5D</ce:cross-ref>).</ce:para><ce:para id="p0500">During the plateau phase of the action potential, calcium ions enter the cell and are mobilised from the sarcoplasmic reticulum. They bind to troponin and thereby precipitate contraction by shortening of the sarcomere through the interdigitation of the actin and myosin molecules. The force of cardiac muscle contraction, or inotropic state, is regulated by the influx of calcium ions through ‘slow calcium channels’. The extent to which the sarcomere can shorten determines stroke volume of the ventricle. It is maximally shortened in response to powerful inotropic drugs or marked exercise. However, the enlargement of the heart seen in heart failure is due to slippage of the myofibrils and adjacent cells rather than lengthening of the sarcomere.</ce:para></ce:section><ce:section id="s0065"><ce:section-title id="st0065">Cardiac peptides</ce:section-title><ce:para id="p0505">Cardiomyocytes secrete peptides that have humoral effects on the vasculature and kidneys. Atrial natriuretic peptide (ANP) is a 28-amino acid peptide, which includes an amino acid ring that acts as a vasodilator, thereby reducing blood pressure (BP), and acts as a diuretic by promoting renal excretion of water and sodium. It is released by atrial myocytes in response to stretch. Brain natriuretic peptide (BNP), which was originally identified in extracts of porcine brain, is a 32-amino acid polypeptide produced by ventricular cardiomyocytes in response to stretch, as occurs in heart failure. Like ANP, it has diuretic properties. Neprilysin is an enzyme present in the circulation that is produced by the kidney and other tissues. It breaks down ANP, BNP and other proteins and, in so doing, acts as a vasoconstrictor. It forms a therapeutic target in patients with heart failure (<ce:cross-ref id="crf9215" refid="s0590">p. 466</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0070"><ce:section-title id="st0070">Circulation</ce:section-title><ce:para id="p0510">The RA receives deoxygenated blood from the superior and inferior venae cavae and discharges blood to the RV, which in turn pumps it into the pulmonary artery. Blood passes through the pulmonary arterial and alveolar capillary bed, where it is oxygenated, then drains through the pulmonary veins into the LA. Blood then passes into the LV, which pumps it into the aorta (see <ce:cross-ref id="crf0315" refid="f0035">Fig. 16.1</ce:cross-ref>). During ventricular contraction (systole), the tricuspid valve in the right heart and the mitral valve in the left heart close, and the pulmonary and aortic valves open. In diastole, the pulmonary and aortic valves close, and the two AV valves open. Collectively, these atrial and ventricular events constitute the cardiac cycle of filling and ejection of blood from one heart beat to the next. Blood passes from the heart through the large central elastic arteries into muscular arteries before encountering the resistance vessels, and ultimately the capillary bed, where there is exchange of nutrients, oxygen and waste products of metabolism. The central arteries, such as the aorta, are predominantly composed of elastic tissue with little or no vascular smooth muscle cells. When blood is ejected from the heart, the compliant aorta expands to accommodate the volume of blood before the elastic recoil sustains BP and flow following cessation of cardiac contraction. This is called the Windkessel effect and it prevents excessive rises in systolic BP while sustaining diastolic BP, thereby reducing cardiac afterload and maintaining coronary perfusion. These benefits are lost with progressive arterial stiffening, which occurs with ageing and advanced renal disease. Passing down the arterial tree, vascular smooth muscle cells progressively play a greater role until the resistance arterioles are encountered. Although all vessels contribute, the resistance vessels (diameter 50–200 µm) provide the greatest contribution to systemic vascular resistance, with small changes in radius having a marked influence on blood flow; resistance is inversely proportional to the fourth power of the radius (Poiseuille's Law). The tone of these resistance vessels is tightly regulated by humoral, neuronal and mechanical factors. Neurogenic constriction operates via α-adrenoceptors on vascular smooth muscle, and dilatation via muscarinic and β<ce:inf loc="post">2</ce:inf>-adrenoceptors. In addition, systemic and locally released vasoactive substances influence tone; vasoconstrictors include noradrenaline (norepinephrine), angiotensin II and endothelin-1, whereas adenosine, bradykinin, prostaglandins and nitric oxide are vasodilators. Resistance to blood flow rises with viscosity and is mainly influenced by the haematocrit.</ce:para><ce:para id="p0515">Coronary blood vessels receive sympathetic and parasympathetic innervation. While stimulation of α-adrenoceptors causes vasoconstriction and stimulation of β<ce:inf loc="post">2</ce:inf>-adrenoceptors causes vasodilatation, the predominant effect of sympathetic stimulation in coronary arteries is vasodilatation. Parasympathetic stimulation also causes modest dilatation of normal coronary arteries. Because of these homeostatic mechanisms that regulate vessel tone, narrowing or stenosis in a coronary artery does not limit flow, even during exercise, until the cross-sectional area of the vessel is reduced by at least 70%.</ce:para></ce:section><ce:section id="s0075"><ce:section-title id="st0075">Endothelium</ce:section-title><ce:para id="p0520">The endothelium plays a vital role in the control of vascular homeostasis. It synthesises and releases many vasoactive mediators that cause vasodilatation, including nitric oxide, prostacyclin and endothelium-derived hyperpolarising factor, and vasoconstriction, including endothelin-1 and angiotensin II. A balance exists whereby the release of such factors contributes to the maintenance and regulation of vascular tone and BP. Damage to the endothelium may disrupt this balance and lead to vascular dysfunction, tissue ischaemia and hypertension.</ce:para><ce:para id="p0525">The endothelium has a major influence on key regulatory steps in the recruitment of inflammatory cells and on the formation and dissolution of thrombus. Once activated, the endothelium expresses surface receptors such as E-selectin, intercellular adhesion molecule type 1 (ICAM-1) and platelet–endothelial cell adhesion molecule type 1 (PECAM-1), which mediate rolling, adhesion and migration of inflammatory leucocytes into the subintima. The endothelium also stores and releases the multimeric glycoprotein von Willebrand factor, which promotes thrombus formation by linking platelet adhesion to denuded surfaces, especially in the arterial vasculature. In contrast, once intravascular thrombus forms, tissue plasminogen activator is rapidly released from a dynamic storage pool within the endothelium to induce fibrinolysis and thrombus dissolution. These processes are critically involved in the development and progression of atherosclerosis, and endothelial function and injury are seen as central to the pathogenesis of many cardiovascular disease states.</ce:para></ce:section><ce:section id="s0080"><ce:section-title id="st0080">Respiration</ce:section-title><ce:para id="p0530">Cardiac output, BP and pulse rate change with respiration as the result of changes in blood flow to the right and left heart, as summarised in <ce:cross-ref id="crf0320" refid="b0035">Box 16.1</ce:cross-ref><ce:float-anchor refid="b0035"/>. During inspiration the fall in intrathoracic pressure causes increased return of venous blood into the chest and right side of the heart, which increases cardiac output from the RV. A substantial amount of blood is sequestered in the lungs, however, due to increased capacitance of the pulmonary vascular bed, which causes a reduction in blood flow to the left side of the heart. This causes a reduction in cardiac output from the LV and a slight fall in BP. With expiration the opposite sequence of events occurs; there is a fall in venous return to the right heart with a reduction in RV output, and a rise in the venous return to the left side of the heart with an increase in LV output. As the result of these changes, BP normally falls during inspiration but rises during expiration. These changes are exaggerated in patients with severe airways obstruction secondary to asthma or chronic obstructive pulmonary disease (COPD) leading to pulsus paradoxus, which describes an exaggerated fall in BP during inspiration. As well as being found in airways obstruction, pulsus paradoxus is also characteristic of cardiac tamponade (<ce:cross-ref id="crf9220" refid="s2845">p. 544</ce:cross-ref>). Here, cardiac filling is constrained by external pressure, and on inspiration compression of the RV impedes the normal increase in flow through it on inspiration. The interventricular septum then moves to the left, impeding left ventricular filling and cardiac output. This produces a marked fall in BP (&#x003E; 10 mmHg fall during inspiration).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0085"><ce:section-title id="st0085">Investigation of cardiovascular disease</ce:section-title><ce:para id="p0540">Several investigations may be required in the diagnosis of cardiac disease and assessment of its severity. Basic tests, such as electrocardiography, chest X-ray and echocardiography, can be performed in an outpatient clinic or at the bedside, whereas more complex procedures such as cardiac catheterisation, radionuclide imaging, computed tomography (CT) and magnetic resonance imaging (MRI) require specialised facilities.</ce:para><ce:section id="s0090"><ce:section-title id="st0090">Electrocardiogram</ce:section-title><ce:para id="p0545">The electrocardiogram (ECG) is used to assess cardiac rhythm and conduction, and is the main test used in the diagnosis of myocardial ischaemia and infarction.</ce:para><ce:para id="p0550">The physiological basis of an ECG recording is the fact that electrical depolarisation of myocardial tissue produces a small dipole current, which can be detected by electrode pairs on the body surface. These signals are amplified and either printed or displayed on a monitor (<ce:cross-ref id="crf0335" refid="f0060">Fig. 16.6</ce:cross-ref><ce:float-anchor refid="f0060"/>). During sinus rhythm, the SA node triggers atrial depolarisation, producing a P wave. Depolarisation proceeds slowly through the AV node, which is too small to produce a depolarisation wave detectable from the body surface. The bundle of His, bundle branches and Purkinje system are then activated, initiating ventricular myocardial depolarisation, which produces the QRS complex. The muscle mass of the ventricles is much larger than that of the atria, so the QRS complex is larger than the P wave. The interval between the onset of the P wave and the onset of the QRS complex is termed the ‘PR interval’ and largely reflects the duration of AV nodal conduction. Injury to the left or right bundle branch delays ventricular depolarisation, widening the QRS complex. Selective injury of one of the left fascicles (hemiblock, <ce:cross-ref id="crf9225" refid="s0910">p. 479</ce:cross-ref>) affects the electrical axis. Repolarisation is slower and spreads from the epicardium to the endocardium. Atrial repolarisation does not cause a detectable signal but ventricular repolarisation produces the T wave. The QT interval represents the total duration of ventricular depolarisation and repolarisation.</ce:para><ce:section id="s0095"><ce:section-title id="st0095">The 12-lead ECG</ce:section-title><ce:para id="p0555">The 12-lead ECG (<ce:cross-ref id="crf0345" refid="b0040">Box 16.2</ce:cross-ref><ce:float-anchor refid="b0040"/>) is generated from 10 electrodes that are attached to the skin. One electrode is attached to each limb and six electrodes are attached to the chest. In addition, the left arm, right arm and left leg electrodes are attached to a central terminal acting as an additional virtual electrode in the centre of the chest (the right leg electrode acts as an earthing electrode). The 12 ‘leads’ of the ECG refer to recordings made from pairs or sets of these electrodes. They comprise three groups: three dipole limb leads, three augmented voltage limb leads and six unipole chest leads.</ce:para><ce:para id="p0565">Leads I, II and III are the dipole limb leads and refer to recordings obtained from pairs of limb electrodes. Lead I records the signal between the right (negative) and left (positive) arms. Lead II records the signal between the right arm (negative) and left leg (positive). Lead III records the signal between the left arm (negative) and left leg (positive). These three leads thus record electrical activity along three different axes in the frontal plane. Leads aVR, aVL and aVF are the augmented voltage limb leads. These record electrical activity between a limb electrode and a modified central terminal. For example, lead aVL records the signal between the left arm (positive) and a central (negative) terminal, formed by connecting the right arm and left leg electrodes (<ce:cross-ref id="crf0355" refid="f0065">Fig. 16.7</ce:cross-ref><ce:float-anchor refid="f0065"/>). Similarly augmented signals are obtained from the right arm (aVR) and left leg (aVF). These leads also record electrical activity in the frontal plane, with each lead 120° apart. Lead aVF thus examines activity along the axis +90°, and lead aVL along the axis −30°, and so on.</ce:para><ce:para id="p0570">When depolarisation moves towards a positive electrode, it produces a positive deflection in the ECG; depolarisation in the opposite direction produces a negative deflection. The average vector of ventricular depolarisation is known as the frontal cardiac axis. When the vector is at right angles to a lead, the depolarisation in that lead is equally negative and positive (isoelectric). In <ce:cross-ref id="crf0360" refid="f0065">Figure 16.7A</ce:cross-ref>, the QRS complex is isoelectric in aVL, negative in aVR and most strongly positive in lead II; the main vector or axis of depolarisation is therefore 60°. The normal cardiac axis lies between −30° and +90°. Examples of left and right axis deviation are shown in <ce:cross-ref id="crf0365" refid="f0065">Figures 16.7B and C</ce:cross-ref>.</ce:para><ce:para id="p0575">There are six chest leads, V<ce:inf loc="post">1</ce:inf>–V<ce:inf loc="post">6</ce:inf>, derived from electrodes placed on the anterior and lateral left side of the chest, over the heart. Each lead records the signal between the corresponding chest electrode (positive) and the central terminal (negative). Leads V<ce:inf loc="post">1</ce:inf> and V<ce:inf loc="post">2</ce:inf> lie approximately over the RV, V<ce:inf loc="post">3</ce:inf> and V<ce:inf loc="post">4</ce:inf> over the interventricular septum, and V<ce:inf loc="post">5</ce:inf> and V<ce:inf loc="post">6</ce:inf> over the LV (<ce:cross-ref id="crf0370" refid="f0070">Fig. 16.8</ce:cross-ref><ce:float-anchor refid="f0070"/>). The LV has the greater muscle mass and contributes the major component of the QRS complex.</ce:para><ce:para id="p0580">The shape of the QRS complex varies across the chest leads. Depolarisation of the interventricular septum occurs first and moves from left to right; this generates a small initial negative deflection in lead V<ce:inf loc="post">6</ce:inf> (Q wave) and an initial positive deflection in lead V<ce:inf loc="post">1</ce:inf> (R wave). The second phase of depolarisation is activation of the body of the LV, which creates a large positive deflection or R wave in V<ce:inf loc="post">6</ce:inf> (with reciprocal changes in V<ce:inf loc="post">1</ce:inf>). The third and final phase involves the RV and produces a small negative deflection or S wave in V<ce:inf loc="post">6.</ce:inf></ce:para></ce:section><ce:section id="s0100"><ce:section-title id="st0100">Exercise ECG</ce:section-title><ce:para id="p0585">In exercise or stress electrocardiography a 12-lead ECG is recorded during exercise on a treadmill or bicycle ergometer. It is similar to a resting ECG, except that the limb electrodes are placed on the shoulders and hips rather than the wrists and ankles. The Bruce Protocol is the most commonly used. During an exercise ECG, BP is recorded and symptoms are assessed. Common indications for exercise testing are shown in <ce:cross-ref id="crf0375" refid="b0045">Box 16.3</ce:cross-ref><ce:float-anchor refid="b0045"/>. The test is considered positive if angina occurs, BP falls or fails to increase, or if there are ST segment shifts of more than 1 mm (see <ce:cross-ref id="crf0380" refid="f0075">Fig. 16.57</ce:cross-ref>, <ce:cross-ref id="crf9230" refid="p3480">p. 490</ce:cross-ref>). Exercise testing is useful in confirming the diagnosis of coronary artery disease in patients with suspected angina, and under these circumstances has good sensitivity and specificity (<ce:cross-ref id="crf0385" refid="b0045">Box 16.3</ce:cross-ref>). False-negative results can, however, occur in patients with coronary artery disease, and not all patients with a positive test have coronary disease. This is especially true in low-risk individuals, such as asymptomatic young or middle-aged women, in whom an abnormal response is more likely to represent a false-positive than a true-positive test. Stress testing is contraindicated in the presence of acute coronary syndrome, decompensated heart failure and severe hypertension.</ce:para></ce:section><ce:section id="s0115"><ce:section-title id="st0115">Ambulatory ECG</ce:section-title><ce:para id="p0645">Ambulatory ECG recordings can be obtained using a portable digital recorder. These devices usually provide limb lead ECG recordings only, on a continuous basis for periods of between 1 and 7 days. The main indication for ambulatory ECG is in the investigation of patients with suspected arrhythmia, such as those with intermittent palpitation, dizziness or syncope. In this situation a standard ECG provides only a snapshot of the cardiac rhythm and is unlikely to detect an intermittent arrhythmia, so a longer period of recording is required (see <ce:cross-ref id="crf0390" refid="f0080">Fig. 16.32</ce:cross-ref>, <ce:cross-ref id="crf9235" refid="s0695">p. 469</ce:cross-ref>). Ambulatory ECG can also be used to assess rate control in patients with atrial fibrillation, and to detect transient myocardial ischaemia using ST segment analysis. If symptoms are infrequent, special recorders can be issued that can be activated by the patient when a symptom episode occurs and placed on the chest wall to record the cardiac rhythm at that point in time. With some devices, the recording can be transmitted to hospital electronically. If the symptoms are very infrequent but potentially serious, such as syncope, implantable ‘loop recorders’ resembling a leadless pacemaker can be used and implanted subcutaneously to record cardiac rhythm for prolonged periods of between 1 and 3 years.</ce:para></ce:section></ce:section><ce:section id="s0120"><ce:section-title id="st0120">Cardiac biomarkers</ce:section-title><ce:para id="p0650">Several biomarkers are available that can be measured in peripheral blood to assess myocardial dysfunction and ischaemia.</ce:para><ce:section id="s0125"><ce:section-title id="st0125">Brain natriuretic peptide</ce:section-title><ce:para id="p0655">Brain natriuretic peptide (BNP) is a peptide hormone of 32 amino acids with diuretic properties. It is secreted by the LV as a 108-amino acid prohormone, which is cleaved to produce active BNP, and an inactive 76-amino acid N-terminal fragment (NT-proBNP). Circulating levels are elevated in conditions associated with LV systolic dysfunction. Generally, NT-proBNP is measured in preference to BNP since it has a longer half-life. Measurements of NT-proBNP are indicated for the diagnosis of LV dysfunction and to assess prognosis and response to therapy in patients with heart failure (<ce:cross-ref id="crf9240" refid="s0440">p. 461</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0130"><ce:section-title id="st0130">Cardiac troponins</ce:section-title><ce:para id="p0660">Troponin I and troponin T are structural cardiac muscle proteins (see <ce:cross-ref id="crf0395" refid="f0055">Fig. 16.5</ce:cross-ref>) that are released during myocyte damage and necrosis, and represent the cornerstone of the diagnosis of acute myocardial infarction (MI, <ce:cross-ref id="crf0400" refid="b0265">Box 16.47</ce:cross-ref>, <ce:cross-ref id="crf9245" refid="s1340">p. 493</ce:cross-ref>). Modern assays are extremely sensitive, however, and can detect minor degrees of myocardial damage, so that elevated plasma troponin concentrations may be observed in conditions other than acute MI, such as pulmonary embolus, septic shock and pulmonary oedema.</ce:para></ce:section></ce:section><ce:section id="s0135"><ce:section-title id="st0135">Chest X-ray</ce:section-title><ce:para id="p0665">This is useful for determining the size and shape of the heart, and the state of the pulmonary blood vessels and lung fields. Most information is given by a postero-anterior (PA) projection taken in full inspiration. Anteroposterior (AP) projections can be performed when patient movement is restricted but result in magnification of the cardiac shadow.</ce:para><ce:para id="p0670">An estimate of overall heart size can be made by comparing the maximum width of the cardiac outline with the maximum internal transverse diameter of the thoracic cavity. The term cardiomegaly is used to describe an enlarged cardiac silhouette when the ratio of cardiac width to the width of the lung fields is greater than 0.5. Cardiomegaly can be caused by chamber dilatation, especially left ventricular dilatation, or by a pericardial effusion, but may also be due to a mediastinal mass or pectus excavatum (<ce:intra-ref id="ii0070" xlink:href="pii:B978-0-7020-7028-0.00017-2#s2200">p. 628</ce:intra-ref>). Cardiomegaly is not a sensitive indicator of left ventricular systolic dysfunction since the cardiothoracic ratio is normal in many patients with poor left ventricular function and is not specific, since many patients with cardiomegaly on chest X-ray have normal echocardiograms.</ce:para><ce:para id="p0675">Dilatation of individual cardiac chambers can be recognised by the characteristic alterations to the cardiac silhouette (<ce:cross-ref id="crf0405" refid="f0085">Fig. 16.9</ce:cross-ref><ce:float-anchor refid="f0085"/>):<ce:list id="ulist0100"><ce:list-item id="u0450"><ce:label>•</ce:label><ce:para id="p0680">Left atrial dilatation results in prominence of the left atrial appendage, creating the appearance of a straight left heart border, a double cardiac shadow to the right of the sternum, and widening of the angle of the carina (bifurcation of the trachea) as the left main bronchus is pushed upwards.</ce:para></ce:list-item><ce:list-item id="u0455"><ce:label>•</ce:label><ce:para id="p0685">Right atrial enlargement projects from the right heart border towards the right lower lung field.</ce:para></ce:list-item><ce:list-item id="u0460"><ce:label>•</ce:label><ce:para id="p0690">Left ventricular dilatation causes prominence of the left heart border and enlargement of the cardiac silhouette. Left ventricular hypertrophy produces rounding of the left heart border (<ce:cross-ref id="crf0410" refid="f0090">Fig. 16.10</ce:cross-ref><ce:float-anchor refid="f0090"/>).</ce:para></ce:list-item><ce:list-item id="u0465"><ce:label>•</ce:label><ce:para id="p0695">Right ventricular dilatation increases heart size, displaces the apex upwards and straightens the left heart border.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0700">Lateral or oblique projections may be useful for detecting pericardial calcification in patients with constrictive pericarditis (<ce:cross-ref id="crf9250" refid="s2800">p. 543</ce:cross-ref>) or a calcified thoracic aortic aneurysm, as these abnormalities may be obscured by the spine on the PA view.</ce:para><ce:para id="p0705">The lung fields on the chest X-ray may show congestion and oedema in patients with heart failure (see <ce:cross-ref id="crf0415" refid="f0095">Fig. 16.27</ce:cross-ref>, <ce:cross-ref id="crf9255" refid="s0525">p. 464</ce:cross-ref>), and an increase in pulmonary blood flow (‘pulmonary plethora’) in those with left-to-right shunt. Pleural effusions may also occur in heart failure.</ce:para></ce:section><ce:section id="s0140"><ce:section-title id="st0140">Echocardiography</ce:section-title><ce:section id="s0145"><ce:section-title id="st0145">Transthoracic echocardiography</ce:section-title><ce:para id="p0710">Transthoracic echocardiography, commonly referred to as ‘echo’, is obtained by placing an ultrasound transducer on the chest wall to image the heart structures as a real-time two-dimensional ‘slice’. This can be used for rapid evaluation of various aspects of cardiac structure and function. Common indications for echocardiography are shown in <ce:cross-ref id="crf0420" refid="b0050">Box 16.4</ce:cross-ref><ce:float-anchor refid="b0050"/>.</ce:para></ce:section><ce:section id="s0150"><ce:section-title id="st0150">Doppler echocardiography</ce:section-title><ce:para id="p0750">Doppler echocardiography provides information on blood flow within the heart and the great vessels. It is based on the Doppler principle that sound waves reflected from moving objects, such as red blood cells, undergo a frequency shift. Doppler echocardiography can therefore detect the speed and direction of blood flow in the heart chambers and great vessels. The greater the frequency shift, the faster the blood is moving. The information can be presented either as a plot of blood velocity against time for a particular point in the heart (<ce:cross-ref id="crf0425" refid="f0100">Fig. 16.11</ce:cross-ref><ce:float-anchor refid="f0100"/>) or as a colour overlay on a two-dimensional real-time echo picture (colour-flow Doppler, <ce:cross-ref id="crf0430" refid="f0105">Fig. 16.12</ce:cross-ref><ce:float-anchor refid="f0105"/>). Doppler echocardiography is useful in the detection of valvular regurgitation, where the direction of blood flow is reversed and turbulence is seen, and is also used to detect pressure gradients across stenosed valves. For example, the normal resting systolic flow velocity across the aortic valve is approximately 1 m/sec; in the presence of aortic stenosis, this is increased as blood accelerates through the narrow orifice. In severe aortic stenosis, the peak aortic velocity may be increased to 5 m/sec (see <ce:cross-ref id="crf0435" refid="f0100">Fig. 16.11</ce:cross-ref>). An estimate of the pressure gradient across a valve or lesion is given by the modified Bernoulli equation:<ce:display><ce:formula id="e0010"><mml:math altimg="si1.gif" display="block" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:maligngroup/><mml:malignmark/><mml:mtext> </mml:mtext><mml:mtext>Pressure gradient</mml:mtext><mml:mtext> </mml:mtext><mml:mo>(</mml:mo><mml:mtext>mmHg</mml:mtext><mml:mo>)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:maligngroup/><mml:mo>=</mml:mo><mml:malignmark/><mml:mn>4</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mtext>peak velocity in m/sec</mml:mtext><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mtd></mml:mtr></mml:mtable></mml:math></ce:formula></ce:display></ce:para><ce:para id="p0755">Advanced techniques include three-dimensional echocardiography, intravascular ultrasound (defines vessel wall abnormalities and guides coronary intervention), intracardiac ultrasound (provides high-resolution images), tissue Doppler imaging (quantifies myocardial contractility and diastolic function) and speckle tracking (assesses myocardial motion and strain).</ce:para></ce:section><ce:section id="s0155"><ce:section-title id="st0155">Transoesophageal echocardiography</ce:section-title><ce:para id="p0760">Transoesophageal echocardiography (TOE) involves passing an endoscope-like ultrasound probe into the oesophagus and upper stomach under light sedation and positioning it behind the LA. It is particularly useful for imaging structures such as the left atrial appendage, pulmonary veins, thoracic aorta and interatrial septum, which may be poorly visualised by transthoracic echocardiography, especially if the patient is overweight or has obstructive airway disease. The high-resolution images that can be obtained makes TOE particularly valuable for investigating patients with prosthetic (especially mitral) valve dysfunction, congenital abnormalities such as atrial septal defects, aortic dissection, infective endocarditis (vegetations that are too small to be detected by transthoracic echocardiography) and systemic embolism (intracardiac thrombus or masses).</ce:para></ce:section><ce:section id="s0160"><ce:section-title id="st0160">Stress echocardiography</ce:section-title><ce:para id="p0765">Stress echocardiography is used to investigate patients with suspected coronary artery disease who are unsuitable for exercise stress testing, such as those with mobility problems or pre-existing bundle branch block. A two-dimensional echo is performed before and after infusion of a moderate to high dose of an inotrope, such as dobutamine. Myocardial segments with poor perfusion become ischaemic and contract poorly under stress, manifesting as a wall motion abnormality on the scan. Stress echocardiography is sometimes used to examine myocardial viability in patients with impaired left ventricular function. Low-dose dobutamine can induce contraction in ‘hibernating’ myocardium; such patients may benefit from bypass surgery or percutaneous coronary intervention.</ce:para></ce:section></ce:section><ce:section id="s0165"><ce:section-title id="st0165">Computed tomography</ce:section-title><ce:para id="p0770">Computed tomography (CT) is useful for imaging the cardiac chambers, great vessels, pericardium, and mediastinal structures and masses. Multidetector scanners can acquire up to 320 slices per rotation, allowing very high-resolution imaging in a single heart beat. CT is often performed using a timed injection of X-ray contrast to produce clear images of blood vessels and associated pathologies. Contrast scans are very useful for imaging the aorta in suspected aortic dissection (see <ce:cross-ref id="crf0440" refid="f0410">Fig. 16.74</ce:cross-ref>, <ce:cross-ref id="crf9260" refid="p4825">p. 507</ce:cross-ref>), and the pulmonary arteries and branches in suspected pulmonary embolism (<ce:intra-ref id="ii0090" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1880">p. 619</ce:intra-ref>).</ce:para><ce:para id="p0775">Some centres use cardiac CT scans for quantification of coronary artery calcification, which may serve as an index of cardiovascular risk. However, modern multidetector scanning allows non-invasive coronary angiography (<ce:cross-ref id="crf0445" refid="f0110">Fig. 16.13</ce:cross-ref><ce:float-anchor refid="f0110"/>) with a spatial resolution approaching that of conventional coronary arteriography and at a lower radiation dose. CT coronary angiography is particularly useful in the initial assessment of patients with chest pain and a low or intermediate likelihood of disease, since it has a high negative predictive value in excluding coronary artery disease. Modern volume scanners are also able to assess myocardial perfusion, often at the same sitting.</ce:para></ce:section><ce:section id="s0170"><ce:section-title id="st0170">Magnetic resonance imaging</ce:section-title><ce:para id="p0780">Magnetic resonance imaging (MRI) can be used to generate cross-sectional images of the heart, lungs and mediastinal structures. It provides better differentiation of soft tissue structures than CT but is poor at demonstrating calcification. MRI scans need to be ‘gated’ to the ECG, allowing the scanner to produce moving images of the heart and mediastinal structures throughout the cardiac cycle. MRI is very useful for imaging the aorta, including suspected dissection (see <ce:cross-ref id="crf0450" refid="f0405">Fig. 16.73</ce:cross-ref>, <ce:cross-ref id="crf9265" refid="p4825">p. 507</ce:cross-ref>), and can define the anatomy of the heart and great vessels in patients with congenital heart disease. It is also useful for detecting infiltrative conditions affecting the heart and for evaluation of the RV that is difficult to image by echocardiography.</ce:para><ce:para id="p0785">Physiological data can be obtained from the signal returned from moving blood, which allows quantification of blood flow across regurgitant or stenotic valves. It is also possible to analyse regional wall motion in patients with suspected coronary disease or cardiomyopathy.</ce:para><ce:para id="p0790">Myocardial perfusion and viability can also be readily assessed by MRI. When enhanced by gadolinium-based contrast media, areas of myocardial hypoperfusion can be identified with better spatial resolution than nuclear medicine techniques. Later redistribution of this contrast, so-called delayed enhancement, can be used to identify myocardial scarring and fibrosis: this is a particular strength of cardiac MRI (<ce:cross-ref id="crf0455" refid="f0115">Fig. 16.14</ce:cross-ref><ce:float-anchor refid="f0115"/>). This can help in selecting patients for revascularisation procedures, or in identifying those with myocardial infiltration, such as that seen with sarcoid heart disease and arrhythmogenic right ventricular cardiomyopathy.</ce:para></ce:section><ce:section id="s0175"><ce:section-title id="st0175">Cardiac catheterisation</ce:section-title><ce:para id="p0795">This involves passing a specialised catheter through a peripheral vein or artery into the heart under X-ray guidance. Cardiac catheterisation allows BP and oxygen saturation to be measured in the cardiac chambers and great vessels, and is used to perform angiograms by injecting contrast media into a chamber or blood vessel.</ce:para><ce:para id="p0800">Left heart catheterisation involves accessing the arterial circulation, usually through the radial artery, to allow catheterisation of the aorta, LV and coronary arteries. Coronary angiography is the most widely performed procedure, in which the left and right coronary arteries are selectively imaged, providing information about the extent and severity of coronary stenoses, thrombus and calcification (<ce:cross-ref id="crf0460" refid="f0120">Fig. 16.15</ce:cross-ref><ce:float-anchor refid="f0120"/>). Additional anatomical (intravascular ultrasound, optical coherence tomography) or functional (pressure wire) assessments are sometimes used to define plaque characteristics and severity more precisely. This permits planning of percutaneous coronary intervention and coronary artery bypass graft surgery. Left ventriculography can be performed during the procedure to determine the size and function of the LV and to demonstrate mitral regurgitation. Aortography defines the size of the aortic root and thoracic aorta, and can help quantify aortic regurgitation. Left heart catheterisation is a day-case procedure and is relatively safe, with serious complications occurring in only approximately 1 in 1000 cases.</ce:para><ce:para id="p0805">Right heart catheterisation is used to assess right heart and pulmonary artery pressures, and to detect intracardiac shunts by measuring oxygen saturations in different chambers. For example, a step up in oxygen saturation from 65% in the RA to 80% in the pulmonary artery is indicative of a large left-to-right shunt that might be due to a ventricular septal defect. Cardiac output can also be measured using thermodilution techniques. Left atrial pressure can be measured directly by puncturing the interatrial septum from the RA with a special catheter. For most purposes, however, a satisfactory approximation to left atrial pressure can be obtained by ‘wedging’ an end-hole or balloon catheter in a branch of the pulmonary artery. Swan–Ganz balloon catheters are often used to monitor pulmonary ‘wedge’ pressure as a guide to left heart filling pressure in critically ill patients (<ce:intra-ref id="ii0100" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0765">p. 206</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0180"><ce:section-title id="st0180">Electrophysiology</ce:section-title><ce:para id="p0810">Patients with known or suspected arrhythmia are investigated by percutaneous placement of electrode catheters into the heart via the femoral and neck veins. An electrophysiology study (EPS) is most commonly performed to evaluate patients for catheter ablation and is normally done at the same time as the ablation procedure. EPS is occasionally used for risk stratification of patients suspected of being at risk of ventricular arrhythmias.</ce:para></ce:section><ce:section id="s0185"><ce:section-title id="st0185">Radionuclide imaging</ce:section-title><ce:para id="p0815">Radionuclide imaging can be used to evaluate cardiac function but is declining in popularity due to the availability of MRI, which does not involve exposure to radiation and provides equivalent or superior quality data to radionuclide imaging.</ce:para><ce:section id="s0190"><ce:section-title id="st0190">Blood pool imaging</ce:section-title><ce:para id="p0820">The patient is given an intravenous injection of radioisotope-labelled blood cells, and after 4–5 minutes the distribution of isotope in the heart is evaluated by a gamma camera at different phases of the cardiac cycle, thereby permitting the calculation of ventricular ejection fractions. It also allows the assessment of the size and ‘shape’ of the cardiac chambers.</ce:para></ce:section><ce:section id="s0195"><ce:section-title id="st0195">Myocardial perfusion scanning</ce:section-title><ce:para id="p0825">The patient is given an intravenous injection of a radioactive isotope, such as <ce:sup loc="post">99</ce:sup>technetium tetrofosmin, and scintiscans of the myocardium are subsequently obtained by gamma camera at rest and during stress (see <ce:cross-ref id="crf0465" refid="f0125">Fig. 16.58</ce:cross-ref>, <ce:cross-ref id="crf9270" refid="p3480">p. 490</ce:cross-ref>). Either exercise stress or pharmacological stress (using the inotrope dobutamine or the vasodilator dipyridamole) can be used. More sophisticated quantitative information can be obtained with positron emission tomography (PET), which can also be used to assess myocardial metabolism, but this is available in only a few centres.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0200"><ce:section-title id="st0200">Presenting problems in cardiovascular disease</ce:section-title><ce:para id="p0830">Cardiovascular disease gives rise to a relatively limited range of symptoms. Making the correct diagnosis depends on careful analysis of the factors that provoke symptoms, the subtle differences in how they are described by the patient, the clinical findings and the results of investigations. A close relationship between symptoms and exercise is the hallmark of heart disease. The New York Heart Association (NYHA) functional classification is used to grade disability (<ce:cross-ref id="crf0470" refid="b0055">Box 16.5</ce:cross-ref><ce:float-anchor refid="b0055"/>).</ce:para><ce:section id="s0225"><ce:section-title id="st0225">Chest pain on exertion</ce:section-title><ce:para id="p0875">There are many other non-cardiac causes of chest pain, as discussed in <ce:intra-ref id="ii0110" xlink:href="pii:B978-0-7020-7028-0.00010-X#c00010">Chapter 10</ce:intra-ref>. This section will focus on exertional chest pain, which is a typical presenting symptom of coronary artery disease.</ce:para><ce:section id="s0230"><ce:section id="s0235"><ce:section-title id="st0230">Clinical assessment</ce:section-title><ce:para id="p0880">A careful history is crucial in determining whether chest pain is cardiac or not. Chest pain on effort is the hallmark of angina pectoris (<ce:cross-ref id="crf0475" refid="f0130">Fig. 16.16</ce:cross-ref><ce:float-anchor refid="f0130"/>). The reproducibility, predictability and relationship to physical exertion (and occasionally emotion) of the chest pain are the most important features. The duration of symptoms should be noted because patients with recent-onset angina are at greater risk than those with long-standing and unchanged symptoms. Physical examination is often normal but may reveal evidence of risk factors for cardiovascular disease, such as xanthoma or xanthelasma indicating hyperlipidaemia (<ce:intra-ref id="ii0115" xlink:href="pii:B978-0-7020-7028-0.00014-7#p2885">p. 373</ce:intra-ref>). Signs of anaemia (<ce:intra-ref id="ii0120" xlink:href="pii:B978-0-7020-7028-0.00023-8#s0200">p. 923</ce:intra-ref>) or thyrotoxicosis (<ce:intra-ref id="ii0125" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0095">p. 635</ce:intra-ref>) may be identified, both of which can exacerbate angina. Cardiovascular examination may reveal evidence of left ventricular dysfunction (<ce:cross-ref id="crf9275" refid="s0010">p. 442</ce:cross-ref>) or cardiac murmurs in patients with aortic valve disease and hypertrophic cardiomyopathy. Other manifestations of arterial disease, such as bruits and loss of peripheral pulses, may also be observed.</ce:para></ce:section><ce:section id="s0240"><ce:section-title id="st0235">Investigations</ce:section-title><ce:para id="p0885">A full blood count, fasting blood glucose, lipids, thyroid function tests and a 12-lead ECG are the most important baseline investigations. An exercise ECG is helpful in identifying high-risk patients who require further investigation and treatment but cannot reliably exclude the presence of coronary artery disease (<ce:cross-ref id="crf9280" refid="s0100">p. 449</ce:cross-ref>). In patients with chest pain where the exercise ECG is normal but where there is a suspicion of coronary artery disease, CT coronary angiography should be performed. If a murmur is found, echocardiography should be performed to check for valve disease or hypertrophic cardiomyopathy.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0245"><ce:section-title id="st0240">Severe prolonged chest pain</ce:section-title><ce:para id="p0890">Severe prolonged cardiac chest pain may be due to acute myocardial infarction or to unstable angina (<ce:cross-ref id="crf9285" refid="s1340">p. 493</ce:cross-ref>). These are known collectively as the acute coronary syndromes.</ce:para><ce:section id="s0250"><ce:section id="s0255"><ce:section-title id="st0245">Clinical assessment</ce:section-title><ce:para id="p0895">Acute coronary syndrome is suggested by a previous history of stable angina but an episode of acute severe chest pain at rest can be the first presentation of coronary artery disease. Making the correct diagnosis depends on analysing the character of the pain and its associated features. Physical examination may reveal signs of risk factors for coronary artery disease as described for exertional chest pain, and pallor or sweating, which is indicative of autonomic disturbance and typical of acute coronary syndrome. Other features, such as arrhythmia, hypotension and heart failure, may occur. Patients presenting with symptoms consistent with an acute coronary syndrome require admission to hospital and urgent investigation because there is a high risk of avoidable complications.</ce:para></ce:section><ce:section id="s0260"><ce:section-title id="st0250">Investigations</ce:section-title><ce:para id="p0900">A 12-lead ECG is mandatory and is the most useful method of initial triage, along with measurement of serum troponin I or T. The diagnosis of an acute coronary syndrome is supported by ST segment elevation or depression on ECG and an elevated level of troponin I or T, which demonstrates that there has been myocardial damage.</ce:para><ce:para id="p0905">If the diagnosis remains unclear after initial investigation, repeat ECG recordings should be performed and are particularly useful if they can be obtained during an episode of pain. If the plasma troponin concentrations are normal at baseline, repeat measurements should be made 6–12 hours after the onset of symptoms or admission to hospital. New ECG changes or an elevated plasma troponin concentration confirm the diagnosis of an acute coronary syndrome. If the pain settles and does not recur, there are no new ECG changes and troponin concentrations remain normal, the patient can be discharged from hospital but further investigations may be indicated to look for evidence of coronary artery disease, as discussed on <ce:cross-ref id="crf9290" refid="s1135">page 484</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0265"><ce:section-title id="st0255">Management</ce:section-title><ce:para id="p0910">The differential diagnosis and management of acute coronary syndrome are described in more detail on <ce:cross-ref id="crf9295" refid="s1380">pages 494 and 498</ce:cross-ref>.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0270"><ce:section-title id="st0260">Breathlessness</ce:section-title><ce:para id="p0915">Cardiac causes of breathlessness include cardiac arrhythmias, acute and chronic heart failure, acute coronary syndrome, valvular disease, cardiomyopathy and constrictive pericarditis, all discussed later in this chapter. The differential diagnosis of breathlessness is wide, however, and has many other non-cardiac causes. These are discussed in more detail on <ce:intra-ref id="ii0160" xlink:href="pii:B978-0-7020-7028-0.00010-X#p0665">pages 179 and 557</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0290"><ce:section-title id="st0280">Syncope</ce:section-title><ce:para id="p0970">The term ‘syncope’ refers to loss of consciousness due to reduced cerebral perfusion. The differential diagnosis, investigation and management of syncope are discussed on <ce:intra-ref id="ii0165" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0115">page 181</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0295"><ce:section-title id="st0285">Palpitation</ce:section-title><ce:para id="p0975">Palpitation is a common and sometimes frightening symptom that is usually due to a disorder of cardiac rhythm. Patients use the term to describe many sensations, including an unusually erratic, fast, slow or forceful heart beat, or even chest pain or breathlessness.</ce:para><ce:section id="s0300"><ce:section id="s0305"><ce:section-title id="st0290">Clinical assessment</ce:section-title><ce:para id="p0980">Initial evaluation should concentrate on determining the likely mechanism of palpitation and whether or not there is significant underlying heart disease. A detailed description of the sensation is essential and patients should be asked to describe their symptoms clearly, or to demonstrate the sensation of rhythm by tapping with their hand. A provisional diagnosis can usually be made on the basis of a thorough history (<ce:cross-ref id="crf0495" refid="b0065">Box 16.6</ce:cross-ref><ce:float-anchor refid="b0065"/> and <ce:cross-ref id="crf0500" refid="f0140">Fig. 16.17</ce:cross-ref><ce:float-anchor refid="f0140"/>). Recurrent but short-lived bouts of an irregular heart beat are usually due to atrial or ventricular extrasystoles (ectopic beats). Some patients will describe the experience as a ‘flip’ or a ‘jolt’ in the chest, while others report dropped or missed beats. Extrasystoles are often more frequent during periods of stress or debility; they can be triggered by alcohol or nicotine.</ce:para><ce:para id="p1035">Episodes of a pounding, forceful and relatively fast (90–120/min) heart beat are a common manifestation of anxiety. These may also reflect a hyperdynamic circulation, such as anaemia, pregnancy and thyrotoxicosis, and can occur in some forms of valve disease such as aortic regurgitation. Discrete bouts of a very rapid (over 120/min) heart beat are more likely to be due to a paroxysmal supraventricular or ventricular tachycardia. In contrast, episodes of atrial fibrillation typically present with irregular and usually rapid palpitation.</ce:para></ce:section><ce:section id="s0310"><ce:section-title id="st0295">Investigation</ce:section-title><ce:para id="p1040">If initial assessment suggests that the palpitation is due to an arrhythmia, the diagnosis should be confirmed by an ECG recording during an episode using an ambulatory ECG monitor or a patient-activated ECG recorder. Additional investigations may be required depending on the nature of the arrhythmia, as discussed on <ce:cross-ref id="crf9300" refid="s0655">page 468</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0315"><ce:section-title id="st0300">Management</ce:section-title><ce:para id="p1045">Palpitation is usually benign and even if the patient's symptoms are due to an arrhythmia, the outlook is good if there is no underlying structural heart disease. Most cases are due to an awareness of the normal heart beat, a sinus tachycardia or benign extrasystoles, in which case an explanation and reassurance may be all that is required. Palpitation associated with pre-syncope or syncope (<ce:intra-ref id="ii0180" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0115">p. 181</ce:intra-ref>) may reflect more serious structural or electrical disease and should be investigated without delay. Other arrhythmias may require treatment, as discussed in more detail on <ce:cross-ref id="crf9305" refid="s0910">page 479</ce:cross-ref>.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0320"><ce:section-title id="st0305">Cardiac arrest</ce:section-title><ce:para id="p1050">Cardiac arrest describes the sudden and complete loss of cardiac output due to asystole, ventricular tachycardia or fibrillation, or loss of mechanical cardiac contraction (pulseless electrical activity). The clinical diagnosis is based on the victim being unconscious and pulseless; breathing may take some time to stop completely after cardiac arrest. Death is virtually inevitable, unless effective treatment is given promptly. Sudden cardiac death is usually caused by a catastrophic arrhythmia and accounts for 25–30% of deaths from cardiovascular disease, claiming an estimated 70 000 to 90 000 lives each year in the UK. Many of these deaths are potentially preventable.</ce:para><ce:section id="s0325"><ce:section id="s0330"><ce:section-title id="st0310">Pathogenesis</ce:section-title><ce:para id="p1055">Coronary artery disease is the most common cause of cardiac arrest. Ventricular fibrillation or ventricular tachycardia is common in the first few hours of MI and many victims die before medical help is sought. Up to one-third of people developing MI die before reaching hospital, emphasising the importance of educating the public to recognise symptoms and to seek medical help quickly. Acute myocardial ischaemia in the absence of infarction can also cause these arrhythmias, but less commonly. Patients with a history of previous MI are at increased risk of sudden arrhythmic death, especially if there is extensive left ventricular scarring and impairment, or if there is ongoing myocardial ischaemia. Cardiac arrest may be caused by ventricular fibrillation (<ce:cross-ref id="crf0505" refid="f0145">Fig. 16.18</ce:cross-ref><ce:float-anchor refid="f0145"/>), pulseless ventricular tachycardia (<ce:cross-ref id="crf9310" refid="s0360">p. 457</ce:cross-ref>), asystole or pulseless electrical activity. These can complicate many types of heart disease, including cardiomyopathies, and sometimes can occur in the absence of recognised structural abnormalities. The causes are listed in <ce:cross-ref id="crf0510" refid="b0070">Box 16.7</ce:cross-ref><ce:float-anchor refid="b0070"/>. Sudden death less often occurs because of an acute mechanical catastrophe such as cardiac rupture or aortic dissection (<ce:cross-ref id="crf9315" refid="s1395">pp. 496 and 506</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0350"><ce:section-title id="st0330">Clinical assessment and management</ce:section-title><ce:section id="s0355"><ce:section-title id="st0335">Basic life support</ce:section-title><ce:para id="p1140">When a patient with suspected cardiac arrest is encountered, the ABCDE approach to management should be followed; this involves prompt assessment and restoration of the <ce:bold>A</ce:bold>irway, maintenance of ventilation using rescue <ce:bold>B</ce:bold>reathing (‘mouth-to-mouth’ breathing), and maintenance of the <ce:bold>C</ce:bold>irculation using chest compressions; <ce:bold>D</ce:bold>isability, in resuscitated patients, refers to assessment of neurological status, and <ce:bold>E</ce:bold>xposure entails removal of clothes to enable defibrillation, auscultation of the chest, and assessment for a rash caused by anaphylaxis, for injuries and so on (<ce:cross-ref id="crf0515" refid="f0150">Fig. 16.19</ce:cross-ref><ce:float-anchor refid="f0150"/>). The term basic life support (BLS) encompasses manœuvres that aim to maintain a low level of circulation until more definitive treatment with advanced life support can be given. Chest compression-only (‘hands-only’) cardiopulmonary resuscitation (CPR) is easier for members of the public to learn and administer, and is now advocated in public education campaigns.</ce:para></ce:section><ce:section id="s0360"><ce:section-title id="st0340">Advanced life support</ce:section-title><ce:para id="p1145">Advanced life support (ALS) (<ce:cross-ref id="crf0520" refid="f0155">Fig. 16.20</ce:cross-ref><ce:float-anchor refid="f0155"/>) aims to restore normal cardiac rhythm by defibrillation when the cause of cardiac arrest is a tachyarrhythmia, or to restore cardiac output by correcting other reversible causes of cardiac arrest. The initial priority is to assess the patient's cardiac rhythm by attaching a defibrillator or monitor. Once that this has been done, treatment should be instituted based on the clinical findings.</ce:para><ce:para id="p1150">Ventricular fibrillation or pulseless ventricular tachycardia should be treated with immediate defibrillation. Defibrillation is more likely to be effective if a biphasic shock defibrillator is used, where the polarity of the shock is reversed midway through its delivery. Defibrillation is usually administered using a 150-joule biphasic shock, and CPR resumed immediately for 2 minutes without attempting to confirm restoration of a pulse because restoration of mechanical cardiac output rarely occurs immediately after successful defibrillation. If, after 2 minutes, a pulse is not restored, a further biphasic shock of 150–200 joules should be given. Thereafter, additional biphasic shocks of 150–200 joules are given every 2 minutes after each cycle of CPR. During resuscitation, adrenaline (epinephrine, 1 mg IV) should be given every 3–5 minutes and consideration given to the use of intravenous amiodarone, especially if ventricular fibrillation or ventricular tachycardia re-initiates after successful defibrillation.</ce:para><ce:para id="p1155">Ventricular fibrillation of low amplitude, or ‘fine VF’, may mimic asystole. If asystole cannot be confidently diagnosed, the patient should be treated for VF and defibrillated. If an electrical rhythm is observed that would be expected to produce a cardiac output, ‘pulseless electrical activity’ is present. Pulseless electrical activity should be treated by continuing CPR and adrenaline (epinephrine) administration while seeking such causes. Asystole should be treated similarly, with the additional support of atropine and sometimes external or transvenous pacing in an attempt to generate an electrical rhythm. There are many potentially reversible causes of cardiac arrest; the main ones can be easily remembered as a list of four Hs and four Ts (<ce:cross-ref id="crf0525" refid="f0155">Fig. 16.20</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0365"><ce:section-title id="st0345">The Chain of Survival</ce:section-title><ce:para id="p1160">This term refers to the sequence of events that is necessary to maximise the chances of a cardiac arrest victim surviving (<ce:cross-ref id="crf0530" refid="f0160">Fig. 16.21</ce:cross-ref><ce:float-anchor refid="f0160"/>). Survival is most likely if all links in the chain are strong: that is, if the arrest is witnessed, help is called immediately, basic life support is administered by a trained individual, the emergency medical services respond promptly, and defibrillation is achieved within a few minutes. Good training in both basic and advanced life support is essential and should be maintained by regular refresher courses. In recent years, public access defibrillation has been introduced in places of high population density, particularly where traffic congestion may impede the response of emergency services, such as railway stations, airports and sports stadia. Designated individuals can respond to a cardiac arrest using BLS and an automated external defibrillator.</ce:para></ce:section><ce:section id="s0370"><ce:section-title id="st0350">Survivors of cardiac arrest</ce:section-title><ce:para id="p1165">Patients who survive a cardiac arrest caused by acute MI need no specific treatment beyond that given to those recovering from an uncomplicated infarct, since their prognosis is similar (<ce:cross-ref id="crf9320" refid="s1460">p. 498</ce:cross-ref>). Those with reversible causes, such as exercise-induced ischaemia or aortic stenosis, should have the underlying cause treated if possible. Survivors of ventricular tachycardia or ventricular fibrillation arrest in whom no reversible cause can be identified may be at risk of another episode, and should be considered for an implantable cardiac defibrillator (<ce:cross-ref id="crf9325" refid="s1115">p. 483</ce:cross-ref>) and anti-arrhythmic drug therapy. In these patients, the risk is reduced by treatment of heart failure with β-adrenoceptor antagonists (β-blockers) and angiotensin-converting enzyme (ACE) inhibitors, and by coronary revascularisation.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0375"><ce:section-title id="st0355">Abnormal heart sounds</ce:section-title><ce:para id="p1170">The first indication of heart disease may be the discovery of an abnormal sound on auscultation (<ce:cross-ref id="crf0535" refid="b0075">Box 16.8</ce:cross-ref><ce:float-anchor refid="b0075"/>). This may be incidental – for example, during a routine childhood examination – or may be prompted by symptoms of heart disease.</ce:para><ce:section id="s0380"><ce:section id="s0385"><ce:section-title id="st0360">Clinical assessment</ce:section-title><ce:para id="p1180">The aims of clinical assessment are, firstly, to determine if the abnormal sound is cardiac; secondly, to determine if it is pathological; and thirdly, to try to determine its cause.</ce:para><ce:section id="s0390"><ce:section-title id="st0365">Is the sound cardiac?</ce:section-title><ce:para id="p1185">Additional heart sounds and murmurs demonstrate a consistent relationship to a specific part of the cardiac cycle, whereas extracardiac sounds, such as a pleural rub or venous hum, do not. Pericardial friction produces a characteristic scratching noise termed a pericardial rub, which may have two components corresponding to atrial and ventricular systole, and may vary with posture and respiration.</ce:para></ce:section><ce:section id="s0395"><ce:section-title id="st0370">Is the sound pathological?</ce:section-title><ce:para id="p1190">Pathological sounds and murmurs are the product of turbulent blood flow or rapid ventricular filling due to abnormal loading conditions. Some added sounds are physiological but may also occur in pathological conditions; for example, a third sound is common in young people and in pregnancy but is also a feature of heart failure (<ce:cross-ref id="crf0540" refid="b0075">Box 16.8</ce:cross-ref>). Similarly, a systolic murmur due to turbulence across the right ventricular outflow tract may occur in hyperdynamic states such as anaemia or pregnancy, but may also be due to pulmonary stenosis or an intracardiac shunt leading to volume overload of the RV, such as an atrial septal defect. Benign murmurs do not occur in diastole (<ce:cross-ref id="crf0545" refid="b0080">Box 16.9</ce:cross-ref><ce:float-anchor refid="b0080"/>), and systolic murmurs that radiate or are associated with a thrill are almost always pathological.</ce:para></ce:section><ce:section id="s0400"><ce:section-title id="st0375">What is the origin of the sound?</ce:section-title><ce:para id="p1225">Timing, intensity, location, radiation and quality are all useful clues to the origin and nature of an additional sound or murmur (<ce:cross-ref id="crf0550" refid="b0085">Box 16.10</ce:cross-ref><ce:float-anchor refid="b0085"/>). Radiation of a murmur is determined by the direction of turbulent blood flow and is detectable only when there is a high-velocity jet, such as in mitral regurgitation (radiation from apex to axilla) or aortic stenosis (radiation from base to neck). Similarly, the pitch and quality of the sound can help to distinguish the murmur, such as the ‘blowing’ murmur of mitral regurgitation or the ‘rasping’ murmur of aortic stenosis. The position of a murmur in relation to the cardiac cycle is crucial and should be assessed by timing it with the heart sounds, carotid pulse and apex beat (<ce:cross-ref id="crf0555" refid="f0165">Figs 16.22</ce:cross-ref><ce:float-anchor refid="f0165"/> and <ce:cross-ref id="crf0560" refid="f0170">16.23</ce:cross-ref><ce:float-anchor refid="f0170"/>).</ce:para></ce:section><ce:section id="s0430"><ce:section-title id="st0405">Systolic murmurs</ce:section-title><ce:para id="p1320">Ejection systolic murmurs are associated with ventricular outflow tract obstruction and occur in mid-systole with a crescendo–decrescendo pattern, reflecting the changing velocity of blood flow (<ce:cross-ref id="crf0565" refid="b0090">Box 16.11</ce:cross-ref><ce:float-anchor refid="b0090"/>). Pansystolic murmurs maintain a constant intensity and extend from the first heart sound throughout systole to the second heart sound, sometimes obscuring it. They occur when blood leaks from a ventricle into a low-pressure chamber at an even or constant velocity. Mitral regurgitation, tricuspid regurgitation and ventricular septal defect are the only causes of a pansystolic murmur. Late systolic murmurs are unusual but may occur in mitral valve prolapse, if the mitral regurgitation is confined to late systole, and hypertrophic obstructive cardiomyopathy, if dynamic obstruction occurs late in systole.</ce:para></ce:section><ce:section id="s0435"><ce:section-title id="st0410">Diastolic murmurs</ce:section-title><ce:para id="p1330">These are due to accelerated or turbulent flow across the mitral or tricuspid valves. They are low-pitched noises that are often difficult to hear and should be evaluated with the bell of the stethoscope. A mid-diastolic murmur may be due to mitral stenosis (located at the apex and axilla), tricuspid stenosis (located at the left sternal edge), increased flow across the mitral valve (for example, the to-and-fro murmur of severe mitral regurgitation) or increased flow across the tricuspid valve (for example, a left-to-right shunt through a large atrial septal defect). Early diastolic murmurs have a soft, blowing quality with a decrescendo pattern and should be evaluated with the diaphragm of the stethoscope. They are due to regurgitation across the aortic or pulmonary valves and are best heard at the left sternal edge, with the patient sitting forwards in held expiration.</ce:para></ce:section><ce:section id="s0440"><ce:section-title id="st0415">Continuous murmurs</ce:section-title><ce:para id="p1335">These result from a combination of systolic and diastolic flow, such as occurs with a persistent ductus arteriosus, and must be distinguished from extracardiac noises such as bruits from arterial shunts, venous hums (high rates of venous flow in children) and pericardial friction rubs.</ce:para></ce:section></ce:section><ce:section id="s0445"><ce:section-title id="st0420">Investigations</ce:section-title><ce:para id="p1340">If clinical evaluation suggests that the additional sound is cardiac and likely to be pathological, then echocardiography is indicated to determine the underlying cause.</ce:para></ce:section><ce:section id="s0450"><ce:section-title id="st0425">Management</ce:section-title><ce:para id="p1345">Management of patients with additional cardiac sounds depends on the underlying cause. More details are provided in the sections on specific valve defects and congenital anomalies later in this chapter (<ce:cross-ref id="crf9330" refid="s1945">pp. 514 and 531</ce:cross-ref>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0455"><ce:section-title id="st0430">Heart failure</ce:section-title><ce:para id="p1350">Heart failure describes the clinical syndrome that develops when the heart cannot maintain adequate output, or can do so only at the expense of elevated ventricular filling pressure. In mild to moderate forms of heart failure, symptoms occur only when the metabolic demand increases during exercise or some other form of stress. In severe heart failure, symptoms may be present at rest. In clinical practice, heart failure may be diagnosed when a patient with significant heart disease develops the signs or symptoms of a low cardiac output, pulmonary congestion or systemic venous congestion at rest or on exercise. Three types of heart failure are recognised.</ce:para><ce:section id="s0460"><ce:section id="s0465"><ce:section id="s0470"><ce:section-title id="st0435">Left heart failure</ce:section-title><ce:para id="p1355">This is characterised by a reduction in left ventricular output and an increase in left atrial and pulmonary venous pressure. If left heart failure occurs suddenly – for example, as the result of an acute MI – the rapid increase in left atrial pressure causes pulmonary oedema. If the rise in atrial pressure is more gradual, as occurs with mitral stenosis, there is reflex pulmonary vasoconstriction, which protects the patient from pulmonary oedema. However, the resulting increase in pulmonary vascular resistance causes pulmonary hypertension, which in turn impairs right ventricular function.</ce:para></ce:section><ce:section id="s0475"><ce:section-title id="st0440">Right heart failure</ce:section-title><ce:para id="p1360">This is characterised by a reduction in right ventricular output and an increase in right atrial and systemic venous pressure. The most common causes are chronic lung disease, pulmonary embolism and pulmonary valvular stenosis. The term ‘cor pulmonale’ is used to describe right heart failure that is secondary to chronic lung disease.</ce:para></ce:section><ce:section id="s0480"><ce:section-title id="st0445">Biventricular heart failure</ce:section-title><ce:para id="p1365">In biventricular failure, both sides of the heart are affected. This may occur because the disease process, such as dilated cardiomyopathy or ischaemic heart disease, affects both ventricles or because disease of the left heart leads to chronic elevation of the left atrial pressure, pulmonary hypertension and right heart failure.</ce:para></ce:section></ce:section><ce:section id="s0485"><ce:section-title id="st0450">Epidemiology</ce:section-title><ce:para id="p1370">Heart failure predominantly affects the elderly; the prevalence rises from 1% in those aged 50–59 years to over 10% in those aged 80–89 years. In the UK, most patients admitted to hospital with heart failure are more than 70 years old; they typically remain hospitalised for a week or more and may be left with chronic disability. Although the outlook depends, to some extent, on the underlying cause of the problem, untreated heart failure generally carries a poor prognosis; approximately 50% of patients with severe heart failure due to left ventricular dysfunction will die within 2 years because of either pump failure or malignant ventricular arrhythmias. The most common causes are coronary artery disease and myocardial infarction but almost all forms of heart disease can lead to heart failure, as summarised in <ce:cross-ref id="crf0570" refid="b0095">Box 16.12</ce:cross-ref><ce:float-anchor refid="b0095"/>. An accurate diagnosis is important because treatment of the underlying cause may reverse heart failure or prevent its progression.</ce:para></ce:section><ce:section id="s0490"><ce:section-title id="st0455">Pathogenesis</ce:section-title><ce:para id="p1380">Heart failure occurs when cardiac output fails to meet the demands of the circulation. Cardiac output is determined by preload (the volume and pressure of blood in the ventricles at the end of diastole), afterload (the volume and pressure of blood in the ventricles during systole) and myocardial contractility, forming the basis of Starling's Law (<ce:cross-ref id="crf0575" refid="f0175">Fig. 16.24</ce:cross-ref><ce:float-anchor refid="f0175"/>). The causes of heart failure are discussed below.</ce:para><ce:section id="s0495"><ce:section-title id="st0460">Ventricular dysfunction</ce:section-title><ce:para id="p1385">Ventricular dysfunction is the most common cause of heart failure. This can occur because of impaired systolic contraction due to myocardial disease, or diastolic dysfunction where there is abnormal ventricular relaxation due to a stiff, non-compliant ventricle. This is most commonly found in patients with left ventricular hypertrophy. Systolic dysfunction and diastolic dysfunction often coexist, particularly in patients with coronary artery disease. Ventricular dysfunction reduces cardiac output, which, in turn, activates the sympathetic nervous system (SNS) and renin–angiotensin–aldosterone system (RAAS). Under normal circumstances, activation of the SNS and RAAS supports cardiac function but, in the setting of impaired ventricular function, the consequences are negative and lead to an increase in both afterload and preload (<ce:cross-ref id="crf0580" refid="f0180">Fig. 16.25</ce:cross-ref><ce:float-anchor refid="f0180"/>). A vicious circle may then be established because any additional fall in cardiac output causes further activation of the SNS and RAAS, and an additional increase in peripheral vascular resistance.</ce:para><ce:para id="p1390">Activation of the RAAS causes vasoconstriction and sodium and water retention. This is primarily mediated by angiotensin II, a potent constrictor of arterioles, in both the kidney and the systemic circulation (<ce:cross-ref id="crf0585" refid="f0180">Fig. 16.25</ce:cross-ref>). Activation of the SNS also occurs and can initially sustain cardiac output through increased myocardial contractility and heart rate. Prolonged sympathetic stimulation has negative effects, however, causing cardiac myocyte apoptosis, cardiac hypertrophy and focal myocardial necrosis. Sympathetic stimulation also contributes to vasoconstriction and predisposes to arrhythmias. Sodium and water retention is further enhanced by the release of aldosterone, endothelin-1 (a potent vasoconstrictor peptide with marked effects on the renal vasculature) and, in severe heart failure, vasopressin (antidiuretic hormone, ADH). Natriuretic peptides are released from the atria in response to atrial dilatation and compensate to an extent for the sodium-conserving effect of aldosterone, but this mechanism is overwhelmed in heart failure. Pulmonary and peripheral oedema occurs because of high left and right atrial pressures, and is compounded by sodium and water retention, caused by impairment of renal perfusion and by secondary hyperaldosteronism. If the underlying cause is a myocardial infarction, cardiac contractility is impaired and SNS and RAAS activation causes hypertrophy of non-infarcted segments, with thinning, dilatation and expansion of the infarcted segment (see <ce:cross-ref id="crf0590" refid="f0185">Fig. 16.64</ce:cross-ref>, <ce:cross-ref id="crf9335" refid="s1395">p. 496</ce:cross-ref>). This leads to further deterioration in ventricular function and worsening heart failure.</ce:para></ce:section><ce:section id="s0500"><ce:section-title id="st0465">High-output failure</ce:section-title><ce:para id="p1395">Sometimes cardiac failure can occur in patients without heart disease due to a large arteriovenous shunt, or where there is an excessively high cardiac output due to beri-beri (<ce:intra-ref id="ii0270" xlink:href="pii:B978-0-7020-7028-0.00019-6#p2085">p. 714</ce:intra-ref>), severe anaemia or thyrotoxicosis.</ce:para></ce:section><ce:section id="s0505"><ce:section-title id="st0470">Valvular disease</ce:section-title><ce:para id="p1400">Heart failure can also be caused by valvular disease in which there is impaired filling of the ventricles due to mitral or tricuspid stenosis; where there is obstruction to ventricular outflow, as occurs in aortic and pulmonary stenosis and hypertrophic cardiomyopathy; or as the result of ventricular overload secondary to valvular regurgitation.</ce:para></ce:section></ce:section><ce:section id="s0510"><ce:section-title id="st0475">Clinical assessment</ce:section-title><ce:para id="p1405">Heart failure may develop suddenly, as in MI, or gradually, as in valvular heart disease. When there is gradual impairment of cardiac function, several compensatory changes take place. The term compensated heart failure is sometimes used to describe the condition of those with impaired cardiac function, in whom adaptive changes have prevented the development of overt heart failure. However, a minor event, such as an intercurrent infection or development of atrial fibrillation, may precipitate acute heart failure in these circumstances (<ce:cross-ref id="crf0595" refid="b0100">Box 16.13</ce:cross-ref><ce:float-anchor refid="b0100"/>). Similarly, acute heart failure sometimes supervenes as the result of a decompensating episode, on a background of chronic heart failure; this is called acute-on-chronic heart failure.</ce:para><ce:section id="s0515"><ce:section-title id="st0480">Acute left heart failure</ce:section-title><ce:para id="p1455">Acute left heart failure presents with a sudden onset of dyspnoea at rest that rapidly progresses to acute respiratory distress, orthopnoea and prostration. Often there is a clear precipitating factor, such as an acute MI, which may be apparent from the history. The patient appears agitated, pale and clammy. The peripheries are cool to the touch and the pulse is rapid, but in some cases there may be an inappropriate bradycardia that may contribute to the acute episode of heart failure. The BP is usually high because of SNS activation, but may be normal or low if the patient is in cardiogenic shock.</ce:para><ce:para id="p1460">The jugular venous pressure (JVP) is usually elevated, particularly with associated fluid overload or right heart failure. In acute heart failure, there has been no time for ventricular dilatation and the apex is not displaced. A ‘gallop’ rhythm, with a third heart sound, is heard quite early in the development of acute left-sided heart failure. A new systolic murmur may signify acute mitral regurgitation or ventricular septal rupture. Chest examination may reveal crepitations at the lung bases if there is pulmonary oedema, or crepitations throughout the lungs if this is severe. There may be an expiratory wheeze. Patients with acute-on-chronic heart failure may have additional features of chronic heart failure (see below). Potential precipitants, such as an upper respiratory tract infection or inappropriate cessation of diuretic medication, may be identified on clinical examination or history-taking.</ce:para></ce:section><ce:section id="s0520"><ce:section-title id="st0485">Chronic heart failure</ce:section-title><ce:para id="p1465">Patients with chronic heart failure commonly follow a relapsing and remitting course, with periods of stability and episodes of decompensation, leading to worsening symptoms that may necessitate hospitalisation. The clinical picture depends on the nature of the underlying heart disease, the type of heart failure that it has evoked, and the changes in the SNS and RAAS that have developed (see <ce:cross-ref id="crf0600" refid="b0095">Box 16.12</ce:cross-ref> and <ce:cross-ref id="crf0605" refid="f0190">Fig. 16.26</ce:cross-ref><ce:float-anchor refid="f0190"/>).</ce:para><ce:para id="p1470">Low cardiac output causes fatigue, listlessness and a poor effort tolerance; the peripheries are cold and the BP is low. To maintain perfusion of vital organs, blood flow is diverted away from skeletal muscle and this may contribute to fatigue and weakness. Poor renal perfusion leads to oliguria and uraemia.</ce:para><ce:para id="p1475">Pulmonary oedema due to left heart failure presents with dyspnoea and inspiratory crepitations over the lung bases. In contrast, right heart failure produces a high JVP with hepatic congestion and dependent peripheral oedema. In ambulant patients the oedema affects the ankles, whereas in bed-bound patients it collects around the thighs and sacrum. Ascites or pleural effusion may occur (<ce:cross-ref id="crf0610" refid="f0190">Fig. 16.26</ce:cross-ref>). Heart failure is not the only cause of oedema (<ce:cross-ref id="crf0615" refid="b0105">Box 16.14</ce:cross-ref><ce:float-anchor refid="b0105"/>).</ce:para><ce:para id="p1525">Chronic heart failure is sometimes associated with marked weight loss (cardiac cachexia), caused by a combination of anorexia and impaired absorption due to gastrointestinal congestion, poor tissue perfusion due to a low cardiac output, and skeletal muscle atrophy due to immobility.</ce:para></ce:section></ce:section><ce:section id="s0525"><ce:section-title id="st0490">Complications of heart failure</ce:section-title><ce:para id="p1530">Several complications may occur in advanced heart failure, as described below.<ce:list id="ulist0225"><ce:list-item id="u0830"><ce:label>•</ce:label><ce:para id="p1535"><ce:italic>Renal failure</ce:italic> is caused by poor renal perfusion due to low cardiac output and may be exacerbated by diuretic therapy, ACE inhibitors and angiotensin receptor blockers (ARBs).</ce:para></ce:list-item><ce:list-item id="u0835"><ce:label>•</ce:label><ce:para id="p1540"><ce:italic>Hypokalaemia</ce:italic> may be the result of treatment with potassium-losing diuretics or hyperaldosteronism caused by activation of the renin–angiotensin system and impaired aldosterone metabolism due to hepatic congestion. Most of the body's potassium is intracellular and there may be substantial depletion of potassium stores, even when the plasma concentration is in the reference range.</ce:para></ce:list-item><ce:list-item id="u0840"><ce:label>•</ce:label><ce:para id="p1545"><ce:italic>Hyperkalaemia</ce:italic> may be due to the effects of drugs that promote renal resorption of potassium, in particular the combination of ACE inhibitors, ARBs and mineralocorticoid receptor antagonists. These effects are amplified if there is renal dysfunction due to low cardiac output or atherosclerotic renal vascular disease.</ce:para></ce:list-item><ce:list-item id="u0845"><ce:label>•</ce:label><ce:para id="p1550"><ce:italic>Hyponatraemia</ce:italic> is a feature of severe heart failure and is a poor prognostic sign. It may be caused by diuretic therapy, inappropriate water retention due to high vasopressin secretion, or failure of the cell membrane ion pump.</ce:para></ce:list-item><ce:list-item id="u0850"><ce:label>•</ce:label><ce:para id="p1555"><ce:italic>Impaired liver function</ce:italic> is caused by hepatic venous congestion and poor arterial perfusion, which frequently cause mild jaundice and abnormal liver function tests; reduced synthesis of clotting factors can make anticoagulant control difficult.</ce:para></ce:list-item><ce:list-item id="u0855"><ce:label>•</ce:label><ce:para id="p1560"><ce:italic>Thromboembolism</ce:italic>. Deep vein thrombosis and pulmonary embolism may occur due to the effects of a low cardiac output and enforced immobility. Systemic emboli occur in patients with atrial fibrillation or flutter, or with intracardiac thrombus complicating conditions such as mitral stenosis, MI or left ventricular aneurysm.</ce:para></ce:list-item><ce:list-item id="u0860"><ce:label>•</ce:label><ce:para id="p1565"><ce:italic>Atrial and ventricular arrhythmias</ce:italic> are very common and may be related to electrolyte changes such as hypokalaemia and hypomagnesaemia, the underlying cardiac disease, and the pro-arrhythmic effects of sympathetic activation. Atrial fibrillation occurs in approximately 20% of patients with heart failure and causes further impairment of cardiac function. Ventricular ectopic beats and runs of non-sustained ventricular tachycardia are common findings in patients with heart failure and are associated with an adverse prognosis.</ce:para></ce:list-item><ce:list-item id="u0865"><ce:label>•</ce:label><ce:para id="p1570"><ce:italic>Sudden death</ce:italic> occurs in up to 50% of patients with heart failure and is most probably due to ventricular fibrillation.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0530"><ce:section-title id="st0495">Investigations</ce:section-title><ce:para id="p1575">A chest X-ray should be performed in all cases. This may show abnormal distension of the upper lobe pulmonary veins with the patient in the erect position (<ce:cross-ref id="crf0620" refid="f0095">Fig. 16.27</ce:cross-ref><ce:float-anchor refid="f0095"/>). Vascularity of the lung fields becomes more prominent and the right and left pulmonary arteries dilate. Subsequently, interstitial oedema causes thickened interlobular septa and dilated lymphatics. These are evident as horizontal lines in the costophrenic angles (septal or ‘Kerley B’ lines). More advanced changes due to alveolar oedema cause a hazy opacification spreading from the hilar regions, and pleural effusions. Echocardiography is very useful and should be considered in all patients with heart failure in order to:<ce:list id="ulist0230"><ce:list-item id="u0870"><ce:label>•</ce:label><ce:para id="p1580">determine the aetiology</ce:para></ce:list-item><ce:list-item id="u0875"><ce:label>•</ce:label><ce:para id="p1585">detect hitherto unsuspected valvular heart disease, such as occult mitral stenosis, and other conditions that may be amenable to specific remedies</ce:para></ce:list-item><ce:list-item id="u0880"><ce:label>•</ce:label><ce:para id="p1590">identify patients who will benefit from long-term drug therapy.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1595">Serum urea, creatinine and electrolytes, haemoglobin and thyroid function may help to establish the nature and severity of the underlying heart disease and detect any complications. BNP is elevated in heart failure and is a prognostic marker, as well as being useful in differentiating heart failure from other causes of breathlessness or peripheral oedema.</ce:para></ce:section><ce:section id="s0535"><ce:section-title id="st0500">Management of acute heart failure</ce:section-title><ce:para id="p1600">Acute heart failure with pulmonary oedema is a medical emergency that should be treated urgently. The patient should initially be kept rested, with continuous monitoring of cardiac rhythm, BP and pulse oximetry. Intravenous opiates can be of value in distressed patients but must be used sparingly, as they may cause respiratory depression and exacerbation of hypoxaemia and hypercapnia. The key elements of management are summarised in <ce:cross-ref id="crf0625" refid="b0110">Box 16.15</ce:cross-ref><ce:float-anchor refid="b0110"/>.</ce:para><ce:para id="p1610">If these measures prove ineffective, inotropic agents such as dobutamine (2.5–10 µg/kg/min) may be required to augment cardiac output, particularly in hypotensive patients. Insertion of an intra-aortic balloon pump may be beneficial in patients with acute cardiogenic pulmonary oedema and shock. Following management of the acute episode, additional measures must be instituted to control heart failure in the longer term, as discussed below.</ce:para></ce:section><ce:section id="s0540"><ce:section-title id="st0505">Management of chronic heart failure</ce:section-title><ce:para id="p1615">The aims of treatment in chronic heart failure are to improve cardiac function by increasing contractility, optimising preload or decreasing afterload, and controlling cardiac rate and rhythm (see <ce:cross-ref id="crf0635" refid="f0180">Fig. 16.25</ce:cross-ref>). This can be achieved by a combination of drug treatment or non-drug treatments, as discussed below.</ce:para><ce:section id="s0545"><ce:section-title id="st0510">Education</ce:section-title><ce:para id="p1620">Education of patients and their relatives about the causes and treatment of heart failure can improve adherence to a management plan (<ce:cross-ref id="crf0640" refid="b0115">Box 16.16</ce:cross-ref><ce:float-anchor refid="b0115"/>). Some patients may need to weigh themselves daily, as a measure of fluid load, and adjust their diuretic therapy accordingly.</ce:para></ce:section><ce:section id="s0580"><ce:section-title id="st0545">Drug treatment</ce:section-title><ce:para id="p1690">A wide variety of drug treatments are now available for the treatment of heart failure. Drugs that reduce preload are appropriate in patients with high end-diastolic filling pressures and evidence of pulmonary or systemic venous congestion, whereas those that reduce afterload or increase myocardial contractility are more useful in patients with signs and symptoms of a low cardiac output.</ce:para><ce:section id="s0585"><ce:section-title id="st0550">Diuretics</ce:section-title><ce:para id="p1695">Diuretics promote urinary sodium and water excretion, leading to a reduction in blood plasma volume (<ce:intra-ref id="ii0275" xlink:href="pii:B978-0-7020-7028-0.00014-7#p0805">p. 354</ce:intra-ref>), which in turn reduces preload and improves pulmonary and systemic venous congestion. They may also reduce afterload and ventricular volume, leading to a fall in ventricular wall tension and increased cardiac efficiency. Although a fall in preload (ventricular filling pressure) normally reduces cardiac output, patients with heart failure are beyond the apex of the Starling curve, so there may be a substantial and beneficial fall in filling pressure with either no change or an improvement in cardiac output (see <ce:cross-ref id="crf0645" refid="f0175">Figs 16.24</ce:cross-ref> and <ce:cross-ref id="crf0650" refid="f0195">16.28</ce:cross-ref><ce:float-anchor refid="f0195"/>). Nevertheless, the dose of diuretics needs to be titrated carefully so as to avoid excessive volume depletion, which can cause a fall in cardiac output with hypotension, lethargy and renal failure. This is especially likely in patients with a marked diastolic component to their heart failure.</ce:para><ce:para id="p1700">Oedema may persist, despite oral loop diuretic therapy, in some patients with severe chronic heart failure, particularly if there is renal impairment. Under these circumstances an intravenous infusion of furosemide (5–10 mg/hr) may initiate a diuresis. Combining a loop diuretic with a thiazide diuretic such as bendroflumethiazide (5 mg daily) may also prove effective but care must be taken to avoid an excessive diuresis.</ce:para><ce:para id="p1705"><ce:float-anchor refid="b0120"/></ce:para><ce:para id="p1740">Mineralocorticoid receptor antagonists, such as spironolactone and eplerenone, are potassium-sparing diuretics that are of particular benefit in patients with heart failure with severe left ventricular systolic dysfunction. They have been shown to improve long-term clinical outcome in individuals with severe heart failure or heart failure following acute MI but may cause hyperkalaemia, particularly when used with an ACE inhibitor.</ce:para></ce:section><ce:section id="s0590"><ce:section-title id="st0555">Angiotensin-converting enzyme inhibitors</ce:section-title><ce:para id="p1745">ACE inhibitors play a central role in the management of heart failure since they interrupt the vicious circle of neurohumoral activation that is characteristic of the disease by preventing the conversion of angiotensin I to angiotensin II. This, in turn, reduces peripheral vasoconstriction, activation of the sympathetic nervous system (<ce:cross-ref id="crf0655" refid="f0200">Fig. 16.29</ce:cross-ref><ce:float-anchor refid="f0200"/>), and salt and water retention due to aldosterone release, as well as preventing the activation of the renin–angiotensin system caused by diuretic therapy.</ce:para><ce:para id="p1750">In moderate and severe heart failure, ACE inhibitors can produce a substantial improvement in effort tolerance and in mortality. They can also improve outcome and prevent the onset of overt heart failure in patients with poor residual left ventricular function following MI.</ce:para><ce:para id="p1755">Adverse effects of ACE inhibitors include symptomatic hypotension and impairment of renal function, especially in patients with bilateral renal artery stenosis or those with pre-existing renal disease. An increase in serum potassium concentration may also occur, which can be beneficial in offsetting the hypokalaemia associated with loop diuretic therapy. Short-acting ACE inhibitors can cause marked falls in BP, particularly in the elderly or when started in the presence of hypotension, hypovolaemia or hyponatraemia. In stable patients without hypotension (systolic BP over 100 mmHg), ACE inhibitors can usually be safely started in the community. In other patients, however, it is usually advisable to withhold diuretics for 24 hours before starting treatment with a small dose of a long-acting agent, preferably given at night (<ce:cross-ref id="crf0660" refid="b0125">Box 16.18</ce:cross-ref><ce:float-anchor refid="b0125"/>). Renal function and serum potassium must be monitored and should be checked 1–2 weeks after starting therapy.</ce:para></ce:section><ce:section id="s0595"><ce:section-title id="st0560">Angiotensin receptor blockers</ce:section-title><ce:para id="p1765">ARBs act by blocking the action of angiotensin II on the heart, peripheral vasculature and kidney. In heart failure, they produce beneficial haemodynamic changes that are similar to the effects of ACE inhibitors (<ce:cross-ref id="crf0665" refid="f0200">Fig. 16.29</ce:cross-ref>) but are generally better tolerated. They have comparable effects on mortality and are a useful alternative for patients who cannot tolerate ACE inhibitors. Like ACE inhibitors they should be started at a low dose and titrated upwards, depending on response (<ce:cross-ref id="crf0670" refid="b0125">Box 16.18</ce:cross-ref>). Unfortunately, they share all the more serious adverse effects of ACE inhibitors, including renal dysfunction and hyperkalaemia. ARBs are normally used as an alternative to ACE inhibitors, but the two can be combined in patients with resistant or recurrent heart failure.</ce:para></ce:section><ce:section id="s0600"><ce:section-title id="st0565">Neprilysin inhibitors</ce:section-title><ce:para id="p1770">The only drug currently in this class is sacubitril, a small-molecule inhibitor of neprilysin, which is responsible for the breakdown of the endogenous diuretics ANP and BNP. Used in combination with the ARB valsartan (sacubitril–valsartan), it has been shown to produce additional symptomatic and mortality benefit over ACE inhibition and is now recommended in the management of resistant heart failure.</ce:para></ce:section><ce:section id="s0605"><ce:section-title id="st0570">Vasodilators</ce:section-title><ce:para id="p1775">These drugs are valuable in chronic heart failure, when ACE inhibitors or ARBs are contraindicated. Venodilators, such as nitrates, reduce preload, and arterial dilators, such as hydralazine, reduce afterload (see <ce:cross-ref id="crf0675" refid="f0195">Fig. 16.28</ce:cross-ref>). Their use is limited by pharmacological tolerance and hypotension.</ce:para></ce:section><ce:section id="s0610"><ce:section-title id="st0575">Beta-adrenoceptor blockers</ce:section-title><ce:para id="p1780">Beta-blockade helps to counteract the deleterious effects of enhanced sympathetic stimulation and reduces the risk of arrhythmias and sudden death. When initiated in standard doses β-blockers may precipitate acute-on-chronic heart failure, but when given in small incremental doses they can increase ejection fraction, improve symptoms, reduce the frequency of hospitalisation and reduce mortality in patients with chronic heart failure. A typical regimen is bisoprolol, starting at a dose of 1.25 mg daily and increased gradually over a 12-week period to a target maintenance dose of 10 mg daily. Beta-blockers are more effective at reducing mortality than ACE inhibitors, with a relative risk reduction of 33% versus 20%, respectively.</ce:para></ce:section><ce:section id="s0615"><ce:section-title id="st0580">Ivabradine</ce:section-title><ce:para id="p1785">Ivabradine acts on the I<ce:inf loc="post">f</ce:inf> inward current in the SA node, resulting in reduction of heart rate. It reduces hospital admission and mortality rates in patients with heart failure due to moderate or severe left ventricular systolic impairment. In trials, its effects were most marked in patients with a relatively high heart rate (over 77/min), so ivabradine is best suited to patients who cannot take β-blockers or whose heart rate remains high despite β-blockade. It is ineffective in patients with atrial fibrillation.</ce:para></ce:section><ce:section id="s0620"><ce:section-title id="st0585">Digoxin</ce:section-title><ce:para id="p1790">Digoxin (<ce:cross-ref id="crf9340" refid="s1085">p. 482</ce:cross-ref>) can be used to provide rate control in patients with heart failure and atrial fibrillation. In patients with severe heart failure (NYHA class III–IV, see <ce:cross-ref id="crf0680" refid="b0055">Box 16.5</ce:cross-ref>), digoxin reduces the likelihood of hospitalisation for heart failure, although it has no effect on long-term survival.</ce:para></ce:section><ce:section id="s0625"><ce:section-title id="st0590">Amiodarone</ce:section-title><ce:para id="p1795">This is a potent anti-arrhythmic drug (<ce:cross-ref id="crf9345" refid="p2850">p. 481</ce:cross-ref>) that has little negative inotropic effect and may be valuable in patients with poor left ventricular function. It is effective only in the treatment of symptomatic arrhythmias and should not be used as a preventative agent in asymptomatic patients. Amiodarone is used for prevention of symptomatic atrial arrhythmias and of ventricular arrhythmias when other pharmacological options have been exhausted.</ce:para></ce:section></ce:section><ce:section id="s0630"><ce:section-title id="st0595">Non-pharmacological treatments</ce:section-title><ce:section id="s0635"><ce:section-title id="st0600">Implantable cardiac defibrillators</ce:section-title><ce:para id="p1800">These devices are indicated in patients with symptomatic ventricular arrhythmias and heart failure, since they improve prognosis and survival (<ce:cross-ref id="crf9350" refid="s1115">p. 483</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0640"><ce:section-title id="st0605">Resynchronisation devices</ce:section-title><ce:para id="p1805">In patients with marked intraventricular conduction delay, prolonged depolarisation may lead to uncoordinated left ventricular contraction. When this is associated with severe symptomatic heart failure, cardiac resynchronisation devices may be helpful. Here, both the LV and RV are paced simultaneously (<ce:cross-ref id="crf0685" refid="f0205">Fig. 16.30</ce:cross-ref><ce:float-anchor refid="f0205"/>) to generate a more coordinated left ventricular contraction and improve cardiac output. This is associated with improved symptoms and survival.</ce:para></ce:section><ce:section id="s0645"><ce:section-title id="st0610">Coronary revascularisation</ce:section-title><ce:para id="p1810">Coronary artery bypass surgery or percutaneous coronary intervention may improve function in areas of the myocardium that are ‘hibernating’ because of inadequate blood supply, and can be used to treat carefully selected patients with heart failure and coronary artery disease. If necessary, ‘hibernating’ myocardium can be identified by stress echocardiography and specialised nuclear or magnetic resonance imaging.</ce:para></ce:section><ce:section id="s0650"><ce:section-title id="st0615">Cardiac transplantation</ce:section-title><ce:para id="p1815">Cardiac transplantation is an established and successful treatment for patients with intractable heart failure. Coronary artery disease and dilated cardiomyopathy are the most common indications. The use of transplantation is limited by the efficacy of modern drug and device therapies, as well as the availability of donor hearts, so it is generally reserved for young patients with severe symptoms despite optimal therapy.</ce:para><ce:para id="p1820">Conventional heart transplantation is contraindicated in patients with pulmonary vascular disease due to long-standing left heart failure, complex congenital heart disease such as Eisenmenger's syndrome, or primary pulmonary hypertension because the RV of the donor heart may fail in the face of high pulmonary vascular resistance. However, heart–lung transplantation can be successful in patients with Eisenmenger's syndrome, and lung transplantation has been used for primary pulmonary hypertension.</ce:para><ce:para id="p1825">Although cardiac transplantation usually produces a dramatic improvement in the recipient's quality of life, serious complications may occur:<ce:list id="ulist0270"><ce:list-item id="u0945"><ce:label>•</ce:label><ce:para id="p1830"><ce:italic>Rejection</ce:italic>. In spite of routine therapy with ciclosporin A, azathioprine and glucocorticoids, episodes of rejection are common and may present with heart failure, arrhythmias or subtle ECG changes. Cardiac biopsy is often used to confirm the diagnosis before starting treatment with high-dose glucocorticoids.</ce:para></ce:list-item><ce:list-item id="u0950"><ce:label>•</ce:label><ce:para id="p1835"><ce:italic>Accelerated atherosclerosis</ce:italic>. Recurrent heart failure is often due to progressive atherosclerosis in the coronary arteries of the donor heart. This is not confined to patients who underwent transplantation for coronary artery disease and is probably a manifestation of chronic rejection. Angina is rare because the heart has been denervated.</ce:para></ce:list-item><ce:list-item id="u0955"><ce:label>•</ce:label><ce:para id="p1840"><ce:italic>Infection</ce:italic>. Opportunistic infection with organisms such as cytomegalovirus or <ce:italic>Aspergillus</ce:italic> remains a major cause of death in transplant recipients.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0655"><ce:section-title id="st0620">Ventricular assist devices</ce:section-title><ce:para id="p1845">Because of the limited supply of donor organs, ventricular assist devices (VAD) may be employed as a bridge to cardiac transplantation and as short-term restoration therapy following a potentially reversible insult such as viral myocarditis. In some patients, VADs may be used as a long-term therapy if no other options exist.</ce:para><ce:para id="p1850">These devices assist cardiac output by using a roller, centrifugal or pulsatile pump that, in some cases, is implantable and portable. They withdraw blood through cannulae inserted in the atria or ventricular apex and pump it into the pulmonary artery or aorta. They are designed not only to unload the ventricles but also to provide support to the pulmonary and systemic circulations. Their more widespread application is limited by high complication rates (haemorrhage, systemic embolism, infection, neurological and renal sequelae), although some improvements in survival and quality of life have been demonstrated in patients with severe heart failure.</ce:para></ce:section></ce:section></ce:section></ce:section></ce:section></ce:section><ce:section id="s0660"><ce:section-title id="st0625">Cardiac arrhythmias</ce:section-title><ce:para id="p1855">A cardiac arrhythmia is defined as a disturbance of the electrical rhythm of the heart. Cardiac arrhythmias are often a manifestation of structural heart disease but may also occur because of abnormal conduction or depolarisation in an otherwise healthy heart. There are many types of cardiac arrhythmia, as discussed later in this section. By convention, however, a heart rate of more than 100/min is called a tachycardia, and a heart rate of less than 60/min is called a bradycardia.</ce:para><ce:section id="s0665"><ce:section id="s0670"><ce:section id="s0675"><ce:section-title id="st0630">Pathogenesis</ce:section-title><ce:para id="p1860">Cardiac arrhythmias usually occur as the result of pathology affecting the conduction system of the heart. The cardiac cycle is normally initiated by an electrical discharge from the SA node. The atria and ventricles then activate sequentially as electrical depolarisation passes through specialised conducting tissues (see <ce:cross-ref id="crf0690" refid="f0050">Fig. 16.4</ce:cross-ref>, <ce:cross-ref id="crf9355" refid="p0475">p. 445</ce:cross-ref>). The sinus node acts as a pacemaker and its intrinsic rate is regulated by the autonomic nervous system; vagal activity decreases the heart rate and sympathetic activity increases heart rate through cardiac sympathetic nerves and circulating catecholamines.</ce:para><ce:para id="p1865">There are three main mechanisms of tachycardia:<ce:list id="ulist0275"><ce:list-item id="u0960"><ce:label>•</ce:label><ce:para id="p1870"><ce:italic>Increased automaticity.</ce:italic> The tachycardia is produced by spontaneous depolarisation of an ectopic focus in the atria, atrioventricular junction or ventricles, often in response to catecholamines. Single depolarisations lead to atrial, junctional or ventricular premature (ectopic) beats. Repeated depolarisation leads to atrial, junctional or ventricular tachycardia.</ce:para></ce:list-item><ce:list-item id="u0965"><ce:label>•</ce:label><ce:para id="p1875"><ce:italic>Re-entry.</ce:italic> The tachycardia is initiated by an ectopic beat and sustained by a re-entry circuit (<ce:cross-ref id="crf0695" refid="f0210">Fig. 16.31</ce:cross-ref><ce:float-anchor refid="f0210"/>). Most tachyarrhythmias are caused by re-entry.</ce:para></ce:list-item><ce:list-item id="u0970"><ce:label>•</ce:label><ce:para id="p1880"><ce:italic>Triggered activity.</ce:italic> This can cause ventricular arrhythmias in patients with coronary artery disease. It is a form of secondary depolarisation arising from an incompletely repolarised cell membrane. Arrhythmias may be supraventricular (sinus, atrial or junctional) or ventricular in origin.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p9025">Supraventricular rhythms usually produce narrow QRS complexes because the ventricles are depolarised in their normal sequence via the AV node, the bundle of His and associated Purkinje fibres. In contrast, ventricular rhythms produce broad, bizarre QRS complexes because the ventricles are activated in an abnormal sequence. Occasionally, supraventricular tachycardia can mimic ventricular tachycardia and present as a broad-complex tachycardia due to coexisting bundle branch block or the presence of an additional atrioventricular connection (accessory pathway, see below).</ce:para><ce:para id="p1885">Bradycardia may be due to reduced automaticity of the SA node or abnormalities of conduction through the AV node. If the sinus rate becomes unduly slow, another, more distal part of the conducting system may assume the role of pacemaker. This is known as an escape rhythm and may arise in the AV node or His bundle (junctional rhythm) or in the ventricles (idioventricular rhythm).</ce:para></ce:section><ce:section id="s0680"><ce:section-title id="st0635">Clinical features</ce:section-title><ce:para id="p1890">Many arrhythmias are asymptomatic but sustained tachycardias typically present with rapid palpitation, dizziness, chest discomfort or breathlessness. Extreme tachycardias can also cause syncope because the heart is unable to contract or relax properly at extreme rates. Bradycardias tend to cause symptoms that reflect low cardiac output, including fatigue, lightheadedness and syncope. Extreme bradycardias or tachycardias can precipitate sudden death or cardiac arrest.</ce:para></ce:section><ce:section id="s0685"><ce:section-title id="st0640">Investigations</ce:section-title><ce:para id="p1895">The first-line investigation is a standard 12-lead ECG, which can be diagnostic in many cases. If arrhythmias are intermittent and the resting ECG is normal, an attempt should be made to capture the abnormal rhythm using an ambulatory ECG or a patient-activated ECG.</ce:para></ce:section><ce:section id="s0690"><ce:section-title id="st0645">Management</ce:section-title><ce:para id="p1900">Features of individual arrhythmias are discussed below. Management depends on the nature of the arrhythmia and the general principles of medical management are discussed on <ce:cross-ref id="crf9360" refid="s0910">page 479</ce:cross-ref>.</ce:para></ce:section></ce:section><ce:section id="s0695"><ce:section-title id="st0650">Sinus arrhythmia</ce:section-title><ce:para id="p1905">This is defined as a cyclical alteration of the heart rate during respiration, with an increase during inspiration and a decrease during expiration. Sinus arrhythmia is a normal phenomenon and can be quite pronounced in children. Absence of this normal variation in heart rate with breathing or with changes in posture may be a feature of diabetic neuropathy (<ce:intra-ref id="ii0305" xlink:href="pii:B978-0-7020-7028-0.00020-2#p3310">p. 758</ce:intra-ref>), autonomic involvement in patients with diseases of peripheral nerves (<ce:intra-ref id="ii9000" xlink:href="pii:B978-0-7020-7028-0.00025-1#s2035">p. 1138</ce:intra-ref>) or increased sympathetic drive. Sinus arrhythmia does not require treatment.</ce:para></ce:section><ce:section id="s0700"><ce:section-title id="st0655">Sinus bradycardia</ce:section-title><ce:para id="p1910">This may occur in healthy people at rest and is a common finding in athletes. Some pathological causes are listed in <ce:cross-ref id="crf0700" refid="b0130">Box 16.19</ce:cross-ref><ce:float-anchor refid="b0130"/>. If sinus bradycardia is asymptomatic, then no treatment is required. Symptomatic sinus bradycardia may occur acutely during an MI and can be treated with intravenous atropine (0.6–1.2 mg). Patients with recurrent or persistent symptomatic sinus bradycardia should be considered for pacemaker implantation.</ce:para></ce:section><ce:section id="s0705"><ce:section-title id="st0660">Sinus tachycardia</ce:section-title><ce:para id="p1990">Sinus tachycardia is usually due to an increase in sympathetic activity associated with exercise, emotion and pregnancy. Healthy young adults can produce a rapid sinus rate, up to 200/min, during intense exercise. Sinus tachycardia does not require treatment but sometimes may reflect an underlying disease, as summarised in <ce:cross-ref id="crf0705" refid="b0130">Box 16.19</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0710"><ce:section-title id="st0665">Sick sinus syndrome</ce:section-title><ce:para id="p1995">Sick sinus syndrome can occur at any age but is most common in older people. It is caused by fibrosis, degenerative changes or ischaemia of the SA node and is characterised by a variety of arrhythmias (<ce:cross-ref id="crf0710" refid="b0135">Box 16.20</ce:cross-ref><ce:float-anchor refid="b0135"/>). The typical presentation is with palpitation, dizzy spells or syncope, due to intermittent tachycardia, bradycardia, or pauses with no atrial or ventricular activity (SA block or sinus arrest) (<ce:cross-ref id="crf0715" refid="f0080">Fig. 16.32</ce:cross-ref><ce:float-anchor refid="f0080"/>).</ce:para><ce:para id="p2030">A permanent pacemaker may benefit patients with troublesome symptoms due to spontaneous bradycardias, or those with symptomatic bradycardias induced by drugs required to prevent tachyarrhythmias. Atrial pacing may prevent episodes of atrial fibrillation. Pacing improves symptoms but not prognosis, and is not indicated in patients who are asymptomatic.</ce:para></ce:section><ce:section id="s0715"><ce:section-title id="st0670">Atrial ectopic beats</ce:section-title><ce:para id="p2035">Atrial ectopic beats usually cause no symptoms but can give the sensation of a missed beat or an abnormally strong beat. The ECG (<ce:cross-ref id="crf0720" refid="f0215">Fig. 16.33</ce:cross-ref><ce:float-anchor refid="f0215"/>) shows a premature but otherwise normal QRS complex; if visible, the preceding P wave has a different morphology because the atria activate from an abnormal site. In most cases these are of no consequence, although very frequent atrial ectopic beats may herald the onset of atrial fibrillation. Treatment is rarely necessary but β-blockers can be used if symptoms are intrusive.</ce:para></ce:section><ce:section id="s0720"><ce:section-title id="st0675">Atrial tachycardia</ce:section-title><ce:para id="p2040">Atrial tachycardia may be a manifestation of increased atrial automaticity, sinoatrial disease or digoxin toxicity. It produces a narrow-complex tachycardia with abnormal P-wave morphology, sometimes associated with AV block if the atrial rate is rapid. It may respond to β-blockers, which reduce automaticity, or class I or III anti-arrhythmic drugs (see <ce:cross-ref id="crf0725" refid="b0185">Box 16.30</ce:cross-ref> below). The ventricular response in rapid atrial tachycardias may be controlled by AV node-blocking drugs. Catheter ablation (<ce:cross-ref id="crf9365" refid="s1135">p. 484</ce:cross-ref>) can be used to target the ectopic site and should be offered as an alternative to anti-arrhythmic drugs in patients with recurrent atrial tachycardia.</ce:para></ce:section><ce:section id="s0725"><ce:section-title id="st0680">Atrial flutter</ce:section-title><ce:para id="p2045">Atrial flutter is characterised by a large (macro) re-entry circuit, usually within the right atrium encircling the tricuspid annulus. The atrial rate is approximately 300/min, and is usually associated with 2 : 1, 3 : 1 or 4 : 1 AV block (with corresponding heart rates of 150, 100 or 75/min). Rarely, in young patients, every flutter wave is conducted, producing a rate of 300/min and, potentially, haemodynamic compromise. The ECG shows saw-tooth flutter waves (<ce:cross-ref id="crf0730" refid="f0220">Fig. 16.34</ce:cross-ref><ce:float-anchor refid="f0220"/>). When there is regular 2 : 1 AV block, it may be difficult to identify flutter waves that are buried in QRS complexes and T waves. Atrial flutter should always be suspected when there is a narrow-complex tachycardia of 150/min. Carotid sinus pressure or intravenous adenosine may help to establish the diagnosis by temporarily increasing the degree of AV block and revealing flutter waves (<ce:cross-ref id="crf0735" refid="f0225">Fig. 16.35</ce:cross-ref><ce:float-anchor refid="f0225"/>).</ce:para><ce:section id="s0730"><ce:section-title id="st0685">Management</ce:section-title><ce:para id="p2050">Medical management with digoxin, β-blockers or verapamil is often successful in controlling the ventricular rate (<ce:cross-ref id="crf9370" refid="s0910">p. 479</ce:cross-ref>). In many cases, however, it may be preferable to try to restore sinus rhythm by direct current (DC) cardioversion. Following cardioversion, β-blockers or amiodarone can be used to prevent recurrent episodes of atrial flutter. Class Ic anti-arrhythmic drugs such as flecainide are contraindicated because there is a risk of slowing the flutter circuit, facilitating 1 : 1 AV nodal conduction and producing a paradoxical extreme tachycardia and haemodynamic compromise. Catheter ablation is a highly effective treatment, offering a greater than 90% chance of complete cure, and is the treatment of choice for patients with persistent symptoms. Anticoagulant management in patients with atrial flutter, including management around cardioversion, is identical to that of patients with atrial fibrillation (<ce:cross-ref id="crf9375" refid="s0755">p. 471</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s0735"><ce:section-title id="st0690">Atrial fibrillation</ce:section-title><ce:para id="p2055">Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with an overall prevalence of 0.5% in the adult population of the UK. The prevalence rises with age, affecting 1% of those aged 60–64 years, increasing to 9% of those aged over 80 years. It is associated with significant morbidity and a twofold increase in mortality. This is mainly because of its association with underlying heart disease but also because of its association with systemic embolism and stroke.</ce:para><ce:section id="s0740"><ce:section-title id="st0695">Pathogenesis</ce:section-title><ce:para id="p2060">AF is a complex arrhythmia characterised by both abnormal automatic firing and the presence of multiple interacting re-entry circuits looping around the atria. Episodes of AF are initiated by rapid bursts of ectopic beats arising from conducting tissue in the pulmonary veins or from diseased atrial tissue. It becomes sustained because of re-entrant conduction within the atria or sometimes because of continuous ectopic firing (<ce:cross-ref id="crf0740" refid="f0230">Fig. 16.36</ce:cross-ref><ce:float-anchor refid="f0230"/>). Re-entry is more likely to occur in atria that are enlarged or in which conduction is slow, as is the case in many forms of heart disease. During episodes of AF, the atria beat rapidly but in an uncoordinated and ineffective manner. The ventricles are activated irregularly at a rate determined by conduction through the AV node. This produces the characteristic ‘irregularly irregular’ pulse. The ECG (<ce:cross-ref id="crf0745" refid="f0235">Fig. 16.37</ce:cross-ref><ce:float-anchor refid="f0235"/>) shows normal but irregular QRS complexes; there are no P waves but the baseline may show irregular fibrillation waves. Commonly, AF is classified as paroxysmal (intermittent episodes that self-terminate within 7 days), persistent (prolonged episodes that can be terminated by electrical or pharmacological cardioversion) or permanent. It can be difficult to identify what type of AF patients have at first presentation but this usually becomes clearer as time progresses. Unfortunately for many patients, paroxysmal AF becomes permanent as the underlying disease process progresses. This is partly because of electrophysiological changes that occur in the atria within a few hours of the onset of AF and which tend to maintain fibrillation: a process called electrical remodelling. When AF persists for a period of months, structural remodelling also occurs, leading to atrial fibrosis and dilatation that predispose to chronicity of the AF. Early treatment of AF can sometimes prevent the arrhythmia from becoming persistent.</ce:para><ce:para id="p2065">Many forms of heart disease can present with AF (<ce:cross-ref id="crf0750" refid="b0140">Box 16.21</ce:cross-ref><ce:float-anchor refid="b0140"/>), particularly those that are associated with enlargement or dilatation of the atria. Alcohol excess, hyperthyroidism and chronic lung disease are also common causes of AF, although multiple predisposing factors may coexist, such as the combination of alcohol, hypertension and coronary artery disease. About 50% of all patients with paroxysmal AF and 20% of patients with persistent or permanent AF have structurally normal hearts; this is known as ‘lone atrial fibrillation’.</ce:para></ce:section><ce:section id="s0745"><ce:section-title id="st0700">Clinical features</ce:section-title><ce:para id="p2135">The typical presentation is with palpitation, breathlessness and fatigue. In patients with poor ventricular function or valve disease, AF may precipitate or aggravate cardiac failure because of loss of atrial function and heart rate control. A fall in BP may cause lightheadedness, and chest pain may occur with underlying coronary artery disease. In older patients, AF may not be associated with a rapid ventricular rate and may be asymptomatic, only to be discovered as a result of a routine examination or an ECG. Asymptomatic AF may also present with systemic embolism and is a major cause of stroke in the elderly.</ce:para></ce:section><ce:section id="s0750"><ce:section-title id="st0705">Investigations</ce:section-title><ce:para id="p2140">Assessment of patients with newly diagnosed AF should include a full history, physical examination, a 12-lead ECG, echocardiogram and thyroid function tests to exclude thyrotoxicosis. This is an unusual but potentially treatable cause of AF. Additional investigations may be needed to determine the nature and extent of any underlying heart disease. In particular echocardiographic assessment is useful to identify any structural heart disease, particularly mitral valve disease.</ce:para></ce:section><ce:section id="s0755"><ce:section-title id="st0710">Management</ce:section-title><ce:para id="p2145">Management depends on whether the AF is transient or persistent and whether there is a clear precipitating factor. When AF complicates an acute illness such as a chest infection or pulmonary embolism, treatment of the underlying disorder will often restore sinus rhythm. Where AF does not resolve, the main objectives are to control heart rate during periods of AF, restore sinus rhythm, prevent recurrence of AF and reduce the risk of thromboembolism. Management of paroxysmal and persistent AF is discussed below.</ce:para><ce:section id="s0760"><ce:section-title id="st0715">Paroxysmal atrial fibrillation</ce:section-title><ce:para id="p2150">Occasional attacks of AF that are well tolerated do not necessarily require treatment. Beta-blockers are normally used as first-line therapy if symptoms are troublesome, since they reduce the ectopic firing that normally initiates the arrhythmia. They are particularly useful for treating patients with AF associated with coronary artery disease, hypertension and cardiac failure. Class Ic drugs (see <ce:cross-ref id="crf0755" refid="b0185">Box 16.30</ce:cross-ref>), such as propafenone or flecainide, are also effective at preventing episodes but should not be given to patients with coronary artery disease or left ventricular dysfunction. Flecainide is seldom used alone, since it can precipitate atrial flutter, and is usually prescribed with a rate-limiting β-blocker. Class III drugs can also be used; amiodarone is the most effective agent for preventing AF but side-effects restrict its use to when other measures fail. Dronedarone is an effective alternative but is contraindicated in patients with heart failure or significant left ventricular impairment. Digoxin and verapamil are not effective for the prevention of AF but can help with rate control by slowing conduction through the AV node. Catheter ablation can be considered where anti-arrhythmic drug therapy is ineffective or causes side-effects. Ablation can disconnect the pulmonary veins from the LA electrically, preventing ectopic triggering of AF. In addition, lines of conduction block can be created within the atria to prevent re-entry. Ablation prevents AF in approximately 75% of patients with prior drug-resistant episodes, although a repeat procedure is sometimes required before this is achieved. Ablation for AF is an attractive treatment when drugs are ineffective or poorly tolerated but may be complicated by cardiac tamponade, stroke, phrenic nerve injury and, rarely, pulmonary vein stenosis.</ce:para></ce:section><ce:section id="s0765"><ce:section-title id="st0720">Persistent atrial fibrillation</ce:section-title><ce:para id="p2155">There are two options for treating persistent AF. One is to attempt to restore and maintain sinus rhythm and the second is to accept the presence of AF and to try to control the ventricular rate. With both options prophylaxis against thromboembolism is required on either a short-term or long-term basis.</ce:para><ce:section id="s0770"><ce:section-title id="st0725">Rhythm control</ce:section-title><ce:para id="p2160">An attempt to restore sinus rhythm is particularly appropriate if the arrhythmia causes troublesome symptoms and if there is a modifiable or treatable underlying cause. Electrical DC cardioversion (<ce:cross-ref id="crf9380" refid="s1085">p. 482</ce:cross-ref>) or pharmacological cardioversion may be used. Cardioversion is initially successful in most patients but relapse is frequent (25–50% at 1 month and 70–90% at 1 year). Attempts to restore and maintain sinus rhythm are most successful if AF has been present for less than 3 months, the patient is young and there is no important structural heart disease.</ce:para><ce:para id="p2165">Immediate cardioversion is appropriate if AF has been present for less than 48 hours. In stable patients with no history of structural heart disease, intravenous flecainide (2 mg/kg over 30 mins, maximum dose 150 mg) can be used for pharmacological cardioversion and will restore sinus rhythm in 75% of patients within 8 hours. In patients with structural or ischaemic heart disease, intravenous amiodarone can be given through a central venous catheter. Cardioversion is an alternative treatment and is often effective when drugs fail. If AF has been present for 48 hours or longer, or if there is doubt about its duration, cardioversion should be deferred until the patient has been established on effective oral anticoagulation for a minimum of 4 weeks and any underlying problems, such as hypertension or alcohol excess, have been corrected. Consideration should be given to prophylactic treatment with amiodarone to reduce the risk of recurrence. Catheter ablation is sometimes used to restore and maintain sinus rhythm in resistant cases but is a less effective treatment than for paroxysmal AF.</ce:para><ce:para id="p2170"><ce:float-anchor refid="b0145"/></ce:para></ce:section><ce:section id="s0775"><ce:section-title id="st0730">Rate control</ce:section-title><ce:para id="p2220">If sinus rhythm cannot be restored, treatment should be directed at maintaining an appropriate heart rate. Digoxin, β-blockers and rate-limiting calcium antagonists, such as verapamil or diltiazem (<ce:cross-ref id="crf9385" refid="s0910">p. 479</ce:cross-ref>), reduce the ventricular rate by slowing AV conduction. This alone may produce a striking improvement in cardiac function, particularly in patients with mitral stenosis. Beta-blockers and rate-limiting calcium antagonists are more effective than digoxin at controlling the heart rate during exercise and have additional benefits in patients with hypertension or structural heart disease. Combination therapy with digoxin and a β-blocker can help with rate control but calcium channel antagonists should not be used with β-blockers because of the risk of bradycardia.</ce:para><ce:para id="p2225">In exceptional cases, poorly controlled and symptomatic AF can be treated by implanting a permanent pacemaker and then deliberately inducing complete AV nodal block with catheter ablation. This is known as the ‘pace and ablate’ strategy.</ce:para></ce:section><ce:section id="s0780"><ce:section-title id="st0735">Thromboprophylaxis</ce:section-title><ce:para id="p2230">Loss of atrial contraction and left atrial dilatation cause stasis of blood in the LA and may lead to thrombus formation in the left atrial appendage. This predisposes patients to stroke and other forms of systemic embolism. Patients undergoing cardioversion to restore sinus rhythm require temporary anticoagulation to reduce the risk of systemic embolus. This can be achieved with warfarin, aiming for an international normalised ratio (INR) target of 2.0–3.0. Increasingly, direct-acting oral anticoagulant drugs (see below) are used as an alternative. Anticoagulation should be started for at least 4 weeks before cardioversion and should be maintained for at least 3 months following successful cardioversion.</ce:para><ce:para id="p2235">In patients with chronic AF, the annual risk of stroke is influenced by many factors and a decision has to be made in which the risk of stroke is balanced against the risk of bleeding with anticoagulation. Patients with AF secondary to mitral valve disease should always be anticoagulated because the risk is so high. In other patients, clinical scoring systems can be used to assess the risk of stroke and bleeding. The risk of stroke is usually assessed by the CHA<ce:inf loc="post">2</ce:inf>DS<ce:inf loc="post">2</ce:inf>-VASc score (<ce:cross-ref id="crf0760" refid="b0150">Box 16.23</ce:cross-ref><ce:float-anchor refid="b0150"/>), whereas the HAS-BLED score can be used to estimate the bleeding risk (<ce:cross-ref id="crf0765" refid="b0155">Box 16.24</ce:cross-ref><ce:float-anchor refid="b0155"/>). Patients with a HAS-BLED score of 3 or more points may require more careful monitoring if anticoagulated.</ce:para><ce:para id="p2250">In patients with intermittent AF, stroke risk is similar to that in patients with persistent AF when adjusted for CHA<ce:inf loc="post">2</ce:inf>DS<ce:inf loc="post">2</ce:inf>-VASc score. The risk of embolism is only weakly related to the frequency and duration of AF episodes, so stroke prevention guidelines do not distinguish between those with paroxysmal, persistent and permanent AF.</ce:para><ce:para id="p2255">Several agents can be used to reduce stroke risk in AF. Warfarin therapy adjusted to a target INR of 2.0–3.0 reduces the risk of stroke by about two-thirds at the cost of an annual risk of bleeding of 1–1.5% and is indicated for patients with a CHA<ce:inf loc="post">2</ce:inf>D<ce:inf loc="post">S</ce:inf>-VASc score of 2 or more, unless there are coexisting clinical risk factors that increase the risk of bleeding. These include peptic ulcer, uncontrolled hypertension, alcohol misuse, frequent falls, poor adherence and the use of other drugs that might interact with warfarin. If bleeding does occur in warfarin-treated patients, anticoagulation can be reversed by administering vitamin K or clotting factors.</ce:para><ce:para id="p2260">The factor Xa inhibitors rivaroxaban, apixaban and edoxaban, and the direct thrombin inhibitor dabigatran (collectively referred to as directly acting oral anticoagulants, or DOACs), can be used as an alternative. They are at least as effective as warfarin at preventing thrombotic stroke and are associated with a lower risk of intracranial haemorrhage. Other advantages include the lack of requirement for monitoring and the fact that they have fewer drug interactions. Agents that reverse the effects of DOACs have been developed. These include idarucizumab, which binds to dabigatran and allows acute bleeding complications to be managed more effectively.</ce:para><ce:para id="p2265">Aspirin should not be used since it has little or no effect on embolic stroke and is associated with significant bleeding risk.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0785"><ce:section-title id="st0740">Supraventricular tachycardia</ce:section-title><ce:para id="p2270">The term supraventricular tachycardia (SVT) describes the occurrence of a group of regular tachycardias that have a similar appearance on ECG. These are usually narrow-complex tachycardias and are characterised by a re-entry circuit or automatic focus involving the atria. The three principal types are atrioventricular nodal re-entrant tachycardia (AVNRT), atrioventricular re-entrant tachycardia (AVRT) and atrial tachycardia. The term SVT is technically incorrect as, in many cases, the ventricles also form part of the re-entry circuit.</ce:para></ce:section><ce:section id="s0790"><ce:section-title id="st0745">Atrioventricular nodal re-entrant tachycardia</ce:section-title><ce:para id="p2275">AVNRT is a type of SVT caused by re-entry in a circuit involving the AV node and its two right atrial input pathways: a superior ‘fast’ pathway and an inferior ‘slow’ pathway (see <ce:cross-ref id="crf0770" refid="f0245">Fig. 16.39A</ce:cross-ref> below). This produces a regular tachycardia with a rate of 120–240/min. It tends to occur in the absence of structural heart disease and episodes may last from a few seconds to many hours. The patient is usually aware of a rapid, very forceful, regular heart beat and may experience chest discomfort, lightheadedness or breathlessness. Polyuria, mainly due to the release of ANP, is sometimes a feature. The ECG (<ce:cross-ref id="crf0775" refid="f0240">Fig. 16.38</ce:cross-ref><ce:float-anchor refid="f0240"/>) usually shows a tachycardia with normal QRS complexes but occasionally there may be rate-dependent bundle branch block.</ce:para><ce:section id="s0795"><ce:section-title id="st0750">Management</ce:section-title><ce:para id="p2280">Treatment is not always necessary. However, an acute episode may be terminated by carotid sinus pressure or by the Valsalva manœuvre. Adenosine (3–12 mg rapidly IV in incremental doses until tachycardia stops) or verapamil (5 mg IV over 1 min) will restore sinus rhythm in most cases. Intravenous β-blocker or flecainide can also be used. In rare cases, when there is severe haemodynamic compromise, the tachycardia should be terminated by DC cardioversion (<ce:cross-ref id="crf9390" refid="s1085">p. 482</ce:cross-ref>).</ce:para><ce:para id="p2285">In patients with recurrent SVT, catheter ablation (<ce:cross-ref id="crf9395" refid="s1135">p. 484</ce:cross-ref>) is the most effective therapy and will permanently prevent SVT in more than 90% of cases. Alternatively, prophylaxis with oral β-blocker, verapamil or flecainide may be used but commits predominantly young patients to long-term drug therapy and can create difficulty in female patients, as these drugs are normally avoided during pregnancy.</ce:para></ce:section></ce:section><ce:section id="s0800"><ce:section-title id="st0755">Atrioventricular re-entrant tachycardia</ce:section-title><ce:para id="p2290">In this condition there is an abnormal band of conducting tissue that connects the atria and ventricles. This so-called accessory pathway comprises rapidly conducting fibres that resemble Purkinje tissue, in that they conduct very rapidly and are rich in sodium channels. In about 50% of cases, this pathway conducts only in the retrograde direction (from ventricles to atria) and thus does not alter the appearance of the ECG in sinus rhythm. This is known as a concealed accessory pathway. In the rest, the pathway also conducts in an antegrade direction (from atria to ventricles), so AV conduction in sinus rhythm is mediated via both the AV node and the accessory pathway, distorting the QRS complex. Premature ventricular activation via the pathway shortens the PR interval and produces a ‘slurred’ initial deflection of the QRS complex, called a delta wave (<ce:cross-ref id="crf0780" refid="f0245">Fig. 16.39B</ce:cross-ref><ce:float-anchor refid="f0245"/>). This is known as a manifest accessory pathway. As the AV node and accessory pathway have different conduction speeds and refractory periods, a re-entry circuit can develop, causing tachycardia (<ce:cross-ref id="crf0785" refid="f0245">Fig. 16.39C</ce:cross-ref>); when associated with symptoms, the condition is known as Wolff–Parkinson–White syndrome. The ECG during this tachycardia is almost indistinguishable from that of AVNRT (<ce:cross-ref id="crf0790" refid="f0245">Fig. 16.39A</ce:cross-ref>).</ce:para><ce:section id="s0805"><ce:section-title id="st0760">Management</ce:section-title><ce:para id="p2295">Carotid sinus pressure or intravenous adenosine can terminate the tachycardia. If AF occurs, it may produce a dangerously rapid ventricular rate because the accessory pathway lacks the rate-limiting properties of the AV node (<ce:cross-ref id="crf0795" refid="f0245">Fig. 16.39D</ce:cross-ref>). This is known as pre-excited atrial fibrillation and may cause collapse, syncope and even death. It should be treated as an emergency, usually with DC cardioversion.</ce:para><ce:para id="p2300">Catheter ablation is first-line treatment in symptomatic patients and is nearly always curative. Alternatively, prophylactic anti-arrhythmic drugs, such as flecainide or propafenone (<ce:cross-ref id="crf9400" refid="p2850">p. 481</ce:cross-ref>), can be used to slow conduction in, and prolong the refractory period of, the accessory pathway. Long-term drug therapy is not the preferred treatment for most patients and amiodarone should not be used, as its side-effect profile cannot be justified and ablation is safer and more effective. Digoxin and verapamil shorten the refractory period of the accessory pathway and should not be used.</ce:para></ce:section></ce:section><ce:section id="s0810"><ce:section-title id="st0765">Ventricular premature beats</ce:section-title><ce:para id="p2305">Ventricular premature beats (VPBs) are frequently found in healthy people and their prevalence increases with age. Ectopic beats in patients with otherwise normal hearts are more prominent at rest and disappear with exercise. Sometimes VPBs are a manifestation of subclinical coronary artery disease or cardiomyopathy but also may occur in patients with established heart disease following an MI. Most patients with VPBs are asymptomatic but some present with an irregular heart beat, missed beats or abnormally strong beats, due to increased cardiac output of the post-ectopic sinus beat. On examination the pulse is irregular, with weak or missed beats as a result of the fact that the stroke volume is low because left ventricular contraction occurs before filling is complete (<ce:cross-ref id="crf0800" refid="f0250">Fig. 16.40</ce:cross-ref><ce:float-anchor refid="f0250"/>). The ECG shows broad and bizarre complexes because the ventricles are activated sequentially rather than simultaneously. The complexes may be unifocal (identical beats arising from a single ectopic focus) or multifocal (varying morphology with multiple foci, <ce:cross-ref id="crf0805" refid="f0250">Fig. 16.40</ce:cross-ref>). ‘Couplet’ and ‘triplet’ are the terms used to describe two or three successive ectopic beats. A run of alternating sinus and ventricular ectopic beats is known as ventricular ‘bigeminy’. The significance depends on the presence or absence of underlying heart disease.</ce:para><ce:section id="s0815"><ce:section-title id="st0770">Management</ce:section-title><ce:para id="p2310">Treatment may not be necessary, unless the patient is highly symptomatic, in which case β-blockers or, in some situations, catheter ablation can be used. There is no evidence that anti-arrhythmic therapy improves prognosis but the discovery of very frequent VPBs in a patient not known to have heart disease should prompt further investigations with echocardiography and an exercise ECG to screen for structural heart disease and ischaemic heart disease. It is common for VPBs to occur during the course of an acute MI. Persistent, frequent VPBs (over 10/hr) in patients who have survived the acute phase of MI indicate a poorer long-term outcome. In this situation, anti-arrhythmic drugs do not improve and may even worsen prognosis. The exception is β-blockers, which should be prescribed for other reasons (<ce:cross-ref id="crf9405" refid="s1485">p. 500</ce:cross-ref>). Similarly, heart failure of any cause is associated with VPBs. While they indicate an adverse prognosis, this is not improved by anti-arrhythmic drugs. Effective treatment of the heart failure may suppress the ectopic beats. VPBs are also a feature of digoxin toxicity.</ce:para></ce:section></ce:section><ce:section id="s0820"><ce:section-title id="st0775">Ventricular tachycardia</ce:section-title><ce:para id="p2315">Ventricular tachycardia (VT) occurs most commonly in the settings of acute MI, chronic coronary artery disease and cardiomyopathy. It is associated with extensive ventricular disease, impaired left ventricular function and ventricular aneurysm. In these settings, VT may cause haemodynamic compromise or degenerate into ventricular fibrillation (<ce:cross-ref id="crf9410" refid="s0320">p. 456</ce:cross-ref>). VT is caused by abnormal automaticity or triggered activity in ischaemic tissue, or by re-entry within scarred ventricular tissue. Patients may complain of palpitation or symptoms of low cardiac output, including dyspnoea, lightheadedness and syncope. The ECG shows tachycardia and broad, abnormal QRS complexes with a rate of more than 120/min (<ce:cross-ref id="crf0810" refid="f0255">Fig. 16.41</ce:cross-ref><ce:float-anchor refid="f0255"/>). It may be difficult to distinguish VT from SVT with bundle branch block or pre-excitation (WPW syndrome) on ECG but features in favour of VT are listed in <ce:cross-ref id="crf0815" refid="b0160">Box 16.25</ce:cross-ref><ce:float-anchor refid="b0160"/>. A 12-lead ECG (<ce:cross-ref id="crf0825" refid="f0260">Fig. 16.42</ce:cross-ref><ce:float-anchor refid="f0260"/>) or electrophysiology study (<ce:cross-ref id="crf9415" refid="p0805">p. 454</ce:cross-ref>) may help establish the diagnosis. When there is doubt, it is safer to manage the problem as VT.</ce:para><ce:para id="p2355">Patients recovering from MI sometimes have periods of idioventricular rhythm (‘slow’ VT) at a rate only slightly above the preceding sinus rate and below 120/min. These episodes often reflect reperfusion of the infarct territory and may be a good sign. They are usually self-limiting and asymptomatic, and do not require treatment. Other forms of sustained VT require treatment, often as an emergency.</ce:para><ce:para id="p2360">Occasionally, VT occurs in patients with otherwise healthy hearts (‘normal heart VT’), usually because of abnormal automaticity in the right ventricular outflow tract or one of the fascicles of the left bundle branch.</ce:para><ce:section id="s0825"><ce:section-title id="st0780">Management</ce:section-title><ce:para id="p2365">Prompt action to restore sinus rhythm is required and should usually be followed by prophylactic therapy. Synchronised DC cardioversion is the treatment of choice if systolic BP is less than 90 mmHg. If the arrhythmia is well tolerated, intravenous amiodarone may be given as a bolus, followed by a continuous infusion (<ce:cross-ref id="crf9420" refid="p2850">p. 481</ce:cross-ref>). Intravenous lidocaine can be used but may depress left ventricular function, causing hypotension or acute heart failure. Hypokalaemia, hypomagnesaemia, acidosis and hypoxia should be corrected if present.</ce:para><ce:para id="p2370">Beta-blockers are effective at preventing VT by reducing ventricular automaticity. Amiodarone can be added if additional control is needed. Class Ic anti-arrhythmic drugs should not be used for prevention of VT in patients with coronary artery disease or heart failure because they depress myocardial function and can increase the likelihood of a dangerous arrhythmia. In patients with poor left ventricular function or where VT is associated with haemodynamic compromise, the use of an implantable cardiac defibrillator is recommended (<ce:cross-ref id="crf9425" refid="s1115">p. 483</ce:cross-ref>). Rarely, surgery with resection of a ventricular aneurysm or catheter ablation can be used to interrupt the arrhythmia focus or circuit in patients with VT associated with a myocardial infarct scar. The treatment of choice for VT occurring in a normal heart is catheter ablation, which often can be curative.</ce:para></ce:section></ce:section><ce:section id="s0830"><ce:section-title id="st0785">Torsades de pointes</ce:section-title><ce:para id="p2375">This form of polymorphic VT is a complication of prolonged ventricular repolarisation (prolonged QT interval). The ECG shows rapid irregular complexes that seem to twist around the baseline as the mean QRS axis changes (<ce:cross-ref id="crf0830" refid="f0265">Fig. 16.43</ce:cross-ref><ce:float-anchor refid="f0265"/>). The arrhythmia is usually non-sustained and repetitive, but may degenerate into ventricular fibrillation. During periods of sinus rhythm, the ECG will usually show a prolonged QT interval (&#x003E; 0.44 sec in men, &#x003E; 0.46 sec in women when corrected to a heart rate of 60/min).</ce:para><ce:para id="p2380">Some of the common causes are listed in <ce:cross-ref id="crf0835" refid="b0165">Box 16.26</ce:cross-ref><ce:float-anchor refid="b0165"/>. The arrhythmia is more common in women and is often triggered by a combination of factors, such as administration of QT-prolonging medications and hypokalaemia. The congenital long QT syndromes are a family of genetic disorders that are characterised by mutations in genes that code for cardiac sodium or potassium channels. Long QT syndrome subtypes have different triggers, which are important when counselling patients. Adrenergic stimulation through vigorous exercise is a common trigger in long QT type 1, and a sudden noise may trigger arrhythmias in long QT type 2. Arrhythmias are more common during sleep in type 3.</ce:para><ce:section id="s0855"><ce:section-title id="st0810">Management</ce:section-title><ce:para id="p2470">Intravenous magnesium (8 mmol over 15 mins, then 72 mmol over 24 hrs) should be given in all cases. If this is ineffective, atrial pacing should be tried, since it can suppress the arrhythmia through rate-dependent shortening of the QT interval. Intravenous isoprenaline is a reasonable alternative to pacing but should be avoided in patients with the congenital long QT syndromes. Once initial control has been achieved, efforts should be made to identify and treat the underlying cause or stop medications that predispose to the arrhythmia. If the underlying cause cannot be corrected or the arrhythmia is the result of an inherited syndrome, then long-term pharmacological therapy may be necessary. Beta-blockers are effective at preventing syncope in patients with congenital long QT syndrome. Some patients, particularly those with extreme QT interval prolongation (&#x003E; 500 msecs) or certain high-risk genotypes, should be considered for an implantable defibrillator. Left stellate ganglion block may be of value in patients with resistant arrhythmias.</ce:para><ce:para id="p2475">Brugada syndrome is a related genetic disorder that may present with polymorphic VT or sudden death. It is characterised by a defect in sodium channel function and an abnormal ECG (right bundle branch block and ST elevation in V<ce:inf loc="post">1</ce:inf> and V<ce:inf loc="post">2</ce:inf> but not usually prolongation of the QT interval). The only known effective treatment is an implantable defibrillator.</ce:para></ce:section></ce:section><ce:section id="s0860"><ce:section-title id="st0815">Atrioventricular block</ce:section-title><ce:para id="p2480">This usually occurs as the result of disease affecting the AV node. AV block can be intermittent, however, and may become evident only when the conducting tissue is stressed by a rapid atrial rate. Reflecting this fact, atrial tachyarrhythmias are often associated with AV block (see <ce:cross-ref id="crf0845" refid="f0235">Fig. 16.37</ce:cross-ref>). Episodes of ventricular asystole may also complicate complete heart block or Mobitz type II second-degree AV block. Several types of AV block are recognised.</ce:para><ce:section id="s0865"><ce:section id="s0870"><ce:section-title id="st0820">First-degree atrioventricular block</ce:section-title><ce:para id="p2485">In this condition, AV conduction is delayed and so the PR interval is prolonged (&#x003E; 0.20 sec; <ce:cross-ref id="crf0850" refid="f0270">Fig. 16.44</ce:cross-ref><ce:float-anchor refid="f0270"/>). It rarely causes symptoms and does not usually require treatment.</ce:para></ce:section><ce:section id="s0875"><ce:section-title id="st0825">Second-degree atrioventricular block</ce:section-title><ce:para id="p2490">Here dropped beats occur because some impulses from the atria fail to conduct to the ventricles. Two subtypes are recognised. In Mobitz type I second-degree AV block (<ce:cross-ref id="crf0855" refid="f0275">Fig. 16.45</ce:cross-ref><ce:float-anchor refid="f0275"/>), there is progressive lengthening of successive PR intervals, culminating in a dropped beat. The cycle then repeats itself. This is known as the Wenckebach phenomenon and is usually due to impaired conduction in the AV node itself. The phenomenon may be physiological and is sometimes observed at rest or during sleep in athletic young adults with high vagal tone.</ce:para><ce:para id="p2495">In Mobitz type II second-degree AV block (<ce:cross-ref id="crf0860" refid="f0280">Fig. 16.46</ce:cross-ref><ce:float-anchor refid="f0280"/>), the PR interval of the conducted impulses remains constant but some P waves are not conducted. This is usually caused by disease of the His–Purkinje system and carries a risk of asystole.</ce:para><ce:para id="p2500">In 2 : 1 AV block (<ce:cross-ref id="crf0865" refid="f0285">Fig. 16.47</ce:cross-ref><ce:float-anchor refid="f0285"/>), alternate P waves are conducted, so it is impossible to distinguish between Mobitz type I and type II block.</ce:para></ce:section><ce:section id="s0880"><ce:section-title id="st0830">Third-degree atrioventricular block</ce:section-title><ce:para id="p2505">In third-degree AV block, conduction fails completely and the atria and ventricles beat independently. This is known as AV dissociation, as shown in <ce:cross-ref id="crf0870" refid="f0290">Fig. 16.48</ce:cross-ref><ce:float-anchor refid="f0290"/>. Ventricular activity is maintained by an escape rhythm arising in the AV node or bundle of His (narrow QRS complexes) or the distal Purkinje tissues (broad QRS complexes). Distal escape rhythms tend to be slower and less reliable. Complete AV block (<ce:cross-ref id="crf0875" refid="b0170">Box 16.27</ce:cross-ref><ce:float-anchor refid="b0170"/>) produces a slow (25–50/min), regular pulse that does not vary with exercise, except in the case of congenital complete AV block. There is usually a compensatory increase in stroke volume, producing a large-volume pulse. Cannon waves may be visible in the neck and the intensity of the first heart sound varies due to the loss of AV synchrony.</ce:para></ce:section></ce:section><ce:section id="s0895"><ce:section-title id="st0840">Clinical features</ce:section-title><ce:para id="p2575">The typical presentation is with recurrent syncope or ‘Stokes–Adams’ attacks. These episodes are characterised by sudden loss of consciousness that occurs without warning and results in collapse. A brief anoxic seizure (due to cerebral ischaemia) may occur if there is prolonged asystole. There is pallor and a death-like appearance during the attack, but when the heart starts beating again there is a characteristic flush. In distinction to epilepsy, recovery is rapid. Sinoatrial disease and neurocardiogenic syncope (<ce:intra-ref id="ii0380" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0115">p. 181</ce:intra-ref>) may cause similar symptoms.</ce:para></ce:section><ce:section id="s0900"><ce:section-title id="st0845">Management</ce:section-title><ce:para id="p2580">This depends on the clinical circumstances. Acute inferior MI is often complicated by transient AV block because the right coronary artery (RCA) supplies the AV node. There is usually a reliable escape rhythm and, if the patient remains well, no treatment is required. Symptomatic second- or third-degree AV block may respond to atropine (0.6 mg IV, repeated as necessary) or, if this fails, a temporary pacemaker. In most cases, the AV block will resolve within 7–10 days.</ce:para><ce:para id="p2585">Second- or third-degree AV heart block complicating acute anterior MI indicates extensive ventricular damage involving both bundle branches and carries a poor prognosis. Asystole may ensue and a temporary pacemaker should be inserted promptly. If the patient presents with asystole, intravenous atropine (3 mg) or intravenous isoprenaline (2 mg in 500 mL 5% dextrose, infused at 10–60 mL/hr) may help to maintain the circulation until a temporary pacing electrode can be inserted. Temporary pacing can provide effective rhythm support in the short term.</ce:para><ce:para id="p2590">Patients with symptomatic bradyarrhythmias associated with AV block should be treated with a permanent pacemaker. Asymptomatic first-degree or Mobitz type I second-degree AV block (Wenckebach phenomenon) does not require treatment but may be an indication of underlying heart disease. A permanent pacemaker is usually indicated in patients with asymptomatic Mobitz type II second-degree AV block or third-degree AV heart block because of the risk of asystole and sudden death. Pacing improves prognosis.</ce:para></ce:section></ce:section><ce:section id="s0905"><ce:section-title id="st0850">Bundle branch block</ce:section-title><ce:para id="p2595">Damage to the right or left bundle branch of the conducting system can occur as a result of many pathologies, including ischaemic heart disease, hypertensive heart disease and cardiomyopathy. However, right bundle branch block (RBBB) can occur as a normal variant in healthy individuals (<ce:cross-ref id="crf0880" refid="b0175">Box 16.28</ce:cross-ref><ce:float-anchor refid="b0175"/>). In left bundle branch block (LBBB) and RBBB, depolarisation proceeds through a slow myocardial route in the affected ventricle rather than through the rapidly conducting Purkinje tissues that constitute the bundle branches. This causes delayed conduction into the LV or RV, broadens the QRS complex (≥ 0.12 sec) and produces characteristic alterations in QRS morphology (<ce:cross-ref id="crf0885" refid="f0295">Figs 16.49</ce:cross-ref><ce:float-anchor refid="f0295"/> and <ce:cross-ref id="crf0890" refid="f0300">16.50</ce:cross-ref><ce:float-anchor refid="f0300"/>). Damage to the left bundle can also occur after it divides into anterior and posterior fascicles, when it is called hemiblock. In this case, the QRS complex is not broadened but the direction of ventricular depolarisation is changed, causing left axis deviation in left anterior hemiblock and right axis deviation in left posterior hemiblock (see <ce:cross-ref id="crf0895" refid="f0065">Fig. 16.7</ce:cross-ref>, <ce:cross-ref id="crf9430" refid="s0100">p. 449</ce:cross-ref>). The combination of RBBB and left anterior or posterior hemiblock is known as bifascicular block. LBBB usually signifies important underlying heart disease and also causes ventricular incoordination, which may aggravate symptoms in patients with heart failure. This can be treated in selected patients by cardiac resynchronisation therapy (<ce:cross-ref id="crf9435" refid="s1135">p. 484</ce:cross-ref>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0910"><ce:section-title id="st0855">Principles of management of cardiac arrhythmias</ce:section-title><ce:para id="p2645">Cardiac arrhythmias can be managed with either anti-arrhythmic drug therapy or external devices that depolarise the heart by passing an electric current through it. These strategies are relevant across a range of indications and are discussed in more detail here.</ce:para><ce:section id="s0915"><ce:section-title id="st0860">Anti-arrhythmic drugs</ce:section-title><ce:para id="p2650">Traditionally, the Vaughan Williams system has been used to categorise anti-arrhythmic drugs based on their effects on the action potential. More recently, increased understanding of the mechanisms of action has allowed further subclassification, based on the cardiac ion channels and receptors on which they act (<ce:cross-ref id="crf0900" refid="b0180">Box 16.29</ce:cross-ref><ce:float-anchor refid="b0180"/> and <ce:cross-ref id="crf0910" refid="f0305">Fig. 16.51</ce:cross-ref><ce:float-anchor refid="f0305"/>). The individual agents, dosages and most common side-effects are summarised in <ce:cross-ref id="crf0915" refid="b0185">Box 16.30</ce:cross-ref><ce:float-anchor refid="b0185"/> and the general principles of use are summarised in <ce:cross-ref id="crf0920" refid="b0190">Box 16.31</ce:cross-ref><ce:float-anchor refid="b0190"/>.</ce:para><ce:section id="s0955"><ce:section-title id="st0900">Class I drugs</ce:section-title><ce:para id="p2795">Class I drugs act principally by suppressing excitability and slowing conduction in atrial or ventricular muscle. They block sodium channels, of which there are several types in cardiac tissue. These drugs should generally be avoided in patients with heart failure because they depress myocardial function, and class Ia and Ic drugs are often pro-arrhythmic.</ce:para><ce:section id="s0960"><ce:section-title id="st0905">Class Ia drugs</ce:section-title><ce:para id="p2800">These prolong cardiac action potential duration and increase the tissue refractory period. They are used to prevent both atrial and ventricular arrhythmias.</ce:para><ce:section id="s0965"><ce:section-title id="st0910">Disopyramide</ce:section-title><ce:para id="p2805">This is an effective drug but causes anticholinergic side-effects, such as urinary retention, and can precipitate glaucoma. It can depress myocardial function and should be avoided in cardiac failure.</ce:para></ce:section><ce:section id="s0970"><ce:section-title id="st0915">Quinidine</ce:section-title><ce:para id="p2810">Now rarely used, quinidine increases mortality and causes gastrointestinal upset.</ce:para></ce:section></ce:section><ce:section id="s0975"><ce:section-title id="st0920">Class Ib drugs</ce:section-title><ce:para id="p2815">These shorten the action potential and tissue refractory period. They act on channels found predominantly in ventricular myocardium and so are used to treat or prevent VT and VF.</ce:para><ce:section id="s0980"><ce:section-title id="st0925">Lidocaine</ce:section-title><ce:para id="p2820">This must be given intravenously and has a very short plasma half-life.</ce:para></ce:section><ce:section id="s0985"><ce:section-title id="st0930">Mexiletine</ce:section-title><ce:para id="p2825">This can be given intravenously or orally but has many side-effects.</ce:para></ce:section></ce:section><ce:section id="s0990"><ce:section-title id="st0935">Class Ic drugs</ce:section-title><ce:para id="p2830">These affect the slope of the action potential without altering its duration or refractory period. They are used mainly for prophylaxis of AF but are effective in prophylaxis and treatment of supraventricular or ventricular arrhythmias. They are useful for WPW syndrome because they block conduction in accessory pathways. They should not be used in patients with previous MI because they increase the risk of arrhythmia in this setting.</ce:para><ce:section id="s0995"><ce:section-title id="st0940">Flecainide</ce:section-title><ce:para id="p2835">This is effective for prevention of AF, and an intravenous infusion may be used for pharmacological cardioversion of AF of less than 24 hours' duration. <ce:italic>Since flecainide can cause slow atrial flutter with a paradoxically rapid ventricular rate, it should be prescribed along with an AV node-blocking drug such as a β-blocker to control the ventricular rate.</ce:italic></ce:para></ce:section><ce:section id="s1000"><ce:section-title id="st0945">Propafenone</ce:section-title><ce:para id="p2840">This also has some β-blocker (class II) properties. Important interactions with digoxin, warfarin and cimetidine have been described.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1005"><ce:section-title id="st0950">Class II drugs</ce:section-title><ce:para id="p2845">This group comprises the β-adrenoceptor antagonists (β-blockers). These agents reduce the rate of SA node depolarisation and cause relative block in the AV node, making them useful for rate control in atrial flutter and AF. They can be used to prevent VT and SVT. They reduce myocardial excitability and the risk of arrhythmic death in patients with coronary artery disease and heart failure.</ce:para><ce:section id="s1010"><ce:section id="s1015"><ce:section-title id="st0955">Non-selective β-blockers</ce:section-title><ce:para id="p2850">These act on both β<ce:inf loc="post">1</ce:inf> and β<ce:inf loc="post">2</ce:inf> receptors. Beta<ce:inf loc="post">2</ce:inf>-blockade causes side-effects, such as bronchospasm and peripheral vasoconstriction. Propranolol is non-selective and is subject to extensive first-pass metabolism in the liver. The effective oral dose is therefore unpredictable and must be titrated after treatment is started with a small dose. Other non-selective drugs include nadolol and carvedilol.</ce:para></ce:section><ce:section id="s1020"><ce:section-title id="st0960">Cardioselective β-blockers</ce:section-title><ce:para id="p2855">These act mainly on myocardial β<ce:inf loc="post">1</ce:inf> receptors and are relatively well tolerated. Bisoprolol and metoprolol are examples of cardioselective β-blockers.</ce:para></ce:section><ce:section id="s1025"><ce:section-title id="st0965">Sotalol</ce:section-title><ce:para id="p2860">This is a racemic mixture of two isomers with non-selective β-blocker (mainly l-sotalol) and class III (mainly d-sotalol) activity. It may cause torsades de pointes.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1030"><ce:section-title id="st0970">Class III drugs</ce:section-title><ce:para id="p2865">Class III drugs act by prolonging the plateau phase of the action potential, thus lengthening the refractory period. These drugs are very effective at preventing atrial and ventricular tachyarrhythmias. They cause QT interval prolongation and can predispose to torsades de pointes and VT, especially in patients with other predisposing risk factors (see <ce:cross-ref id="crf0925" refid="b0165">Box 16.26</ce:cross-ref>). Disopyramide and sotalol have some class III activity but the main drug in this class is amiodarone, as discussed below.</ce:para><ce:section id="s1035"><ce:section id="s1040"><ce:section-title id="st0975">Amiodarone</ce:section-title><ce:para id="p2870">While amiodarone is primarily considered a class III drug, it also has class I, II and IV activity. It is probably the most effective drug currently available for controlling paroxysmal AF. It is also used to prevent episodes of recurrent VT, particularly in patients with poor left ventricular function or those with implantable defibrillators (to prevent unnecessary DC shocks). Amiodarone has a very long tissue half-life (25–110 days). An intravenous or oral loading regime is often used to achieve therapeutic tissue concentrations rapidly. The drug's effects may last for weeks or months after treatment has been stopped. Side-effects are common (up to one-third of patients), numerous and potentially serious. Drug interactions are also common (see <ce:cross-ref id="crf0930" refid="b0185">Box 16.30</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1045"><ce:section-title id="st0980">Dronedarone</ce:section-title><ce:para id="p2875">Dronedarone is related to amiodarone but has a short tissue half-life and fewer side-effects. It has recently been shown to be effective at preventing episodes of atrial flutter and AF. It is contraindicated in patients with permanent AF, or if there is heart failure or left ventricular impairment, because it increases mortality. Regular liver function test monitoring is required.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1050"><ce:section-title id="st0985">Class IV drugs</ce:section-title><ce:para id="p2880">These block the ‘slow calcium channel’, which is important for impulse generation and conduction in atrial and nodal tissue, although it is also present in ventricular muscle. Their main indications are prevention of SVT (by blocking the AV node) and rate control in patients with AF.</ce:para><ce:section id="s1055"><ce:section id="s1060"><ce:section-title id="st0990">Verapamil</ce:section-title><ce:para id="p2885">This is the most widely used drug in this class. Intravenous verapamil may cause profound bradycardia or hypotension, and should not be used in conjunction with β-blockers.</ce:para></ce:section><ce:section id="s1065"><ce:section-title id="st0995">Diltiazem</ce:section-title><ce:para id="p2890">This has similar properties to verapamil.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1070"><ce:section-title id="st1000">Other anti-arrhythmic drugs</ce:section-title><ce:section id="s1075"><ce:section id="s1080"><ce:section-title id="st1005">Atropine sulphate</ce:section-title><ce:para id="p2895">Atropine is a muscarinic receptor antagonist that increases the sinus rate and SA and AV conduction. It is the treatment of choice for severe bradycardia or hypotension due to vagal over-activity. It is used for initial management of symptomatic bradyarrhythmias complicating inferior MI, and in cardiac arrest due to asystole. The usual dose is 0.6 mg IV, repeated if necessary to a maximum of 3 mg. Repeat dosing may be necessary because the drug disappears rapidly from the circulation after parenteral administration. Side-effects are listed in <ce:cross-ref id="crf0935" refid="b0185">Box 16.30</ce:cross-ref>.</ce:para></ce:section><ce:section id="s1085"><ce:section-title id="st1010">Adenosine</ce:section-title><ce:para id="p2900">This works by binding to A1 receptors in conducting tissue, producing a transient AV block lasting a few seconds. It is used to terminate SVTs when the AV node is part of the re-entry circuit, or to help establish the diagnosis in difficult arrhythmias, such as atrial flutter with 2 : 1 AV block (see <ce:cross-ref id="crf0940" refid="f0220">Fig. 16.35</ce:cross-ref>) or broad-complex tachycardia (<ce:cross-ref id="crf0945" refid="b0185">Boxes 16.30</ce:cross-ref> and <ce:cross-ref id="crf0950" refid="b0195">16.32</ce:cross-ref><ce:float-anchor refid="b0195"/>). Adenosine is given as an intravenous bolus, initially 3 mg over 2 secs (see <ce:cross-ref id="crf0955" refid="b0185">Box 16.30</ce:cross-ref>). If there is no response after 1–2 minutes, 6 mg should be given; if necessary, after another 1–2 minutes the maximum dose of 12 mg may be given. Patients should be warned to expect short-lived and sometimes distressing flushing, breathlessness and chest pain. Adenosine can cause bronchospasm and should be avoided in patients with asthma; its effects are greatly potentiated by dipyridamole and inhibited by theophylline and other xanthines.</ce:para></ce:section><ce:section id="s1090"><ce:section-title id="st1015">Digoxin</ce:section-title><ce:para id="p2910">Digoxin is a glycoside purified from the European foxglove, <ce:italic>Digitalis lanata</ce:italic>, which slows conduction and prolongs the refractory period in the AV node. This effect helps to control the ventricular rate in AF and may interrupt SVTs involving the AV node. Digoxin also shortens refractory periods and enhances excitability and conduction in other parts of the heart, including accessory conduction pathways. It may therefore increase atrial and ventricular ectopic activity and can lead to more complex atrial and ventricular tachyarrhythmias. Digoxin is largely excreted by the kidneys, and the maintenance dose (see <ce:cross-ref id="crf0960" refid="b0185">Box 16.30</ce:cross-ref>) should be reduced in children, older people and those with renal impairment. It is widely distributed and has a long tissue half-life (36 hours), so that effects may persist for several days. Measurement of plasma digoxin concentration helps identify digoxin toxicity or under-treatment (<ce:cross-ref id="crf0965" refid="b0200">Box 16.33</ce:cross-ref><ce:float-anchor refid="b0200"/>).</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1095"><ce:section-title id="st1020">Non-pharmacological treatments</ce:section-title><ce:para id="p2965">A variety of non-pharmacological treatments are available for the treatment of arrhythmias. These include the use of electrical devices that work by passing an electric current through the heart, and catheter-based strategies that disrupt abnormal conduction tissues responsible for the generation of arrhythmias.</ce:para><ce:section id="s1100"><ce:section-title id="st1025">Electrical cardioversion</ce:section-title><ce:para id="p2970">Electrical cardioversion, also known as direct current (DC) cardioversion, is useful for terminating an organised rhythm, such as AF or VT. The electric current interrupts the arrhythmia and produces a brief period of asystole, which is usually followed by the resumption of sinus rhythm. Cardioversion is usually carried out as an elective procedure under general anaesthesia. The electric shock is delivered immediately after the R wave because, if it is applied during ventricular repolarisation (on the T wave), it may provoke VF. High-energy shocks may cause chest wall pain post-procedure, so, if there is no urgency, it is appropriate to begin with a lower-amplitude shock of about 50 joules initially, going on to larger shocks if necessary.</ce:para></ce:section><ce:section id="s1105"><ce:section-title id="st1030">Defibrillation</ce:section-title><ce:para id="p2975">Defibrillators deliver a DC, high-energy, short-duration shock via two large electrodes or paddles coated with conducting jelly or a gel pad, positioned over the upper right sternal edge and the apex. Defibrillators are primarily used in the management of cardiac arrest due to VF and deliver an unsynchronised shock, since the precise timing of the discharge is not important in this situation. Modern units deliver a biphasic shock, during which the shock polarity is reversed mid-shock. This reduces the total shock energy required to depolarise the heart. In VF and other emergencies, the energy of the first and second shocks should be 150 joules and thereafter up to 200 joules; there is no need for an anaesthetic, as the patient is unconscious.</ce:para></ce:section><ce:section id="s1110"><ce:section-title id="st1035">Temporary pacemakers</ce:section-title><ce:para id="p2980">Temporary pacing involves delivery of an electrical impulse into the heart to initiate tissue depolarisation and to trigger cardiac contraction. This is achieved by inserting a bipolar pacing electrode through the internal jugular, subclavian or femoral vein and positioning it at the apex of the RV, using fluoroscopic imaging. The electrode is connected to an external pacemaker with an adjustable energy output and pacing rate. The ECG of right ventricular pacing is characterised by regular broad QRS complexes with a left bundle branch block pattern. Each complex is immediately preceded by a ‘pacing spike’ (<ce:cross-ref id="crf0970" refid="f0315">Fig. 16.52</ce:cross-ref><ce:float-anchor refid="f0315"/>). Nearly all pulse generators are used in the ‘demand’ mode, so that the pacemaker will operate only if the heart rate falls below a preset level. Occasionally, temporary atrial or dual-chamber pacing (see below) is used.</ce:para><ce:para id="p2985">Temporary pacing is indicated in the management of transient AV block and other arrhythmias complicating acute MI or cardiac surgery, to maintain the rhythm in other situations of reversible bradycardia (such as metabolic disturbance or drug overdose), or as a bridge to permanent pacing. Complications include pneumothorax, brachial plexus or subclavian artery injury, local infection or sepsis (usually with <ce:italic>Staphylococcus aureus</ce:italic>), and pericarditis. Failure of the system may be due to lead displacement or a progressive increase in the threshold (exit block) caused by tissue oedema. Complication rates increase with time and so a temporary pacing system should ideally not be used for more than 7 days.</ce:para><ce:para id="p2990">Transcutaneous pacing is administered by delivering an electrical stimulus through two large adhesive gel pad electrodes placed over the apex and upper right sternal edge, or over the anterior and posterior chest. It is easy and quick to set up, but causes discomfort because it induces forceful pectoral and intercostal muscle contraction. Modern external cardiac defibrillators often incorporate a transcutaneous pacing system that can be used during an emergency until transvenous pacing is established.</ce:para></ce:section><ce:section id="s1115"><ce:section-title id="st1040">Permanent pacemakers</ce:section-title><ce:para id="p2995">Permanent pacemakers are small, flat, metal devices that are implanted under the skin, usually in the pectoral area. They contain a battery, a pulse generator, and programmable electronics that allow adjustment of pacing and memory functions. Pacing electrodes (leads) can be placed via the subclavian or cephalic veins into the RV (usually at the apex), the right atrial appendage or, to maintain AV synchrony, both.</ce:para><ce:para id="p3000">Permanent pacemakers are controlled using an external programmer through a wireless telemetry system, allowing rate, output, timing and other parameters to be adjusted. This allows the device settings to be tailored to the patient's needs. Aside from their therapeutic role, pacemakers store useful diagnostic data about the patient's heart rate trends and the occurrence of tachyarrhythmias, such as VT.</ce:para><ce:para id="p3005">Single-chamber atrial pacing is indicated in patients with SA disease without AV block and also in patients with continuous AF and bradycardia. Here the pacemaker acts as an external sinus node. Dual-chamber pacing is most often used in patients with second- or third-degree AV block. Here, the atrial electrode is used to detect spontaneous atrial activity and trigger ventricular pacing (<ce:cross-ref id="crf0975" refid="f0315">Fig. 16.52</ce:cross-ref>), thereby preserving AV synchrony and allowing the ventricular rate to increase, together with the sinus node rate, during exercise and other forms of stress. Dual-chamber pacing has many advantages over ventricular pacing, including superior haemodynamics and better effort tolerance; a lower prevalence of atrial arrhythmias in patients with SA disease; and avoidance of ‘pacemaker syndrome’, in which a fall in BP and dizziness occur due to loss of AV synchrony.</ce:para><ce:para id="p3010">A code is used to signify the pacing mode (<ce:cross-ref id="crf0980" refid="b0205">Box 16.34</ce:cross-ref><ce:float-anchor refid="b0205"/>). For example, a system that paces the atrium, senses the atrium and is inhibited if it senses spontaneous activity is designated AAI. Most dual-chamber pacemakers are programmed to a mode termed DDD; in this case, ventricular pacing is triggered by a sensed sinus P wave and inhibited by a sensed spontaneous QRS complex. A fourth letter, ‘R’, is added if the pacemaker has a rate response function. For example, the letters AAIR indicate an atrial demand pacemaker with a rate response function. Rate-responsive pacemakers are used in patients with chronotropic incompetence, who are unable to increase their heart rate during exercise. These devices have a sensor that triggers an increase in heart rate in response to movement or increased respiratory rate. The sensitivity of the sensor is programmable, as is the maximum paced heart rate.</ce:para><ce:para id="p3020">Early complications of permanent pacing include pneumothorax, cardiac tamponade, infection and lead displacement. Late complications include infection (which usually necessitates removing the pacing system), erosion of the generator or lead, chronic pain related to the implant site, and lead fracture due to mechanical fatigue.</ce:para></ce:section><ce:section id="s1120"><ce:section-title id="st1045">Implantable cardiac defibrillators</ce:section-title><ce:para id="p3025">In addition to the functions of a permanent pacemaker, implantable cardiac defibrillators (ICDs) can also detect and terminate life-threatening ventricular tachyarrhythmias. ICDs are larger than pacemakers mainly because of the need for a large battery and capacitor to enable cardioversion or defibrillation. ICD leads are similar to pacing leads but have one or two shock coils along the length of the lead, used for delivering defibrillation. ICDs treat ventricular tachyarrhythmias using overdrive pacing, cardioversion or defibrillation. They are implanted in a similar manner to pacemakers and carry a similar risk of complications. In addition, patients can be prone to psychological problems and anxiety, particularly if they have experienced repeated shocks from their device.</ce:para><ce:para id="p3030">The evidence-based indications for ICD implantation are shown in <ce:cross-ref id="crf0985" refid="b0210">Box 16.35</ce:cross-ref><ce:float-anchor refid="b0210"/>. These can be divided into secondary prevention indications, when patients have already had a potentially life-threatening ventricular arrhythmia, and primary prevention indications, when patients are considered to be at significant future risk of arrhythmic death. A common primary prevention indication is in patients with inherited conditions associated with a high risk of sudden cardiac death, such as long QT syndrome (<ce:cross-ref id="crf9440" refid="s0830">p. 476</ce:cross-ref>), hypertrophic cardiomyopathy (<ce:cross-ref id="crf9445" refid="s2680">p. 539</ce:cross-ref>) and arrhythmogenic right ventricular dysplasia (<ce:cross-ref id="crf9450" refid="p7595">p. 540</ce:cross-ref>). Treatment with ICDs is expensive and so the indications for which the devices are routinely implanted depend on the health-care resources available.</ce:para></ce:section><ce:section id="s1135"><ce:section-title id="st1060">Cardiac resynchronisation therapy</ce:section-title><ce:para id="p3070">Cardiac resynchronisation therapy (CRT) is a useful treatment for selected patients with heart failure, in whom cardiac function is impaired by the presence of left bundle branch block. This conduction defect is associated with poorly coordinated left ventricular contraction that can aggravate heart failure in susceptible patients. The systems used to deliver CRT comprise a right atrial lead, a right ventricular lead, and a third lead that is placed via the coronary sinus into one of the veins on the epicardial surface of the LV (see <ce:cross-ref id="crf0990" refid="f0205">Fig. 16.30</ce:cross-ref>, <ce:cross-ref id="crf9455" refid="s0605">p. 467</ce:cross-ref>). Simultaneous septal and left ventricular epicardial pacing resynchronises left ventricular contraction.</ce:para><ce:para id="p3075">CRT improves symptoms and quality of life, and reduces mortality in patients with moderate to severe (NYHA class III–IV) heart failure who are in sinus rhythm, with left bundle branch block and left ventricular ejection fraction of 35% or less. CRT also prevents heart failure progression in similar patients with mild (NYHA class I–II) heart failure symptoms. These devices are more effective in patients in sinus rhythm than in those with AF. Most devices are also defibrillators (CRT-D) because many patients with heart failure are predisposed to ventricular arrhythmias. CRT pacemakers (CRT-P) are used when the focus is palliation of symptoms rather than prolonging life.</ce:para></ce:section><ce:section id="s1140"><ce:section-title id="st1065">Catheter ablation therapy</ce:section-title><ce:para id="p3080">Catheter ablation therapy is the treatment of choice for patients with SVT or atrial flutter, and is a useful treatment for some patients with AF or ventricular arrhythmias (<ce:cross-ref id="crf0995" refid="f0320">Fig. 16.53</ce:cross-ref><ce:float-anchor refid="f0320"/>). It involves inserting a series of catheter electrodes into the heart through the venous system. These are used to record the activation sequence of the heart in sinus rhythm, during tachycardia and after pacing manœuvres. Once the arrhythmia focus or circuit, such as an accessory pathway in WPW syndrome, has been identified, a catheter is used to ablate the culprit tissue. This can be done either by using heat, which is termed radiofrequency ablation, or by freezing, which is termed cryoablation. The procedure takes approximately 1–4 hours and does not require a general anaesthetic, although the patient may experience some discomfort during the ablation procedure. Serious complications are rare (&#x003C; 1%) but include complete heart block requiring pacemaker implantation, and cardiac tamponade. For many arrhythmias, radiofrequency ablation is very attractive because it offers the prospect of a lifetime cure, thereby eliminating the need for long-term drug therapy.</ce:para><ce:para id="p3085">The technique has revolutionised the management of many arrhythmias and is now the treatment of choice for AVNRT and AV re-entrant (accessory pathway) tachycardias, when it is curative in over 90% of cases. Focal atrial tachycardias and atrial flutter can also be treated by radiofrequency ablation, although some patients subsequently experience episodes of AF. The applications of the technique are expanding and it can now be used to treat some forms of VT. Catheter ablation techniques are also employed to prevent AF. This involves ablation at two sites: the ostia of the pulmonary veins, from which ectopic beats may trigger paroxysms of arrhythmia, and in the LA itself, where re-entry circuits maintain AF, once established. This is effective at reducing episodes of AF in around 70–80% of younger patients with structurally normal hearts, and tends to be reserved for patients with drug-resistant AF because the procedure carries a risk of cardiac tamponade, and rarely stroke or death.</ce:para><ce:para id="p3090">In patients with permanent AF and poor rate control, in whom drugs are ineffective or are not tolerated, rate control can be achieved by implantation of a permanent pacemaker, followed by ablation of the AV node to induce complete AV block and bradycardia, thus allowing the pacemaker to assume control of the heart rate.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1145"><ce:section-title id="st1070">Coronary artery disease</ce:section-title><ce:para id="p3095">Coronary artery disease (CAD) is the most common cause of angina and acute coronary syndrome and the most common cause of death worldwide. The World Health Organisation (WHO) has estimated that 3.8 million men and 3.4 million women die from cardiovascular disease (CVD) each year, and since 1990, more people have died from CVD than any other cause. It also has a devastating effect on quality of life. Disability-adjusted life years, a measure of healthy years of life lost, can be used to indicate the burden of disease rather than the resulting deaths. It has been estimated that CAD is responsible for 10% of disability-adjusted life years in low-income countries and 18% in high-income ones. In the UK, 1 in 3 men and 1 in 4 women die from CAD, an estimated 188 000 people have a myocardial infarct each year, and approximately 2.3 million people are living with CAD. The death rates from CAD in the UK are among the highest in Western Europe (more than 70 000 people) but are falling, particularly in younger age groups; over the last 50 years, CAD mortality has more than halved. In Eastern Europe and much of Asia, however, the rates of CAD are rapidly rising. Occult CAD is common in those who present with other forms of atherosclerotic vascular disease, such as intermittent claudication or stroke, and is an important cause of morbidity and mortality in these patients.</ce:para><ce:section id="s1150"><ce:section id="s1155"><ce:section id="s1160"><ce:section-title id="st1075">Pathogenesis</ce:section-title><ce:para id="p3100">In the vast majority of patients, CAD is caused by atherosclerosis (<ce:cross-ref id="crf1000" refid="b0215">Box 16.36</ce:cross-ref><ce:float-anchor refid="b0215"/>) but rarely it can occur as the result of aortitis (<ce:cross-ref id="crf9460" refid="p4835">p. 508</ce:cross-ref>), vasculitis (<ce:intra-ref id="ii0415" xlink:href="pii:B978-0-7020-7028-0.00024-X#p5220">p. 1040</ce:intra-ref>) and autoimmune connective tissue diseases (<ce:intra-ref id="ii9005" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1310">p. 1034</ce:intra-ref>). Atherosclerosis is a progressive inflammatory disorder of the arterial wall that is characterised by focal lipid-rich deposits of atheroma that remain clinically silent until they become large enough to impair tissue perfusion, or until ulceration and disruption of the lesion result in thrombotic occlusion or distal embolisation of the vessel. Atherosclerosis begins early in life with deposits of lipids in the vessel wall, which tend to occur at sites of altered arterial shear stress, such as bifurcations, and are associated with abnormalities of endothelial function at that site. Abnormalities of arterial function have been detected among high-risk children and adolescents, such as cigarette smokers and those with familial hyperlipidaemia or hypertension. Early lesions have been found in the arteries of victims of accidental death in the second and third decades of life but clinical manifestations often do not appear until the sixth, seventh or eighth decade. During evolution of an atherosclerotic plaque, monocytes and other inflammatory cells bind to receptors expressed by endothelial cells. Subsequently, they migrate into the intima, and take up oxidised low-density lipoprotein (LDL) particles by phagocytosis to become lipid-laden macrophages or foam cells. Extracellular lipid pools appear in the intimal space when foam cells die and release their contents (<ce:cross-ref id="crf1005" refid="f0325">Fig. 16.54</ce:cross-ref><ce:float-anchor refid="f0325"/>). In response to cytokines and growth factors produced by activated macrophages, smooth muscle cells migrate from the media of the arterial wall into the intima, and change from a contractile to a fibroblastic phenotype, which can stabilise the atherosclerotic lesion. If this is successful, the lipid core will be covered by smooth muscle cells and matrix, producing a stable atherosclerotic plaque that will remain asymptomatic until it becomes large enough to obstruct arterial flow.</ce:para><ce:para id="p3110">In an established atherosclerotic plaque, macrophages mediate inflammation and smooth muscle cells promote repair. If inflammation predominates, the plaque becomes active or unstable and may be complicated by ulceration and thrombosis. Cytokines, such as interleukin-1, tumour necrosis factor-alpha, interferon-gamma, platelet-derived growth factors and matrix metalloproteinases, are released by activated macrophages. They cause the intimal smooth muscle cells overlying the plaque to become senescent and the collagen cross-links within the plaque to degrade. This results in thinning of the protective fibrous cap, making the lesion vulnerable to mechanical stress that ultimately causes erosion, fissuring or rupture of the plaque surface (<ce:cross-ref id="crf1010" refid="f0325">Fig. 16.54</ce:cross-ref>). Any breach in the integrity of the plaque will expose its contents to blood and will trigger platelet aggregation and thrombosis that extend into the atheromatous plaque and the arterial lumen. This may cause partial or complete obstruction at the site of the lesion or distal embolisation, resulting in infarction or ischaemia of the affected organ. This common mechanism underlies acute coronary syndromes, as well as other manifestations of atherosclerotic disease such as lower limb ischaemia (<ce:cross-ref id="crf9465" refid="p4280">p. 502</ce:cross-ref>) and stroke (<ce:intra-ref id="ii0425" xlink:href="pii:B978-0-7020-7028-0.00026-3#c00026">Ch. 26</ce:intra-ref>).</ce:para><ce:para id="p3115">The number and complexity of arterial plaques increase with age and risk factors (see below) but the rate of progression of individual plaques is variable. There is a complex and dynamic interaction between mechanical wall stress and atherosclerotic lesions. Vulnerable plaques are characterised by a lipid-rich core, a thin fibrocellular cap, speckled calcification and an increase in inflammatory cells that release specific enzymes to degrade matrix proteins. In contrast, stable plaques are typified by a small lipid pool, a thick fibrous cap, heavy calcification and plentiful collagenous cross-links. Fissuring or rupture tends to occur at sites of maximal mechanical stress, particularly the margins of an eccentric plaque, and may be triggered by a surge in BP, such as during exercise or emotional stress. Surprisingly, most plaque events are subclinical and heal spontaneously, although this may allow thrombus to be incorporated into the lesion, producing plaque growth and further obstruction to flow.</ce:para><ce:para id="p3120">Atherosclerosis may induce complex changes in the media that lead to arterial remodelling. Some arterial segments may slowly constrict (negative remodelling), while others may gradually enlarge (positive remodelling). These changes are important because they may amplify or minimise the degree to which atheroma encroaches into the arterial lumen.</ce:para><ce:para id="p3125">Many risk factors have been identified for atherosclerosis but the causes are incompletely understood, since unknown factors account for up to 40% of the variation in risk from one person to the next.</ce:para><ce:section id="s1165"><ce:section-title id="st1080">Age and sex</ce:section-title><ce:para id="p3130">Age is the most powerful independent risk factor for atherosclerosis and gender also plays a role. Pre-menopausal women have lower rates of disease than men, although the gender difference disappears after the menopause. Hormone replacement therapy (HRT) is not effective in the prevention of CAD, and HRT in post-menopausal women is associated with an increased risk of cardiovascular events.</ce:para></ce:section><ce:section id="s1170"><ce:section-title id="st1085">Genetics</ce:section-title><ce:para id="p3135">Atherosclerotic CAD often runs in families and a positive family history is common in patients with early-onset disease (age &#x003C; 50 in men and &#x003C; 55 in women). Twin studies have shown that a monozygotic twin of an affected individual has an eightfold increased risk and a dizygotic twin a fourfold increased risk of dying from CAD, compared to the general population due to a combination of shared genetic, environmental and lifestyle factors. The most common risk factors, such as hypertension, hyperlipidaemia and diabetes mellitus, are inherited in a polygenic manner.</ce:para></ce:section><ce:section id="s1175"><ce:section-title id="st1090">Smoking</ce:section-title><ce:para id="p3140">There is a strong relationship between cigarette smoking and CAD, especially in younger (&#x003C; 70 years) individuals, and this is probably the most important modifiable risk factor.</ce:para></ce:section><ce:section id="s1180"><ce:section-title id="st1095">Hypertension</ce:section-title><ce:para id="p3145">The incidence of atherosclerosis increases as BP rises, and this is related to systolic and diastolic BP, as well as pulse pressure. Antihypertensive therapy reduces cardiovascular mortality, stroke and heart failure.</ce:para></ce:section><ce:section id="s1185"><ce:section-title id="st1100">Hypercholesterolaemia</ce:section-title><ce:para id="p3150">The risk of atherosclerosis rises with serum cholesterol concentrations and lowering serum total and LDL cholesterol concentrations reduces the risk of cardiovascular events.</ce:para></ce:section><ce:section id="s1190"><ce:section-title id="st1105">Diabetes mellitus</ce:section-title><ce:para id="p3155">This is a potent risk factor for all forms of atherosclerosis, especially type 2 diabetes mellitus. It is often associated with diffuse disease that is difficult to treat. Insulin resistance (normal glucose homeostasis with high levels of insulin) is associated with obesity and physical inactivity, and is also a risk factor for CAD (<ce:intra-ref id="ii0430" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0205">p. 730</ce:intra-ref>). Glucose intolerance makes a major contribution to the high incidence of ischaemic heart disease in people from the Indian subcontinent and some other ethnic groups.</ce:para></ce:section><ce:section id="s1195"><ce:section-title id="st1110">Haemostatic factors</ce:section-title><ce:para id="p3160">Platelet activation and high plasma fibrinogen concentrations are associated with an increased risk of coronary thrombosis, whereas antiphospholipid antibodies are associated with recurrent arterial thromboses (<ce:intra-ref id="ii0435" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1775">p. 977</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1200"><ce:section-title id="st1115">Physical activity</ce:section-title><ce:para id="p3165">Regular exercise (brisk walking, cycling or swimming for 20 minutes two or three times a week) has a protective effect, whereas inactivity roughly doubles the risk of CAD and is a major risk factor for stroke.</ce:para></ce:section><ce:section id="s1205"><ce:section-title id="st1120">Obesity</ce:section-title><ce:para id="p3170">Obesity, particularly if central or truncal, is an independent risk factor, although it is often associated with other adverse factors such as hypertension, diabetes mellitus and physical inactivity.</ce:para></ce:section><ce:section id="s1210"><ce:section-title id="st1125">Alcohol</ce:section-title><ce:para id="p3175">Excess alcohol consumption is associated with hypertension and cerebrovascular disease.</ce:para></ce:section><ce:section id="s1215"><ce:section-title id="st1130">Diet</ce:section-title><ce:para id="p3180">Diets deficient in fresh fruit, vegetables and polyunsaturated fatty acids are associated with an increased risk of cardiovascular disease. The introduction of a Mediterranean-style diet reduces cardiovascular events. However, dietary supplements, such as vitamins C and E, beta-carotene, folate and fish oils, do not reduce cardiovascular events and, in some cases, have been associated with harm.</ce:para></ce:section><ce:section id="s1220"><ce:section-title id="st1135">Personality</ce:section-title><ce:para id="p3185">While certain personality traits are associated with an increased risk of coronary disease there is no evidence to support the popular belief that stress is a major cause of CAD.</ce:para></ce:section><ce:section id="s1225"><ce:section-title id="st1140">Social deprivation</ce:section-title><ce:para id="p3190">Social deprivation is strongly related to cardiovascular disease. This may be partly due to associations with lifestyle risk factors, such as smoking and alcohol excess, which are more common in socially deprived individuals. Social deprivation does appear to be an independent risk factor for cardiovascular disease, however. Current guidelines recommend that treatment thresholds should be lowered for patients from socially deprived areas.</ce:para><ce:para id="p3195">The effect of risk factors can be multiplicative rather than additive. People with a combination of risk factors are at greatest risk and so assessment should take account of all identifiable risk factors. It is important to distinguish between relative risk (the proportional increase in risk) and absolute risk (the actual chance of an event). For example, a man of 35 years with a plasma cholesterol of 7 mmol/L (approximately 170 mg/dL), who smokes 40 cigarettes a day, is much more likely to die from coronary disease within the next decade than a non-smoking man of the same age with a normal cholesterol, but the absolute likelihood of his dying during this time is still small (high relative risk, low absolute risk).</ce:para></ce:section></ce:section><ce:section id="s1230"><ce:section-title id="st1145">Management</ce:section-title><ce:para id="p3200">Two approaches can be employed. Primary prevention aims to introduce lifestyle changes or therapeutic interventions to prevent CAD and other forms of atherosclerosis in the whole population or in healthy individuals with an elevated risk of disease. Secondary prevention involves initiating treatment in patients who already have had an event, with the aim of reducing the risk of subsequent events.</ce:para><ce:section id="s1235"><ce:section-title id="st1150">Primary prevention</ce:section-title><ce:para id="p3205">The population-based strategy aims to modify the risk factors of the whole population through diet and lifestyle advice, on the basis that even a small reduction in smoking or average cholesterol, or modification of exercise and diet will produce worthwhile benefits (<ce:cross-ref id="crf1015" refid="b0220">Box 16.37</ce:cross-ref><ce:float-anchor refid="b0220"/>). Some risk factors, such as obesity and smoking, are also associated with a higher risk of other diseases and should be actively discouraged through public health measures. The effectiveness of this approach has been demonstrated by introduction of legislation to restrict smoking in public places, which has been associated with reductions in rates of MI.</ce:para><ce:para id="p3240">The targeted strategy aims to identify and treat high-risk individuals, who usually have a combination of risk factors that can be quantified by composite scoring systems. It is important to consider the absolute risk of atheromatous cardiovascular disease that an individual is facing before initiating treatment, since this will help to determine whether the potential benefits of intervention are likely to outweigh the expense, inconvenience and possible side-effects of treatment. For example, a 65-year-old man with an average BP of 150/90 mmHg, who smokes and has diabetes mellitus with a total:high-density lipoprotein (HDL) cholesterol ratio of 8, has a 10-year risk of MI or stroke of 56%. Conversely, a 55-year-old woman who has an identical BP, is a non-smoker, does not have diabetes mellitus, and has a total:HDL cholesterol ratio of 6 has a much better outlook, with a 10-year coronary MI or stroke risk of 5.7%. Lowering cholesterol will reduce the risk in both of these individuals by 30% and lowering BP will produce a further 20% reduction. In combination, both strategies would reduce the risk of an event from 56% to 25% in the male patient and from 5.7% to 2.5% in the female patient. Thresholds for treatment vary in different countries. In the UK and North America, current guidelines recommend initiation of cholesterol and BP-lowering therapies in individuals with a 10-year cardiovascular risk of 7.5–10%.</ce:para></ce:section><ce:section id="s1240"><ce:section-title id="st1155">Secondary prevention</ce:section-title><ce:para id="p3245">This involves targeting interventions at individuals who already have evidence of cardiovascular disease. Patients who recover from a clinical event such as an MI are usually keen to help themselves and are particularly receptive to lifestyle advice, such as dietary modification and smoking cessation. Additional interventions that should be introduced in patients with angina pectoris or an acute coronary syndrome are discussed in more detail below.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1245"><ce:section-title id="st1160">Angina pectoris</ce:section-title><ce:para id="p3250">Angina pectoris is a symptom complex caused by transient myocardial ischaemia, which occurs whenever there is an imbalance between myocardial oxygen supply and demand (<ce:cross-ref id="crf1020" refid="b0225">Box 16.38</ce:cross-ref><ce:float-anchor refid="b0225"/>).</ce:para><ce:section id="s1250"><ce:section id="s1255"><ce:section-title id="st1165">Pathogenesis</ce:section-title><ce:para id="p3315">Atherosclerosis is by far the most common cause of angina pectoris. Angina may also occur in aortic valve disease and hypertrophic cardiomyopathy, and when the coronary arteries are involved with vasculitis or aortitis. The underlying mechanisms and risk factors for atherosclerosis have already been discussed. Approximately 10% of patients who report stable angina on effort have normal coronary arteries on angiography. The main causes are discussed in more detail below.</ce:para><ce:section id="s1260"><ce:section-title id="st1170">Coronary artery spasm</ce:section-title><ce:para id="p3320">Angina may result from vasospasm of the coronary arteries. This may coexist with atherosclerosis, especially in unstable angina (see below), but may occur as an isolated phenomenon in less than 1% of cases, in patients with normal coronary arteries on angiography. This is sometimes known as variant angina; when it is accompanied by transient ST elevation on the ECG, it is termed Prinzmetal's angina.</ce:para></ce:section><ce:section id="s1265"><ce:section-title id="st1175">Syndrome X</ce:section-title><ce:para id="p3325">The constellation of typical angina on effort, objective evidence of myocardial ischaemia on stress testing, and normal coronary arteries on angiography is sometimes known as syndrome X. Many of these patients are women and the mechanism of their symptoms is often unclear. This disorder is poorly understood; it carries a good prognosis but may respond to anti-anginal therapy.</ce:para></ce:section><ce:section id="s1270"><ce:section-title id="st1180">Other causes</ce:section-title><ce:para id="p3330">Angina can occur in association with aortic stenosis, hypertrophic obstructive cardiomyopathy and aortitis, all of which are discussed in more detail later in this chapter. It may also rarely be found in association with vasculitis (<ce:intra-ref id="ii0440" xlink:href="pii:B978-0-7020-7028-0.00024-X#p5220">p. 1040</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s1275"><ce:section-title id="st1185">Clinical features</ce:section-title><ce:para id="p3335">The history is the most important factor in making the diagnosis (<ce:cross-ref id="crf9470" refid="p0805">p. 454</ce:cross-ref>). Stable angina is characterised by central chest pain, discomfort or breathlessness that is predictably precipitated by exertion or other forms of stress (<ce:cross-ref id="crf1030" refid="b0230">Box 16.39</ce:cross-ref><ce:float-anchor refid="b0230"/>), and is promptly relieved by rest (see <ce:intra-ref id="ii0450" xlink:href="pii:B978-0-7020-7028-0.00010-X#f0025">Fig. 10.1</ce:intra-ref>, <ce:intra-ref id="ii9010" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0080">p. 178</ce:intra-ref>). Some patients find the discomfort comes when they start walking and that later it does not return despite greater effort (‘warm-up angina’). The Canadian Cardiovascular Society (CCS) scoring system is commonly used to grade the severity of angina (<ce:cross-ref id="crf9075" refid="b0265">Box 16.40</ce:cross-ref><ce:float-anchor refid="b0265"/>). This is of clinical value, not only in documenting the severity of angina but also in assessing prognosis (<ce:cross-ref id="crf9475" refid="s1340">p. 493</ce:cross-ref>).</ce:para><ce:para id="p3375">Physical examination is frequently unremarkable but should include a careful search for evidence of valve disease (particularly aortic), important risk factors (hypertension, diabetes mellitus), left ventricular dysfunction (cardiomegaly, gallop rhythm), other manifestations of arterial disease (carotid bruits, peripheral arterial disease), and unrelated conditions that may exacerbate angina (anaemia, thyrotoxicosis).</ce:para></ce:section><ce:section id="s1280"><ce:section-title id="st1190">Investigations</ce:section-title><ce:para id="p3380">Symptoms are a poor guide to the extent of CAD. Because of this, stress testing and non-invasive imaging are advisable in patients who are potential candidates for revascularisation. An algorithm for the investigation and treatment of patients with stable angina is shown in <ce:cross-ref id="crf1035" refid="f0330">Figure 16.55</ce:cross-ref><ce:float-anchor refid="f0330"/>. The first-line investigation is an exercise ECG, which should be performed using a standard treadmill or bicycle ergometer protocol (<ce:cross-ref id="crf9480" refid="s0100">p. 449</ce:cross-ref>) while monitoring the patient's pulse, BP and general condition. Planar or down-sloping ST segment depression of 1 mm or more is indicative of ischaemia (<ce:cross-ref id="crf1040" refid="f0335">Fig. 16.56</ce:cross-ref><ce:float-anchor refid="f0335"/>). Up-sloping ST depression is less specific; it often occurs in normal individuals and false-positive results can occur with digoxin therapy, left ventricular hypertrophy, bundle branch block and WPW syndrome. The amount of exercise that can be tolerated and the extent of ST segment change (<ce:cross-ref id="crf1045" refid="f0075">Fig. 16.57</ce:cross-ref><ce:float-anchor refid="f0075"/>) that occurs can be of value in identifying high-risk individuals with severe coronary disease in combination with other clinical features (<ce:cross-ref id="crf1050" refid="b0235">Box 16.41</ce:cross-ref><ce:float-anchor refid="b0235"/>). However, exercise testing may be normal in a significant proportion of patients with CAD or may be inconclusive because an adequate heart rate cannot be achieved due to reduced mobility or other non-cardiac problems. Accordingly, if clinical suspicion is high and the exercise ECG is normal or inconclusive, further imaging with myocardial perfusion scanning or stress echocardiography is indicated. A perfusion defect present during stress but not at rest provides evidence of reversible myocardial ischaemia (<ce:cross-ref id="crf1060" refid="f0125">Fig. 16.58</ce:cross-ref><ce:float-anchor refid="f0125"/>), whereas a persistent perfusion defect seen during both phases of the study is usually indicative of previous MI. Increasingly, CT coronary arteriography is being used to document the presence or absence of CAD in patients with suspected angina. It can clarify the diagnosis, help to guide optimal treatment and avoid the need for cardiac catheterisation in patients who do not have CAD or who have mild disease only (see <ce:cross-ref id="crf1065" refid="f0330">Fig. 16.55</ce:cross-ref>).</ce:para><ce:para id="p3390">Coronary angiography provides detailed anatomical information about the extent and nature of CAD (see <ce:cross-ref id="crf1070" refid="f0120">Fig. 16.15</ce:cross-ref>, <ce:cross-ref id="crf9485" refid="p0790">p. 453</ce:cross-ref>). It is usually performed when coronary artery bypass graft surgery or percutaneous coronary intervention is being considered (<ce:cross-ref id="crf9490" refid="s1315">p. 491</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1285"><ce:section-title id="st1195">Management</ce:section-title><ce:para id="p3395">This should begin with a careful explanation of the problem and a discussion of the lifestyle and medical interventions that can be deployed to relieve symptoms and improve prognosis (<ce:cross-ref id="crf1075" refid="b0240">Box 16.42</ce:cross-ref><ce:float-anchor refid="b0240"/>). Anxiety and misconceptions often contribute to disability; for example, some patients avoid all forms of exertion because they believe that each attack of angina is a ‘mini-heart attack’ that results in permanent damage. Education and reassurance can dispel these misconceptions and make a huge difference to the patient's quality of life.</ce:para><ce:para id="p3430">The principles of management involve:<ce:list id="ulist0510"><ce:list-item id="u1665"><ce:label>•</ce:label><ce:para id="p3435">a careful assessment of the extent and severity of arterial disease</ce:para></ce:list-item><ce:list-item id="u1670"><ce:label>•</ce:label><ce:para id="p3440">identification and treatment of risk factors</ce:para></ce:list-item><ce:list-item id="u1675"><ce:label>•</ce:label><ce:para id="p3445">advice on smoking cessation</ce:para></ce:list-item><ce:list-item id="u1680"><ce:label>•</ce:label><ce:para id="p3450">introduction of drug treatment for symptom control</ce:para></ce:list-item><ce:list-item id="u1685"><ce:label>•</ce:label><ce:para id="p3455">identification of high-risk patients for treatment to improve life expectancy.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p3460">All patients with angina secondary to CAD should receive antiplatelet therapy. Low-dose (75 mg) aspirin should be prescribed for all patients and continued indefinitely since it reduces the risk of MI. Clopidogrel (75 mg daily) is an equally effective alternative if aspirin causes dyspepsia or other side-effects. Similarly, all patients should be prescribed a statin, even if cholesterol is normal.</ce:para></ce:section><ce:section id="s1290"><ce:section-title id="st1200">Anti-anginal drug therapy</ce:section-title><ce:para id="p3465">The goal of anti-anginal therapy is to control symptoms using a regimen that is as simple as possible and does not cause side-effects. Five groups of drug can be used in the prevention and treatment of angina but there is little evidence that one group is more effective than another. It is conventional to start therapy with sublingual glyceryl trinitrate (GTN) and a β-blocker, and then add a calcium channel antagonist or a long-acting nitrate if needed. If the combination of two drugs fails to achieve an acceptable symptomatic response, revascularisation should be considered</ce:para><ce:section id="s1295"><ce:section-title id="st1205">Nitrates</ce:section-title><ce:para id="p3470">Nitrates act directly on vascular smooth muscle to produce venous and arteriolar dilatation. Several preparations are available, as shown in <ce:cross-ref id="crf1080" refid="b0245">Box 16.43</ce:cross-ref><ce:float-anchor refid="b0245"/>. They help angina by lowering preload and afterload, which reduces myocardial oxygen demand, and by increasing myocardial oxygen supply through coronary vasodilatation. Sublingual GTN, administered from a metered-dose aerosol (400 µg per spray) or as a tablet (300 or 500 µg), is indicated for acute attacks and will usually relieve an attack in 2–3 minutes. Patients should also be encouraged to use the drug prophylactically before taking exercise that is liable to provoke symptoms. Sublingual GTN has a short duration of action and side-effects include headache, symptomatic hypotension and, rarely, syncope. A more prolonged therapeutic effect can be achieved by giving GTN transcutaneously as a patch (5–10 mg daily) or as a slow-release buccal tablet (1–5 mg 4 times daily). Isosorbide dinitrate (10–20 mg 3 times daily) and isosorbide mononitrate (20–60 mg once or twice daily) can be given by mouth, unlike GTN, which undergoes extensive metabolism in the liver. Headache is common with oral nitrates but tends to diminish if the patient perseveres with the treatment. Continuous nitrate therapy can cause pharmacological tolerance but this can be avoided by a 6–8-hour nitrate-free period, best achieved at night when the patient is inactive. If nocturnal angina is a predominant symptom, long-acting nitrates can be given at the end of the day.</ce:para></ce:section><ce:section id="s1300"><ce:section-title id="st1210">Beta-blockers</ce:section-title><ce:para id="p3480">These lower myocardial oxygen demand by reducing heart rate, BP and myocardial contractility, but they may provoke bronchospasm in patients with asthma. The properties and side-effects of β-blockers are discussed on <ce:cross-ref id="crf9495" refid="s1485">page 500</ce:cross-ref>. In theory, non-selective β-blockers may aggravate coronary vasospasm by blocking coronary artery β<ce:inf loc="post">2</ce:inf>-adrenoceptors, and so a once-daily cardioselective preparation such as slow-release metoprolol (50–200 mg daily) or bisoprolol (5–15 mg daily) is preferable. Beta-blockers should not be withdrawn abruptly, as rebound effects may precipitate dangerous arrhythmias, worsening angina or MI. This is known as the β-blocker withdrawal syndrome.</ce:para></ce:section><ce:section id="s1305"><ce:section-title id="st1215">Calcium channel antagonists</ce:section-title><ce:para id="p3485">These drugs lower myocardial oxygen demand by reducing BP and myocardial contractility. Since dihydropyridine calcium antagonists, such as nifedipine and amlodipine, may cause a reflex tachycardia, it is best to use them in combination with a β-blocker. In contrast, verapamil and diltiazem can be used as monotherapy because they slow SA node firing, inhibit conduction through the AV node and tend to cause bradycardia. They are particularly useful when β-blockers are contraindicated. Calcium channel antagonists reduce myocardial contractility and must be used with care in patients with poor LV function, since they can aggravate or precipitate heart failure. Other unwanted effects include peripheral oedema, flushing, headache and dizziness (<ce:cross-ref id="crf1085" refid="b0250">Box 16.44</ce:cross-ref><ce:float-anchor refid="b0250"/>).</ce:para></ce:section><ce:section id="s1310"><ce:section-title id="st1220">Potassium channel activators</ce:section-title><ce:para id="p3495">Nicorandil (10–30 mg twice daily orally) is the only drug in this class that is currently available for clinical use. It acts as a vasodilator with effects on the arterial and venous systems, and has the advantage that it does not exhibit the tolerance seen with nitrates.</ce:para></ce:section><ce:section id="s1315"><ce:section-title id="st1225">I<ce:inf loc="post">f</ce:inf> channel antagonist</ce:section-title><ce:para id="p3500">Ivabradine is the first of this class of drug. It induces bradycardia by modulating ion channels in the sinus node. It does not inhibit myocardial contractility and appears to be safe in patients with heart failure.</ce:para></ce:section><ce:section id="s1320"><ce:section-title id="st1230">Ranolazine</ce:section-title><ce:para id="p3505">This drug inhibits the late inward sodium current in coronary artery smooth muscle cells, with a secondary effect on calcium flux and vascular tone, reducing angina symptoms.</ce:para></ce:section></ce:section><ce:section id="s1325"><ce:section-title id="st1235">Non-pharmacological treatments</ce:section-title><ce:section id="s1330"><ce:section-title id="st1240">Percutaneous coronary intervention</ce:section-title><ce:para id="p3510">Percutaneous coronary intervention (PCI) involves passing a fine guidewire across a coronary stenosis under radiographic control and using it to position a balloon, which is then inflated to dilate the stenosis (<ce:cross-ref id="crf1105" refid="f0340">Fig. 16.59</ce:cross-ref><ce:float-anchor refid="f0340"/>). This can be combined with deployment of a coronary stent, which is a piece of metallic ‘scaffolding’ that can be impregnated with drugs with antiproliferative properties and that helps to maximise and maintain dilatation of a stenosed vessel. The routine use of stents in appropriate vessels reduces both acute complications and the incidence of clinically important restenosis (<ce:cross-ref id="crf1110" refid="f0385">Fig. 16.60</ce:cross-ref><ce:float-anchor refid="f0385"/>).</ce:para><ce:para id="p3515">Treatment with PCI often provides excellent symptom control but it does not improve survival in patients with chronic stable angina. It is mainly used in single- or two-vessel disease. Stenoses in bypass grafts can be dilated, as well as those in the native coronary arteries. The technique is often used to provide palliative therapy for patients with recurrent angina after coronary artery bypass grafting.</ce:para><ce:para id="p3520">The main acute complications of PCI are occlusion of the target vessel or a side branch by thrombus or a loose flap of intima (coronary artery dissection), and consequent myocardial damage. This occurs in about 2–5% of procedures and can often be corrected by deploying a stent, although emergency coronary artery bypass grafting may occasionally be required if stenting is unsuccessful. Minor myocardial damage, as indicated by elevation of sensitive intracellular markers (<ce:cross-ref id="crf9500" refid="s1450">p. 497</ce:cross-ref>), occurs in up to 10% of cases. The main long-term complication of PCI is restenosis, in up to one-third of cases. This is due to a combination of elastic recoil and smooth muscle proliferation and tends to occur within 3 months. Stenting substantially reduces the risk of restenosis, probably because it allows the operator to achieve more complete dilatation. Drug-eluting stents reduce this risk further by allowing an antiproliferative drug, such as sirolimus or paclitaxel, to elute slowly from the coating and prevent neo-intimal hyperplasia and in-stent restenosis. These are especially indicated in diabetic patients, or in patients with long or calcific lesions, or small target-vessel diameter. Recurrent angina (affecting up to 5–10% of patients receiving an intracoronary stent at 6 months) may require further PCI or bypass grafting.</ce:para><ce:para id="p3525">The risk of complications and the likely success of the procedure are closely related to the morphology of the stenoses, the experience of the operator and the presence of important comorbidity, such as diabetes and peripheral arterial disease. A good outcome is less likely if the target lesion is complex, long, eccentric or calcified, lies on a bend or within a tortuous vessel, involves a branch or contains thrombus.</ce:para><ce:para id="p3530">Adjunctive therapy with a potent platelet inhibitor such as the P2Y12 receptor antagonists (clopidogrel, prasugrel or ticagrelor) in combination with aspirin and heparin improves the outcome following PCI.</ce:para></ce:section><ce:section id="s1335"><ce:section-title id="st1245">Coronary artery bypass grafting</ce:section-title><ce:para id="p3535">The internal mammary arteries, radial arteries or reversed segments of the patient's own saphenous vein can be used to bypass coronary artery stenoses (<ce:cross-ref id="crf1115" refid="f0345">Fig. 16.61</ce:cross-ref><ce:float-anchor refid="f0345"/>). This usually involves major surgery under cardiopulmonary bypass but, in some cases, grafts can be applied to the beating heart: ‘off-pump’ surgery. The operative mortality is approximately 1.5% but risks are higher in elderly patients, those with poor left ventricular function and those with significant comorbidity, such as renal failure.</ce:para><ce:para id="p3540">Approximately 90% of patients are free of angina 1 year after coronary artery bypass grafting (CABG), but fewer than 60% of patients are asymptomatic after 5 or more years. Early post-operative angina is usually due to graft failure arising from technical problems during the operation, or poor ‘run-off’ due to disease in the distal native coronary vessels. Late recurrence of angina may be caused by progressive disease in the native coronary arteries or graft degeneration. Fewer than 50% of vein grafts are patent 10 years after surgery. Arterial grafts have a much better long-term patency rate, however, with more than 80% of internal mammary artery grafts patent at 10 years. This has led many surgeons to consider total arterial revascularisation during CABG surgery. Aspirin (75–150 mg daily) and clopidogrel (75 mg daily) both improve graft patency, and one or the other should be prescribed indefinitely. Intensive lipid-lowering therapy slows the progression of disease in the native coronary arteries and bypass grafts, and reduces clinical cardiovascular events. There is substantial excess cardiovascular morbidity and mortality in patients who continue to smoke after bypass grafting. Persistent smokers are twice as likely to die in the 10 years following surgery than those who give up at surgery.</ce:para><ce:para id="p3545">Survival is improved by CABG in symptomatic patients with left main stem stenosis or three-vessel coronary disease when the LAD, CX and right coronary arteries are involved, or two-vessel disease involving the proximal LAD coronary artery. Improvement in survival is most marked in those with impaired left ventricular function or positive stress testing prior to surgery and in those who have undergone left internal mammary artery grafting.</ce:para><ce:para id="p3550">Neurological complications are common, with a 1–5% risk of perioperative stroke. Between 30% and 80% of patients develop short-term cognitive impairment that typically resolves within 6 months. There are also reports of long-term cognitive decline that may be evident in more than 30% of patients at 5 years. PCI and CABG are compared in <ce:cross-ref id="crf1120" refid="b0255">Box 16.45</ce:cross-ref><ce:float-anchor refid="b0255"/>.</ce:para><ce:para id="p3560"><ce:float-anchor refid="b0260"/></ce:para></ce:section></ce:section><ce:section id="s1340"><ce:section-title id="st1250">Prognosis</ce:section-title><ce:para id="p3595">The prognosis of CAD is related to the number of diseased vessels and the degree of left ventricular dysfunction. A patient with single-vessel disease and good left ventricular function has a 5-year survival of more than 90%. In contrast, a patient with severe left ventricular dysfunction and extensive three-vessel disease has a 5-year survival of less than 30% unless revascularisation is performed. Symptoms are a poor guide to prognosis, since spontaneous improvement in angina due to the development of collateral vessels is common. Nevertheless, the 5-year mortality of patients with severe angina (CCS angina scale III or IV, see <ce:cross-ref id="crf1130" refid="b0265">Box 16.40</ce:cross-ref>) is nearly double that of patients with mild symptoms.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1365"><ce:section-title id="st1275">Acute coronary syndrome</ce:section-title><ce:para id="p3640">Acute coronary syndrome is a term that encompasses both unstable angina and myocardial infarction. Unstable angina is characterised by new-onset or rapidly worsening angina (crescendo angina), angina on minimal exertion or angina at rest in the absence of myocardial damage. Myocardial infarction differs from unstable angina, since there is evidence of myocardial necrosis. The term acute myocardial infarction (MI) should be used when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischaemia. Under these conditions, any one of the criteria shown in <ce:cross-ref id="crf1135" refid="b0270">Box 16.47</ce:cross-ref><ce:float-anchor refid="b0270"/> fulfils the criteria for the diagnosis of an acute MI. The diagnosis of a previous MI can be made when any one of the features shown in <ce:cross-ref id="crf1140" refid="b0275">Box 16.48</ce:cross-ref><ce:float-anchor refid="b0275"/> is present.</ce:para><ce:para id="p3720">Acute coronary syndrome may present as a new phenomenon in patients with no previous history of heart disease or against a background of chronic stable angina. Approximately 12% of patients with acute coronary syndrome die within 1 month and 20% within 6 months of the index event. The risk markers that are indicative of an adverse prognosis include recurrent ischaemia, extensive ECG changes at rest or during pain, raised troponin I or T levels, arrhythmias and haemodynamic complications (hypotension, mitral regurgitation) during episodes of ischaemia. Careful assessment and risk stratification are important because these guide the use of more complex pharmacological and interventional treatments (<ce:cross-ref id="crf1145" refid="f0350">Figs 16.62</ce:cross-ref><ce:float-anchor refid="f0350"/> and <ce:cross-ref id="crf1150" refid="f0135">16.70</ce:cross-ref>), which can improve outcome (<ce:cross-ref id="crf9505" refid="s1505">p. 501</ce:cross-ref>).</ce:para><ce:section id="s1370"><ce:section id="s1375"><ce:section-title id="st1280">Pathogenesis</ce:section-title><ce:para id="p3725">Acute coronary syndrome almost always occurs in patients who have atherosclerosis. The culprit lesion that precipitates the acute event is usually a complex ulcerated or fissured atheromatous plaque with adherent platelet-rich thrombus and local coronary artery spasm (see <ce:cross-ref id="crf1155" refid="f0325">Fig. 16.54</ce:cross-ref>). These vascular changes during an acute coronary syndrome are dynamic, such that the degree of obstruction may either increase, leading to complete vessel occlusion, or regress due to the effects of platelet disaggregation and endogenous fibrinolysis. In acute MI, occlusive thrombus is almost always present at the site of rupture or erosion of an atheromatous plaque. The thrombus may undergo spontaneous lysis over the course of the next few days, although, by this time, irreversible myocardial damage has occurred. Without treatment, the artery responsible for the MI remains permanently occluded in 20–30% of patients. Since the process of infarction progresses over several hours (<ce:cross-ref id="crf1160" refid="f0355">Fig. 16.63</ce:cross-ref><ce:float-anchor refid="f0355"/>), most patients present when it is still possible to salvage myocardium and improve outcome.</ce:para></ce:section><ce:section id="s1380"><ce:section-title id="st1285">Clinical features</ce:section-title><ce:para id="p3730">The differential diagnosis of acute coronary syndrome is wide and includes most causes of central chest pain or collapse (<ce:intra-ref id="ii0500" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0030">p. 176</ce:intra-ref>). Chest pain at rest is the cardinal symptom but breathlessness, vomiting and collapse are also common features (<ce:cross-ref id="crf1165" refid="b0280">Box 16.49</ce:cross-ref><ce:float-anchor refid="b0280"/>). The pain occurs in the same sites as angina but is usually more severe and lasts longer; it is often described as a tightness, heaviness or constriction in the chest. In acute MI the pain can be excruciating, and the patient's expression and pallor may vividly convey the seriousness of the situation. Most patients are breathless and, in some, this is the only symptom. Painless or ‘silent’ MI may also occur and is particularly common in older patients or those with diabetes mellitus. If syncope occurs, it is usually caused by an arrhythmia or profound hypotension. Vomiting and sinus bradycardia are often due to vagal stimulation and are particularly common in patients with inferior MI. Nausea and vomiting may also be caused or aggravated by opiates given for pain relief. Sometimes infarction occurs in the absence of physical signs. Sudden death, from ventricular fibrillation or asystole, may occur immediately and often within the first hour. If the patient survives this most critical stage, the liability to dangerous arrhythmias remains, but diminishes as each hour goes by. It is vital that patients know not to delay calling for help if symptoms occur. Complications may occur in all forms of acute coronary syndrome but have become less frequent in the modern era of immediate or early coronary revascularisation. Specific complications of acute coronary syndromes and their management are discussed below.</ce:para><ce:section id="s1385"><ce:section-title id="st1290">Arrhythmias</ce:section-title><ce:para id="p3900">Arrhythmias are common in patients with acute coronary syndrome (<ce:cross-ref id="crf1170" refid="b0285">Box 16.50</ce:cross-ref><ce:float-anchor refid="b0285"/>) but are often transient and of no haemodynamic or prognostic importance. The risk of arrhythmia can be minimised by adequate pain relief, rest and the correction of hypokalaemia. VF occurs in 5–10% of patients who reach hospital and is thought to be the major cause of death in those who die before receiving medical attention. Prompt defibrillation restores sinus rhythm and is life-saving. The prognosis of patients with early VF (within the first 48 hours) who are successfully and promptly resuscitated is identical to that of patients who do not suffer VF. The presence of ventricular arrhythmias during the convalescent phase of acute coronary syndrome may be a marker of poor ventricular function and may herald sudden death. Selected patients may benefit from electrophysiological testing and specific anti-arrhythmic therapy (including ICDs, <ce:cross-ref id="crf9510" refid="s1115">p. 483</ce:cross-ref>). AF is a common but frequently transient arrhythmia, and usually does not require emergency treatment. However, if it causes a rapid ventricular rate with hypotension or circulatory collapse, prompt cardioversion is essential. In other situations, digoxin or a β-blocker is usually the treatment of choice. AF may be a feature of impending or overt left ventricular failure, and therapy may be ineffective if heart failure is not recognised and treated appropriately. Anticoagulation is required if AF persists. Bradycardia may occur but does not require treatment unless there is hypotension or haemodynamic deterioration, in which case atropine (0.6–1.2 mg IV) may be given. Inferior MI may be complicated by AV block, which is usually temporary and often resolves following reperfusion therapy. If there is clinical deterioration due to second-degree or complete AV block, a temporary pacemaker should be considered. AV block complicating anterior infarction is more serious because asystole may suddenly supervene. A prophylactic temporary pacemaker should be inserted in these patients (<ce:cross-ref id="crf9515" refid="s1085">p. 482</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1390"><ce:section-title id="st1295">Recurrent angina</ce:section-title><ce:para id="p3950">Patients who develop recurrent angina at rest or on minimal exertion following an acute coronary syndrome are at high risk and should be considered for prompt coronary angiography with a view to revascularisation. Patients with dynamic ECG changes and ongoing pain should be treated with intravenous glycoprotein IIb/IIIa receptor antagonists. Patients with resistant pain or marked haemodynamic changes should be considered for intra-aortic balloon counterpulsation and emergency coronary revascularisation. Post-infarct angina occurs in up to 50% of patients treated with thrombolysis. Most patients have a residual stenosis in the infarct-related vessel, despite successful thrombolysis, and this may cause angina if there is still viable myocardium downstream. For this reason, all patients who have received successful thrombolysis should be considered for early (within the first 6–24 hours) coronary angiography with a view to coronary revascularisation.</ce:para></ce:section><ce:section id="s1395"><ce:section-title id="st1300">Acute heart failure</ce:section-title><ce:para id="p3955">Acute heart failure usually reflects extensive myocardial damage and is associated with a poor prognosis. All the other complications of MI are more likely to occur when acute heart failure is present. The assessment and management of heart failure is discussed in more detail on <ce:cross-ref id="crf9520" refid="s0500">pages 463 and 465</ce:cross-ref>.</ce:para></ce:section><ce:section id="s1400"><ce:section-title id="st1305">Pericarditis</ce:section-title><ce:para id="p3960">This only occurs following infarction and is particularly common on the second and third days. The patient may recognise that a different pain has developed, even though it is at the same site, and that it is positional and tends to be worse or sometimes present only on inspiration. A pericardial rub may be audible. Opiate-based analgesia should be used. Non-steroidal (NSAIDs) and steroidal anti-inflammatory drugs may increase the risk of aneurysm formation and myocardial rupture in the early recovery period, and should be avoided.</ce:para></ce:section><ce:section id="s1405"><ce:section-title id="st1310">Dressler's syndrome</ce:section-title><ce:para id="p3965">This syndrome is characterised by persistent fever, pericarditis and pleurisy, and is probably due to autoimmunity. The symptoms tend to occur a few weeks or even months after MI and often subside after a few days. If the symptoms are prolonged or severe, treatment with high-dose aspirin, NSAIDs or even glucocorticoids may be required.</ce:para></ce:section><ce:section id="s1410"><ce:section-title id="st1315">Papillary muscle rupture</ce:section-title><ce:para id="p3970">This typically presents with acute pulmonary oedema and shock due to the sudden onset of severe mitral regurgitation. Examination usually reveals a pansystolic murmur and third heart sound but the murmur may be quiet or absent in patients with severe mitral regurgitation. The diagnosis is confirmed by echocardiography, and emergency valve replacement may be necessary. Lesser degrees of mitral regurgitation due to papillary muscle dysfunction are common and may be transient.</ce:para></ce:section><ce:section id="s1415"><ce:section-title id="st1320">Ventricular septum rupture</ce:section-title><ce:para id="p3975">This usually presents with sudden haemodynamic deterioration accompanied by a new and loud pansystolic murmur radiating to the right sternal border, which may be difficult to distinguish from acute mitral regurgitation. Rupture of the interventricular septum causes left-to-right shunting through a ventricular septal defect, which tends to cause acute right heart failure rather than pulmonary oedema. Doppler echocardiography and right heart catheterisation will confirm the diagnosis. Treatment is by emergency surgical repair; without this, the condition is usually fatal.</ce:para></ce:section><ce:section id="s1420"><ce:section-title id="st1325">Ventricular rupture</ce:section-title><ce:para id="p3980">Rupture of the ventricle may lead to cardiac tamponade and is usually fatal (<ce:cross-ref id="crf9525" refid="s2845">p. 544</ce:cross-ref>), although it is occasionally possible to support a patient with an incomplete rupture until emergency surgery can be performed.</ce:para></ce:section><ce:section id="s1425"><ce:section-title id="st1330">Embolism</ce:section-title><ce:para id="p3985">Thrombus often forms on the endocardial surface of freshly infarcted myocardium. This can lead to systemic embolism and occasionally causes a stroke or ischaemic limb. Venous thrombosis and pulmonary embolism may occur but have become less common with the use of prophylactic anticoagulants and early mobilisation.</ce:para></ce:section><ce:section id="s1430"><ce:section-title id="st1335">Ventricular remodelling</ce:section-title><ce:para id="p3990">This is a potential complication of an acute transmural MI due to thinning and stretching of the infarcted segment. This leads to an increase in wall stress with progressive dilatation and hypertrophy of the remaining ventricle (ventricular remodelling, <ce:cross-ref id="crf1175" refid="f0185">Fig. 16.64</ce:cross-ref><ce:float-anchor refid="f0185"/>). As the ventricle dilates, it becomes less efficient and heart failure may supervene. Infarct expansion occurs over a few days and weeks but ventricular remodelling can take years. ACE inhibitor and mineralocorticoid receptor antagonist therapies reduce late ventricular remodelling and can prevent the onset of heart failure (<ce:cross-ref id="crf9530" refid="s0540">p. 465</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1435"><ce:section-title id="st1340">Ventricular aneurysm</ce:section-title><ce:para id="p3995">Ventricular aneurysm develops in approximately 10% of patients with MI and is particularly common when there is persistent occlusion of the infarct-related vessel. Heart failure, ventricular arrhythmias, mural thrombus and systemic embolism are all recognised complications of aneurysm formation. Other features include a paradoxical impulse on the chest wall, persistent ST elevation on the ECG, and sometimes an unusual bulge from the cardiac silhouette on the chest X-ray. Echocardiography is diagnostic. Surgical removal of a left ventricular aneurysm carries a high morbidity and mortality but is sometimes necessary.</ce:para></ce:section></ce:section><ce:section id="s1440"><ce:section-title id="st1345">Investigations</ce:section-title><ce:section id="s1445"><ce:section-title id="st1350">Electrocardiogram</ce:section-title><ce:para id="p4000">The standard 12-lead ECG is central to confirming the diagnosis but may be difficult to interpret if there is bundle branch block or previous MI. The initial ECG may be normal or non-diagnostic in one-third of cases. Repeated ECGs are important, especially where the diagnosis is uncertain or the patient has recurrent or persistent symptoms. The earliest ECG change is usually ST-segment deviation. With proximal occlusion of a major coronary artery, ST-segment elevation (or new bundle branch block) is seen initially, with later diminution in the size of the R wave and, in transmural (full-thickness) infarction, development of a Q wave. Subsequently, the T wave becomes inverted because of a change in ventricular repolarisation; this change persists after the ST segment has returned to normal. These sequential features (<ce:cross-ref id="crf1180" refid="f0360">Fig. 16.65</ce:cross-ref><ce:float-anchor refid="f0360"/>) are sufficiently reliable for the approximate age of the infarct to be deduced.</ce:para><ce:para id="p4005">In non-ST segment elevation acute coronary syndrome, there is partial occlusion of a major vessel or complete occlusion of a minor vessel, causing unstable angina or partial-thickness (subendocardial) MI. This is usually associated with ST-segment depression and T-wave changes. In the presence of infarction, this may be accompanied by some loss of R waves in the absence of Q waves (<ce:cross-ref id="crf1185" refid="f0365">Fig. 16.66</ce:cross-ref><ce:float-anchor refid="f0365"/>).</ce:para><ce:para id="p4010">The ECG changes are best seen in the leads that ‘face’ the ischaemic or infarcted area. When there has been anteroseptal infarction, abnormalities are found in one or more leads from V<ce:inf loc="post">1</ce:inf> to V<ce:inf loc="post">4</ce:inf>, while anterolateral infarction produces changes from V<ce:inf loc="post">4</ce:inf> to V<ce:inf loc="post">6</ce:inf>, in aVL and in lead I. Inferior infarction is best shown in leads II, III and aVF, while, at the same time, leads I, aVL and the anterior chest leads may show ‘reciprocal’ changes of ST depression (<ce:cross-ref id="crf1190" refid="f0370">Figs 16.67</ce:cross-ref><ce:float-anchor refid="f0370"/> and <ce:cross-ref id="crf1195" refid="f0375">16.68</ce:cross-ref><ce:float-anchor refid="f0375"/>). Infarction of the posterior wall of the LV does not cause ST elevation or Q waves in the standard leads, but can be diagnosed by the presence of reciprocal changes (ST depression and a tall R wave in leads V<ce:inf loc="post">1</ce:inf>–V<ce:inf loc="post">4</ce:inf>). Some infarctions (especially inferior) also involve the RV. This may be identified by recording from additional leads placed over the right precordium.</ce:para></ce:section><ce:section id="s1450"><ce:section-title id="st1355">Cardiac biomarkers</ce:section-title><ce:para id="p4015">Serial measurements of serum troponin should be taken. In unstable angina, there is no detectable rise in troponin and the diagnosis is made on the basis of the clinical history and ECG changes. In contrast, MI causes a rise in plasma troponin T and I concentrations and other cardiac muscle enzymes (<ce:cross-ref id="crf9535" refid="s0115">p. 450</ce:cross-ref>; <ce:cross-ref id="crf1200" refid="f0380">Fig. 16.69</ce:cross-ref><ce:float-anchor refid="f0380"/> and see <ce:cross-ref id="crf1205" refid="b0270">Box 16.47</ce:cross-ref>). Levels of troponins T and I increase within 3–6 hours, peak at about 36 hours and remain elevated for up to 2 weeks. A full blood count may reveal the presence of a leucocytosis, which reaches a peak on the first day. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are also elevated. Lipids should be measured within 24 hours of presentation because there is often a transient fall in cholesterol in the 3 months following infarction.</ce:para></ce:section><ce:section id="s1455"><ce:section-title id="st1360">Radiography</ce:section-title><ce:para id="p4020">A chest X-ray should be performed since this may demonstrate pulmonary oedema that is not evident on clinical examination (see <ce:cross-ref id="crf1210" refid="f0095">Fig. 16.27</ce:cross-ref>, <ce:cross-ref id="crf9540" refid="s0525">p. 464</ce:cross-ref>). The heart size is often normal but there may be cardiomegaly due to pre-existing myocardial damage.</ce:para></ce:section><ce:section id="s1460"><ce:section-title id="st1365">Echocardiography</ce:section-title><ce:para id="p4025">Echocardiography is normally performed before discharge from hospital and is useful for assessing ventricular function and for detecting important complications, such as mural thrombus, cardiac rupture, ventricular septal defect, mitral regurgitation and pericardial effusion.</ce:para></ce:section><ce:section id="s1465"><ce:section-title id="st1370">Coronary angiography</ce:section-title><ce:para id="p4030">Coronary arteriography should be considered with a view to revascularisation in all patients at moderate or high risk of a further event, including those who fail to settle on medical therapy, those with extensive ECG changes, those with an elevated plasma troponin and those with severe pre-existing stable angina (<ce:cross-ref id="crf9080" refid="f0135">Fig. 16.70</ce:cross-ref><ce:float-anchor refid="f0135"/>). This often reveals disease that is amenable to PCI or urgent CABG (see below).</ce:para></ce:section></ce:section><ce:section id="s1470"><ce:section-title id="st1375">Management</ce:section-title><ce:para id="p4035">All patients with suspected acute coronary syndrome should be admitted urgently to hospital because there is a significant risk of death or recurrent myocardial ischaemia during the early unstable phase. Appropriate medical therapy can reduce the incidence of these complications by at least 60%. The key elements of immediate in-hospital management are shown in <ce:cross-ref id="crf1215" refid="f0135">Figure 16.70</ce:cross-ref>. Patients should ideally be managed in a dedicated cardiac unit, where the necessary expertise, monitoring and resuscitation facilities are available. Clinical risk factor analysis using tools such as the GRACE score (see <ce:cross-ref id="crf1220" refid="f0350">Fig. 16.62</ce:cross-ref>) should be performed to identify patients that should be selected for intensive therapy, and specifically early inpatient coronary angiography (thresholds vary, but a score of 140 points or more indicates early intervention). If there are no complications and risk factor analysis shows that angiography is not required, the patient can be mobilised from the second day and discharged after 2–3 days. Low-risk patients without spontaneous angina should undergo an exercise tolerance test approximately 4 weeks after the acute coronary syndrome. This will help to identify those individuals with residual myocardial ischaemia who require further investigation, and may help to boost the confidence of the remainder. Management of the acute event is discussed below and the principles of long-term management are summarised in <ce:cross-ref id="crf1225" refid="b0290">Box 16.51</ce:cross-ref><ce:float-anchor refid="b0290"/>.</ce:para><ce:section id="s1475"><ce:section-title id="st1380">Analgesia</ce:section-title><ce:para id="p4100">Adequate analgesia is essential, not only to relieve distress but also to lower adrenergic drive and thereby reduce vascular resistance, BP, infarct size and susceptibility to ventricular arrhythmias. Intravenous opiates (initially, morphine sulphate 5–10 mg or diamorphine 2.5–5 mg) and antiemetics (initially, metoclopramide 10 mg) should be administered, and titrated by giving repeated small aliquots until the patient is comfortable. Intramuscular injections should be avoided because the clinical effect may be delayed by poor skeletal muscle perfusion, and a painful haematoma may form following thrombolytic or antithrombotic therapy.</ce:para></ce:section><ce:section id="s1480"><ce:section-title id="st1385">Reperfusion therapy</ce:section-title><ce:para id="p4105">Immediate reperfusion therapy with PCI (see <ce:cross-ref id="crf9085" refid="f0385">Fig. 16.60</ce:cross-ref>) is indicated when the ECG shows new bundle branch block or characteristic ST-segment elevation in two contiguous leads of 1 mm or more in the limb leads or 2 mm or more in the chest leads. This procedure has revolutionised the outcomes for these patients and is the treatment of choice for those presenting within 12 hours of symptom onset (<ce:cross-ref id="crf9090" refid="f0135">Fig. 16.70</ce:cross-ref>). If PCI cannot be performed within 120 minutes for any reason, and thrombolysis is contraindicated, the procedure should be performed as soon as practically possible. Patients should be considered for PCI within the first 24 hours, even if they have reperfused spontaneously or with thrombolytic therapy. Coronary artery patency is restored in over 95% of patients undergoing PCI. The procedure preserves left ventricular function with a marked reduction in the progression to heart failure, more than halves rates of recurrent MI and dramatically improves mortality with more than 95% 1-year survival rates in clinical trials. Successful therapy is also associated with rapid pain relief, resolution of acute ST elevation and occasional transient arrhythmias. Selected medium- to high-risk patients do benefit from in-hospital coronary angiography and coronary revascularisation but this does not need to take place in the first 12 hours unless there are high-risk features, such as ongoing chest pain or ECG changes. Reperfusion therapy with PCI confers no immediate mortality benefit in patients with non-ST segment elevation acute coronary syndrome.</ce:para></ce:section><ce:section id="s1485"><ce:section-title id="st1390">Thrombolytic therapy</ce:section-title><ce:para id="p4110">If primary PCI cannot be achieved in a timely manner (see <ce:cross-ref id="crf9095" refid="f0135">Fig. 16.70</ce:cross-ref>), thrombolytic therapy should be administered. Although the survival advantage is not as good as primary PCI, mortality is reduced and this is maintained for at least 10 years. The benefit of thrombolytic therapy is greatest in those patients who receive treatment within the first 12 hours and especially the first 2 hours. Modern thrombolytic agents, such as tenecteplase (TNK) and reteplase (rPA), are analogues of human tissue plasminogen activator and can be given as an intravenous bolus, assisting prompt treatment in the emergency department or in the pre-hospital setting. The major hazard of thrombolytic therapy is bleeding. Cerebral haemorrhage causes 4 extra strokes per 1000 patients treated, and the incidence of other major bleeds is between 0.5% and 1%. Accordingly, the treatment should be withheld if there is a significant risk of serious bleeding (<ce:cross-ref id="crf1240" refid="b0295">Box 16.52</ce:cross-ref><ce:float-anchor refid="b0295"/>). For some patients, thrombolytic therapy is contraindicated or fails to achieve coronary arterial reperfusion (<ce:cross-ref id="crf1245" refid="f0135">Fig. 16.70</ce:cross-ref>). Emergency PCI may then be considered, particularly where there is evidence of cardiogenic shock. Even where thrombolysis successfully achieves reperfusion, PCI should be considered within 24 hours to prevent recurrent infarction and improve outcome.</ce:para></ce:section><ce:section id="s1490"><ce:section-title id="st1395">Antithrombotic therapy</ce:section-title><ce:para id="p4155">Oral administration of 75–325 mg aspirin daily improves survival, with a 25% relative risk reduction in mortality. The first tablet (300 mg) should be given orally within the first 12 hours and therapy should be continued indefinitely if there are no side-effects. A P2Y12 receptor antagonist should be given in combination with aspirin for up to 12 months. The strongest evidence is for ticagrelor (180 mg, followed by 90 mg twice daily) but prasugrel (60 mg, followed by 10 mg daily) is an alternative. If the patient is intolerant of aspirin, clopidogrel is a suitable alternative (300 mg, followed by 75 mg daily). Glycoprotein IIb/IIIa receptor antagonists, such as tirofiban and abciximab, block the final common pathway of platelet aggregation and are potent inhibitors of platelet-rich thrombus formation. They are of particular benefit in high-risk patients with acute coronary syndromes who undergo PCI, especially those with a high thrombus burden at angiography or who have received inadequate prior antiplatelet therapy. These intravenous agents are administered in addition to oral aspirin and a P2Y12 inhibitor such as clopidogrel. Anticoagulation further reduces the risk of thromboembolic complications, and prevents re-infarction in the absence of reperfusion therapy or after successful thrombolysis. Anticoagulation can be achieved using unfractionated heparin, fractioned (low-molecular-weight) heparin or a pentasaccharide such as subcutaneous fondaparinux (2.5 mg daily). Comparative clinical trials show that the pentasaccharides have the best safety and efficacy profile but low-molecular-weight heparin, such as subcutaneous enoxaparin (1 mg/kg twice daily), is a reasonable alternative. Anticoagulation should be continued for 8 days or until discharge from hospital or coronary revascularisation has been completed. A period of treatment with warfarin should be considered if there is persistent AF or evidence of extensive anterior infarction with mural thrombus because these patients are at increased risk of systemic thromboembolism.</ce:para></ce:section><ce:section id="s1495"><ce:section-title id="st1400">Anti-anginal therapy</ce:section-title><ce:para id="p4160"><ce:float-anchor refid="b0300"/></ce:para><ce:para id="p4195">Sublingual glyceryl trinitrate (300–500 µg) is a valuable first-aid measure in unstable angina or threatened infarction, and intravenous nitrates (glyceryl trinitrate 0.6–1.2 mg/hr or isosorbide dinitrate 1–2 mg/hr) are useful for the treatment of left ventricular failure and the relief of recurrent or persistent ischaemic pain. Intravenous β-blockers (atenolol 5–10 mg or metoprolol 5–15 mg given over 5 mins) relieve pain, reduce arrhythmias and improve short-term mortality in patients who present within 12 hours of the onset of symptoms (<ce:cross-ref id="crf1250" refid="f0135">Fig. 16.70</ce:cross-ref>). However, they should be avoided if there is heart failure (pulmonary oedema), hypotension (systolic BP &#x003C; 105 mmHg) or bradycardia (heart rate &#x003C; 65/min). Nifedipine or amlodipine can be added to the β-blocker if there is persistent chest discomfort but these drugs may cause tachycardia if used alone. Verapamil and diltiazem should be used if a β-blocker is contraindicated. In the longer term, treatment with an oral β-blocker reduces long-term mortality by approximately 25% among the survivors of an acute MI. Patients with heart failure, irreversible COPD or peripheral arterial disease derive similar, if not greater, secondary preventative benefits from β-blocker therapy and should receive maintenance therapy unless it is poorly tolerated. Unfortunately, a minority of patients do not tolerate β-blockers because of bradycardia, AV block, hypotension or asthma.</ce:para></ce:section><ce:section id="s1500"><ce:section-title id="st1405">Renin–angiotensin blockade</ce:section-title><ce:para id="p4200">Long-term treatment with ACE inhibitors such as enalapril (10 mg twice daily) or ramipril (2.5–5 mg twice daily) can counteract ventricular remodelling, prevent the onset of heart failure, improve survival, reduce recurrent MI and avoid rehospitalisation. The benefits are greatest in those with overt heart failure (clinical or radiological) but extend to patients with asymptomatic left ventricular dysfunction and those with preserved left ventricular function. They should therefore be considered in all patients with acute coronary syndrome. Caution must be exercised in hypovolaemic or hypotensive patients because ACE inhibition may exacerbate hypotension and impair coronary perfusion. In patients intolerant of ACE inhibitors, ARBs such as valsartan (40–160 mg twice daily) or candesartan (4–16 mg daily) are alternatives and are better tolerated.</ce:para></ce:section><ce:section id="s1505"><ce:section-title id="st1410">Mineralocorticoid receptor antagonists</ce:section-title><ce:para id="p4205">Patients with acute MI and left ventricular dysfunction (ejection fraction &#x003C; 35%) and either pulmonary oedema or diabetes mellitus further benefit from additional mineralocorticoid receptor antagonism (eplerenone 25–50 mg daily, or spironolactone 25–50 mg daily).</ce:para></ce:section><ce:section id="s1510"><ce:section-title id="st1415">Lipid-lowering therapy</ce:section-title><ce:para id="p4210">The benefits of lowering serum cholesterol following acute coronary syndrome have been demonstrated in several large-scale randomised trials. All patients should receive therapy with HMG CoA reductase enzyme inhibitors (statins) after acute coronary syndrome, irrespective of serum cholesterol concentrations. Patients with serum LDL cholesterol concentrations above 3.2 mmol/L (approximately 120 mg/dL) benefit from more intensive therapy, such as atorvastatin (80 mg daily). Other agents, such as ezetimibe, fibrates, anion exchange resins and injectable PCSK9 inhibitors, may be used in cases where total cholesterol or LDL cholesterol cannot be lowered adequately using statins alone.</ce:para></ce:section><ce:section id="s1515"><ce:section-title id="st1420">Smoking cessation</ce:section-title><ce:para id="p4215">The 5-year mortality of patients who continue to smoke cigarettes is double that of those who quit smoking at the time of their acute coronary syndrome. Giving up smoking is the single most effective contribution a patient can make to his or her future. The success of smoking cessation can be increased by supportive advice and pharmacological therapy (<ce:intra-ref id="ii0550" xlink:href="pii:B978-0-7020-7028-0.00005-6#s0050">p. 94</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1520"><ce:section-title id="st1425">Diet and exercise</ce:section-title><ce:para id="p4220">Maintaining an ideal body weight, eating a Mediterranean-style diet, taking regular exercise, and achieving good control of hypertension and diabetes mellitus may all improve the long-term outlook.</ce:para></ce:section><ce:section id="s1525"><ce:section-title id="st1430">Rehabilitation</ce:section-title><ce:para id="p4225">The necrotic muscle of an acute myocardial infarct takes 4–6 weeks to be replaced with fibrous tissue and it is conventional to restrict physical activities during this period. When there are no complications, the patient can mobilise on the second day, return home in 2–3 days and gradually increase activity, with the aim of returning to work in 4 weeks. The majority of patients may resume driving after 1–4 weeks, although, in most countries, drivers of heavy goods and public service vehicles require special assessment before returning to work. Emotional problems, such as denial, anxiety and depression, are common and must be addressed. Some patients are severely and even permanently incapacitated as a result of the psychological effects of acute coronary syndrome rather than the physical ones, and all benefit from thoughtful explanation, counselling and reassurance. Many patients mistakenly believe that stress was the cause of their heart attack and may restrict their activity inappropriately. The patient's spouse or partner will also require emotional support, information and counselling. Formal rehabilitation programmes, based on graded exercise protocols with individual and group counselling, are often very successful and, in some cases, have been shown to improve the long-term outcome.</ce:para></ce:section><ce:section id="s1530"><ce:section-title id="st1435">Implantable defibrillators</ce:section-title><ce:para id="p4230">ICDs are of benefit in preventing sudden cardiac death in patients who have severe left ventricular impairment (ejection fraction ≤ 30%) after MI (<ce:cross-ref id="crf9545" refid="s1115">p. 483</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s1535"><ce:section-title id="st1440">Prognosis</ce:section-title><ce:para id="p4235">The prognosis of patients who have survived an acute coronary syndrome is related to the extent of residual myocardial ischaemia, the degree of myocardial damage and the presence of ventricular arrhythmias. In almost one-quarter of all cases of MI, death occurs within a few minutes without medical care. Half the deaths occur within 24 hours of the onset of symptoms and about 40% of all affected patients die within the first month. The prognosis of those who survive to reach hospital is much better, with a 28-day survival of more than 85%. Patients with unstable angina have a mortality of approximately half that of patients with MI. Early death is usually due to an arrhythmia and is independent of the extent of MI. However, late outcomes are determined by the extent of myocardial damage, and unfavourable features include poor left ventricular function, AV block and persistent ventricular arrhythmias. The prognosis is worse for anterior than for inferior infarcts. Bundle branch block and high cardiac marker levels both indicate extensive myocardial damage. Old age, depression and social isolation are also associated with a higher mortality. Of those who survive an acute attack, more than 80% live for a further year, about 75% for 5 years, 50% for 10 years and 25% for 20 years.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1540"><ce:section-title id="st1445">Non-cardiac surgery in patients with heart disease</ce:section-title><ce:para id="p4240">Non-cardiac surgery, particularly major vascular, abdominal or thoracic surgery, can precipitate serious perioperative cardiac complications, such as MI and death, in patients with CAD and other forms of heart disease. Careful pre-operative cardiac assessment may help to determine the balance of benefit versus risk on an individual basis, and identify measures that minimise the operative risk (<ce:cross-ref id="crf1255" refid="b0305">Box 16.54</ce:cross-ref><ce:float-anchor refid="b0305"/>).</ce:para><ce:para id="p4275">A hypercoagulable state is part of the normal physiological response to surgery, and may promote coronary thrombosis leading to an acute coronary syndrome in the early post-operative period. Patients with a history of recent PCI or acute coronary syndrome are at greatest risk and, whenever possible, elective non-cardiac surgery should be avoided for 3 months after such an event. Where possible, antiplatelet agents, statins and β-blocker therapies should be continued throughout the perioperative period.</ce:para><ce:para id="p4280">Careful attention to fluid balance during and after surgery is particularly important in patients with impaired left ventricular function and valvular heart disease because vasopressin is released as part of the normal physiological response to surgery and, in these circumstances, the over-zealous administration of intravenous fluids can easily precipitate heart failure. Patients with severe valvular heart disease, particularly aortic stenosis and mitral stenosis, are also at increased risk because they may not be able to increase their cardiac output in response to the stress of surgery.</ce:para><ce:para id="p4285">AF may be triggered by hypoxia, myocardial ischaemia or heart failure, and is a common post-operative complication in patients with pre-existing heart disease. It usually terminates spontaneously when the precipitating factors have been eliminated, but digoxin or β-blockers can be prescribed to control the heart rate.</ce:para></ce:section></ce:section><ce:section id="s1545"><ce:section-title id="st1450">Peripheral arterial disease</ce:section-title><ce:para id="p4290">Peripheral arterial disease (PAD) has been estimated to affect about 20% of individuals aged 55–75 years in the UK. Only 25% of patients present with symptoms, the most common of which is intermittent claudication (IC). About 1–2% of patients with IC per year progress to a point where amputation and/or revascularisation are required. However, the annual mortality rate of people with IC is about 5%, which is 2–3 times higher than the general population of the same age and gender. The cause of death is typically an MI or stroke, reflecting the fact that IC nearly always occurs in association with widespread atherosclerosis.</ce:para><ce:section id="s1550"><ce:section id="s1555"><ce:section id="s1560"><ce:section-title id="st1455">Pathogenesis</ce:section-title><ce:para id="p4295">In developed countries, almost all PAD is due to atherosclerosis and the risk factors are the same as described in patients with CAD. As with CAD, plaque rupture is responsible for the most serious manifestations of PAD, and not infrequently occurs in a plaque that hitherto has been asymptomatic. The clinical manifestations depend on the anatomical site, the presence or absence of a collateral supply, the speed of onset and the mechanism of injury (<ce:cross-ref id="crf1260" refid="b0310">Box 16.55</ce:cross-ref><ce:float-anchor refid="b0310"/>). Approximately 5–10% of patients with PAD have diabetes but this proportion increases to 30–40% in those with severe limb ischaemia. The mechanism of PAD in diabetes is atheroma affecting the medium-sized to large arteries rather than obstructive microangiopathy and so diabetes is not a contraindication to lower limb revascularisation. Nevertheless, diabetic patients with PAD pose a number of particular problems (<ce:cross-ref id="crf1265" refid="b0315">Box 16.56</ce:cross-ref><ce:float-anchor refid="b0315"/>).</ce:para></ce:section><ce:section id="s1625"><ce:section-title id="st1520">Clinical features</ce:section-title><ce:para id="p4430">Symptomatic PAD affects the legs about eight times more commonly than the arms. Several locations may be affected, including the aortoiliac vessels, the femoropopliteal vessels and the infrapopliteal vessels. One or more of these segments may be affected in a variable and asymmetric manner. In the arm, the subclavian artery is the most common site of disease. Peripheral artery disease can present clinically in a variety of ways, as detailed below.</ce:para><ce:section id="s1630"><ce:section-title id="st1525">Intermittent claudication</ce:section-title><ce:para id="p4435">This is the most common presentation of PAD affecting the lower limbs. It is characterised by ischaemic pain affecting the muscles of the leg. The pain is usually felt in the calf because the disease most commonly affects the superficial femoral artery, but it may be felt in the thigh or buttock if the iliac arteries are involved. Typically, the pain comes on after walking, often once a specific distance has been covered, and rapidly subsides on resting. Resumption of walking leads to a return of the pain. Most patients describe a cyclical pattern of exacerbation and resolution due to the progression of disease and the subsequent development of collaterals. When PAD affects the upper limbs, arm claudication may occur, although this is uncommon.</ce:para></ce:section><ce:section id="s1635"><ce:section-title id="st1530">Critical limb ischaemia</ce:section-title><ce:para id="p4440">Critical limb ischaemia (CLI) is defined as rest pain requiring opiate analgesia, and/or ulceration or gangrene that has been present for more than 2 weeks, in the presence of an ankle BP of less than 50 mmHg. The typical progression of symptoms in CLI is summarised in <ce:cross-ref id="crf1270" refid="f0390">Figure 16.71</ce:cross-ref><ce:float-anchor refid="f0390"/>. Rest pain only, with ankle pressures above 50 mmHg, is known as subcritical limb ischaemia (SCLI). The term severe limb ischaemia (SLI) is used to describe the situation where either CLI and SCLI occurs. Whereas IC is usually due to single-segment plaque, SLI is always due to multilevel disease. Many patients with SLI have not previously sought medical advice, principally because they have other comorbidity that prevents them from walking to a point where IC develops. Patients with SLI are at high risk of losing their limb, and sometimes their life, in a matter of weeks or months without surgical bypass or endovascular revascularisation by angioplasty or stenting. Treatment of these patients is difficult, however, because most are elderly with extensive and severe disease and significant multisystem comorbidities.</ce:para></ce:section><ce:section id="s1640"><ce:section-title id="st1535">Acute limb ischaemia</ce:section-title><ce:para id="p4445">This is most frequently caused by acute thrombotic occlusion of a pre-existing stenotic arterial segment, thromboembolism, and trauma that may be iatrogenic. The typical presentation is with paralysis (inability to wiggle toes/fingers) and paraesthesia (loss of light touch over the dorsum of the foot/hand), the so-called ‘Ps of acute ischaemia’ (<ce:cross-ref id="crf1275" refid="b0320">Box 16.57</ce:cross-ref><ce:float-anchor refid="b0320"/>). These features are non-specific, however, and inconsistently related to its severity. Pain on squeezing the calf indicates muscle infarction and impending irreversible ischaemia. All patients with suspected acutely ischaemic limbs must be discussed immediately with a vascular surgeon; a few hours can make the difference between death/amputation and complete recovery of limb function. If there are no contraindications (acute aortic dissection or trauma, particularly head injury), an intravenous bolus of heparin (3000–5000 U) should be administered to limit propagation of thrombus and protect the collateral circulation. Distinguishing thrombosis from embolism is frequently difficult but is important because treatment and prognosis are different (<ce:cross-ref id="crf1280" refid="b0325">Box 16.58</ce:cross-ref><ce:float-anchor refid="b0325"/>). Acute limb ischaemia due to thrombosis in situ can usually be treated medically in the first instance with intravenous heparin (target activated partial thromboplastin time (APTT) 2.0–3.0), antiplatelet agents, high-dose statins, intravenous fluids to avoid dehydration, correction of anaemia, oxygen and sometimes prostaglandins, such as iloprost. Embolism will normally result in extensive tissue necrosis within 6 hours unless the limb is revascularised. The indications for thrombolysis, if any, remain controversial. Irreversible ischaemia mandates early amputation or palliative care.</ce:para></ce:section><ce:section id="s1645"><ce:section-title id="st1540">Atheroembolism</ce:section-title><ce:para id="p4460">This may be a presenting feature of PAD affecting the subclavian arteries. The presentation is with blue fingers, which are due to small emboli lodging in digital arteries. This may be confused with Raynaud's phenomenon (<ce:intra-ref id="ii0560" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1335">p. 1035</ce:intra-ref>) but the symptoms of atheroembolism are typically unilateral rather than bilateral as in Raynaud's.</ce:para></ce:section><ce:section id="s1650"><ce:section-title id="st1545">Subclavian steal</ce:section-title><ce:para id="p4465">This can be a feature of PAD affecting the upper limbs. The presentation is with dizziness, cortical blindness and/or collapse, which occurs when the arm is used and is thought to be caused by diversion (or steal) of blood from the brain to the limbs via the vertebral artery.</ce:para></ce:section></ce:section><ce:section id="s1655"><ce:section-title id="st1550">Investigations</ce:section-title><ce:para id="p4470">The presence and severity of ischaemia can usually be determined by clinical examination (<ce:cross-ref id="crf1285" refid="b0330">Box 16.59</ce:cross-ref><ce:float-anchor refid="b0330"/>) and measurement of the ankle–brachial pressure index (ABPI), which is the ratio between the highest systolic ankle and brachial blood pressures. In health, the ABPI is over 1.0, in IC typically 0.5–0.9 and in CLI usually less than 0.5. Further investigation with duplex ultrasonography, MRI or CT with intravenous injection of contrast agents may be used to characterise the sites of involvement further. Intra-arterial digital subtraction angiography (IA-DSA) is usually reserved for those undergoing endovascular revascularisation. Other investigations should include a full blood count to look for evidence of treatable secondary causes, such as thrombocythaemia; measurement of lipids to check for evidence of hyperlipidaemia; and measurement of blood glucose to check for evidence of diabetes.</ce:para></ce:section><ce:section id="s1660"><ce:section-title id="st1555">Management</ce:section-title><ce:para id="p4520">Key elements of medical management are summarised in <ce:cross-ref id="crf1290" refid="b0335">Box 16.60</ce:cross-ref><ce:float-anchor refid="b0335"/>. This consists of smoking cessation (if applicable), taking regular exercise, antiplatelet therapy with low-dose aspirin or clopidogrel, therapy with a statin, and treatment of coexisting disease such as diabetes, hypertension or polycythaemia. Recently, the antiplatelet drug vorapaxar, a selective antagonist of the protease-activated receptor 1 (PAR-1) that regulates platelet activation, has been licensed in combination with either aspirin or clopidogrel in patients with PAD. The peripheral vasodilator cilostazol has been shown to improve walking distance and should be considered in patients who do not respond adequately to best medical therapy. Intervention with angioplasty, stenting, endarterectomy or bypass is usually considered only after medical therapy has been given at least 6 months to effect symptomatic improvement, and then just in patients who are severely disabled or whose livelihood is threatened by their disability. Subclavian artery disease is usually treated by means of angioplasty and stenting, as carotid–subclavian bypass surgery can be technically difficult.</ce:para><ce:para id="p4590"><ce:float-anchor refid="b0340"/></ce:para></ce:section></ce:section><ce:section id="s1665"><ce:section-title id="st1560">Buerger's disease</ce:section-title><ce:para id="p4620">Buerger's disease or thromboangiitis obliterans is an inflammatory disease of the arteries that is distinct from atherosclerosis and usually presents in young (20–30 years) male smokers. It is most common in those from the Mediterranean and North Africa. It characteristically affects distal arteries, giving rise to claudication in the feet or rest pain in the fingers or toes. Wrist and ankle pulses are absent but brachial and popliteal pulses are present. It may also affect the veins, giving rise to superficial thrombophlebitis. It often remits if the patient stops smoking. Symptomatic therapy with vasodilators such as prostacyclin and calcium antagonists or sympathectomy may also be helpful. Major limb amputation is the most frequent outcome if patients continue to smoke.</ce:para></ce:section><ce:section id="s1670"><ce:section-title id="st1565">Raynaud's syndrome</ce:section-title><ce:para id="p4625">This common disorder affects 5–10% of young women aged 15–30 years in temperate climates. It does not progress to ulceration or infarction, and significant pain is unusual. The underlying cause is unclear and no investigation is necessary. The patient should be reassured and advised to avoid exposure to cold. Usually, no other treatment is required, although vasodilators such as nifedipine can may be helpful if symptoms are troublesome. More severe Raynaud's syndrome can also occur in association with digital ulceration in patients with connective tissue disease. This is discussed in more detail on <ce:intra-ref id="ii0565" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1335">page 1035</ce:intra-ref>.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1675"><ce:section-title id="st1570">Diseases of the aorta</ce:section-title><ce:section id="s1680"><ce:section-title id="st1575">Aortic aneurysm</ce:section-title><ce:para id="p4630">Aortic aneurysm is defined to exist when there is an abnormal dilatation of the aortic lumen. The most common site is the infrarenal abdominal aorta. The suprarenal abdominal aorta and a variable length of the descending thoracic aorta may be affected in 10–20% of patients but the ascending aorta is usually spared. Abdominal aortic aneurysms (AAAs) affect men three times more commonly than women and are estimated to occur in about 5% of men over the age of 60 years.</ce:para><ce:section id="s1685"><ce:section id="s1690"><ce:section-title id="st1580">Pathogenesis</ce:section-title><ce:para id="p4635">The most common cause of aortic aneurysm is atherosclerosis, the risk factors for which have previously been described (<ce:cross-ref id="crf9550" refid="s1135">p. 484</ce:cross-ref>). Genetic factors that predispose to hypertension, hyperlipidaemia and diabetes all play a role in the pathogenesis of aortic aneurysm but there appears to be an additional and specific genetic component since aortic aneurysm tends to run in families. This may explain in part why only some patients with risk factors for atheroma develop aneurysmal disease. Marfan's syndrome is an inherited disorder of connective tissue that is associated with aortic aneurysm and aortic dissection (<ce:cross-ref id="crf9555" refid="p4835">p. 508</ce:cross-ref>). The features and management of this disorder are discussed on <ce:cross-ref id="crf9560" refid="p4835">page 508</ce:cross-ref>.</ce:para></ce:section><ce:section id="s1695"><ce:section-title id="st1585">Clinical features</ce:section-title><ce:para id="p4640">The clinical presentation is dependent on the site of the aneurysm. Thoracic aneurysms may typically present with acute severe chest pain (<ce:intra-ref id="ii0575" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0030">p. 176</ce:intra-ref>) but other features, including aortic regurgitation, compressive symptoms such as stridor (trachea, bronchus), hoarseness (recurrent laryngeal nerve) and superior vena cava syndrome, may occur (<ce:cross-ref id="crf1295" refid="f0400">Fig. 16.72A</ce:cross-ref><ce:float-anchor refid="f0400"/>). If the aneurysm erodes into an adjacent structure, such as the oesophagus or bronchus, the presentation may be with massive bleeding. AAAs affect the infrarenal segment of the aorta. They can present in a number of ways, as summarised in <ce:cross-ref id="crf1300" refid="b0345">Box 16.62</ce:cross-ref><ce:float-anchor refid="b0345"/>. The usual age at presentation is 65–75 years for elective presentations and 75–85 years for emergency presentations.</ce:para></ce:section><ce:section id="s1725"><ce:section-title id="st1615">Investigations</ce:section-title><ce:para id="p4710">Ultrasound is the best way of establishing the diagnosis of an abdominal aneurysm and of following up patients with asymptomatic aneurysms that are not yet large enough to warrant surgical repair. In the UK, a national screening programme for men over 65 years of age has been introduced using ultrasound scanning. For every 10 000 men scanned, 65 ruptures are prevented and 52 lives saved. CT provides more accurate information about the size and extent of the aneurysm, the surrounding structures and the presence of any other intra-abdominal pathology. It is the standard pre-operative investigation but is not suitable for surveillance because of the high cost and radiation dose.</ce:para></ce:section><ce:section id="s1730"><ce:section-title id="st1620">Management</ce:section-title><ce:para id="p4715">The risks of surgery generally outweigh the risks of rupture until an asymptomatic AAA has reached a maximum of 5.5 cm in diameter. All symptomatic AAAs should be considered for repair, not only to rid the patient of symptoms but also because pain often predates rupture. Distal embolisation is a strong indication for repair, regardless of size, because otherwise limb loss is common. Most patients with a ruptured AAA do not survive to reach hospital, but if they do and surgery is thought to be appropriate, there must be no delay in getting them to the operating theatre to clamp the aorta.</ce:para><ce:para id="p4720">Open AAA repair has been the treatment of choice in both the elective and the emergency settings, and entails replacing the aneurysmal segment with a prosthetic (usually Dacron) graft. The 30-day mortality for this procedure is approximately 5–8% for elective asymptomatic AAA, 10–20% for emergency symptomatic AAA and 50% for ruptured AAA. However, patients who survive the operation to leave hospital have a long-term survival approaching that of the normal population. Increasingly, endovascular aneurysm repair (EVAR), using a stent graft introduced via the femoral arteries in the groin, is replacing open surgery. It is cost-effective and likely to become the treatment of choice for infrarenal AAA. It is possible to treat many suprarenal and thoraco-abdominal aneurysms by EVAR too. If the aneurysm is secondary to Marfan's syndrome, treatment with β-blockers reduces the rate of aortic dilatation and the risk of rupture. Elective replacement of the ascending aorta may also be considered in patients with evidence of progressive aortic dilatation but carries a mortality of 5–10%.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1735"><ce:section-title id="st1625">Aortic dissection</ce:section-title><ce:para id="p4725">Aortic dissection occurs when a breach in the integrity of the aortic wall allows arterial blood to enter the media, which is then split into two layers, creating a false lumen alongside the existing or true lumen (<ce:cross-ref id="crf1305" refid="f0400">Fig. 16.72B</ce:cross-ref>). The aortic valve may be damaged and the branches of the aorta may be compromised. Typically, the false lumen eventually re-enters the true lumen, creating a double-barrelled aorta, but it may also rupture into the left pleural space or pericardium with fatal consequences. The peak incidence is in the sixth and seventh decades but dissection can occur in younger patients, usually in association with Marfan's syndrome, pregnancy or trauma; men are affected twice as frequently as women.</ce:para><ce:section id="s1740"><ce:section id="s1745"><ce:section-title id="st1630">Pathogenesis</ce:section-title><ce:para id="p4730">The primary event is often a spontaneous or iatrogenic tear in the intima of the aorta; multiple tears or entry points are common. Other dissections are triggered by primary haemorrhage in the media of the aorta, which then ruptures through the intima into the true lumen. This form of spontaneous bleeding from the vasa vasorum is sometimes confined to the aortic wall, when it may present as a painful intramural haematoma. Aortic disease and hypertension are the most important aetiological factors but other conditions may also be implicated (<ce:cross-ref id="crf1310" refid="b0350">Box 16.63</ce:cross-ref><ce:float-anchor refid="b0350"/>). Chronic dissections may lead to aneurysmal dilatation of the aorta, and thoracic aneurysms may be complicated by dissection. It can therefore be difficult to identify the primary pathology.</ce:para><ce:para id="p4820">Aortic dissection is classified anatomically and for management purposes into type A and type B (see <ce:cross-ref id="crf1315" refid="f0400">Fig. 16.72B</ce:cross-ref>), involving or sparing the ascending aorta, respectively. Type A dissections account for two-thirds of cases and frequently also extend into the descending aorta.</ce:para></ce:section><ce:section id="s1750"><ce:section-title id="st1635">Clinical features</ce:section-title><ce:para id="p4825">Involvement of the ascending aorta typically gives rise to anterior chest pain, and involvement of the descending aorta to intrascapular back pain. The pain is typically described as ‘tearing’ and very abrupt in onset; collapse is common. Unless there is major haemorrhage, the patient is invariably hypertensive. There may be asymmetry of the brachial, carotid or femoral pulses and signs of aortic regurgitation. Occlusion of aortic branches may cause MI (coronary), stroke (carotid), paraplegia (spinal), mesenteric infarction with an acute abdomen (coeliac and superior mesenteric), renal failure (renal) and acute limb (usually leg) ischaemia.</ce:para></ce:section><ce:section id="s1755"><ce:section-title id="st1640">Investigations</ce:section-title><ce:para id="p4830">The investigations of choice are CT or MR angiography (<ce:cross-ref id="crf1320" refid="f0405">Figs 16.73</ce:cross-ref><ce:float-anchor refid="f0405"/> and <ce:cross-ref id="crf1325" refid="f0410">16.74</ce:cross-ref><ce:float-anchor refid="f0410"/>), both of which are highly specific and sensitive. A chest X-ray should be performed. It characteristically shows broadening of the upper mediastinum and distortion of the aortic ‘knuckle’ but these findings are absent in 10% of cases. A left-sided pleural effusion is common. The ECG may show left ventricular hypertrophy in patients with hypertension or, rarely, changes of acute MI (usually inferior). Doppler echocardiography may show aortic regurgitation, a dilated aortic root and, occasionally, the flap of the dissection. TOE is particularly helpful because transthoracic echocardiography can provide images of the first 3–4 cm of the ascending aorta only (<ce:cross-ref id="crf1330" refid="f0415">Fig. 16.75</ce:cross-ref><ce:float-anchor refid="f0415"/>).</ce:para></ce:section><ce:section id="s1760"><ce:section-title id="st1645">Management</ce:section-title><ce:para id="p4835">The early mortality of acute dissection is approximately 1–5% per hour and so treatment is urgently required. Initial management comprises pain control and antihypertensive treatment. Type A dissections require emergency surgery to replace the ascending aorta. Type B aneurysms are treated medically unless there is actual or impending external rupture, or vital organ (gut, kidneys) or limb ischaemia, as the morbidity and mortality associated with surgery are very high. The aim of medical management is to maintain a mean arterial pressure (MAP) of 60–75 mmHg to reduce the force of the ejection of blood from the LV. First-line therapy is with β-blockers; the additional α-blocking properties of labetalol make it especially useful. Rate-limiting calcium channel blockers, such as verapamil or diltiazem, are used if β-blockers are contraindicated. Sodium nitroprusside may be considered if these fail to control BP adequately.</ce:para><ce:para id="p4840">Percutaneous or minimal access endoluminal repair is sometimes possible and involves either ‘fenestrating’ (perforating) the intimal flap so that blood can return from the false to the true lumen (so decompressing the former), or implanting a stent graft placed from the femoral artery (see <ce:cross-ref id="crf1335" refid="f0410">Fig. 16.74</ce:cross-ref>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s1765"><ce:section-title id="st1650">Aortitis</ce:section-title><ce:para id="p4845">Syphilis is a rare cause of aortitis that characteristically produces saccular aneurysms of the ascending aorta containing calcification. Other rare conditions associated with aortitis include Takayasu's disease (<ce:intra-ref id="ii0580" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1540">p. 1041</ce:intra-ref>), reactive arthritis (<ce:intra-ref id="ii0585" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1220">p. 1031</ce:intra-ref>), giant cell arteritis (<ce:intra-ref id="ii9015" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1555">p. 1042</ce:intra-ref>) and ankylosing spondylitis (<ce:intra-ref id="ii0590" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1165">p. 1028</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1770"><ce:section-title id="st1655">Marfan's syndrome</ce:section-title><ce:para id="p4850">Marfan's syndrome is an inherited disorder of connective tissue that is associated with a high risk of aortic aneurysm and dissection. It is inherited in an autosomal dominant manner but some cases are due to new mutations. It is a rare disorder that is estimated to affect about 0.02% of the population. Marfan's syndrome is caused by protein-coding mutations affecting the <ce:italic>FBN1</ce:italic> gene, which encodes fibrillin, an extracellular matrix protein. The causal mutations disrupt the mechanical integrity of connective tissue, giving rise to a wide range of clinical features.</ce:para><ce:section id="s1775"><ce:section id="s1780"><ce:section-title id="st1660">Clinical features</ce:section-title><ce:para id="p4855">Aortic dissection and aneurysm are the most serious complications of Marfan's syndrome but many other clinical manifestations may be observed. These include aortic and mitral valve regurgitation; skin laxity and joint hypermobility; abnormalities of body habitus, including long arms, legs and fingers (arachnodactyly), scoliosis, pectus excavatum and a high-arched palate; ocular abnormalities, such as lens dislocation and retinal detachment; and an increased risk of pneumothorax.</ce:para></ce:section><ce:section id="s1785"><ce:section-title id="st1665">Investigations</ce:section-title><ce:para id="p4860">The diagnosis is usually suspected on the basis of the characteristic clinical features and can be confirmed by genetic testing. Imaging by chest X-ray may reveal evidence of aortic dilatation but echocardiography is more sensitive and can also demonstrate valvular disease, if present. Patients with Marfan's syndrome should undergo serial monitoring of the aortic root by echocardiography; if evidence of dilatation is observed, then elective surgery should be considered.</ce:para></ce:section><ce:section id="s1790"><ce:section-title id="st1670">Management</ce:section-title><ce:para id="p4865">Treatment with β-blockers reduces the risk of aortic dilatation and should be given in all patients with Marfan's syndrome. Activities that are associated with increases in cardiac output are best avoided. Surgery to replace the aortic root can be performed in patients with progressive aortic dilatation.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1795"><ce:section-title id="st1675">Coarctation of the aorta</ce:section-title><ce:para id="p4870">Coarctation of the aorta is the term used to describe a narrowing distal to the origin of the left subclavian artery. It is most commonly due to congenital heart disease (<ce:cross-ref id="crf9565" refid="s2450">p. 531</ce:cross-ref>), but narrowing of the aorta leading to similar symptoms can occur in other conditions such as Takayasu's arteritis (<ce:intra-ref id="ii0600" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1540">p. 1041</ce:intra-ref>) and trauma. Diagnosis and management of coarctation are discussed on <ce:cross-ref id="crf9570" refid="p7100">page 534</ce:cross-ref>.</ce:para></ce:section><ce:section id="s1800"><ce:section-title id="st1680">Hypertension</ce:section-title><ce:para id="p4875">The risk of cardiovascular diseases such as stroke and CAD is closely related to levels of BP. BP follows a normal distribution in the general population and there is no specific cut-off above which the risk of cardiovascular risk suddenly increases. The diagnosis of hypertension is therefore made when systolic and diastolic values rise above a specific threshold that corresponds to the level of BP at which the risk of cardiovascular complications and benefits of treatment outweigh the treatment costs and potential side-effects of therapy. The British Hypertension Society classification, provided in <ce:cross-ref id="crf1340" refid="b0355">Box 16.64</ce:cross-ref><ce:float-anchor refid="b0355"/>, defines mild hypertension as existing when the BP is above 140/90 mmHg. Similar thresholds have been published by the European Society of Hypertension and the WHO–International Society of Hypertension. The cardiovascular risks associated with high BP depend on the combination of risk factors in an individual, such as age, gender, weight, physical activity, smoking, family history, serum cholesterol, diabetes mellitus and pre-existing vascular disease.</ce:para><ce:section id="s1805"><ce:section id="s1810"><ce:section-title id="st1685">Pathogenesis</ce:section-title><ce:para id="p4885">Many factors may contribute to the regulation of BP and the development of hypertension, including renal dysfunction, peripheral resistance, vessel tone, endothelial dysfunction, autonomic tone, insulin resistance and neurohumoral factors. In more than 95% of cases, however, no specific underlying cause of hypertension can be found. Such patients are said to have essential hypertension. Hypertension is more common in some ethnic groups, particularly African Americans and Japanese, and approximately 40–60% is explained by genetic factors. Age is a strong risk factor in all ethnic groups. Important environmental factors include a high salt intake, heavy consumption of alcohol, obesity and lack of exercise. Impaired intrauterine growth and low birth weight are associated with an increased risk of hypertension later in life. In about 5% of cases, hypertension is secondary to a specific disease, as summarised in <ce:cross-ref id="crf1345" refid="b0360">Box 16.65</ce:cross-ref><ce:float-anchor refid="b0360"/>.</ce:para><ce:para id="p4965">Hypertension has a number of adverse effects on the cardiovascular system. In larger arteries (&#x003E; 1 mm in diameter), the internal elastic lamina is thickened, smooth muscle is hypertrophied and fibrous tissue is deposited. The vessels dilate and become tortuous, and their walls become less compliant. In smaller arteries (&#x003C; 1 mm), hyaline arteriosclerosis occurs in the wall, the lumen narrows and aneurysms may develop. Widespread atheroma develops and may lead to coronary and cerebrovascular disease, particularly if other risk factors are present. These structural changes in the vasculature often perpetuate and aggravate hypertension by increasing peripheral vascular resistance and reducing renal blood flow, thereby activating the renin–angiotensin–aldosterone axis (<ce:cross-ref id="crf9575" refid="s0440">p. 461</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1815"><ce:section-title id="st1690">Clinical features</ce:section-title><ce:para id="p4970">Hypertension is usually asymptomatic until the diagnosis is made at a routine physical examination or when a complication arises. Reflecting this fact, a BP check is advisable every 5 years in adults over 40 years of age to pick up occult hypertension. Sometimes clinical features may be observed that can give a clue to the underlying cause of hypertension. These include radio-femoral delay in patients with coarctation of the aorta (see <ce:cross-ref id="crf1350" refid="f0500">Fig. 16.93</ce:cross-ref>, <ce:cross-ref id="crf9580" refid="p7100">p. 534</ce:cross-ref>), enlarged kidneys in patients with polycystic kidney disease (<ce:intra-ref id="ii0625" xlink:href="pii:B978-0-7020-7028-0.00015-9#p1755">p. 405</ce:intra-ref>), abdominal bruits that may suggest renal artery stenosis (<ce:intra-ref id="ii0630" xlink:href="pii:B978-0-7020-7028-0.00015-9#p1870">p. 406</ce:intra-ref>), and the characteristic facies and habitus of Cushing's syndrome (<ce:cross-ref id="crf1355" refid="b0360">Box 16.65</ce:cross-ref>). Examination may also reveal evidence of risk factors for hypertension, such as central obesity and hyperlipidaemia. Other signs may be observed that are due to the complications of hypertension. These include signs of left ventricular hypertrophy, accentuation of the aortic component of the second heart sound, and a fourth heart sound. AF is common and may be due to diastolic dysfunction caused by left ventricular hypertrophy or the effects of CAD.</ce:para><ce:para id="p4975">Severe hypertension can cause left ventricular failure in the absence of CAD, particularly when there is an impairment of renal function. The optic fundi are often abnormal (see <ce:cross-ref id="crf1360" refid="f0420">Fig. 16.76</ce:cross-ref><ce:float-anchor refid="f0420"/> below) and there may be evidence of generalised atheroma or specific complications, such as aortic aneurysm, PAD or stroke. Examination of the optic fundi reveals a gradation of changes linked to the severity of hypertension; fundoscopy can, therefore, provide an indication of the arteriolar damage occurring elsewhere (<ce:cross-ref id="crf1365" refid="b0365">Box 16.66</ce:cross-ref><ce:float-anchor refid="b0365"/>). ‘Cotton wool’ exudates are associated with retinal ischaemia or infarction, and fade in a few weeks (<ce:cross-ref id="crf1370" refid="f0420">Fig. 16.76A</ce:cross-ref>). ‘Hard’ exudates (small, white, dense deposits of lipid) and microaneurysms (‘dot’ haemorrhages) are more characteristic of diabetic retinopathy (see <ce:intra-ref id="ii0635" xlink:href="pii:B978-0-7020-7028-0.00027-5#f0045">Fig. 27.8</ce:intra-ref>, <ce:intra-ref id="ii0640" xlink:href="pii:B978-0-7020-7028-0.00027-5#s0430">p. 1176</ce:intra-ref>). Hypertension is also associated with central retinal vein thrombosis (<ce:cross-ref id="crf1375" refid="f0420">Fig. 16.76B</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1840"><ce:section-title id="st1715">Investigations</ce:section-title><ce:para id="p5020">A decision to embark on antihypertensive therapy effectively commits the patient to life-long treatment, so readings must be as accurate as possible. The objectives are to:<ce:list id="ulist0885"><ce:list-item id="u2530"><ce:label>•</ce:label><ce:para id="p5025">confirm the diagnosis by obtaining accurate, representative BP measurements</ce:para></ce:list-item><ce:list-item id="u2535"><ce:label>•</ce:label><ce:para id="p5030">identify contributory factors and any underlying causes</ce:para></ce:list-item><ce:list-item id="u2540"><ce:label>•</ce:label><ce:para id="p5035">assess other risk factors and quantify cardiovascular risk</ce:para></ce:list-item><ce:list-item id="u2545"><ce:label>•</ce:label><ce:para id="p5040">detect any complications that are already present</ce:para></ce:list-item><ce:list-item id="u2550"><ce:label>•</ce:label><ce:para id="p5045">identify comorbidity that may influence the choice of antihypertensive therapy.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s1845"><ce:section-title id="st1720">Blood pressure measurements</ce:section-title><ce:para id="p5050">BP measurements should be made to the nearest 2 mmHg, in the sitting position with the arm supported, and repeated after 5 minutes' rest if the first recording is high (<ce:cross-ref id="crf1380" refid="b0370">Box 16.67</ce:cross-ref><ce:float-anchor refid="b0370"/>). To avoid spuriously high readings in obese subjects, the cuff should contain a bladder that encompasses at least two-thirds of the arm circumference. Exercise, anxiety, discomfort and unfamiliar surroundings can all lead to a transient rise in BP. Sphygmomanometry, particularly when performed by a doctor, can cause a transient elevation in BP, which has been termed ‘white coat’ hypertension. It has been estimated that up to 20% of patients who are found to have raised BP at outpatient clinics have a normal BP when it is recorded by automated devices used at home. The risk of cardiovascular disease in these patients is less than that in patients with sustained hypertension but greater than that in normotensive subjects. If clinic BP measurements show borderline levels of BP or if white coat hypertension is suspected, then ambulatory measurement or home-based measurements may be of value in confirming the diagnosis.</ce:para></ce:section><ce:section id="s1850"><ce:section-title id="st1725">Ambulatory blood pressure measurements</ce:section-title><ce:para id="p5105">A series of automated ambulatory BP measurements obtained over 24 hours or longer provide a better profile than a limited number of clinic readings and correlate more closely with evidence of target organ damage than casual BP measurements. Treatment thresholds and targets (see <ce:cross-ref id="crf1385" refid="b0390">Box 16.71</ce:cross-ref> below) must be adjusted downwards, however, because ambulatory BP readings are systematically lower (approximately 12/7 mmHg) than clinic measurements. The average ambulatory daytime (not 24-hour or night-time) BP should be used to guide management decisions.</ce:para></ce:section><ce:section id="s1855"><ce:section-title id="st1730">Home blood pressure measurements</ce:section-title><ce:para id="p5110">Patients can measure their own BP at home using a range of commercially available semi-automatic devices. The value of such measurements is less well established and is dependent on the environment and timing of the readings measured. Home or ambulatory BP measurements are particularly helpful in patients with unusually labile BP, those with refractory hypertension, those who may have symptomatic hypotension, and those in whom white coat hypertension is suspected.</ce:para></ce:section><ce:section id="s1860"><ce:section-title id="st1735">Other investigations</ce:section-title><ce:para id="p5115">All hypertensive patients should undergo a limited number of investigations (<ce:cross-ref id="crf1390" refid="b0375">Box 16.68</ce:cross-ref><ce:float-anchor refid="b0375"/>) but additional investigations are appropriate in patients younger than 40 years of age or those with resistant hypertension (<ce:cross-ref id="crf1395" refid="b0380">Box 16.69</ce:cross-ref><ce:float-anchor refid="b0380"/>). Family history, lifestyle (exercise, salt intake, smoking habit) and other risk factors should also be recorded. A careful history will identify those patients with drug- or alcohol-induced hypertension and may elicit the symptoms of other causes of secondary hypertension, such as phaeochromocytoma (paroxysmal headache, palpitation and sweating, <ce:intra-ref id="ii0660" xlink:href="pii:B978-0-7020-7028-0.00018-4#p4045">p. 675</ce:intra-ref>) or complications such as CAD.</ce:para></ce:section></ce:section><ce:section id="s1865"><ce:section-title id="st1740">Management</ce:section-title><ce:para id="p5210">The objective of antihypertensive therapy is to reduce the incidence of adverse cardiovascular events, particularly CAD, stroke and heart failure. Randomised controlled trials have demonstrated that antihypertensive therapy can reduce the incidence of stroke and, to a lesser extent, CAD. The relative benefits (approximately 30% reduction in risk of stroke and 20% reduction in risk of CAD) are similar in all patient groups<ce:italic>,</ce:italic> so the absolute benefit of treatment (total number of events prevented) is greatest in those at highest risk<ce:italic>.</ce:italic> For example, to extrapolate from the Medical Research Council (MRC) Mild Hypertension Trial (1985), 566 young patients would have to be treated with bendroflumethiazide for 1 year to prevent 1 stroke, while in the MRC trial of antihypertensive treatment in the elderly (1992), 1 stroke was prevented for every 286 patients treated for 1 year.</ce:para><ce:para id="p5215">A formal estimate of absolute cardiovascular risk, which takes account of all the relevant risk factors, may help to determine whether the likely benefits of therapy will outweigh its costs and hazards. A variety of risk algorithms are available for this purpose, such as the Joint British Societies risk calculator (<ce:cross-ref id="crf1400" refid="f0425">Fig. 16.77</ce:cross-ref><ce:float-anchor refid="f0425"/> and see ‘Further information’). Most of the excess morbidity and mortality associated with hypertension are attributable to CAD and many treatment guidelines are therefore based on estimates of the 10-year CAD risk. Total cardiovascular risk can be estimated by multiplying CAD risk by 4/3 (i.e. if CAD risk is 30%, cardiovascular risk is 40%). The value of this approach can be illustrated by comparing the two hypothetical cases on <ce:cross-ref id="crf9585" refid="s1245">page 487</ce:cross-ref>.</ce:para><ce:section id="s1870"><ce:section-title id="st1745">Intervention thresholds</ce:section-title><ce:para id="p5220">Systolic BP and diastolic BP are both powerful predictors of cardiovascular risk. The British Hypertension Society management guidelines therefore utilise both readings, and treatment should be initiated if they exceed the given threshold (<ce:cross-ref id="crf1405" refid="f0430">Fig. 16.78</ce:cross-ref><ce:float-anchor refid="f0430"/>).</ce:para><ce:para id="p5225">Patients with diabetes or cardiovascular disease are at particularly high risk and the threshold for initiating antihypertensive therapy is therefore lower (≥ 140/90 mmHg) in these patient groups. The thresholds for treatment in the elderly are the same as for younger patients (<ce:cross-ref id="crf1410" refid="b0385">Box 16.70</ce:cross-ref><ce:float-anchor refid="b0385"/>).</ce:para></ce:section><ce:section id="s1875"><ce:section-title id="st1750">Treatment targets</ce:section-title><ce:para id="p5265">The optimum BP for reduction of major cardiovascular events has been found to be 139/83 mmHg, and even lower in patients with diabetes mellitus. Moreover, reducing BP below this level causes no harm. The targets suggested by the British Hypertension Society (<ce:cross-ref id="crf1415" refid="b0390">Box 16.71</ce:cross-ref><ce:float-anchor refid="b0390"/>) are ambitious. Primary care strategies have been devised to improve screening and detection of hypertension that, in the past, remained undetected in up to half of affected individuals. Application of new guidelines should help establish patients on appropriate treatment, and allow step-up if lifestyle modification and first-line drug therapy fail to control hypertension.</ce:para><ce:para id="p5275">Patients taking antihypertensive therapy require follow-up at regular intervals to monitor BP, minimise side-effects and reinforce lifestyle advice.</ce:para></ce:section><ce:section id="s1880"><ce:section-title id="st1755">Non-drug therapy</ce:section-title><ce:para id="p5280">Appropriate lifestyle measures may obviate the need for drug therapy in patients with borderline hypertension, reduce the dose and/or the number of drugs required in patients with established hypertension, and directly reduce cardiovascular risk.</ce:para><ce:para id="p5285">Correcting obesity, reducing alcohol intake, restricting salt intake, taking regular physical exercise and increasing consumption of fruit and vegetables can all lower BP. Moreover, stopping smoking, eating oily fish and adopting a diet that is low in saturated fat may produce further reductions in cardiovascular risk that are independent of changes in BP.</ce:para></ce:section><ce:section id="s1885"><ce:section-title id="st1760">Drug therapy</ce:section-title><ce:section id="s1890"><ce:section-title id="st1765">Thiazides</ce:section-title><ce:para id="p5290">The mechanism of action of these drugs is incompletely understood and it may take up to a month for the maximum effect to be observed. An appropriate daily dose is 2.5 mg bendroflumethiazide or 0.5 mg cyclopenthiazide. More potent loop diuretics, such as furosemide (40 mg daily) or bumetanide (1 mg daily), have few advantages over thiazides in the treatment of hypertension, unless there is substantial renal impairment or they are used in conjunction with an ACE inhibitor.</ce:para></ce:section><ce:section id="s1895"><ce:section-title id="st1770">ACE inhibitors</ce:section-title><ce:para id="p5295">ACE inhibitors (enalapril 20 mg daily, ramipril 5–10 mg daily or lisinopril 10–40 mg daily) are effective and usually well tolerated. They should be used with care in patients with impaired renal function or renal artery stenosis because they can reduce glomerular filtration rate and precipitate renal failure. Electrolytes and creatinine should be checked before and 1–2 weeks after commencing therapy. Side-effects include first-dose hypotension, cough, rash, hyperkalaemia and renal dysfunction.</ce:para></ce:section><ce:section id="s1900"><ce:section-title id="st1775">Angiotensin receptor blockers</ce:section-title><ce:para id="p5300">ARBs (irbesartan 150–300 mg daily, valsartan 40–160 mg daily) have similar efficacy to ACE inhibitors but they do not cause cough and are better tolerated.</ce:para></ce:section><ce:section id="s1905"><ce:section-title id="st1780">Calcium channel antagonists</ce:section-title><ce:para id="p5305">Amlodipine (5–10 mg daily) and nifedipine (30–90 mg daily) are effective and usually well-tolerated antihypertensive drugs that are particularly useful in older people. Side-effects include flushing, palpitations and fluid retention. The rate-limiting calcium channel antagonists (diltiazem 200–300 mg daily, verapamil 240 mg daily) can be useful when hypertension coexists with angina but may cause bradycardia. The main side-effect of verapamil is constipation.</ce:para></ce:section><ce:section id="s1910"><ce:section-title id="st1785">Beta-blockers</ce:section-title><ce:para id="p5310">These are no longer used as first-line antihypertensive therapy, except in patients with another indication for the drug such as angina. Metoprolol (100–200 mg daily), atenolol (50–100 mg daily) and bisoprolol (5–10 mg daily), which preferentially block cardiac β<ce:inf loc="post">1</ce:inf>-adrenoceptors, should be used rather than non-selective agents that also block β<ce:inf loc="post">2</ce:inf>-adrenoceptors, which mediate vasodilatation and bronchodilatation.</ce:para></ce:section><ce:section id="s1915"><ce:section-title id="st1790">Combined β- and α-blockers</ce:section-title><ce:para id="p5315">Labetalol (200 mg–2.4 g daily in divided doses) and carvedilol (6.25–25 mg twice daily) are combined β- and α-adrenoceptor antagonists that are sometimes more effective than pure β-blockers. Labetalol can be used as an infusion in malignant phase hypertension (see below).</ce:para></ce:section><ce:section id="s1920"><ce:section-title id="st1795">Other vasodilators</ce:section-title><ce:para id="p5320">A variety of other vasodilators may be used. These include the α<ce:inf loc="post">1</ce:inf>-adrenoceptor antagonists prazosin (0.5–20 mg daily in divided doses), indoramin (25–100 mg twice daily) and doxazosin (1–16 mg daily), and drugs that act directly on vascular smooth muscle, such as hydralazine (25–100 mg twice daily) and minoxidil (10–50 mg daily). Side-effects include first-dose and postural hypotension, headache, tachycardia and fluid retention. Minoxidil also causes increased facial hair and is therefore unsuitable for female patients.</ce:para></ce:section><ce:section id="s1925"><ce:section-title id="st1800">Aspirin</ce:section-title><ce:para id="p5325">Antiplatelet therapy is a powerful means of reducing cardiovascular risk but may cause bleeding, particularly intracerebral haemorrhage, in a small number of patients. The benefits are thought to outweigh the risks in hypertensive patients aged 50 years or over who have well-controlled BP and either target organ damage or diabetes or a 10-year CAD risk of at least 15% (or 10-year cardiovascular disease risk of at least 20%).</ce:para></ce:section><ce:section id="s1930"><ce:section-title id="st1805">Statins</ce:section-title><ce:para id="p5330">Treating hyperlipidaemia can produce a substantial reduction in cardiovascular risk. These drugs are strongly indicated in patients who have established vascular disease, or hypertension with a high (at least 10% in 10 years) risk of developing cardiovascular disease (<ce:intra-ref id="ii0670" xlink:href="pii:B978-0-7020-7028-0.00014-7#u1955">p. 376</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s1935"><ce:section-title id="st1810">Choice of antihypertensive drug</ce:section-title><ce:para id="p5335">Trials that have compared thiazides, calcium antagonists, ACE inhibitors and ARBs have not shown consistent differences in outcome, efficacy, side-effects or quality of life. Beta-blockers, which previously featured as first-line therapy in guidelines, have a weaker evidence base. The choice of antihypertensive therapy is initially dictated by the patient's age and ethnic background, although cost and convenience will influence the exact drug and preparation used. Response to initial therapy and side-effects guide subsequent treatment. Comorbid conditions also have an influence on initial drug selection (<ce:cross-ref id="crf1430" refid="b0395">Box 16.72</ce:cross-ref><ce:float-anchor refid="b0395"/>); for example, a β-blocker might be the most appropriate treatment for a patient with angina. Thiazide diuretics and dihydropyridine calcium channel antagonists are the most suitable drugs for treatment in older people.</ce:para></ce:section><ce:section id="s1940"><ce:section-title id="st1815">Combination therapy</ce:section-title><ce:para id="p5345">Although some patients can be treated with a single antihypertensive drug, a combination of drugs is often required to achieve optimal control (<ce:cross-ref id="crf1495" refid="f0435">Fig. 16.79</ce:cross-ref><ce:float-anchor refid="f0435"/>). Combination therapy may be desirable for other reasons; for example, low-dose therapy with two drugs may produce fewer unwanted effects than treatment with the maximum dose of a single drug. Some drug combinations have complementary or synergistic actions; for example, thiazides increase activity of the renin–angiotensin system, while ACE inhibitors block it.</ce:para></ce:section><ce:section id="s1945"><ce:section-title id="st1820">Refractory hypertension</ce:section-title><ce:para id="p5350">Refractory hypertension refers to the situation where multiple drug treatments do not give adequate control of BP. Although this may be due to genuine resistance to therapy in some cases, a more common cause of treatment failure is non-adherence to drug therapy. Resistant hypertension can also be caused by failure to recognise an underlying cause, such as renal artery stenosis or phaeochromocytoma. There is no easy solution to problems with adherence but simple treatment regimens, attempts to improve rapport with the patient and careful supervision can all help. Spironolactone is a particularly useful addition in patients with treatment-resistant hypertension.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1950"><ce:section-title id="st1825">Accelerated hypertension</ce:section-title><ce:para id="p5355">Accelerated or malignant hypertension is a rare condition that can complicate hypertension of any aetiology. It is characterised by accelerated microvascular damage with necrosis in the walls of small arteries and arterioles (fibrinoid necrosis) and by intravascular thrombosis. The diagnosis is based on evidence of high BP and rapidly progressive end-organ damage, such as retinopathy (grade 3 or 4), renal dysfunction (especially proteinuria) and/or hypertensive encephalopathy (see above). Left ventricular failure may occur and, if this is untreated, death occurs within months.</ce:para><ce:section id="s1955"><ce:section-title id="st1830">Management</ce:section-title><ce:para id="p5360">In accelerated phase hypertension, lowering BP too quickly may compromise tissue perfusion due to altered autoregulation and can cause cerebral damage, including occipital blindness, and precipitate coronary or renal insufficiency. Even in the presence of cardiac failure or hypertensive encephalopathy, a controlled reduction to a level of about 150/90 mmHg over a period of 24–48 hours is ideal.</ce:para><ce:para id="p5365">In most patients, it is possible to avoid parenteral therapy and bring BP under control with bed rest and oral drug therapy. Intravenous or intramuscular labetalol (2 mg/min to a maximum of 200 mg), intravenous GTN (0.6–1.2 mg/hr), intramuscular hydralazine (5 or 10 mg aliquots repeated at half-hourly intervals) and intravenous sodium nitroprusside (0.3–1.0 µg/kg body weight/min) are all effective but require careful supervision, preferably in a high-dependency unit.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1960"><ce:section-title id="st1835">Diseases of the heart valves</ce:section-title><ce:para id="p5370">The heart valves allow forward movement of blood through the cardiac chambers when they are open and prevent backward flow when they are closed. Diseased valve may become narrowed, obstructing forward flow, or become leaky, causing backward flow or regurgitation. Breathlessness is a common symptom of valve disease, and acute severe breathlessness may be a presenting symptom of valve failure. The causes of this are shown in <ce:cross-ref id="crf9100" refid="b0060">Box 16.73</ce:cross-ref><ce:float-anchor refid="b0060"/>. Predisposition to valvular disease may be genetically determined, can arise as the result of rheumatic fever or infections, or can occur in association with dilatation of the cardiac chambers in heart failure. The principal causes of valvular disease are summarised in <ce:cross-ref id="crf1500" refid="b0400">Box 16.74</ce:cross-ref><ce:float-anchor refid="b0400"/>.</ce:para><ce:section id="s1965"><ce:section-title id="st1840">Rheumatic heart disease</ce:section-title><ce:section id="s1970"><ce:section-title id="st1845">Acute rheumatic fever</ce:section-title><ce:para id="p5440">Acute rheumatic fever usually affects children and young adults between the ages of 5 and 15 years. It is now rare in high-income countries in Western Europe and North America, where the incidence is about 0.5 cases per 100 000, but remains endemic in the Indian subcontinent, Africa and South America. Recent studies indicate that the current incidence of rheumatic heart disease in India ranges between 13 and 150 cases per 100 000 population per year and it is by far the most common cause of acquired heart disease in childhood and adolescence in that country.</ce:para><ce:section id="s1975"><ce:section-title id="st1850">Pathogenesis</ce:section-title><ce:para id="p5445">The condition is triggered by an immune-mediated delayed response to infection with specific strains of group A streptococci, which have antigens that cross-react with cardiac myosin and sarcolemmal membrane proteins. Antibodies produced against the streptococcal antigens cause inflammation in the endocardium, myocardium and pericardium, as well as the joints and skin. Histologically, fibrinoid degeneration is seen in the collagen of connective tissues. Aschoff nodules are pathognomonic and occur only in the heart. They are composed of multinucleated giant cells surrounded by macrophages and T lymphocytes, and are not seen until the subacute or chronic phases of rheumatic carditis.</ce:para></ce:section><ce:section id="s1980"><ce:section-title id="st1855">Clinical features</ce:section-title><ce:para id="p5450">Acute rheumatic fever is a multisystem disorder that usually presents with fever, anorexia, lethargy and joint pain, 2–3 weeks after an episode of streptococcal pharyngitis. There may be no history of sore throat, however. Arthritis occurs in approximately 75% of patients. Other features include rashes, subcutaneous nodules, carditis and neurological changes (<ce:cross-ref id="crf1510" refid="f0440">Fig. 16.80</ce:cross-ref><ce:float-anchor refid="f0440"/>). The diagnosis, made using the revised Jones criteria (<ce:cross-ref id="crf1515" refid="b0405">Box 16.75</ce:cross-ref><ce:float-anchor refid="b0405"/>), is based on two or more major manifestations, or one major and two or more minor manifestations, along with evidence of preceding streptococcal infection. A presumptive diagnosis of acute rheumatic fever can be made without evidence of preceding streptococcal infection in cases of isolated chorea or pancarditis, if other causes of these have been excluded. In cases of established rheumatic heart disease or prior rheumatic fever, a diagnosis of acute rheumatic fever can be made based only on the presence of multiple minor criteria and evidence of preceding group A streptococcal pharyngitis.</ce:para><ce:section id="s1985"><ce:section-title id="st1860">Carditis</ce:section-title><ce:para id="p5520">Rheumatic fever causes a pancarditis involving the endocardium, myocardium and pericardium to varying degrees. Its incidence declines with increasing age, ranging from 90% at 3 years to around 30% in adolescence. It may manifest as breathlessness (due to heart failure or pericardial effusion), palpitations or chest pain (usually due to pericarditis or pancarditis). Other features include tachycardia, cardiac enlargement and new or changed murmurs. A soft systolic murmur due to mitral regurgitation is very common. A soft mid-diastolic murmur (the Carey Coombs murmur) is typically due to valvulitis, with nodules forming on the mitral valve leaflets. Aortic regurgitation occurs in 50% of cases but the tricuspid and pulmonary valves are rarely involved. Pericarditis may cause chest pain, a pericardial friction rub and precordial tenderness. Cardiac failure may be due to myocardial dysfunction or valvular regurgitation. ECG evidence commonly includes ST and T wave changes. Conduction defects, including AV block, sometimes occur and may cause syncope.</ce:para></ce:section><ce:section id="s1990"><ce:section-title id="st1865">Arthritis</ce:section-title><ce:para id="p5525">This is the most common major manifestation and occurs early when streptococcal antibody titres are high. An acute painful, asymmetric and migratory inflammation of the large joints typically affects the knees, ankles, elbows and wrists. The joints are involved in quick succession and are usually red, swollen and tender for between a day and 4 weeks.</ce:para></ce:section><ce:section id="s1995"><ce:section-title id="st1870">Skin lesions</ce:section-title><ce:para id="p5530">Erythema marginatum occurs in less than 5% of patients. The lesions start as red macules that fade in the centre but remain red at the edges, and occur mainly on the trunk and proximal extremities but not the face. The resulting red rings or ‘margins’ may coalesce or overlap (<ce:cross-ref id="crf1525" refid="f0440">Fig. 16.80</ce:cross-ref>). Subcutaneous nodules occur in 5–7% of patients. They are small (0.5–2.0 cm), firm and painless, and are best felt over extensor surfaces of bone or tendons. They typically appear more than 3 weeks after the onset of other manifestations and therefore help to confirm rather than make the diagnosis.</ce:para></ce:section><ce:section id="s2000"><ce:section-title id="st1875">Sydenham's chorea</ce:section-title><ce:para id="p5535">Sydenham's chorea, also known as St Vitus dance, is a late neurological manifestation that appears at least 3 months after the episode of acute rheumatic fever, when all the other signs may have disappeared. It occurs in up to one-third of cases and is more common in females. Emotional lability may be the first feature and is typically followed by purposeless, involuntary, choreiform movements of the hands, feet or face. Speech may be explosive and halting. Spontaneous recovery usually occurs within a few months. Approximately one-quarter of affected patients will go on to develop chronic rheumatic valve disease.</ce:para></ce:section><ce:section id="s2005"><ce:section-title id="st1880">Other features</ce:section-title><ce:para id="p5540">Other systemic manifestations, such as pleurisy, pleural effusion and pneumonia, may occur but are rare.</ce:para></ce:section></ce:section><ce:section id="s2010"><ce:section-title id="st1885">Investigations</ce:section-title><ce:para id="p5545">Blood should be taken for measurement of ESR and CRP since these are useful for monitoring progress of the disease (<ce:cross-ref id="crf1530" refid="b0410">Box 16.76</ce:cross-ref><ce:float-anchor refid="b0410"/>). Throat cultures should be taken but positive results are obtained in only 10–25% of cases since the infection has often resolved by the time of presentation. Serology for antistreptolysin O antibodies (ASO) should be performed. Raised levels provide supportive evidence for the diagnosis but are normal in one-fifth of adult cases of rheumatic fever and most cases of chorea. Echocardiography should be carried out and typically shows mitral regurgitation with dilatation of the mitral annulus and prolapse of the anterior mitral leaflet; it may also demonstrate aortic regurgitation and pericardial effusion.</ce:para></ce:section><ce:section id="s2030"><ce:section-title id="st1905">Management</ce:section-title><ce:para id="p5595">The aims of management are to limit cardiac damage and relieve symptoms.</ce:para><ce:section id="s2035"><ce:section-title id="st1910">Bed rest</ce:section-title><ce:para id="p5600">Bed rest is important, as it lessens joint pain and reduces cardiac workload. The duration should be guided by symptoms, along with temperature, leucocyte count and ESR, and should be continued until these have settled. Patients can then return to normal physical activity but strenuous exercise should be avoided in those who have had carditis.</ce:para></ce:section><ce:section id="s2040"><ce:section-title id="st1915">Treatment of cardiac failure</ce:section-title><ce:para id="p5605">Cardiac failure should be treated as necessary. Some patients, particularly those in early adolescence, can develop a fulminant form of the disease with severe mitral regurgitation and, sometimes, concomitant aortic regurgitation. If heart failure in these cases does not respond to medical treatment, valve replacement may be necessary and is often associated with a dramatic decline in rheumatic activity. Occasionally, AV block may occur but is seldom progressive and usually resolves spontaneously. Rarely, pacemaker insertion may be required.</ce:para></ce:section><ce:section id="s2045"><ce:section-title id="st1920">Antibiotics</ce:section-title><ce:para id="p5610">A single dose of benzathine benzylpenicillin (1.2 million U IM) or oral phenoxymethylpenicillin (250 mg 4 times daily for 10 days) should be given on diagnosis to eliminate any residual streptococcal infection. If the patient is penicillin-allergic, erythromycin or a cephalosporin can be used. Patients are susceptible to further attacks of rheumatic fever if another streptococcal infection occurs, and long-term prophylaxis with penicillin should be given with oral phenoxymethylpenicillin (250 mg twice daily) or as benzathine benzylpenicillin (1.2 million U IM monthly), if adherence is in doubt. Sulfadiazine or erythromycin may be used if the patient is allergic to penicillin; sulphonamides prevent infection but are not effective in the eradication of group A streptococci. Further attacks of rheumatic fever are unusual after the age of 21, when antibiotic treatment can usually be stopped. The duration of prophylaxis should be extended if an attack has occurred in the last 5 years, or if the patient lives in an area of high prevalence and has an occupation (such as teaching) with a high risk of exposure to streptococcal infection. In those with residual heart disease, prophylaxis should continue until 10 years after the last episode or 40 years of age, whichever is later. While long-term antibiotic prophylaxis prevents further attacks of acute rheumatic fever, it does not protect against infective endocarditis.</ce:para></ce:section><ce:section id="s2050"><ce:section-title id="st1925">Aspirin</ce:section-title><ce:para id="p5615">This usually relieves the symptoms of arthritis rapidly and a response within 24 hours helps confirm the diagnosis. A reasonable starting dose is 60 mg/kg body weight/day, divided into six doses. In adults, 100 mg/kg per day may be needed up to the limits of tolerance or a maximum of 8 g per day. Mild toxicity includes nausea, tinnitus and deafness; vomiting, tachypnoea and acidosis are more serious. Aspirin should be continued until the ESR has fallen and then gradually tailed off.</ce:para></ce:section><ce:section id="s2055"><ce:section-title id="st1930">Glucocorticoids</ce:section-title><ce:para id="p5620">These produce more rapid symptomatic relief than aspirin and are indicated in cases with carditis or severe arthritis. There is no evidence that long-term steroids are beneficial. Prednisolone (1.0–2.0 mg/kg per day in divided doses) should be continued until the ESR is normal and then tailed off.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2060"><ce:section-title id="st1935">Chronic rheumatic heart disease</ce:section-title><ce:para id="p5625">Chronic valvular heart disease develops in at least half of those affected by rheumatic fever with carditis. Two-thirds of cases occur in women. Some episodes of rheumatic fever pass unrecognised and it is possible to elicit a history of rheumatic fever or chorea in only about half of all patients with chronic rheumatic heart disease.</ce:para><ce:para id="p5630">The mitral valve is affected in more than 90% of cases; the aortic valve is the next most frequently involved, followed by the tricuspid and then the pulmonary valve. Isolated mitral stenosis accounts for about 25% of all cases, and an additional 40% have mixed mitral stenosis and regurgitation.</ce:para><ce:section id="s2065"><ce:section-title id="st1940">Pathogenesis</ce:section-title><ce:para id="p5635">The main pathological process in chronic rheumatic heart disease is progressive fibrosis. The heart valves are predominantly affected but involvement of the pericardium and myocardium also occurs and may contribute to heart failure and conduction disorders. Fusion of the mitral valve commissures and shortening of the chordae tendineae may lead to mitral stenosis with or without regurgitation. Similar changes in the aortic and tricuspid valves produce distortion and rigidity of the cusps, leading to stenosis and regurgitation. Once a valve has been damaged, the altered haemodynamic stresses perpetuate and extend the damage, even in the absence of a continuing rheumatic process.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2070"><ce:section-title id="st1945">Mitral valve disease</ce:section-title><ce:section id="s2075"><ce:section-title id="st1950">Mitral stenosis</ce:section-title><ce:para id="p5640">Mitral stenosis is almost always rheumatic in origin, although in older people it can be caused by heavy calcification of the mitral valve. There is also a rare form of congenital mitral stenosis.</ce:para><ce:section id="s2080"><ce:section-title id="st1955">Pathogenesis</ce:section-title><ce:para id="p5645">In rheumatic mitral stenosis, the mitral valve orifice is slowly diminished by progressive fibrosis, calcification of the valve leaflets, and fusion of the cusps and subvalvular apparatus. The mitral valve orifice is normally about 5 cm<ce:sup loc="post">2</ce:sup> in diastole but can be reduced to &#x003C; 1 cm<ce:sup loc="post">2</ce:sup> in severe mitral stenosis. The patient is usually asymptomatic until the orifice is &#x003C; 2 cm<ce:sup loc="post">2</ce:sup>. As stenosis progresses, left ventricular filling becomes more dependent on left atrial contraction. There is dilatation and hypertrophy of the LA and left atrial pressure rises, leading to pulmonary venous congestion and breathlessness. Any increase in heart rate shortens diastole when the mitral valve is open and produces a further rise in left atrial pressure. Situations that demand an increase in cardiac output, such as pregnancy and exercise, also increase left atrial pressure and are poorly tolerated.</ce:para><ce:para id="p5650">Atrial fibrillation is very common due to progressive dilatation of the LA. Its onset often precipitates pulmonary oedema because the accompanying tachycardia and loss of atrial contraction lead to marked haemodynamic deterioration and a rapid rise in left atrial pressure. In the absence of AF, a more gradual rise in left atrial pressure may occur. In the presence or absence of AF, pulmonary hypertension may occur, which can protect the patient from pulmonary oedema. Pulmonary hypertension leads to right ventricular hypertrophy and dilatation, tricuspid regurgitation and right heart failure. Fewer than 20% of patients remain in sinus rhythm but many of these have a small fibrotic LA and severe pulmonary hypertension.</ce:para></ce:section><ce:section id="s2085"><ce:section-title id="st1960">Clinical features</ce:section-title><ce:para id="p5655">Effort-related dyspnoea is usually the dominant symptom (<ce:cross-ref id="crf1535" refid="b0415">Box 16.77</ce:cross-ref><ce:float-anchor refid="b0415"/>). Typically, exercise tolerance diminishes very slowly over many years until symptoms eventually occur at rest. Patients frequently do not appreciate the extent of their disability until the diagnosis is made and their valve disease is treated. Acute pulmonary oedema or pulmonary hypertension can lead to haemoptysis. Fatigue is a common symptom due to a low cardiac output. Thromboembolism is a common complication, especially in patients with AF. Prior to the advent of anticoagulant therapy, emboli caused one-quarter of all deaths.</ce:para><ce:para id="p5665">The physical signs of mitral stenosis are often found before symptoms develop and their recognition is of particular importance in pregnancy. The forces that open and close the mitral valve increase as left atrial pressure rises. The first heart sound (S1) is therefore loud and can be palpable (tapping apex beat). An opening snap may be audible and moves closer to the second sound (S2) as the stenosis becomes more severe and left atrial pressure rises. However, the first heart sound and opening snap may be inaudible if the valve is heavily calcified.</ce:para><ce:para id="p5670">Turbulent flow produces the characteristic low-pitched mid-diastolic murmur and sometimes a thrill (<ce:cross-ref id="crf1540" refid="f0445">Fig. 16.81</ce:cross-ref><ce:float-anchor refid="f0445"/>). The murmur is accentuated by exercise and during atrial systole (pre-systolic accentuation). Early in the disease, a pre-systolic murmur may be the only auscultatory abnormality, but in patients with symptoms, the murmur extends from the opening snap to the first heart sound. Coexisting mitral regurgitation causes a pansystolic murmur that radiates towards the axilla.</ce:para><ce:para id="p5675">Pulmonary hypertension may ultimately lead to right ventricular hypertrophy and dilatation with secondary tricuspid regurgitation, which causes a systolic murmur and giant ‘<ce:italic>v</ce:italic> waves’ in the venous pulse.</ce:para></ce:section><ce:section id="s2090"><ce:section-title id="st1965">Investigations</ce:section-title><ce:para id="p5680">Doppler echocardiography is the investigation of choice for evaluation of suspected mitral stenosis (<ce:cross-ref id="crf1545" refid="f0445">Fig. 16.81</ce:cross-ref>). Cardiac catheterisation may also be required if surgery or valvuloplasty is being considered, to screen for coexisting conditions such as CAD. The ECG may show either AF or bifid P waves (P mitrale) associated with left atrial hypertrophy (<ce:cross-ref id="crf1550" refid="b0420">Box 16.78</ce:cross-ref><ce:float-anchor refid="b0420"/>). A typical chest X-ray is shown in <ce:cross-ref id="crf1555" refid="f0085">Figure 16.9</ce:cross-ref> (<ce:cross-ref id="crf9590" refid="s0140">p. 451</ce:cross-ref>).</ce:para></ce:section><ce:section id="s2095"><ce:section-title id="st1970">Management</ce:section-title><ce:para id="p5760">Patients with mild symptoms can be treated medically but intervention by balloon valvuloplasty, mitral valvotomy or mitral valve replacement should be considered if the patient remains symptomatic despite medical treatment or if pulmonary hypertension develops.</ce:para><ce:section id="s2100"><ce:section-title id="st1975">Medical management</ce:section-title><ce:para id="p5765">This consists of anticoagulation to reduce the risk of systemic embolism, ventricular rate control with digoxin, β-blockers or rate-limiting calcium antagonists in AF, and diuretic to control pulmonary congestion. Antibiotic prophylaxis against infective endocarditis is no longer routinely recommended.</ce:para></ce:section><ce:section id="s2105"><ce:section-title id="st1980">Mitral balloon valvuloplasty and valve replacement</ce:section-title><ce:para id="p5770">Valvuloplasty is the treatment of choice if specific criteria are fulfilled (<ce:cross-ref id="crf1560" refid="b0425">Box 16.79</ce:cross-ref><ce:float-anchor refid="b0425"/> and <ce:cross-ref id="crf1570" refid="f9000">Fig. 16.82</ce:cross-ref><ce:float-anchor refid="f9000"/>), although surgical closed or open mitral valvotomy is an acceptable alternative. Patients who have undergone mitral valvuloplasty or valvotomy should be followed up at 1–2-yearly intervals because restenosis may occur. Clinical symptoms and signs are a guide to the severity of mitral restenosis but Doppler echocardiography provides a more accurate assessment.</ce:para><ce:para id="p5805">Valve replacement is indicated if there is substantial mitral reflux or if the valve is rigid and calcified (<ce:cross-ref id="crf9595" refid="p6505">p. 526</ce:cross-ref>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s2110"><ce:section-title id="st1985">Mitral regurgitation</ce:section-title><ce:para id="p5810">Rheumatic disease is the principal cause in countries where rheumatic fever is common but elsewhere, including in the UK, other causes are more important (<ce:cross-ref id="crf1575" refid="b0430">Box 16.80</ce:cross-ref><ce:float-anchor refid="b0430"/>). Mitral regurgitation may also follow mitral valvotomy or valvuloplasty.</ce:para><ce:section id="s2115"><ce:section-title id="st1990">Pathogenesis</ce:section-title><ce:para id="p5845">Chronic mitral regurgitation causes gradual dilatation of the LA with little increase in pressure and therefore relatively few symptoms. Nevertheless, the LV dilates slowly and the left ventricular diastolic and left atrial pressures gradually increase as a result of chronic volume overload of the LV. In contrast, acute mitral regurgitation causes a rapid rise in left atrial pressure (because left atrial compliance is normal) and marked symptomatic deterioration.</ce:para><ce:section id="s2120"><ce:section-title id="st1995">Mitral valve prolapse</ce:section-title><ce:para id="p5850">This is also known as ‘floppy’ mitral valve and is a common cause of mild mitral regurgitation (<ce:cross-ref id="crf1580" refid="f0450">Fig. 16.83</ce:cross-ref><ce:float-anchor refid="f0450"/>). Some cases are thought to be due to a developmental abnormality of the mitral valve and others due to degenerative myxomatous change in a normal mitral valve. Rarely, mitral valve prolapse may occur in association with Marfan's syndrome (<ce:cross-ref id="crf9600" refid="p4835">p. 508</ce:cross-ref>).</ce:para><ce:para id="p5855">In its mildest forms, the valve remains competent but bulges back into the atrium during systole, causing a mid-systolic click but no murmur. In the presence of a regurgitant valve, the click is followed by a late systolic murmur, which lengthens as the regurgitation becomes more severe. A click is not always audible and the physical signs may vary with both posture and respiration. Progressive elongation of the chordae tendineae leads to increasing mitral regurgitation, and if chordal rupture occurs, regurgitation suddenly becomes severe. This is rare before the fifth or sixth decade of life.</ce:para><ce:para id="p5860">Mitral valve prolapse is associated with a variety of typically benign arrhythmias, atypical chest pain and a very small risk of embolic stroke or transient ischaemic attack (TIA). Nevertheless, the overall long-term prognosis is good.</ce:para></ce:section><ce:section id="s2125"><ce:section-title id="st2000">Other causes of mitral regurgitation</ce:section-title><ce:para id="p5865">Mitral valve function depends on the chordae tendineae and their papillary muscles; dilatation of the LV distorts the geometry of these and may cause mitral regurgitation (<ce:cross-ref id="crf1585" refid="b0430">Box 16.80</ce:cross-ref>). Dilated cardiomyopathy and heart failure from CAD are common causes of so-called ‘functional’ mitral regurgitation. Endocarditis is an important cause of acute mitral regurgitation.</ce:para></ce:section></ce:section><ce:section id="s2130"><ce:section-title id="st2005">Clinical features</ce:section-title><ce:para id="p5870">Symptoms and signs depend on the underlying cause and how suddenly the regurgitation develops (<ce:cross-ref id="crf1590" refid="b0435">Box 16.81</ce:cross-ref><ce:float-anchor refid="b0435"/>). Chronic mitral regurgitation produces a symptom complex that is similar to that of mitral stenosis but sudden-onset mitral regurgitation usually presents with acute pulmonary oedema.</ce:para><ce:para id="p5880">The regurgitant jet causes an apical systolic murmur (<ce:cross-ref id="crf1595" refid="f0450">Fig. 16.83</ce:cross-ref>), which radiates into the axilla and may be accompanied by a thrill. Increased forward flow through the mitral valve causes a loud third heart sound and even a short mid-diastolic murmur. The apex beat feels active and rocking due to left ventricular volume overload and is usually displaced to the left as a result of left ventricular dilatation.</ce:para></ce:section><ce:section id="s2135"><ce:section-title id="st2010">Investigations</ce:section-title><ce:para id="p5885">Echocardiography is a pivotal investigation. The severity of regurgitation can be assessed by Doppler and information may also be gained on papillary muscle function and valve prolapse. An ECG should be performed and commonly shows AF, as a consequence of atrial dilatation. Cardiac catheterisation is indicated when surgery is being considered (<ce:cross-ref id="crf1600" refid="b0440">Box 16.82</ce:cross-ref><ce:float-anchor refid="b0440"/>). During catheterisation, the severity of mitral regurgitation can be assessed by left ventriculography and by the size of the <ce:italic>v</ce:italic> (systolic) waves in the left atrial or pulmonary artery wedge pressure trace.</ce:para></ce:section><ce:section id="s2140"><ce:section-title id="st2015">Management</ce:section-title><ce:para id="p5960">Mitral regurgitation of moderate severity can be treated medically with diuretics and vasodilators. Digoxin and anticoagulants should be given if AF is present (<ce:cross-ref id="crf1605" refid="b0445">Box 16.83</ce:cross-ref><ce:float-anchor refid="b0445"/>). If systemic hypertension is present, it should be treated with vasodilators such as ACE inhibitors or ARBs, since high afterload may worsen the degree of regurgitation. All patients should be reviewed at regular intervals, both clinically and by echocardiography. Worsening symptoms, progressive cardiomegaly or echocardiographic evidence of deteriorating left ventricular function are indications for mitral valve replacement or repair. Mitral valve repair is now the treatment of choice for severe mitral regurgitation, even in asymptomatic patients, because results are excellent and early repair prevents irreversible left ventricular damage. Mitral regurgitation often accompanies left ventricular failure associated with CAD. If such patients are to undergo CABG surgery, it is common practice to repair the valve and restore mitral valve function by inserting an annuloplasty ring to overcome annular dilatation and to bring the valve leaflets closer together. Unfortunately, it can be difficult to determine whether it is the ventricular dilatation or the mitral regurgitation that is the predominant problem. If ventricular dilatation is the underlying cause of mitral regurgitation, then mitral valve repair or replacement may actually worsen ventricular function, as the ventricle can no longer empty into the low-pressure LA.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2145"><ce:section-title id="st2020">Aortic valve disease</ce:section-title><ce:section id="s2150"><ce:section-title id="st2025">Aortic stenosis</ce:section-title><ce:para id="p5990">There are several causes of aortic stenosis but the age at which patients present can give a clue to the most likely diagnosis (<ce:cross-ref id="crf1610" refid="b0450">Box 16.84</ce:cross-ref><ce:float-anchor refid="b0450"/>). In congenital aortic stenosis, obstruction is present from birth or becomes apparent during infancy. With bicuspid aortic valves, obstruction may take years to develop as the valve becomes fibrotic and calcified, and these patients present as young to middle-aged adults. Rheumatic disease of the aortic valve presents at a similar age but is usually accompanied by mitral valve disease. In older people, structurally normal aortic valves may become stenotic as the result of fibrosis and calcification. Haemodynamically significant stenosis develops slowly, typically occurring at 30–60 years in those with rheumatic disease, 50–60 years in those with bicuspid aortic valves and 70–90 years in those with calcific tricuspid disease.</ce:para><ce:section id="s2170"><ce:section-title id="st2045">Pathogenesis</ce:section-title><ce:para id="p6050">Cardiac output is initially maintained in patients with aortic stenosis at the cost of a steadily increasing pressure gradient across the aortic valve. With progression of the stenosis the LV becomes increasingly hypertrophied and coronary blood flow may be inadequate to supply the myocardium, such that angina can develop even in the absence of coexisting CAD. The fixed outflow obstruction limits the increase in cardiac output required on exercise. Eventually, the LV can no longer overcome the outflow tract obstruction and LV failure results, leading to pulmonary oedema.</ce:para></ce:section><ce:section id="s2175"><ce:section-title id="st2050">Clinical features</ce:section-title><ce:para id="p6055">Aortic stenosis is commonly picked up in asymptomatic patients at routine clinical examination but the three cardinal symptoms are angina, breathlessness and syncope (<ce:cross-ref id="crf1615" refid="b0455">Box 16.85</ce:cross-ref><ce:float-anchor refid="b0455"/>). Angina arises either because of the increased demands of the hypertrophied LV working against the high-pressure outflow tract obstruction, or the presence of coexisting CAD, which affects over 50% of patients. Exertional breathlessness suggests cardiac decompensation as a consequence of the excessive pressure overload placed on the LV. Syncope usually occurs on exertion when cardiac output fails to rise to meet demand, leading to a fall in BP. Sometimes patients with severe aortic stenosis do not complain of symptoms. If, on clinical evaluation, this appears to be due to a sedentary lifestyle, a careful exercise test may reveal symptoms on modest exertion.</ce:para><ce:para id="p6120">The characteristic clinical signs of severe aortic stenosis are shown in <ce:cross-ref id="crf1620" refid="b0455">Box 16.85</ce:cross-ref>. A harsh ejection systolic murmur radiates to the neck, with a soft second heart sound, particularly in those with calcific valves. The murmur is often likened to a saw cutting wood and may (especially in older patients) have a musical quality like the ‘mew’ of a seagull (<ce:cross-ref id="crf1625" refid="f0455">Fig. 16.84</ce:cross-ref><ce:float-anchor refid="f0455"/>). The severity of aortic stenosis may be difficult to gauge clinically, as older patients with a non-compliant ‘stiff’ arterial system may have an apparently normal carotid upstroke in the presence of severe aortic stenosis. Milder degrees of stenosis may be difficult to distinguish from aortic sclerosis, in which the valve is thickened or calcified but not obstructed. A careful examination should be made for other valve lesions, particularly in rheumatic heart disease, when there is frequently concomitant mitral valve disease. In contrast to patients with mitral stenosis, which tends to progress very slowly, patients with aortic stenosis typically remain asymptomatic for many years but deteriorate rapidly when symptoms develop; if otherwise untreated, they usually die within 3–5 years of presentation.</ce:para></ce:section><ce:section id="s2180"><ce:section-title id="st2055">Investigations</ce:section-title><ce:para id="p6125">Echocardiography is a pivotal investigation in patients suspected of having aortic stenosis. It can demonstrate restricted valve opening (<ce:cross-ref id="crf1635" refid="f0460">Fig. 16.85</ce:cross-ref><ce:float-anchor refid="f0460"/>) and Doppler assessment permits calculation of the systolic gradient across the aortic valve, from which the severity of stenosis can be assessed (see <ce:cross-ref id="crf1640" refid="f0100">Fig. 16.11</ce:cross-ref>, <ce:cross-ref id="crf9605" refid="s0140">p. 451</ce:cross-ref>). In patients with impaired left ventricular function, velocities across the aortic valve may be diminished because of a reduced stroke volume; this is called low-flow aortic stenosis. When marked aortic regurgitation or elevated cardiac output is present, velocities are increased because of an increased stroke volume and this may overestimate stenosis severity on Doppler echocardiography. In advanced cases, ECG features of hypertrophy (<ce:cross-ref id="crf1645" refid="b0460">Box 16.86</ce:cross-ref><ce:float-anchor refid="b0460"/>) are often pronounced (<ce:cross-ref id="crf1650" refid="f0465">Fig. 16.86</ce:cross-ref><ce:float-anchor refid="f0465"/>), and down-sloping ST segments and T inversion (‘strain pattern’) are seen in the lateral leads, reflecting left ventricular fibrosis. Nevertheless, the ECG can be normal, despite severe stenosis. Imaging with CT and MRI may be useful in assessing the degree of valve calcification and stenosis, respectively, and may help where there is uncertainty.</ce:para></ce:section><ce:section id="s2210"><ce:section-title id="st2085">Management</ce:section-title><ce:para id="p6195">Irrespective of the severity of valve stenosis, patients with asymptomatic aortic stenosis have a good immediate prognosis and conservative management is appropriate. Such patients should be kept under review, as the development of angina, syncope, symptoms of low cardiac output or heart failure has a poor prognosis and is an indication for prompt surgery. In practice, patients with moderate or severe stenosis should be evaluated every 1–2 years with Doppler echocardiography to detect evidence of progression in severity. The intervals between reviews should be more frequent (typically 3–6-monthly) in older patients with heavily calcified valves.</ce:para><ce:para id="p6200">Patients with symptomatic severe aortic stenosis should have prompt aortic valve replacement. Delay exposes the patient to the risk of sudden death or irreversible deterioration in ventricular function. Old age is not a contraindication to valve replacement and results are very good in experienced centres, even for those in their eighties (<ce:cross-ref id="crf1655" refid="b0465">Box 16.87</ce:cross-ref><ce:float-anchor refid="b0465"/>). This is especially the case with transcatheter aortic valve implantation (TAVI, <ce:cross-ref id="crf9610" refid="s2365">p. 527</ce:cross-ref>). Aortic balloon valvuloplasty is useful in congenital aortic stenosis but has limited value in older patients with calcific aortic stenosis.</ce:para><ce:para id="p6235">Anticoagulants are required only in patients who have AF or those who have had a valve replacement with a mechanical prosthesis.</ce:para></ce:section></ce:section><ce:section id="s2215"><ce:section-title id="st2090">Aortic regurgitation</ce:section-title><ce:para id="p6240">This condition can result from either disease of the aortic valve cusps, infection, trauma or dilatation of the aortic root. The causes are summarised in <ce:cross-ref id="crf1660" refid="b0470">Box 16.88</ce:cross-ref><ce:float-anchor refid="b0470"/>.</ce:para><ce:section id="s2230"><ce:section-title id="st2105">Pathogenesis</ce:section-title><ce:para id="p6305">Regurgitation of blood through the aortic valve causes the LV to dilate as cardiac output increases to maintain the demands of the circulation. The stroke volume of the LV may eventually be doubled and the major arteries are then conspicuously pulsatile. As the disease progresses, left ventricular failure develops, leading to a rise in left ventricular end-diastolic pressure and pulmonary oedema.</ce:para></ce:section><ce:section id="s2235"><ce:section-title id="st2110">Clinical features</ce:section-title><ce:para id="p6310">Until the onset of breathlessness, the only symptom may be an awareness of the heart beat (<ce:cross-ref id="crf1665" refid="b0475">Box 16.89</ce:cross-ref><ce:float-anchor refid="b0475"/>), particularly when lying on the left side, which results from the increased stroke volume. Paroxysmal nocturnal dyspnoea is sometimes the first symptom, and peripheral oedema or angina may occur. The characteristic murmur is best heard to the left of the sternum during held expiration (<ce:cross-ref id="crf1670" refid="f0470">Fig. 16.87</ce:cross-ref><ce:float-anchor refid="f0470"/>); a thrill is rare. A systolic murmur due to the increased stroke volume is common and does not necessarily indicate stenosis. The regurgitant jet causes fluttering of the mitral valve and, if severe, causes partial closure of the anterior mitral leaflet, leading to functional mitral stenosis and a soft mid-diastolic (Austin Flint) murmur.</ce:para><ce:para id="p6425">Acute severe regurgitation may occur as the result of perforation of an aortic cusp in endocarditis. In this circumstance, there may be no time for compensatory left ventricular hypertrophy and dilatation to develop and the features of heart failure may predominate. The classical signs of aortic regurgitation in such patients may be masked by tachycardia and an abrupt rise in left ventricular end-diastolic pressure. The pulse pressure may also be normal or near-normal and the diastolic murmur may be short or even absent.</ce:para></ce:section><ce:section id="s2275"><ce:section-title id="st2150">Investigations</ce:section-title><ce:para id="p6430">Doppler echocardiography is the investigation of first choice for detecting regurgitation (<ce:cross-ref id="crf1675" refid="b0480">Box 16.90</ce:cross-ref><ce:float-anchor refid="b0480"/>). In severe acute aortic regurgitation, the rapid rise in left ventricular diastolic pressure may cause premature mitral valve closure. Cardiac catheterisation and aortography are usually performed to assess the severity of regurgitation, to determine if there is dilatation of the aorta and to screen for the presence of coexisting CAD. MRI can also be useful in assessing the degree and extent of aortic dilatation if this is suspected on chest X-ray or echocardiography.</ce:para></ce:section><ce:section id="s2280"><ce:section-title id="st2155">Management</ce:section-title><ce:para id="p6490">Treatment may be required for underlying conditions, such as endocarditis or syphilis. Aortic valve replacement is indicated if aortic regurgitation causes symptoms, and this may need to be combined with aortic root replacement and coronary bypass surgery. Those with chronic aortic regurgitation can remain asymptomatic for many years because compensatory ventricular dilatation and hypertrophy occur, but should be advised to report the development of any symptoms of breathlessness or angina. Asymptomatic patients should also be followed up annually with echocardiography for evidence of increasing ventricular size. If this occurs or if the end-systolic dimension increases to 55 mm or more, then aortic valve replacement should be undertaken. If systemic hypertension is present, vasodilators should be used to control systolic BP. There is conflicting evidence regarding the need for aortic valve replacement in asymptomatic patients with severe aortic regurgitation. When aortic root dilatation is the cause of aortic regurgitation, as can occur in Marfan's syndrome, aortic root replacement is usually necessary.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2285"><ce:section-title id="st2160">Tricuspid valve disease</ce:section-title><ce:section id="s2290"><ce:section-title id="st2165">Tricuspid stenosis</ce:section-title><ce:para id="p6495">Tricuspid stenosis is usually rheumatic in origin and is rare in developed countries. Tricuspid disease occurs in fewer than 5% of patients with rheumatic heart disease and then nearly always occurs in association with mitral and aortic valve disease. Tricuspid stenosis and regurgitation may also occur in the carcinoid syndrome (<ce:intra-ref id="ii0710" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1305">p. 678</ce:intra-ref>).</ce:para><ce:section id="s2295"><ce:section-title id="st2170">Clinical features and investigations</ce:section-title><ce:para id="p6500">Although the symptoms of mitral and aortic valve disease predominate, tricuspid stenosis may cause symptoms of right heart failure, including hepatic discomfort and peripheral oedema.</ce:para><ce:para id="p6505">The main clinical feature is a raised JVP with a prominent <ce:italic>a</ce:italic> wave, and a slow <ce:italic>y</ce:italic> descent due to the loss of normal rapid right ventricular filling (<ce:cross-ref id="crf9615" refid="b0010">p. 443</ce:cross-ref>). There is also a mid-diastolic murmur, best heard at the lower left or right sternal edge. This is generally higher-pitched than the murmur of mitral stenosis and is increased by inspiration. Right heart failure causes hepatomegaly with pre-systolic pulsation (large <ce:italic>a</ce:italic> wave), ascites and peripheral oedema. The diagnosis can be confirmed by Doppler echocardiography, which shows similar appearances to those of rheumatic mitral stenosis.</ce:para></ce:section><ce:section id="s2300"><ce:section-title id="st2175">Management</ce:section-title><ce:para id="p6510">In patients who require surgery to other valves, either the tricuspid valve can also be replaced or treated with valvotomy. Balloon valvuloplasty can be used to treat rare cases of isolated tricuspid stenosis.</ce:para></ce:section></ce:section><ce:section id="s2305"><ce:section-title id="st2180">Tricuspid regurgitation</ce:section-title><ce:para id="p6515">Tricuspid regurgitation is common, and is most frequently functional, occurring as a result of right ventricular dilatation due to right heart failure or biventricular failure. It may also be the result of other conditions, as summarised in <ce:cross-ref id="crf1685" refid="b0485">Box 16.91</ce:cross-ref><ce:float-anchor refid="b0485"/>.</ce:para><ce:section id="s2320"><ce:section-title id="st2195">Clinical features</ce:section-title><ce:para id="p6560">Symptoms are usually non-specific, with tiredness related to reduced cardiac output, and oedema and hepatic enlargement due to venous congestion. The most prominent sign is a ‘giant’ <ce:italic>v</ce:italic> wave in the jugular venous pulse (a <ce:italic>cv</ce:italic> wave replaces the normal <ce:italic>x</ce:italic> descent). Other features include a pansystolic murmur at the left sternal edge and a pulsatile liver. Echocardiography may reveal dilatation of the RV. If the valve has been affected by rheumatic disease, the leaflets will appear thickened and, in endocarditis, vegetations may be seen.</ce:para></ce:section><ce:section id="s2325"><ce:section-title id="st2200">Management</ce:section-title><ce:para id="p6565">Tricuspid regurgitation due to right ventricular dilatation often improves when the cardiac failure is treated. Patients with a normal pulmonary artery pressure tolerate isolated tricuspid reflux well, and valves damaged by endocarditis do not usually need to be replaced. Patients undergoing mitral valve replacement, who have tricuspid regurgitation due to marked dilatation of the tricuspid annulus, benefit from valve repair with an annuloplasty ring to bring the leaflets closer together. Those with rheumatic damage may require tricuspid valve replacement.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2330"><ce:section-title id="st2205">Pulmonary valve disease</ce:section-title><ce:section id="s2335"><ce:section-title id="st2210">Pulmonary stenosis</ce:section-title><ce:para id="p6570">This can occur in the carcinoid syndrome but is usually congenital, in which case it may be isolated or associated with other abnormalities, such as Fallot's tetralogy (<ce:cross-ref id="crf9620" refid="p7190">p. 536</ce:cross-ref>).</ce:para><ce:section id="s2340"><ce:section-title id="st2215">Clinical features</ce:section-title><ce:para id="p6575">The principal finding on examination is an ejection systolic murmur, loudest at the left upper sternum and radiating towards the left shoulder. There may be a thrill, best felt when the patient leans forwards and breathes out. The murmur is often preceded by an ejection sound (click). Delay in right ventricular ejection may cause wide splitting of the second heart sound. Severe pulmonary stenosis is characterised by a loud, harsh murmur, an inaudible pulmonary closure sound (P<ce:inf loc="post">2</ce:inf>), an increased right ventricular heave, and prominent <ce:italic>a</ce:italic> waves in the jugular pulse.</ce:para></ce:section><ce:section id="s2345"><ce:section-title id="st2220">Investigations</ce:section-title><ce:para id="p6580">Doppler echocardiography is the definitive investigation. ECG may show evidence of right ventricular hypertrophy, and post-stenotic dilatation in the pulmonary artery may be observed on the chest X-ray.</ce:para></ce:section><ce:section id="s2350"><ce:section-title id="st2225">Management</ce:section-title><ce:para id="p6585">Mild to moderate isolated pulmonary stenosis is relatively common and does not usually progress or require treatment. Severe pulmonary stenosis (resting gradient &#x003E; 50 mmHg with a normal cardiac output) can be treated by percutaneous pulmonary balloon valvuloplasty or, if this is not available, by surgical valvotomy. Long-term results are very good. Post-operative pulmonary regurgitation is common but benign.</ce:para></ce:section></ce:section><ce:section id="s2355"><ce:section-title id="st2230">Pulmonary regurgitation</ce:section-title><ce:para id="p6590">This is rare in isolation and is usually associated with pulmonary artery dilatation due to pulmonary hypertension. It may complicate mitral stenosis, producing an early diastolic decrescendo murmur at the left sternal edge that is difficult to distinguish from aortic regurgitation (Graham Steell murmur). The pulmonary hypertension may be secondary to other disease of the left side of the heart, primary pulmonary vascular disease or Eisenmenger's syndrome (<ce:cross-ref id="crf9625" refid="f0485">p. 532</ce:cross-ref>). Trivial pulmonary regurgitation is a frequent finding in normal individuals and has no clinical significance.</ce:para></ce:section></ce:section><ce:section id="s2360"><ce:section-title id="st2235">Prosthetic valves</ce:section-title><ce:para id="p6595">Diseased heart valves can be replaced with mechanical or biological prostheses. The three most commonly used types of mechanical prosthesis are the ball and cage, tilting single disc and tilting bi-leaflet valves. All generate prosthetic sounds or clicks on auscultation. Pig or allograft valves mounted on a supporting stent are the most commonly used biological valves. They generate normal heart sounds. All prosthetic valves used in the aortic position produce a systolic flow murmur.</ce:para><ce:para id="p6600">All mechanical valves require long-term anticoagulation because they can cause systemic thromboembolism or may develop valve thrombosis or obstruction (<ce:cross-ref id="crf1695" refid="b0490">Box 16.92</ce:cross-ref><ce:float-anchor refid="b0490"/>); the prosthetic clicks may become inaudible if the valve malfunctions. Biological valves have the advantage of not requiring anticoagulants to maintain proper function; however, many patients undergoing valve replacement surgery, especially mitral valve replacement, will have AF that requires anticoagulation anyway. Biological valves are less durable than mechanical valves and may degenerate 7 or more years after implantation, particularly when used in the mitral position. They are more durable in the aortic position and in older patients, so are particularly appropriate for patients over 65 undergoing aortic valve replacement.</ce:para><ce:section id="s2365"><ce:section-title id="st2240">Transcatheter aortic valve implantation</ce:section-title><ce:para id="p6610">For patients being considered for aortic valve surgery, especially due to aortic stenosis, transcatheter aortic valve implantation (TAVI) is an emerging alternative to surgical aortic valve replacement. The native valve is not removed but is compressed by the new bioprosthetic valve, which is implanted within it. The bioprosthetic valve is mounted on a large stent-like structure and is implanted through a catheter inserted in the femoral artery (<ce:cross-ref id="crf1700" refid="f0475">Fig. 16.88</ce:cross-ref><ce:float-anchor refid="f0475"/>). TAVI has several major advantages. It avoids the need for a sternotomy, is associated with a short recovery period, can be used in high-risk and otherwise inoperable patients, and is much better tolerated by elderly patients. Complications include stroke (2%) and heart block necessitating pacemaker implantation (5–15%).</ce:para></ce:section><ce:section id="s2370"><ce:section-title id="st2245">Prosthetic valve dysfunction</ce:section-title><ce:para id="p6615">Symptoms or signs of unexplained heart failure in a patient with a prosthetic heart valve may be due to valve dysfunction, and urgent assessment is required. Metallic valves can suffer strut fracture and fail, causing catastrophic regurgitation. Alternatively, they may thrombose and cause systemic thromboembolism or valve obstruction, especially in the presence of inadequate anticoagulation. Biological valve dysfunction is usually associated with the development of a regurgitant murmur and may begin to develop 8–10 years after implantation.</ce:para></ce:section></ce:section><ce:section id="s2375"><ce:section-title id="st2250">Infective endocarditis</ce:section-title><ce:para id="p6620">This is caused by microbial infection of a heart valve, the lining of a cardiac chamber or blood vessel, or a congenital anomaly. Both native and prosthetic valves can be affected. The most common causes of infective endocarditis are streptococci and staphylococci but other organisms may also be involved.</ce:para><ce:section id="s2380"><ce:section id="s2385"><ce:section-title id="st2255">Epidemiology</ce:section-title><ce:para id="p6625">The incidence of infective endocarditis in community-based studies ranges from 5 to 15 cases per 100 000 per annum. More than 50% of patients are over 60 years of age (<ce:cross-ref id="crf1705" refid="b0495">Box 16.93</ce:cross-ref><ce:float-anchor refid="b0495"/>). In a large British study, the underlying condition was rheumatic heart disease in 24% of patients, congenital heart disease in 19%, and other cardiac abnormalities such as calcified aortic valve or floppy mitral valve in 25%. The remaining 32% were not thought to have a pre-existing cardiac abnormality. Bacterial endocarditis is a serious illness; the case fatality is approximately 20% even with treatment, and is even higher in those with prosthetic valve endocarditis and those infected with antibiotic-resistant organisms.</ce:para></ce:section><ce:section id="s2390"><ce:section-title id="st2260">Pathophysiology</ce:section-title><ce:para id="p6650">Infective endocarditis typically occurs at sites of pre-existing endocardial damage, but infection with particularly virulent or aggressive organisms such as <ce:italic>Staphylococcus aureus</ce:italic> can cause endocarditis in a previously normal heart. Staphylococcal endocarditis of the tricuspid valve is a common complication of intravenous drug use. Many acquired and congenital cardiac lesions are vulnerable, particularly areas of endocardial damage caused by a high-pressure jet of blood, such as ventricular septal defect, mitral regurgitation and aortic regurgitation, many of which are haemodynamically insignificant. In contrast, the risk of endocarditis at the site of haemodynamically important low-pressure lesions, such as a large atrial septal defect, is minimal.</ce:para><ce:para id="p6655">Infection tends to occur at sites of endothelial damage because they attract deposits of platelets and fibrin that are vulnerable to colonisation by blood-borne organisms. The avascular valve tissue and presence of fibrin and platelet aggregates help to protect proliferating organisms from host defence mechanisms. When the infection is established, vegetations composed of organisms, fibrin and platelets grow and may become large enough to cause obstruction or embolism. Adjacent tissues are destroyed and abscesses may form. Valve regurgitation may develop or increase if the affected valve is damaged by tissue distortion, cusp perforation or disruption of chordae. Extracardiac manifestations, such as vasculitis and skin lesions, may occur as the result of either emboli or immune complex deposition. Mycotic aneurysms may develop in arteries at the site of infected emboli. In fatal cases, infarction of the spleen and kidneys and, sometimes, an immune glomerulonephritis may be found at postmortem.</ce:para><ce:section id="s2395"><ce:section-title id="st2265">Microbiology</ce:section-title><ce:para id="p6660">Over three-quarters of cases are caused by streptococci or staphylococci. Viridans streptococci, such as <ce:italic>Streptococcus mitis</ce:italic> and <ce:italic>Strep. sanguis</ce:italic>, which are commensals in the oral cavity, can enter the blood stream on chewing or tooth-brushing, or at the time of dental treatment, and are common causes of subacute endocarditis (<ce:cross-ref id="crf1710" refid="b0500">Box 16.94</ce:cross-ref><ce:float-anchor refid="b0500"/>). Other organisms, including <ce:italic>Enterococcus faecalis</ce:italic>, <ce:italic>E. faecium</ce:italic> and <ce:italic>Strep. gallolyticus</ce:italic> subsp. <ce:italic>gallolyticus</ce:italic> (previously known as <ce:italic>Strep. bovis</ce:italic>), may enter the blood from the bowel or urinary tract. Patients who are found to have endocarditis caused by <ce:italic>Strep. gallolyticus</ce:italic> should undergo colonoscopy, since this organism is associated with large-bowel malignancy.</ce:para><ce:para id="p6670"><ce:italic>Staph. aureus</ce:italic> has now overtaken streptococci as the most common cause of acute endocarditis. It originates from skin infections, abscesses or vascular access sites such as intravenous and central lines, or from intravenous drug use. It is highly virulent and invasive, usually producing florid vegetations, rapid valve destruction and abscess formation. Other causes of acute endocarditis include <ce:italic>Strep. pneumoniae</ce:italic> and <ce:italic>Strep. pyogenes</ce:italic>.</ce:para><ce:para id="p6675">Post-operative endocarditis after cardiac surgery may affect native or prosthetic heart valves or other prosthetic materials. The most common organisms are coagulase-negative staphylococci such as <ce:italic>Staph. epidermidis</ce:italic>, which are part of the normal skin flora. There is frequently a history of wound infection with the same organism. Coagulase-negative staphylococci cause native valve endocarditis in approximately 5% of cases and this possibility should always be considered before they are dismissed as blood culture contaminants. Another coagulase-negative staphylococcus, <ce:italic>Staph. lugdenensis</ce:italic>, causes a rapidly destructive acute endocarditis that is associated with previously normal valves and multiple emboli. Unless accurately identified, it may also be overlooked as a contaminant.</ce:para><ce:para id="p6680">In Q fever endocarditis due to <ce:italic>Coxiella burnetii</ce:italic>, the patient often has a history of contact with farm animals. The aortic valve is usually affected and there may also be hepatitis, pneumonia and purpura. Life-long antibiotic therapy may be required.</ce:para><ce:para id="p6685">In about 3–4% of cases, endocarditis may be caused by Gram-negative bacteria of the so-called HACEK group (<ce:italic><ce:bold><ce:underline>H</ce:underline></ce:bold>aemophilus aphrophilus</ce:italic> – now known as <ce:italic>Aggregatibacter aphrophilus</ce:italic>–<ce:italic><ce:bold><ce:underline>A</ce:underline></ce:bold>ggregatibacter actinomycetemcomitans</ce:italic>; <ce:italic><ce:bold><ce:underline>C</ce:underline></ce:bold>ardiobacterium hominis</ce:italic>; <ce:italic><ce:bold><ce:underline>E</ce:underline></ce:bold>ikenella corrodens</ce:italic>; and <ce:italic><ce:bold><ce:underline>K</ce:underline></ce:bold>ingella kingae</ce:italic>). These are slow-growing, fastidious Gram-negative organisms that are oropharyngeal commensals. The diagnosis may be revealed only after prolonged culture and the organisms may be resistant to penicillin.</ce:para><ce:para id="p6690"><ce:italic>Brucella</ce:italic> endocarditis is associated with a history of contact with goats or cattle and often affects the aortic valve.</ce:para><ce:para id="p6695">Yeasts and fungi, such as <ce:italic>Candida</ce:italic> and <ce:italic>Aspergillus</ce:italic>, may attack previously normal or prosthetic valves, particularly in immunocompromised patients or those with in-dwelling intravenous catheters. Abscesses and emboli are common, therapy is difficult, surgery is often required and mortality is high. Concomitant bacterial infection may be present.</ce:para></ce:section></ce:section><ce:section id="s2400"><ce:section-title id="st2270">Clinical features</ce:section-title><ce:para id="p6700">Endocarditis can take either an acute or a more insidious ‘subacute’ form. There is considerable overlap, however, because the clinical pattern is influenced not only by the organism but also by the site of infection, prior antibiotic therapy and the presence of a valve or shunt prosthesis. The subacute form may abruptly develop acute life-threatening complications, such as valve disruption or emboli. The Duke criteria for diagnosis of infective endocarditis are shown in <ce:cross-ref id="crf1720" refid="b0505">Box 16.95</ce:cross-ref><ce:float-anchor refid="b0505"/>.</ce:para><ce:section id="s2405"><ce:section-title id="st2275">Subacute endocarditis</ce:section-title><ce:para id="p6705">This should be suspected when a patient with congenital or valvular heart disease develops a persistent fever, complains of unusual tiredness, night sweats or weight loss, or develops new signs of valve dysfunction or heart failure. Less often, it presents as an embolic stroke or peripheral arterial embolism. Other features (<ce:cross-ref id="crf1715" refid="f0480">Fig. 16.89</ce:cross-ref><ce:float-anchor refid="f0480"/>) include purpura and petechial haemorrhages in the skin and mucous membranes, and splinter haemorrhages under the fingernails or toenails. Osler's nodes are painful, tender swellings at the fingertips that are probably the product of vasculitis; they are rare. Digital clubbing is a late sign. The spleen is frequently palpable; in <ce:italic>Coxiella</ce:italic> infections, the spleen and the liver may be considerably enlarged. Non-visible haematuria is common. The finding of any of these features in a patient with persistent fever or malaise is an indication for re-examination to detect hitherto unrecognised heart disease.</ce:para></ce:section><ce:section id="s2410"><ce:section-title id="st2280">Acute endocarditis</ce:section-title><ce:para id="p6710">This presents as a severe febrile illness with prominent and changing heart murmurs and petechiae. Clinical stigmata of chronic endocarditis are usually absent. Embolic events are common, and cardiac or renal failure may develop rapidly. Abscesses may be detected on echocardiography. Partially treated acute endocarditis behaves like subacute endocarditis.</ce:para></ce:section><ce:section id="s2415"><ce:section-title id="st2285">Post-operative endocarditis</ce:section-title><ce:para id="p6715">This may present as an unexplained fever in a patient who has had heart valve surgery. The infection usually involves the valve ring and may resemble subacute or acute endocarditis, depending on the virulence of the organism. Morbidity and mortality are high and revision surgery is often required. The range of organisms is similar to that seen in native valve disease, but when endocarditis occurs during the first few weeks after surgery it is usually due to infection with a coagulase-negative staphylococcus that was introduced during the perioperative period.</ce:para></ce:section></ce:section><ce:section id="s2440"><ce:section-title id="st2310">Investigations</ce:section-title><ce:para id="p6795">Blood culture (see <ce:intra-ref id="ii0730" xlink:href="pii:B978-0-7020-7028-0.00006-8#f0035">Fig. 6.6</ce:intra-ref>, <ce:intra-ref id="ii0735" xlink:href="pii:B978-0-7020-7028-0.00006-8#s0235">p. 107</ce:intra-ref>) is the pivotal investigation to identify the organism that is the cause of the infection and to guide antibiotic therapy. Three to six sets of blood cultures should be taken prior to commencing therapy and should not wait for episodes of pyrexia. The first two specimens will detect bacteraemia in 90% of culture-positive cases. A meticulous aseptic technique is essential. Taking discrete sets of blood cultures from peripheral sites at intervals of ≥ 6 hours reduces the risk of misdiagnosis due to contamination with skin commensals. Isolation of a typical organism in more than one culture provides strong evidence in favour of the diagnosis (<ce:cross-ref id="crf9105" refid="b0505">Box 16.95</ce:cross-ref>). An in-dwelling line should not be used to take cultures. Both aerobic and anaerobic cultures are required.</ce:para><ce:para id="p6800">Echocardiography is key for detecting and following the progress of vegetations, for assessing valve damage and for detecting abscess formation. Vegetations as small as 2–4 mm can be detected by transthoracic echocardiography, and even smaller ones (1–1.5 mm) can be visualised by trans-oesophageal echocardiography (TOE), which is particularly valuable for identifying abscess formation and investigating patients with prosthetic heart valves. Vegetations may be difficult to distinguish in the presence of an abnormal valve; the sensitivity of transthoracic echo is approximately 65% but that of TOE is more than 90%. Failure to detect vegetations does not exclude the diagnosis.</ce:para><ce:para id="p6805">Elevation of the ESR, a normocytic normochromic anaemia, and leucocytosis are common but not invariable. Measurement of serum CRP is more reliable than the ESR in monitoring progress. Proteinuria may occur and non-visible haematuria is usually present.</ce:para><ce:para id="p6810">The ECG may show the development of AV block (due to aortic root abscess formation) and occasionally infarction due to emboli. The chest X-ray may show evidence of cardiac failure and cardiomegaly.</ce:para></ce:section><ce:section id="s2445"><ce:section-title id="st2315">Management</ce:section-title><ce:para id="p6815">A multidisciplinary approach, with cooperation between the physician, surgeon and microbiologist, increases the chance of a successful outcome. Any source of infection should be removed as soon as possible; for example, a tooth with an apical abscess should be extracted.</ce:para><ce:para id="p6820">Empirical treatment depends on the mode of presentation, the suspected organism and the presence of a prosthetic valve or penicillin allergy. If the presentation is subacute, antibiotic treatment should ideally be withheld until the results of blood cultures are available. However, if empirical antibiotic treatment is considered necessary, amoxicillin (2 g 6 times daily IV) should be considered (with or without gentamicin). If the presentation is acute, empirical therapy should be started with vancomycin (1 g twice daily IV) and gentamicin (1 mg/kg twice daily IV), with dose adjustment based on antibiotic levels. The same regimen is used in true penicillin allergy. Patients with suspected prosthetic valve endocarditis should be treated with vancomycin and gentamicin at the above-mentioned doses, plus rifampicin orally in a dose of 300–600 mg twice daily. Following identification of the causal organism, determination of the minimum inhibitory concentration (MIC) for the organism helps guide antibiotic therapy. Recommended regimens for some of the most common scenarios are shown in <ce:cross-ref id="crf9110" refid="b0510">Box 16.96</ce:cross-ref><ce:float-anchor refid="b0510"/>. More detailed information can be found in the 2012 British Society for Antimicrobial Chemotherapy guidelines (see ‘Further reading’).</ce:para><ce:para id="p6830">A 2-week treatment regimen may be sufficient for fully sensitive strains of streptococci, provided specific conditions are met (<ce:cross-ref id="crf1770" refid="b0515">Box 16.97</ce:cross-ref><ce:float-anchor refid="b0515"/>).</ce:para><ce:para id="p6870">Cardiac surgery with débridement of infected material and valve replacement may be required in a substantial proportion of patients, particularly those with <ce:italic>Staph. aureus</ce:italic> and fungal infections (<ce:cross-ref id="crf1780" refid="b0520">Box 16.98</ce:cross-ref><ce:float-anchor refid="b0520"/>). Antimicrobial therapy must be started before surgery.</ce:para></ce:section><ce:section id="s2450"><ce:section-title id="st2320">Prevention</ce:section-title><ce:para id="p6905">Until recently, antibiotic prophylaxis was routinely given to people at risk of infective endocarditis undergoing interventional procedures. However, as this has not been proven to be effective and the link between episodes of infective endocarditis and interventional procedures has not been demonstrated, antibiotic prophylaxis is no longer offered routinely.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s2455"><ce:section-title id="st2325">Congenital heart disease</ce:section-title><ce:para id="p6910">Congenital heart disease can be the result of defects in the formation of the heart or great vessels or can arise because the anatomical changes that occur during transition between the fetus and the newborn child fail to proceed normally. Congenital heart disease usually presents in childhood but some patients do not present until adult life. It has been estimated that the incidence of haemodynamically significant congenital cardiac abnormalities is about 0.8% of live births (<ce:cross-ref id="crf1790" refid="b0525">Box 16.99</ce:cross-ref><ce:float-anchor refid="b0525"/>). Defects that are well tolerated, such as atrial septal defect, may cause no symptoms until adult life or may be detected incidentally on routine examination or chest X-ray. Congenital defects that were previously fatal in childhood can now be corrected, or at least partially, so that survival to adult life is the norm. Such patients remain well for many years but subsequently re-present in later life with related problems such as arrhythmia or heart failure (<ce:cross-ref id="crf1795" refid="b0530">Box 16.100</ce:cross-ref><ce:float-anchor refid="b0530"/>).</ce:para><ce:section id="s2460"><ce:section id="s2465"><ce:section id="s2470"><ce:section-title id="st2330">Pathophysiology</ce:section-title><ce:para id="p7000">Understanding the fetal circulation helps clarify how some forms of congenital heart disease occur. <ce:cross-ref id="crf1800" refid="f0485">Figure 16.90</ce:cross-ref><ce:float-anchor refid="f0485"/> shows the fetal circulation and the changes that normally occur immediately after birth. In the fetus there is little blood flow through the lungs, which are collapsed because they are not required for gas exchange. Instead, oxygenated blood from the placenta passes directly from the right atrium to the left side of the heart through the foramen ovale without having to flow through the lungs, and also from the pulmonary artery into the aorta via the ductus arteriosus.</ce:para><ce:para id="p7005">During early embryonic life, the heart develops as a single tube that folds back on itself and then divides into two separate circulations. Failure of septation can cause some forms of atrial and ventricular septal defect, whereas failure of alignment of the great vessels with the ventricles contributes to transposition of the great arteries, tetralogy of Fallot and truncus arteriosus. Atrial septal defects occur because the foramen ovale fails to close at birth, as is normal. Similarly, a persistent ductus arteriosus will remain persistent if it fails to close after birth. Failure of the aorta to develop at the point of the aortic isthmus and where the ductus arteriosus attaches can lead to coarctation of the aorta. Maternal infection and exposure to drugs or toxins are important causes of congenital heart disease. Maternal rubella infection is associated with persistent ductus arteriosus, pulmonary valvular and/or artery stenosis, and atrial septal defect. Maternal alcohol misuse is associated with septal defects, and maternal lupus erythematosus with congenital complete heart block. Genetic or chromosomal abnormalities, such as Down's syndrome, may cause septal defects, and gene defects have also been identified as leading to specific abnormalities, such as Marfan's syndrome (<ce:cross-ref id="crf9630" refid="p4835">p. 508</ce:cross-ref>) and DiGeorge's syndrome (deletion in chromosome 22q).</ce:para></ce:section><ce:section id="s2475"><ce:section-title id="st2335">Clinical features</ce:section-title><ce:para id="p7010">Symptoms may be absent, or the child may be breathless or fail to attain normal growth and development. Some defects are not compatible with extrauterine life and lead to neonatal death. Clinical signs vary with the anatomical lesion. Murmurs, thrills or signs of cardiomegaly may be present. In coarctation of the aorta, radio-femoral delay may be noted (<ce:cross-ref id="crf1805" refid="f0490">Fig. 16.91</ce:cross-ref><ce:float-anchor refid="f0490"/>) and some female patients have the features of Turner's syndrome (<ce:intra-ref id="ii0750" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0730">p. 659</ce:intra-ref>). Features of other congenital conditions, such as Marfan's syndrome or Down's syndrome, may also be apparent. Cerebrovascular events and cerebral abscesses may complicate severe cyanotic congenital disease.</ce:para><ce:para id="p7015">Early diagnosis is important because many types of congenital heart disease are amenable to surgery, but this opportunity is lost if secondary changes, such as irreversible pulmonary hypertension, occur.</ce:para><ce:section id="s2480"><ce:section-title id="st2340">Central cyanosis and digital clubbing</ce:section-title><ce:para id="p7020">Central cyanosis of cardiac origin occurs when desaturated blood enters the systemic circulation without passing through the lungs (right-to-left shunting). In the neonate, the most common cause is transposition of the great arteries, in which the aorta arises from the RV and the pulmonary artery from the LV in association with a ventricular septal defect. In older children, cyanosis is usually the consequence of a ventricular septal defect combined with severe pulmonary stenosis (as in tetralogy of Fallot) or with pulmonary vascular disease (Eisenmenger's syndrome). Prolonged cyanosis is associated with finger and toe clubbing (<ce:cross-ref id="crf9635" refid="s0010">p. 442</ce:cross-ref>).</ce:para></ce:section><ce:section id="s2485"><ce:section-title id="st2345">Growth retardation and learning difficulties</ce:section-title><ce:para id="p7025">These may occur with large left-to-right shunts at ventricular or great arterial level, and also with other defects, especially if they form part of a genetic syndrome. Major intellectual impairment is uncommon in children with isolated congenital heart disease; minor learning difficulties can occur, however. Cerebral function can also be affected after cardiac surgery if cerebral perfusion is compromised.</ce:para></ce:section><ce:section id="s2490"><ce:section-title id="st2350">Syncope</ce:section-title><ce:para id="p7030">In the presence of increased pulmonary vascular resistance or severe left or right ventricular outflow obstruction, exercise may provoke syncope as systemic vascular resistance falls but pulmonary vascular resistance rises, worsening right-to-left shunting and cerebral oxygenation. Syncope can also occur because of associated arrhythmias.</ce:para></ce:section><ce:section id="s2495"><ce:section-title id="st2355">Pulmonary hypertension</ce:section-title><ce:para id="p7035">Persistently raised pulmonary flow with a left-to-right shunt causes increased pulmonary vascular resistance followed by pulmonary hypertension. Progressive changes, including obliteration of distal arterioles, take place and are irreversible. At this stage, central cyanosis occurs and digital clubbing develops. The chest X-ray shows enlarged central pulmonary arteries and peripheral ‘pruning’ of the pulmonary vessels. The ECG shows features of right ventricular hypertrophy.</ce:para></ce:section><ce:section id="s2500"><ce:section-title id="st2360">Eisenmenger's syndrome</ce:section-title><ce:para id="p7040">In patients with severe and prolonged pulmonary hypertension the left-to-right shunt may reverse, resulting in right-to-left shunt and marked cyanosis. This is termed Eisenmenger's syndrome. The cyanosis in Eisenmenger's syndrome may be more apparent in the feet and toes than in the upper part of the body, resulting in so-called differential cyanosis. Eisenmenger's syndrome is more common with large ventricular septal defects or persistent ductus arteriosus than with atrial septal defects. Patients with Eisenmenger's syndrome are at particular risk from abrupt changes in afterload that exacerbate right-to-left shunting, such as vasodilatation, anaesthesia and pregnancy.</ce:para></ce:section><ce:section id="s2505"><ce:section-title id="st2365">Congenital heart disease in pregnancy</ce:section-title><ce:para id="p7045">During pregnancy, there is a 50% increase in plasma volume, a 40% increase in whole blood volume and a similar increase in cardiac output, so problems may arise in women with congenital heart disease (<ce:cross-ref id="crf1810" refid="b0535">Box 16.101</ce:cross-ref><ce:float-anchor refid="b0535"/>). Many with palliated or untreated disease will tolerate pregnancy well, however. Pregnancy is particularly hazardous in the presence of conditions associated with cyanosis or severe pulmonary hypertension; maternal mortality in patients with Eisenmenger's syndrome is more than 50%.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2510"><ce:section-title id="st2370">Persistent ductus arteriosus</ce:section-title><ce:para id="p7075">Normally, the ductus arteriosus closes soon after birth but in this anomaly it fails to do so. Persistence of the ductus is often associated with other abnormalities and is more common in females.</ce:para><ce:section id="s2515"><ce:section-title id="st2375">Pathophysiology</ce:section-title><ce:para id="p7080">During fetal life, before the lungs begin to function, most of the blood from the pulmonary artery passes through the ductus arteriosus into the aorta (see <ce:cross-ref id="crf1815" refid="f0485">Fig. 16.90</ce:cross-ref>). Persistence of the ductus causes a continuous AV shunt from the aorta to the pulmonary artery since pressure in the aorta is higher than that in the pulmonary circulation. The volume of the shunt depends on the size of the ductus but as much as 50% of the left ventricular output may be recirculated through the lungs, with a consequent increase in the work of the heart (<ce:cross-ref id="crf1820" refid="f0495">Fig. 16.92</ce:cross-ref><ce:float-anchor refid="f0495"/>). A large left-to-right shunt in infancy may cause a considerable rise in pulmonary artery pressure and sometimes this leads to progressive pulmonary vascular damage.</ce:para></ce:section><ce:section id="s2520"><ce:section-title id="st2380">Clinical features</ce:section-title><ce:para id="p7085">With small shunts there may be no symptoms for years, but when the ductus is large, growth and development may be retarded. Usually, there is no disability in infancy but cardiac failure may eventually ensue, dyspnoea being the first symptom. A continuous ‘machinery’ murmur is heard with late systolic accentuation, maximal in the second left intercostal space below the clavicle (<ce:cross-ref id="crf1825" refid="f0495">Fig. 16.92</ce:cross-ref>). It is frequently accompanied by a thrill. Pulses are increased in volume.</ce:para><ce:para id="p7090">Enlargement of the pulmonary artery may be detected radiologically. The ECG is usually normal. If pulmonary vascular resistance increases, pulmonary artery pressure may rise until it equals or exceeds aortic pressure. The shunt through the defect may then reverse, causing Eisenmenger's syndrome. The murmur becomes quieter, may be confined to systole or may disappear.</ce:para></ce:section><ce:section id="s2525"><ce:section-title id="st2385">Investigations</ce:section-title><ce:para id="p7095">Echocardiography is the investigation of choice although the persistent ductus requires specific echocardiographic views, such as from the suprasternal notch, to reveal it. The ECG shows evidence of right ventricular hypertrophy</ce:para></ce:section><ce:section id="s2530"><ce:section-title id="st2390">Management</ce:section-title><ce:para id="p7100">A persistent ductus can be closed at cardiac catheterisation with an implantable occlusive device. Closure should be undertaken in infancy if the shunt is significant and pulmonary resistance not elevated, but this may be delayed until later childhood in those with smaller shunts, for whom closure remains advisable to reduce the risk of endocarditis. When the ductus is structurally intact, a prostaglandin synthetase inhibitor (indometacin or ibuprofen) may be used in the first week of life to induce closure. However, in the presence of a congenital defect with impaired lung perfusion, such as occurs in severe pulmonary stenosis and left-to-right shunt through the ductus, it may be advisable to improve oxygenation by keeping the ductus open with prostaglandin treatment. Unfortunately, these treatments do not work if the ductus is intrinsically abnormal.</ce:para></ce:section></ce:section><ce:section id="s2535"><ce:section-title id="st2395">Coarctation of the aorta</ce:section-title><ce:para id="p7105">This condition is twice as common in males and occurs in 1 in 4000 children. It is associated with other abnormalities, most frequently bicuspid aortic valve and ‘berry’ aneurysms of the cerebral circulation (<ce:intra-ref id="ii0760" xlink:href="pii:B978-0-7020-7028-0.00026-3#s0285">p. 1160</ce:intra-ref>). Acquired coarctation of the aorta is rare but may follow trauma or occur as a complication of a progressive arteritis (Takayasu's disease, <ce:intra-ref id="ii0765" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1540">p. 1041</ce:intra-ref>).</ce:para><ce:section id="s2540"><ce:section-title id="st2400">Pathogenesis</ce:section-title><ce:para id="p7110">Narrowing of the aorta occurs in the region where the ductus arteriosus joins the aorta, at the isthmus just below the origin of the left subclavian artery (see <ce:cross-ref id="crf1830" refid="f0485">Fig. 16.90</ce:cross-ref>). This causes raised BP affecting vessels of the head and neck proximal to the coarctation, and reduced BP and impaired circulation distally.</ce:para></ce:section><ce:section id="s2545"><ce:section-title id="st2405">Clinical features</ce:section-title><ce:para id="p7115">Aortic coarctation is an important cause of cardiac failure in the newborn but symptoms are often absent in older children or adults. Headaches may occur from hypertension proximal to the coarctation, and occasionally weakness or cramps in the legs may result from decreased circulation in the lower part of the body. The BP is raised in the upper body but normal or low in the legs. The femoral pulses are weak and delayed in comparison with the radial pulse (see <ce:cross-ref id="crf1835" refid="f0490">Fig. 16.91</ce:cross-ref>). A systolic murmur is usually heard posteriorly, over the coarctation. There may also be an ejection click and systolic murmur in the aortic area due to a bicuspid aortic valve. As a result of the aortic narrowing, collaterals form; they mainly involve the periscapular, internal mammary and intercostal arteries, and may result in localised bruits.</ce:para></ce:section><ce:section id="s2550"><ce:section-title id="st2410">Investigations</ce:section-title><ce:para id="p7120">Imaging by MRI is the investigation of choice (<ce:cross-ref id="crf1840" refid="f0500">Fig. 16.93</ce:cross-ref><ce:float-anchor refid="f0500"/>). The chest X-ray in early childhood is often normal but later may show changes in the contour of the aorta (indentation of the descending aorta, ‘3 sign’) and notching of the under-surfaces of the ribs from collaterals. The ECG may show evidence of left ventricular hypertrophy, which can be confirmed by echocardiography.</ce:para></ce:section><ce:section id="s2555"><ce:section-title id="st2415">Management</ce:section-title><ce:para id="p7125">In untreated cases, death may occur from left ventricular failure, dissection of the aorta or cerebral haemorrhage. Surgical correction is advisable in all but the mildest cases. If this is carried out sufficiently early in childhood, persistent hypertension can be avoided. Patients repaired in late childhood or adult life often remain hypertensive or develop recurrent hypertension later on. Recurrence of stenosis may occur as the child grows and this may be managed by balloon dilatation and sometimes stenting. The latter may be used as the primary treatment. Coexistent bicuspid aortic valve, which occurs in over 50% of cases, may lead to progressive aortic stenosis or regurgitation, and also requires long-term follow-up.</ce:para></ce:section></ce:section><ce:section id="s2560"><ce:section-title id="st2420">Atrial septal defect</ce:section-title><ce:para id="p7130">Atrial septal defect is one of the most common congenital heart defects and occurs twice as frequently in females. Most are ‘ostium secundum’ defects, involving the fossa ovalis that, in utero, was the foramen ovale (see <ce:cross-ref id="crf1845" refid="f0485">Fig. 16.90</ce:cross-ref>). ‘Ostium primum’ defects result from a defect in the atrioventricular septum and are associated with a ‘cleft mitral valve’ (split anterior leaflet).</ce:para><ce:section id="s2565"><ce:section-title id="st2425">Pathogenesis</ce:section-title><ce:para id="p7135">Since the normal RV is more compliant than the LV, a patent foramen ovale is associated with shunting of blood from the LA to the RA, and then to the RV and pulmonary arteries (<ce:cross-ref id="crf1850" refid="f0505">Fig. 16.94</ce:cross-ref><ce:float-anchor refid="f0505"/>). As a result, there is gradual enlargement of the right side of the heart and of the pulmonary arteries. Pulmonary hypertension and shunt reversal sometimes complicate atrial septal defect, but are less common and tend to occur later in life than with other types of left-to-right shunt.</ce:para></ce:section><ce:section id="s2570"><ce:section-title id="st2430">Clinical features</ce:section-title><ce:para id="p7140">Most children are asymptomatic for many years and the condition is often detected at routine clinical examination or following a chest X-ray. Symptoms that can occur include dyspnoea, chest infections, cardiac failure and arrhythmias, especially AF. The characteristic physical signs are the result of the volume overload of the RV:<ce:list id="ulist1300"><ce:list-item id="u3660"><ce:label>•</ce:label><ce:para id="p7145">wide, fixed splitting of the second heart sound: wide because of delay in right ventricular ejection (increased stroke volume and RBBB), and fixed because the septal defect equalises left and right atrial pressures throughout the respiratory cycle</ce:para></ce:list-item><ce:list-item id="u3665"><ce:label>•</ce:label><ce:para id="p7150">a systolic flow murmur over the pulmonary valve.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p7155">In children with a large shunt, there may be a diastolic flow murmur over the tricuspid valve. Unlike a mitral flow murmur, this is usually high-pitched.</ce:para></ce:section><ce:section id="s2575"><ce:section-title id="st2435">Investigations</ce:section-title><ce:para id="p7160">Echocardiography is diagnostic. It directly demonstrates the defect and typically shows right ventricular dilatation, right ventricular hypertrophy and pulmonary artery dilatation. The precise size and location of the defect are best defined by TOE (<ce:cross-ref id="crf1855" refid="f0510">Fig. 16.95</ce:cross-ref><ce:float-anchor refid="f0510"/>). The chest X-ray typically shows enlargement of the heart and the pulmonary artery, as well as pulmonary plethora. The ECG usually demonstrates incomplete RBBB because right ventricular depolarisation is delayed as a result of ventricular dilatation (with a ‘primum’ defect, there is also left axis deviation).</ce:para></ce:section><ce:section id="s2580"><ce:section-title id="st2440">Management</ce:section-title><ce:para id="p7165">Atrial septal defects in which pulmonary flow is increased 50% above systemic flow (i.e. a flow ratio of 1.5 : 1) are often large enough to be clinically recognisable and should be closed surgically. (Smaller defects may be managed conservatively and patients are monitored with echocardiography.) Closure can also be accomplished at cardiac catheterisation using implantable closure devices (<ce:cross-ref id="crf1860" refid="f0515">Fig. 16.96</ce:cross-ref><ce:float-anchor refid="f0515"/>). The long-term prognosis thereafter is excellent, unless pulmonary hypertension has developed. Severe pulmonary hypertension and shunt reversal are both contraindications to surgery.</ce:para></ce:section></ce:section><ce:section id="s2585"><ce:section-title id="st2445">Ventricular septal defect</ce:section-title><ce:para id="p7170">Ventricular septal defect is the most common congenital cardiac defect, occurring once in 500 live births. The defect may be isolated or part of complex congenital heart disease.</ce:para><ce:section id="s2590"><ce:section-title id="st2450">Pathogenesis</ce:section-title><ce:para id="p7175">Congenital ventricular septal defect occurs as a result of incomplete septation of the ventricles. Embryologically, the interventricular septum has a membranous and a muscular portion, and the latter is further divided into inflow, trabecular and outflow portions. Most congenital defects are ‘perimembranous’, occurring at the junction of the membranous and muscular portions of the septum.</ce:para></ce:section><ce:section id="s2595"><ce:section-title id="st2455">Clinical features</ce:section-title><ce:para id="p7180">Flow from the high-pressure LV to the low-pressure RV during systole produces a pansystolic murmur, usually heard best at the left sternal edge but radiating all over the precordium (<ce:cross-ref id="crf1865" refid="f0520">Fig. 16.97</ce:cross-ref><ce:float-anchor refid="f0520"/>). A small defect often produces a loud murmur (maladie de Roger) in the absence of other haemodynamic disturbance. Conversely, a large defect produces a softer murmur, particularly if pressure in the RV is elevated. This may be found immediately after birth, while pulmonary vascular resistance remains high, or when the shunt is reversed in Eisenmenger's syndrome. Congenital ventricular septal defect may present as cardiac failure in infants, as a murmur with only minor haemodynamic disturbance in older children or adults, or, rarely, as Eisenmenger's syndrome. In a proportion of infants, the murmur becomes quieter or disappears due to spontaneous closure of the defect.</ce:para><ce:para id="p7185">If cardiac failure complicates a large defect, it is usually absent in the immediate postnatal period and becomes apparent only in the first 4–6 weeks of life. In addition to the murmur, there is prominent parasternal pulsation, tachypnoea and indrawing of the lower ribs on inspiration.</ce:para></ce:section><ce:section id="s2600"><ce:section-title id="st2460">Investigations</ce:section-title><ce:para id="p7190">Doppler echocardiography should be performed since it helps to identify the small septal defects that are not haemodynamically significant and are likely to close spontaneously. Patients with larger defects should be monitored by serial ECG and echocardiography to screen for signs of pulmonary hypertension. With larger defects, the chest X-ray shows pulmonary congestion and the ECG shows bilateral ventricular hypertrophy.</ce:para></ce:section><ce:section id="s2605"><ce:section-title id="st2465">Management</ce:section-title><ce:para id="p7195">Small ventricular septal defects require no specific treatment. If there is cardiac failure in infancy, this should initially be treated medically with digoxin and diuretics. Persisting failure is an indication for surgical repair of the defect. Percutaneous closure devices are under development.</ce:para><ce:para id="p7200">If serial ECG and echocardiography suggest that pulmonary hypertension is developing, surgical repair should be performed. Surgical closure is contraindicated in fully developed Eisenmenger's syndrome, in which case heart–lung transplantation is the only effective treatment. The long-term prognosis is generally very good. An exception is in Eisenmenger's syndrome, when death normally occurs in the second or third decade of life, but a few individuals survive to the fifth decade without transplantation.</ce:para></ce:section></ce:section><ce:section id="s2610"><ce:section-title id="st2470">Tetralogy of Fallot</ce:section-title><ce:para id="p7205">This is complex defect consisting of right ventricular outflow tract obstruction and right ventricular hypertrophy, a large ventricular septal defect and an over-riding aorta that, when combined with the septal defect, allows blood to be pumped directly from the RV into the aorta. It occurs in about 1 in 2000 births and is the most common cause of cyanosis in infancy after the first year of life.</ce:para><ce:section id="s2615"><ce:section-title id="st2475">Pathogenesis</ce:section-title><ce:para id="p7210">Tetralogy of Fallot occurs as the result of abnormal development of the bulbar septum that separates the ascending aorta from the pulmonary artery, and which normally aligns and fuses with the outflow part of the interventricular septum. The right ventricular outflow obstruction is most often subvalvular (infundibular) but may be valvular, supravalvular or a combination of these (<ce:cross-ref id="crf1870" refid="f0525">Fig. 16.98</ce:cross-ref><ce:float-anchor refid="f0525"/>). The subvalvular component of the right ventricular outflow obstruction is dynamic and may increase suddenly under adrenergic stimulation. The ventricular septal defect is usually large and similar in aperture to the aortic orifice. The combination results in elevated right ventricular pressure and right-to-left shunting of cyanotic blood across the ventricular septal defect into the aorta.</ce:para></ce:section><ce:section id="s2620"><ce:section-title id="st2480">Clinical features</ce:section-title><ce:para id="p7215">Children are usually cyanosed but this may not be the case in the neonate because it is only when right ventricular pressure rises to equal or exceed left ventricular pressure that a large right-to-left shunt develops. The affected child may suddenly become increasingly cyanosed, often after feeding or a crying attack, and may become apnoeic and unconscious. These attacks are called ‘Fallot's spells’. In older children, Fallot's spells are uncommon but cyanosis becomes increasingly apparent, with stunting of growth, digital clubbing and polycythaemia. Some children characteristically obtain relief by squatting after exertion, which increases the afterload of the left heart and reduces the right-to-left shunting. This is called Fallot's sign. The natural history before the development of surgical correction was variable but most patients died in infancy or childhood.</ce:para><ce:para id="p7220">On examination, the most characteristic feature is the combination of cyanosis with a loud ejection systolic murmur in the pulmonary area (as for pulmonary stenosis). Cyanosis may be absent in the newborn or in patients with only mild right ventricular outflow obstruction, however. This is called acyanotic tetralogy of Fallot.</ce:para></ce:section><ce:section id="s2625"><ce:section-title id="st2485">Investigations</ce:section-title><ce:para id="p7225">Echocardiography is diagnostic and demonstrates that the aorta is not continuous with the anterior ventricular septum. The ECG shows right ventricular hypertrophy and the chest X-ray shows an abnormally small pulmonary artery and a ‘boot-shaped’ heart.</ce:para></ce:section><ce:section id="s2630"><ce:section-title id="st2490">Management</ce:section-title><ce:para id="p7230">The definitive management is total correction of the defect by surgical relief of the pulmonary stenosis and closure of the ventricular septal defect. Primary surgical correction may be undertaken prior to the age of 5 years. If the pulmonary arteries are too hypoplastic, then palliation in the form of a Blalock–Taussig shunt may be performed, with an anastomosis created between the pulmonary artery and subclavian artery. This improves pulmonary blood flow and pulmonary artery development, and may facilitate later definitive correction.</ce:para><ce:para id="p7235">The prognosis after total correction is good, especially if the operation is performed in childhood. Follow-up is needed to identify residual shunting, recurrent pulmonary stenosis and arrhythmias. An implantable defibrillator is sometimes recommended in adulthood.</ce:para></ce:section></ce:section><ce:section id="s2635"><ce:section-title id="st2495">Other causes of cyanotic congenital heart disease</ce:section-title><ce:para id="p7240">There are other causes of cyanotic congenital heart disease, as summarised in <ce:cross-ref id="crf1875" refid="b0540">Box 16.102</ce:cross-ref><ce:float-anchor refid="b0540"/>. Echocardiography is usually the definitive diagnostic procedure, supplemented, if necessary, by cardiac catheterisation.</ce:para></ce:section><ce:section id="s2640"><ce:section-title id="st2500">Adult congenital heart disease</ce:section-title><ce:para id="p7255">There are increasing numbers of children who have had surgical correction of congenital defects and who may have further problems as adults. The transition period between paediatric and adult care needs to be managed in a carefully planned manner, addressing many diverse aspects of care (<ce:cross-ref id="crf1880" refid="b0545">Box 16.103</ce:cross-ref><ce:float-anchor refid="b0545"/>). Those who have undergone correction of coarctation of the aorta may develop hypertension in adult life. Those with transposition of the great arteries who have had a ‘Mustard’ repair, in which blood is redirected at atrial level leaving the RV connected to the aorta, may develop right ventricular failure in adult life. This is because the RV is unsuited for function at systemic pressures and may begin to dilate and fail when patients are in their twenties or thirties.</ce:para><ce:para id="p7300">Those who have had surgery involving the atria may develop atrial arrhythmias, and those who have ventricular scars may develop ventricular arrhythmias and need consideration for placement of an ICD. Such patients require careful follow-up from the teenage years throughout adult life, so that problems can be identified early and appropriate medical or surgical treatment instituted. The management of patients with grown-up congenital heart disease (GUCH) is complex and has developed as a cardiological subspecialty.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2645"><ce:section-title id="st2505">Diseases of the myocardium</ce:section-title><ce:para id="p7305">Although the myocardium is involved as the result of ischaemia in CAD and in valvular heart disease, this section focus on conditions that primarily affect the heart muscle.</ce:para><ce:section id="s2650"><ce:section-title id="st2510">Myocarditis</ce:section-title><ce:para id="p7310">This is an acute inflammatory condition that can have an infectious, toxic or autoimmune aetiology (<ce:cross-ref id="crf1885" refid="b0550">Box 16.104</ce:cross-ref><ce:float-anchor refid="b0550"/>). Myocarditis can complicate many infections in which inflammation may be due directly to infection of the myocardium or the effects of circulating toxins. Viral infections are the most common causes, such as Coxsackie (35 cases per 1000 infections) and influenza A and B (25 cases per 1000 infections) viruses. Myocarditis may occur several weeks after the initial viral symptoms, and susceptibility is increased by glucocorticoid treatment, immunosuppression, radiation, previous myocardial damage and exercise. Some bacterial and protozoal infections may be complicated by myocarditis; for example, approximately 5% of patients with Lyme disease (<ce:italic>Borrelia burgdorferi</ce:italic>, <ce:intra-ref id="ii0770" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1275">p. 255</ce:intra-ref>) develop myopericarditis, which is often associated with AV block. Toxins such as alcohol and drugs such as cocaine, lithium and doxorubicin may directly injure the myocardium. Other drugs, including penicillins and sulphonamides, and poisons such as lead and carbon monoxide may cause a hypersensitivity reaction and associated myocarditis. Occasionally, autoimmune conditions, such as systemic lupus erythematosus and rheumatoid arthritis, are associated with myocarditis.</ce:para><ce:section id="s2655"><ce:section id="s2660"><ce:section-title id="st2515">Clinical features</ce:section-title><ce:para id="p7420">Myocarditis may present in one of four ways:<ce:list id="ulist1370"><ce:list-item id="u3805"><ce:label>•</ce:label><ce:para id="p7425"><ce:italic>Fulminant myocarditis</ce:italic> follows a viral prodrome or influenza-like illness and results in severe heart failure or cardiogenic shock.</ce:para></ce:list-item><ce:list-item id="u3810"><ce:label>•</ce:label><ce:para id="p7430"><ce:italic>Acute myocarditis</ce:italic> presents over a longer period with heart failure; it can lead to dilated cardiomyopathy.</ce:para></ce:list-item><ce:list-item id="u3815"><ce:label>•</ce:label><ce:para id="p7435"><ce:italic>Chronic active myocarditis</ce:italic> is rare and associated with chronic myocardial inflammation.</ce:para></ce:list-item><ce:list-item id="u3820"><ce:label>•</ce:label><ce:para id="p7440"><ce:italic>Chronic persistent myocarditis</ce:italic> is characterised by focal myocardial infiltrates and can cause chest pain and arrhythmia without necessarily causing ventricular dysfunction.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p7445">Myocarditis is self-limiting in most patients and the immediate prognosis is good. Death may, however, occur due to a ventricular arrhythmia or rapidly progressive heart failure. Myocarditis has been reported as a cause of sudden and unexpected death in young athletes. Some forms of myocarditis may lead to chronic low-grade myocarditis or dilated cardiomyopathy (see below). For example, in Chagas' disease (<ce:intra-ref id="ii0775" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2110">p. 279</ce:intra-ref>), the patient frequently recovers from the acute infection but goes on to develop a chronic dilated cardiomyopathy 10 or 20 years later.</ce:para></ce:section><ce:section id="s2665"><ce:section-title id="st2520">Investigations</ce:section-title><ce:para id="p7450">The diagnosis of myocarditis is often made after other more common causes of cardiac dysfunction have been excluded. Echocardiography should be performed and may reveal left ventricular dysfunction that is sometimes regional (due to focal myocarditis). Cardiac MRI is also useful since it may show diagnostic patterns of myocardial inflammation or infiltration. The ECG is frequently abnormal but the changes are non-specific. Blood should be taken for analysis of troponin I and T, and creatine kinase. Levels may be elevated in the early phases. Occasionally, endomyocardial biopsy may be required to confirm the diagnosis.</ce:para></ce:section><ce:section id="s2670"><ce:section-title id="st2525">Management</ce:section-title><ce:para id="p7455">Treatment of myocarditis is primarily supportive. Treatment for cardiac failure or arrhythmias should be given and patients should be advised to avoid intense physical exertion because there is some evidence that this can induce potentially fatal ventricular arrhythmias. There is no evidence of benefit from treatment with glucocorticoids and immunosuppressive agents.</ce:para><ce:para id="p7460">Specific antimicrobial therapy may be used if a causative organism has been identified but this is rare. Patients who do not respond adequately to medical treatment may temporarily require circulatory support with a mechanical ventricular assist device. Rarely, cardiac transplantation may be required.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2675"><ce:section-title id="st2530">Cardiomyopathy</ce:section-title><ce:para id="p7465">Cardiomyopathies are primary diseases of the myocardium, which are classified according to their effects on cardiac structure and function (<ce:cross-ref id="crf1890" refid="f0530">Fig. 16.99</ce:cross-ref><ce:float-anchor refid="f0530"/>). They can be inherited or be caused by infections or exposure to toxins. In some cases no cause is identified.</ce:para><ce:section id="s2680"><ce:section-title id="st2535">Dilated cardiomyopathy</ce:section-title><ce:para id="p7470">In North America and Europe, symptomatic dilated cardiomyopathy has an incidence of 20 per 100 000 and a prevalence of 38 per 100 000. Men are affected more than twice as often as women.</ce:para><ce:section id="s2685"><ce:section-title id="st2540">Pathogenesis</ce:section-title><ce:para id="p7475">Cardiomyopathy is characterised by dilatation and impaired contraction of the LV and often the RV. Left ventricular mass is increased but wall thickness is normal or reduced (<ce:cross-ref id="crf1895" refid="f0530">Fig. 16.99</ce:cross-ref>). Dilatation of the valve rings can lead to functional mitral and tricuspid incompetence. Histological changes are variable but include myofibrillary loss, interstitial fibrosis and T-cell infiltrates. The term ‘dilated cardiomyopathy’ encompasses a heterogeneous group of conditions. Alcohol may be an important cause in some patients. At least 25% of cases are inherited as an autosomal dominant trait and a variety of single-gene mutations have been identified. Most of these mutations affect proteins in the cytoskeleton of the myocytes, such as dystrophin, lamin A and C, emerin and metavinculin. Many are also associated with abnormalities of skeletal muscle. Conversely, most of the X-linked inherited skeletal muscular dystrophies, such as Becker and Duchenne (<ce:intra-ref id="ii0780" xlink:href="pii:B978-0-7020-7028-0.00025-1#s2215">p. 1143</ce:intra-ref>), are associated with cardiomyopathy. Finally, a late autoimmune reaction to viral myocarditis is thought to be the cause in a substantial subgroup of patients with dilated cardiomyopathy; a similar mechanism is believed to be responsible for the myocardial involvement that occurs in up to 10% of patients with advanced human immunodeficiency virus (HIV) infection.</ce:para></ce:section><ce:section id="s2690"><ce:section-title id="st2545">Clinical features</ce:section-title><ce:para id="p7480">Most patients present with heart failure or are found to have the condition during routine investigation. Arrhythmia, thromboembolism and sudden death may occur at any stage; sporadic chest pain is a surprisingly frequent symptom. The differential diagnosis includes ventricular dysfunction due to CAD, and a diagnosis of dilated cardiomyopathy should be made only when this has been excluded.</ce:para></ce:section><ce:section id="s2695"><ce:section-title id="st2550">Investigations</ce:section-title><ce:para id="p7485">Echocardiography and cardiac MRI are the most useful investigations. Although ECG changes are common, they are non-specific. Genetic testing is indicated if more than one family member is diagnosed with the condition.</ce:para></ce:section><ce:section id="s2700"><ce:section-title id="st2555">Management</ce:section-title><ce:para id="p7490">The focus of management is to control heart failure using the strategies described earlier in this chapter (<ce:cross-ref id="crf9640" refid="s0525">p. 464</ce:cross-ref>). Although some patients remain well for many years, the prognosis is variable and cardiac transplantation may be indicated. Patients with dilated cardiomyopathy and moderate or severe heart failure are at risk of sudden arrhythmic death and this can be reduced by rigorous medical therapy with β-blockers and either ACE inhibitors or ARBs. Some patients may be considered for implantation of a cardiac defibrillator and/or cardiac resynchronisation therapy (<ce:cross-ref id="crf9645" refid="s1115">pp. 483 and 484</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s2705"><ce:section-title id="st2560">Hypertrophic cardiomyopathy</ce:section-title><ce:para id="p7495">This is the most common form of cardiomyopathy, with a prevalence of approximately 100 per 100 000. It is characterised by inappropriate and elaborate left ventricular hypertrophy with malalignment of the myocardial fibres and myocardial fibrosis. The hypertrophy may be generalised or confined largely to the interventricular septum (asymmetric septal hypertrophy, <ce:cross-ref id="crf1900" refid="f0530">Fig. 16.99</ce:cross-ref>) or other regions of the heart. A specific variant termed apical hypertrophic cardiomyopathy is common in the Far East.</ce:para><ce:section id="s2710"><ce:section-title id="st2565">Pathogenesis</ce:section-title><ce:para id="p7500">Hypertrophic cardiomyopathy is a genetic disorder, usually with autosomal dominant transmission, a high degree of penetrance and variable expression. In most patients, it is due to a single-point mutation in one of the genes that encode sarcomeric contractile proteins. There are three common groups of mutation with different phenotypes. Beta-myosin heavy-chain mutations are associated with elaborate ventricular hypertrophy. Troponin mutations are associated with little, and sometimes even no, hypertrophy but marked myocardial fibre disarray, exercise-induced hypotension and a high risk of sudden death. Myosin-binding protein C mutations tend to present late in life and are often associated with hypertension and arrhythmia. In all subtypes, heart failure may develop because the stiff, non-compliant LV impedes diastolic filling. Septal hypertrophy may also cause dynamic left ventricular outflow tract obstruction (hypertrophic obstructive cardiomyopathy, HOCM) and mitral regurgitation due to abnormal systolic anterior motion of the anterior mitral valve leaflet.</ce:para></ce:section><ce:section id="s2715"><ce:section-title id="st2570">Clinical features</ce:section-title><ce:para id="p7505">Effort-related symptoms, such as angina, breathlessness, arrhythmia and sudden death, are the dominant clinical presentations. The symptoms and signs are similar to those of aortic stenosis, except that, in hypertrophic cardiomyopathy, the character of the arterial pulse is jerky (<ce:cross-ref id="crf1905" refid="b0555">Box 16.105</ce:cross-ref><ce:float-anchor refid="b0555"/>). The annual mortality from sudden death is 2–3% among adults and 4–6% in children and adolescents (<ce:cross-ref id="crf1920" refid="b0560">Box 16.106</ce:cross-ref><ce:float-anchor refid="b0560"/>). Sudden death typically occurs during or just after vigorous physical activity and is thought to be due to ventricular arrhythmias. Hypertrophic cardiomyopathy is the most common cause of sudden death in young athletes. In patients who do not suffer fatal arrhythmias, the natural history is variable but clinical deterioration is often slow.</ce:para></ce:section><ce:section id="s2720"><ce:section-title id="st2575">Investigations</ce:section-title><ce:para id="p7595">Echocardiography is the investigation of choice and is usually diagnostic. Sometimes the diagnosis is more difficult when another cause of left ventricular hypertrophy is present but the degree of hypertrophy in hypertrophic cardiomyopathy is usually greater than in physiological hypertrophy and the pattern is asymmetrical. The ECG is abnormal and shows features of left ventricular hypertrophy with a wide variety of often bizarre abnormalities, including deep T-wave inversion. Genetic testing can be performed and is helpful in screening relatives of affected individuals.</ce:para></ce:section><ce:section id="s2725"><ce:section-title id="st2580">Management</ce:section-title><ce:para id="p7600">Beta-blockers, rate-limiting calcium antagonists and disopyramide can help to relieve symptoms and prevent syncopal attacks. Arrhythmias often respond to treatment with amiodarone. No pharmacological treatment has been identified that can improve prognosis, however. Outflow tract obstruction can be improved by partial surgical resection (myectomy) or by iatrogenic infarction of the basal septum (septal ablation) using a catheter-delivered alcohol solution. An ICD should be considered in patients with clinical risk factors for sudden death (<ce:cross-ref id="crf1925" refid="b0560">Box 16.106</ce:cross-ref>). Digoxin and vasodilators may increase outflow tract obstruction and should be avoided.</ce:para></ce:section></ce:section><ce:section id="s2730"><ce:section-title id="st2585">Arrhythmogenic ventricular cardiomyopathy</ce:section-title><ce:para id="p7605">Arrhythmogenic ventricular cardiomyopathy (AVC) predominantly affects the myocardium of the right ventricle. It is inherited in an autosomal dominant manner and has a prevalence of approximately 10 per 100 000. The genetic defect involves desmosomal protein genes, most commonly plakophilin 2 (<ce:italic>PKP-2</ce:italic>), although current genetic testing protocols will not identify the culprit gene in many cases. It is characterised by replacement of patches of the right ventricular myocardium with fibrous and fatty tissue (see <ce:cross-ref id="crf1930" refid="f0530">Fig. 16.99</ce:cross-ref>). In some cases, the LV is also involved and this is associated with a poorer prognosis. The diagnosis is based on a complex set of criteria that take account of the ECG, structural assessment, genetics and arrhythmias. The dominant clinical problems are ventricular arrhythmias, sudden death and right-sided cardiac failure. The ECG typically shows a slightly broadened QRS complex and inverted T waves in the right precordial leads. MRI is a helpful diagnostic tool and is used, along with the 12-lead ECG and ambulatory ECG monitoring, to screen the first-degree relatives of affected individuals. Management is based on treating right-sided cardiac failure with diuretics and cardiac arrhythmias with β-blockers or, in patients at high risk of sudden death, an implantable defibrillator can be offered.</ce:para></ce:section><ce:section id="s2735"><ce:section-title id="st2590">Restrictive cardiomyopathy</ce:section-title><ce:para id="p7610">In this rare condition, ventricular filling is impaired because the ventricles are ‘stiff’ (see <ce:cross-ref id="crf1935" refid="f0530">Fig. 16.99</ce:cross-ref>). This leads to high atrial pressures with atrial hypertrophy, dilatation and, later, AF. Amyloidosis is the most common cause in the UK, although other forms of infiltration due to glycogen storage diseases, idiopathic perimyocyte fibrosis and a familial form of restrictive cardiomyopathy can also occur. The diagnosis can be difficult and requires assessment with Doppler echocardiography, CT or MRI, and endomyocardial biopsy. Treatment is symptomatic but the prognosis is usually poor and transplantation may be indicated.</ce:para></ce:section><ce:section id="s2740"><ce:section-title id="st2595">Obliterative cardiomyopathy</ce:section-title><ce:para id="p7615">This is a rare form of restrictive cardiomyopathy, involving the endocardium of one or both ventricles; it is characterised by thrombosis and fibrosis, with gradual obliteration of the ventricular cavities by fibrous tissue (see <ce:cross-ref id="crf1940" refid="f0530">Fig. 16.99</ce:cross-ref>). The mitral and tricuspid valves become regurgitant. Heart failure and pulmonary and systemic embolism are prominent features. It can sometimes be associated with eosinophilia and can occur in eosinophilic leukaemia and eosinophilic granulomatosis with polyangiitis (formerly known as Churg–Strauss syndrome, <ce:intra-ref id="ii0795" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1580">p. 1043</ce:intra-ref>). In tropical countries, the disease can be responsible for up to 10% of cardiac deaths. Mortality is high: 50% at 2 years. Anticoagulation and antiplatelet therapy are used, and diuretics may help symptoms of heart failure. Surgery (tricuspid and/or mitral valve replacement with decortication of the endocardium) may be helpful in selected cases.</ce:para></ce:section><ce:section id="s2745"><ce:section-title id="st2600">Takotsubo cardiomyopathy</ce:section-title><ce:para id="p7620">Takotsubo cardiomyopathy (Takotsubo syndrome) is a form of acute left ventricular dysfunction characterised by dilatation of the left ventricular apex and adjacent myocardium, with associated left ventricular impairment. The mechanism is poorly understood but may involve noradrenergic coronary vasoconstriction and acute left ventricular outflow obstruction. It is often associated with acute environmental or emotional stress (such as a bereavement) and presents with chest pain, breathlessness and sometimes cardiac failure. It occurs more frequently in women than in men. In terms of both symptoms and the ECG, the condition mimics acute ST elevation acute coronary syndrome. The diagnosis is usually made at coronary angiography, when CAD is found to be absent or minimal. Echocardiography then shows characteristic ‘apical ballooning’ of the LV. The dilated apex and narrow outflow of the LV resemble a Japanese octopus trap, or takotsubo (<ce:cross-ref id="crf9115" refid="f9005">Fig. 16.100</ce:cross-ref><ce:float-anchor refid="f9005"/>).</ce:para><ce:para id="p7625">Left ventricular dysfunction usually recovers within 4–5 days, although this can take weeks in some cases. Treatment is with a β-blocker, to prevent arrhythmia, and an ACE inhibitor, to treat left ventricular dysfunction. These drugs are continued only until cardiac function has recovered.</ce:para></ce:section><ce:section id="s2750"><ce:section-title id="st2605">Secondary causes of cardiomyopathy</ce:section-title><ce:para id="p7630">Many systemic conditions can produce a picture that is indistinguishable from dilated cardiomyopathy, including connective tissue disorders, sarcoidosis, haemochromatosis and alcoholic heart muscle disease (<ce:cross-ref id="crf1945" refid="b0565">Box 16.107</ce:cross-ref><ce:float-anchor refid="b0565"/>). In contrast, amyloidosis and eosinophilic heart disease produce symptoms and signs similar to those found in restrictive or obliterative cardiomyopathy, whereas the heart disease associated with Friedreich's ataxia (<ce:intra-ref id="ii0800" xlink:href="pii:B978-0-7020-7028-0.00025-1#s1235">p. 1116</ce:intra-ref>) can mimic hypertrophic cardiomyopathy.</ce:para><ce:para id="p7765">Treatment and prognosis are determined by the underlying disorder. Abstention from alcohol may lead to a dramatic improvement in patients with alcoholic heart muscle disease.</ce:para></ce:section></ce:section><ce:section id="s2755"><ce:section-title id="st2610">Cardiac tumours</ce:section-title><ce:para id="p7770">Primary cardiac tumours are rare (&#x003C; 0.2% of autopsies) but the heart and mediastinum may be the sites of metastases. Most primary tumours are benign (75%) and, of these, the majority are myxomas. The remainder are fibromas, lipomas, fibroelastomas and haemangiomas.</ce:para><ce:section id="s2760"><ce:section-title id="st2615">Atrial myxoma</ce:section-title><ce:para id="p7775">Myxomas most commonly arise in the LA as single or multiple polypoid tumours, attached by a pedicle to the interatrial septum. They are usually gelatinous but may be solid and even calcified, with superimposed thrombus.</ce:para><ce:para id="p7780">On examination, the first heart sound is usually loud, and there may be a murmur of mitral regurgitation with a variable diastolic sound (tumour ‘plop’) due to prolapse of the mass through the mitral valve. The tumour can be detected incidentally on echocardiography, or following investigation of pyrexia, syncope, arrhythmias or emboli. Occasionally, the condition presents with malaise and features suggestive of a connective tissue disorder, including a raised ESR.</ce:para><ce:para id="p7785">Treatment is by surgical excision. If the pedicle is removed, fewer than 5% of tumours recur.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2765"><ce:section-title id="st2620">Diseases of the pericardium</ce:section-title><ce:para id="p7790">The normal pericardial sac contains about 50 mL of fluid, similar to lymph, which lubricates the surface of the heart. The pericardium limits distension of the heart, contributes to the haemodynamic interdependence of the ventricles, and acts as a barrier to infection. Nevertheless, congenital absence of the pericardium does not result in significant clinical or functional limitations.</ce:para><ce:section id="s2770"><ce:section id="s2775"><ce:section-title id="st2625">Acute pericarditis</ce:section-title><ce:para id="p7795">This is due to an acute inflammatory process affecting the pericardium, which may coexist with myocarditis.</ce:para><ce:section id="s2780"><ce:section-title id="st2630">Pathogenesis</ce:section-title><ce:para id="p7800">A number of causes are recognised (<ce:cross-ref id="crf1950" refid="b0570">Box 16.108</ce:cross-ref><ce:float-anchor refid="b0570"/>), but in some cases the cause is unclear. All forms of pericarditis may produce a pericardial effusion that, depending on the aetiology, may be fibrinous, serous, haemorrhagic or purulent. A fibrinous exudate may eventually lead to varying degrees of adhesion formation, whereas serous pericarditis often produces a large effusion of turbid, straw-coloured fluid with a high protein content. A haemorrhagic effusion is often due to malignant disease, particularly carcinoma of the breast or bronchus, and lymphoma. Purulent pericarditis is rare and may occur as a complication of sepsis, by direct spread from an intrathoracic infection, or from a penetrating injury.</ce:para></ce:section><ce:section id="s2785"><ce:section-title id="st2635">Clinical features</ce:section-title><ce:para id="p7860">The typical presentation is with chest pain that is retrosternal, radiates to the shoulders and neck, and is typically aggravated by deep breathing, movement, a change of position, exercise and swallowing. A low-grade fever is common. A pericardial friction rub is a high-pitched, superficial scratching or crunching noise, produced by movement of the inflamed pericardium, and is diagnostic of pericarditis; it is usually heard in systole but may also be audible in diastole and frequently has a ‘to-and-fro’ quality.</ce:para></ce:section><ce:section id="s2790"><ce:section-title id="st2640">Investigations</ce:section-title><ce:para id="p7865">The diagnosis can often be made on the basis of clinical features and the ECG; the latter shows ST elevation with upward concavity (<ce:cross-ref id="crf1955" refid="f0535">Fig. 16.101</ce:cross-ref><ce:float-anchor refid="f0535"/>) over the affected area, which may be widespread. PR interval depression is a very specific indicator of acute pericarditis. Later, there may be T-wave inversion, particularly if there is a degree of myocarditis. Echocardiography may be normal or may reveal pericardial effusion, in which case regular echocardiographic monitoring is recommended.</ce:para></ce:section><ce:section id="s2795"><ce:section-title id="st2645">Management</ce:section-title><ce:para id="p7870">The pain usually responds to aspirin (600 mg 6 times daily) but a more potent anti-inflammatory agent, such as indometacin (50 mg 3 times daily), may be required. Colchicine or glucocorticoids can also suppress symptoms but there is no evidence that they accelerate cure. In viral pericarditis, recovery usually occurs within a few days or weeks but there may be recurrences (chronic relapsing pericarditis). Purulent pericarditis requires treatment with antimicrobial therapy, pericardiocentesis and, if necessary, surgical drainage.</ce:para></ce:section></ce:section><ce:section id="s2800"><ce:section-title id="st2650">Pericardial effusion</ce:section-title><ce:para id="p7875">Pericardial effusion often accompanies pericarditis and can have a number of causes, as shown in <ce:cross-ref id="crf1960" refid="b0570">Box 16.108</ce:cross-ref>.</ce:para><ce:section id="s2805"><ce:section-title id="st2655">Clinical features</ce:section-title><ce:para id="p7880">With the onset of an effusion the heart sounds may become quieter, and a friction rub, if present, may diminish in intensity but is not always abolished. Larger effusions may be accompanied by a sensation of retrosternal oppression. While most effusions do not have significant haemodynamic effects, large or rapidly developing effusions may cause cardiac tamponade. This term is used to describe acute heart failure due to compression of the heart and is described in detail below. Typical physical findings are a markedly raised JVP, hypotension, pulsus paradoxus (<ce:cross-ref id="crf9650" refid="s0085">p. 448</ce:cross-ref>) and oliguria. Atypical presentations may occur when the effusion is loculated as a result of previous pericarditis or cardiac surgery.</ce:para></ce:section><ce:section id="s2810"><ce:section-title id="st2660">Investigations</ce:section-title><ce:para id="p7885">Echocardiography is the definitive investigation and is helpful in monitoring the size of the effusion and its effect on cardiac function (<ce:cross-ref id="crf1965" refid="f0540">Fig. 16.102</ce:cross-ref><ce:float-anchor refid="f0540"/>). The QRS voltages on the ECG are often reduced in the presence of a large effusion. The QRS complexes may alternate in amplitude due to a to-and-fro motion of the heart within the fluid-filled pericardial sac (electrical alternans). The chest X-ray may show an increase in the size of the cardiac silhouette and, when there is a large effusion, this has a globular appearance. Aspiration of the effusion may be required for diagnostic purposes and, if necessary, for treatment of large effusions, as described below.</ce:para></ce:section><ce:section id="s2815"><ce:section-title id="st2665">Management</ce:section-title><ce:para id="p7890">Patients with large effusions that are causing haemodynamic compromise or cardiac tamponade should undergo aspiration of the effusion. This involves inserting a needle under echocardiographic guidance medial to the cardiac apex or below the xiphoid process, directed upwards towards the left shoulder. The route of choice will depend on the experience of the operator, the shape of the patient and the position of the effusion. A pericardial drain may be placed to provide symptomatic relief. Complications of pericardiocentesis include arrhythmias, damage to a coronary artery and bleeding, with exacerbation of tamponade as a result of injury to the RV. When tamponade is due to cardiac rupture or aortic dissection, pericardial aspiration may precipitate further potentially fatal bleeding and, in these situations, emergency surgery is the treatment of choice. A viscous, loculated or recurrent effusion may also require formal surgical drainage.</ce:para></ce:section></ce:section><ce:section id="s2820"><ce:section-title id="st2670">Tuberculous pericarditis</ce:section-title><ce:para id="p7895">Tuberculous pericarditis may complicate pulmonary tuberculosis but may also be the first manifestation of the infection. In Africa, a tuberculous pericardial effusion is a common feature of AIDS (<ce:intra-ref id="ii0810" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0355">p. 322</ce:intra-ref>). The condition typically presents with chronic malaise, weight loss and a low-grade fever. An effusion usually develops and the pericardium may become thick and unyielding, leading to pericardial constriction or tamponade. An associated pleural effusion is often present.</ce:para><ce:para id="p7900">The diagnosis may be confirmed by aspiration of the fluid and direct examination or culture for tubercle bacilli. Treatment requires specific antituberculous chemotherapy (<ce:intra-ref id="ii0815" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1140">p. 592</ce:intra-ref>); in addition, a 3-month course of prednisolone (initial dose 60 mg a day, tapering down rapidly) improves outcome.</ce:para></ce:section><ce:section id="s2825"><ce:section-title id="st2675">Chronic constrictive pericarditis</ce:section-title><ce:para id="p7905">Constrictive pericarditis is due to progressive thickening, fibrosis and calcification of the pericardium. In effect, the heart is encased in a solid shell and cannot fill properly. The calcification may extend into the myocardium, so there may also be impaired myocardial contraction. The condition often follows an attack of tuberculous pericarditis but can also complicate haemopericardium, viral pericarditis, rheumatoid arthritis and purulent pericarditis. It is often impossible to identify the original insult.</ce:para><ce:section id="s2830"><ce:section-title id="st2680">Clinical features</ce:section-title><ce:para id="p7910">The symptoms and signs of systemic venous congestion are the hallmarks of constrictive pericarditis. AF is common and there is often dramatic ascites and hepatomegaly (<ce:cross-ref id="crf1970" refid="b0575">Box 16.109</ce:cross-ref><ce:float-anchor refid="b0575"/>). Breathlessness is not a prominent symptom because the lungs are seldom congested. The condition is sometimes overlooked but should be suspected in any patient with unexplained right heart failure and a small heart.</ce:para></ce:section><ce:section id="s2835"><ce:section-title id="st2685">Investigations</ce:section-title><ce:para id="p7970">A chest X-ray, which may show pericardial calcification (<ce:cross-ref id="crf1975" refid="f0545">Fig. 16.103</ce:cross-ref><ce:float-anchor refid="f0545"/>), and echocardiography often help to establish the diagnosis. CT scanning is useful for imaging the pericardial calcification. Constrictive pericarditis is often difficult to distinguish from restrictive cardiomyopathy and in such cases complex echo–Doppler studies and cardiac catheterisation may be required.</ce:para></ce:section><ce:section id="s2840"><ce:section-title id="st2690">Management</ce:section-title><ce:para id="p7975">The resulting diastolic heart failure is treated using loop diuretics and aldosterone antagonists, such as spironolactone. Surgical resection of the diseased pericardium can lead to a dramatic improvement but carries a high morbidity, with disappointing results in up to 50% of patients.</ce:para></ce:section></ce:section><ce:section id="s2845"><ce:section-title id="st2695">Cardiac tamponade</ce:section-title><ce:para id="p7980">This term is used to describe acute heart failure due to compression of the heart as the result of a large pericardial effusion. Tamponade may complicate any form of pericarditis but can be caused by malignant disease, by blood in the pericardial space following trauma, or by rupture of the free wall of the myocardium following MI.</ce:para><ce:section id="s2850"><ce:section-title id="st2700">Clinical features</ce:section-title><ce:para id="p7985">Patients with tamponade are unwell, with hypotension, tachycardia and a markedly raised JVP. Other clinical features are summarised in <ce:cross-ref id="crf1980" refid="b0580">Box 16.110</ce:cross-ref><ce:float-anchor refid="b0580"/>.</ce:para></ce:section><ce:section id="s2855"><ce:section-title id="st2705">Investigations</ce:section-title><ce:para id="p8040">The pivotal investigation is echocardiography, which can confirm the diagnosis and also helps to identify the optimum site for aspiration of the fluid. The ECG may show features of the underlying disease, such as pericarditis or acute MI. When there is a large pericardial effusion, the ECG complexes are small and there may be electrical alternans: a changing axis with alternate beats caused by the heart swinging from side to side in the pericardial fluid. A chest X-ray shows an enlarged globular heart but can look normal.</ce:para></ce:section><ce:section id="s2860"><ce:section-title id="st2710">Management</ce:section-title><ce:para id="p8045">Cardiac tamponade is a medical emergency. When the diagnosis is confirmed, percutaneous pericardiocentesis should be performed as soon as possible, which usually results in a dramatic improvement. In some cases, surgical drainage may be required.</ce:para></ce:section></ce:section></ce:section></ce:section></ce:sections><ce:further-reading id="fr0010"><ce:section-title id="st2715">Further information</ce:section-title><ce:further-reading-sec id="fs0010"><ce:section-title id="st2720">Websites</ce:section-title><ce:bib-reference id="bib1"><ce:label>,</ce:label><sb:reference id="sr0010"><sb:host><sb:e-host><ce:inter-ref id="iw0050" xlink:href="http://acc.org">acc.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp1015"><ce:italic>American College of Cardiology (ACC): free access to guidelines for the evaluation and management of many cardiac conditions.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>,</ce:label><sb:reference id="sr0015"><sb:host><sb:e-host><ce:inter-ref id="iw0055" xlink:href="http://americanheart.org">americanheart.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp1020"><ce:italic>American Heart Association (AHA): free access to all the ACC/AHA/ESC guidelines, AHA scientific statements and fact sheets for patients.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>,</ce:label><sb:reference id="sr0020"><sb:host><sb:e-host><ce:inter-ref id="iw0060" xlink:href="http://escardio.org">escardio.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp1025"><ce:italic>European Society of Cardiology (ESC): free access to guidelines for the diagnosis and management of many cardiac conditions, and to educational modules.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>,</ce:label><sb:reference id="sr0025"><sb:host><sb:e-host><ce:inter-ref id="iw0065" xlink:href="http://jbs3risk.com">jbs3risk.com</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp1030"><ce:italic>Joint British Societies for the Prevention of Cardiovascular Disease: risk calculator.</ce:italic></ce:simple-para></ce:note></ce:bib-reference></ce:further-reading-sec><ce:further-reading-sec id="fs9000"><ce:section-title id="st9000">Journal articles</ce:section-title><ce:bib-reference id="bib9000"><ce:label>Gould et al, 2012</ce:label><sb:reference id="sr9000"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>FK</ce:given-name><ce:surname>Gould</ce:surname></sb:author><sb:author><ce:given-name>DW</ce:given-name><ce:surname>Denning</ce:surname></sb:author><sb:author><ce:given-name>TS</ce:given-name><ce:surname>Elliott</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the working party of the British Society for Antimicrobial Chemotherapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Antimicrob Chemother</sb:maintitle></sb:title><sb:volume-nr>67</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>269</sb:first-page><sb:last-page>289</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:further-reading-sec></ce:further-reading></chapter>